
<!DOCTYPE html>
<html>
<head>
<!-- Required meta tags -->
<meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<!-- Check Browser, as well as Hostname and set JS, CSS, Favicon path based on that-->

<!-- Favicon --><!-- cpcommit -->
<!-- <link rel="shortcut icon" type="image/x-icon" href="https://www.sec.gov/favicon.ico"> -->

<script>
	(function() {
		var hostName = window.location.hostname;

		var browserAccepted = function() {

			var ua = window.navigator.userAgent;
			var trident = ua.indexOf('Trident/'); //IE 11;
			var msie = ua.indexOf('MSIE '); // IE 10 or older
			if (msie > 0) {
				return false;
			}
			return true;
		}();

		var pathToLibs = 'https://www.sec.gov/js';
		var pathToError = '/';
		if (hostName === 'www-test.sec.gov' || hostName === 'www.sec.gov') {
			pathToLibs = 'https://www.sec.gov/ixviewer/js';
			pathToError = '/ixviewer/';
		}
		if (browserAccepted) {

			// css
			document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/css/custom-bootstrap.css>');
			document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/lib/fontawesome/css/all.min.css>');
			document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/css/app.css>');

			// js
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/jquery-3.3.1.slim.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/popper.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/bootstrap.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/moment.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/vanilla-picker.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/he.js"><\/script>');

			var date = new Date();
			var todaysDate = date.getDate() + '-' + (date.getMonth() + 1) + '-'
					+ date.getFullYear();
			document.write('<script type = "text/javascript" defer=true src="'
					+ pathToLibs + '/production.min.js?d=' + todaysDate
					+ '"><\/script>');
		} else {
			// user us on a browser that we do not support
			var currentUrl = window.location.href.split('?')[0];
			var browserError = currentUrl.substring(0, currentUrl
					.lastIndexOf('/'));
			browserError += pathToError + 'browser-error.html?url='
					+ encodeURIComponent(window.location.href);
			window.location.href = browserError;
		}
	})();
</script><link rel="stylesheet" href="https://www.sec.gov/ixviewer/js/css/custom-bootstrap.css"><link rel="stylesheet" href="https://www.sec.gov/ixviewer/js/lib/fontawesome/css/all.min.css"><link rel="stylesheet" href="https://www.sec.gov/ixviewer/js/css/app.css"><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/jquery-3.3.1.slim.min.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/popper.min.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/bootstrap.min.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/moment.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/vanilla-picker.min.js"></script><style>.picker_wrapper.no_alpha .picker_alpha{display:none}.picker_wrapper.no_editor .picker_editor{position:absolute;z-index:-1;opacity:0}.picker_wrapper.no_cancel .picker_cancel{display:none}.layout_default.picker_wrapper{display:-webkit-box;display:flex;-webkit-box-orient:horizontal;-webkit-box-direction:normal;flex-flow:row wrap;-webkit-box-pack:justify;justify-content:space-between;-webkit-box-align:stretch;align-items:stretch;font-size:10px;width:25em;padding:.5em}.layout_default.picker_wrapper input,.layout_default.picker_wrapper button{font-size:1rem}.layout_default.picker_wrapper>*{margin:.5em}.layout_default.picker_wrapper::before{content:'';display:block;width:100%;height:0;-webkit-box-ordinal-group:2;order:1}.layout_default .picker_slider,.layout_default .picker_selector{padding:1em}.layout_default .picker_hue{width:100%}.layout_default .picker_sl{-webkit-box-flex:1;flex:1 1 auto}.layout_default .picker_sl::before{content:'';display:block;padding-bottom:100%}.layout_default .picker_editor{-webkit-box-ordinal-group:2;order:1;width:6.5rem}.layout_default .picker_editor input{width:100%;height:100%}.layout_default .picker_sample{-webkit-box-ordinal-group:2;order:1;-webkit-box-flex:1;flex:1 1 auto}.layout_default .picker_done,.layout_default .picker_cancel{-webkit-box-ordinal-group:2;order:1}.picker_wrapper{box-sizing:border-box;background:#f2f2f2;box-shadow:0 0 0 1px silver;cursor:default;font-family:sans-serif;color:#444;pointer-events:auto}.picker_wrapper:focus{outline:none}.picker_wrapper button,.picker_wrapper input{box-sizing:border-box;border:none;box-shadow:0 0 0 1px silver;outline:none}.picker_wrapper button:focus,.picker_wrapper button:active,.picker_wrapper input:focus,.picker_wrapper input:active{box-shadow:0 0 2px 1px dodgerblue}.picker_wrapper button{padding:.4em .6em;cursor:pointer;background-color:whitesmoke;background-image:-webkit-gradient(linear, left bottom, left top, from(gainsboro), to(transparent));background-image:-webkit-linear-gradient(bottom, gainsboro, transparent);background-image:linear-gradient(0deg, gainsboro, transparent)}.picker_wrapper button:active{background-image:-webkit-gradient(linear, left bottom, left top, from(transparent), to(gainsboro));background-image:-webkit-linear-gradient(bottom, transparent, gainsboro);background-image:linear-gradient(0deg, transparent, gainsboro)}.picker_wrapper button:hover{background-color:white}.picker_selector{position:absolute;z-index:1;display:block;-webkit-transform:translate(-50%, -50%);transform:translate(-50%, -50%);border:2px solid white;border-radius:100%;box-shadow:0 0 3px 1px #67b9ff;background:currentColor;cursor:pointer}.picker_slider .picker_selector{border-radius:2px}.picker_hue{position:relative;background-image:-webkit-gradient(linear, left top, right top, from(red), color-stop(yellow), color-stop(lime), color-stop(cyan), color-stop(blue), color-stop(magenta), to(red));background-image:-webkit-linear-gradient(left, red, yellow, lime, cyan, blue, magenta, red);background-image:linear-gradient(90deg, red, yellow, lime, cyan, blue, magenta, red);box-shadow:0 0 0 1px silver}.picker_sl{position:relative;box-shadow:0 0 0 1px silver;background-image:-webkit-gradient(linear, left top, left bottom, from(white), color-stop(50%, rgba(255,255,255,0))),-webkit-gradient(linear, left bottom, left top, from(black), color-stop(50%, rgba(0,0,0,0))),-webkit-gradient(linear, left top, right top, from(gray), to(rgba(128,128,128,0)));background-image:-webkit-linear-gradient(top, white, rgba(255,255,255,0) 50%),-webkit-linear-gradient(bottom, black, rgba(0,0,0,0) 50%),-webkit-linear-gradient(left, gray, rgba(128,128,128,0));background-image:linear-gradient(180deg, white, rgba(255,255,255,0) 50%),linear-gradient(0deg, black, rgba(0,0,0,0) 50%),linear-gradient(90deg, gray, rgba(128,128,128,0))}.picker_alpha,.picker_sample{position:relative;background:url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E") left top/contain white;box-shadow:0 0 0 1px silver}.picker_alpha .picker_selector,.picker_sample .picker_selector{background:none}.picker_editor input{font-family:monospace;padding:.2em .4em}.picker_sample::before{content:'';position:absolute;display:block;width:100%;height:100%;background:currentColor}.picker_arrow{position:absolute;z-index:-1}.picker_wrapper.popup{position:absolute;z-index:2;margin:1.5em}.picker_wrapper.popup,.picker_wrapper.popup .picker_arrow::before,.picker_wrapper.popup .picker_arrow::after{background:#f2f2f2;box-shadow:0 0 10px 1px rgba(0,0,0,0.4)}.picker_wrapper.popup .picker_arrow{width:3em;height:3em;margin:0}.picker_wrapper.popup .picker_arrow::before,.picker_wrapper.popup .picker_arrow::after{content:"";display:block;position:absolute;top:0;left:0;z-index:-99}.picker_wrapper.popup .picker_arrow::before{width:100%;height:100%;-webkit-transform:skew(45deg);transform:skew(45deg);-webkit-transform-origin:0 100%;transform-origin:0 100%}.picker_wrapper.popup .picker_arrow::after{width:150%;height:150%;box-shadow:none}.popup.popup_top{bottom:100%;left:0}.popup.popup_top .picker_arrow{bottom:0;left:0;-webkit-transform:rotate(-90deg);transform:rotate(-90deg)}.popup.popup_bottom{top:100%;left:0}.popup.popup_bottom .picker_arrow{top:0;left:0;-webkit-transform:rotate(90deg) scale(1, -1);transform:rotate(90deg) scale(1, -1)}.popup.popup_left{top:0;right:100%}.popup.popup_left .picker_arrow{top:0;right:0;-webkit-transform:scale(-1, 1);transform:scale(-1, 1)}.popup.popup_right{top:0;left:100%}.popup.popup_right .picker_arrow{top:0;left:0}</style><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/he.js"></script><script type="text/javascript" defer="true" src="https://www.sec.gov/ixviewer/js/production.min.js?d=20-4-2022"></script>
<title>Inline XBRL Viewer</title>
<style type="text/css" id="customized-styles"> #dynamic-xbrl-form [enabled-taxonomy="true"][continued-taxonomy="false"]{border-top:2px solid #FF6600;border-bottom:2px solid #FF6600;display:inline;} #dynamic-xbrl-form [enabled-taxonomy="true"][continued-main-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #FF6600, 2px 0px 0px 0px #FF6600;} #dynamic-xbrl-form [enabled-taxonomy="true"][text-block-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #FF6600, 2px 0px 0px 0px #FF6600;border-top:none;border-bottom:none;} #dynamic-xbrl-form [highlight-taxonomy="true"]{background-color:#FFD700 !important;} #dynamic-xbrl-form [highlight-taxonomy="true"] > *{background-color:#FFD700 !important;} #dynamic-xbrl-form [selected-taxonomy="true"][continued-main-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #003768, 2px 0px 0px 0px #003768;} #dynamic-xbrl-form [selected-taxonomy="true"][text-block-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #003768, 2px 0px 0px 0px #003768;} #dynamic-xbrl-form [selected-taxonomy="true"][continued-taxonomy="false"]{border:3px solid #003768 !important;display:inline;} #dynamic-xbrl-form [hover-taxonomy="true"]{background-color:rgba(255,0,0,0.3);} .tagged-data-example-1{border-top:2px solid #FF6600;border-bottom:2px solid #FF6600;} .search-results-example-1{background-color:#FFD700;} .tag-shading-exmple-1:hover{background-color:rgba(255,0,0,0.3);} .selected-fact-example-1{border:3px solid #003768 !important;}</style></head>
<body style="overflow:auto">
<!--?xml version="1.0" ?--><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:4ce75aec-dfce-4369-8b30-338fd75f8b39,g:d034c22f-d179-4afb-9320-43ce2e1e38c8,d:e1e15c78f2af410c8f1490215e82bdbe--><meta http-equiv="Content-Type" content="text/html">


<title>bbi-20211231</title><div style="display:none"><ix:header><ix:hidden><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="dei:EntityCentralIndexKey" id="fact-identifier-0" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV80L2ZyYWc6ZWM3ODRjZWY3ODAxNGRjZjhlMDY4MTVkZjZmOTFiMzQvdGFibGU6NzBjZmM5NzYzMmM4NDU1NWE0Mjg3MGMxYjRiYjRjMTgvdGFibGVyYW5nZTo3MGNmYzk3NjMyYzg0NTU1YTQyODcwYzFiNGJiNGMxOF8wLTEtMS0xLTE2MzUx_09dc2a0e-d1b1-4de4-847e-c3ba2debff53" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">0000819050</ix:nonnumeric></span><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="dei:DocumentFiscalPeriodFocus" id="fact-identifier-1" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV80L2ZyYWc6ZWM3ODRjZWY3ODAxNGRjZjhlMDY4MTVkZjZmOTFiMzQvdGFibGU6NzBjZmM5NzYzMmM4NDU1NWE0Mjg3MGMxYjRiYjRjMTgvdGFibGVyYW5nZTo3MGNmYzk3NjMyYzg0NTU1YTQyODcwYzFiNGJiNGMxOF8xLTEtMS0xLTE2MzUx_74803d5e-8637-4db1-b816-6041be6e77da" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">FY</ix:nonnumeric></span><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="dei:AmendmentFlag" format="ixt:fixed-false" id="fact-identifier-2" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV80L2ZyYWc6ZWM3ODRjZWY3ODAxNGRjZjhlMDY4MTVkZjZmOTFiMzQvdGFibGU6NzBjZmM5NzYzMmM4NDU1NWE0Mjg3MGMxYjRiYjRjMTgvdGFibGVyYW5nZTo3MGNmYzk3NjMyYzg0NTU1YTQyODcwYzFiNGJiNGMxOF8yLTEtMS0xLTE2MzUx_04c7c675-25da-49a7-9177-5c88fa0ed7f0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">FALSE</ix:nonnumeric></span><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="dei:DocumentFiscalYearFocus" id="fact-identifier-3" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV80L2ZyYWc6ZWM3ODRjZWY3ODAxNGRjZjhlMDY4MTVkZjZmOTFiMzQvdGFibGU6NzBjZmM5NzYzMmM4NDU1NWE0Mjg3MGMxYjRiYjRjMTgvdGFibGVyYW5nZTo3MGNmYzk3NjMyYzg0NTU1YTQyODcwYzFiNGJiNGMxOF8zLTEtMS0xLTE2MzUx_049ad948-6329-4d08-9fa0-609db47cfe53" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">2021</ix:nonnumeric></span></ix:hidden><ix:references xml:lang="en-US"><link:schemaref xlink:type="simple" xlink:href="bbi-20211231.xsd"></link:schemaref></ix:references><ix:resources><xbrli:context id="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia7070bb639334130a8409ffe339a5e23_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i21044c37daf646e383d7678e3b757019_I20220303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i136a713ea34e4a3a8a8e3a24f4fa59ed_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79b48cfc81254328ac1dae75e4c81c8f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitnumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitnumerator><xbrli:unitdenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitdenominator></xbrli:divide></xbrli:unit><xbrli:context id="id87b073018e54ec8ac696cfa2b6026b5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie3531b58557045488edaf451c2b00e9e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i542b4f6af4e04f42a93210db56765f76_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1994e78f9c984a15a811ec9ab649aabf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if68daead4a7e4b788c4551fd5f8f512f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie893733c265e4a34b51045c9d764a9a7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b69e5154f8c4a1ca56c0dd9a760bb9b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic09a42f374cd48b88370d2716dd925ec_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a7b0ff06cf34bf68b059f14a54eef1e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf376e7422e54e0e8bf0e84b0d5bfeb9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9fb02b6818044db5b8a5b172ab2d4f9d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i08425205deea4f038db4f3d05c50394d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ide39c4f1147c4fdd92395bc81230fc80_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i06899d50c5e947f3bd2f6c9185b7da79_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fb7a10770e2462ab8aeb7d91d6b3938_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8cd5bd44234c47dda5f055052702fa7c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic374ef00ae81457d854afc7e19d70628_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i145b5f02df19400f9409a9d7c1854861_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4a03ff97b4484593b0c0ab2fb78e1d93_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i22a3a87ba40a4de8864586d396c22c4f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib3442e37cfcd4a1cbcfe38fd035ec774_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8d854dbfb584e35a2eeedafaa5f9fb7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3d32b10b3574141a67d2bc3a7c2ba6a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d2864ef02b045c08b23d62ca9064de4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>bbi:segment</xbrli:measure></xbrli:unit><xbrli:context id="ife9a1b0f0d6646b6920f29eb20835875_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i10aedd8fb2ac472d99e658bd782e2bd6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie71093466047442fa4c12d9719470f93_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0337d14e1f247559651c4c7555de919_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibefe7702458545ea8f5b2c0e3413b2b8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i72ce39e4fc9c4f4fb4167626cfe366ad_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i73c721546b6043588c18a762c0b2f2fa_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i751d45db4c76499988f110b5325a83ac_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ibab54c3adead408687d6cbac3b5979dd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i070fe27d5536497092d9af2480ee02f4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i79c757803c2946a984ceb18f7309e2d8_I20220222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">bbi:CarnaBiosciencesIncMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i8cc89a88f2c04531a3c91a0c43c75e3b_D20210827-20210827"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">bbi:VoronoiIncMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-08-27</xbrli:startdate><xbrli:enddate>2021-08-27</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i72165e927c8d413c9a775a4ef5166aea_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">bbi:VoronoiIncMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if8a97fd31a9240d3aa4b18008191f7ec_D20210827-20210827"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2021-08-27</xbrli:startdate><xbrli:enddate>2021-08-27</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie765297f3b45432eb04ae5ca2c4c30d3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">bbi:BodorLaboratoriesInc.Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ibbb989d10e29424aac8a88c70c5285d0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">bbi:BodorLaboratoriesInc.Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="icc7525770f5b490db5692d1a694fcf2c_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">bbi:BodorLaboratoriesInc.Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-10-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i35e59a3ab10c4639a54916140c1a0441_D20150301-20150331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2015-03-01</xbrli:startdate><xbrli:enddate>2015-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i439ade89822b4df2858d9b0f7b2d949e_I20150331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9393e64507a84944b92e7bd13ec71c90_D20180501-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2018-05-01</xbrli:startdate><xbrli:enddate>2018-05-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7289f808102044a5acf122d6d9f65ba9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie8e9ad122fed497cab90ee40fd300cd7_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-10-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6a6fa850e9df4db6a3ed2b43eacbee41_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-09-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id82b40dc002940bd9c7491e5b5dee885_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ied3898b760044f5fad97b15508cb4e05_I20200415"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">bbi:PaycheckProtectionProgramMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="renewalterm"><xbrli:measure>bbi:renewalTerm</xbrli:measure></xbrli:unit><xbrli:context id="i4d33a851a96040978ef2f9da670c66f4_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e2ac66356654b37bd53ed713a163f86_I20210419"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-04-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7263d1bd71cd41cf83f618481b17ec62_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i060d4bd2c05e4f3b8b6d111ec3f59f4d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">bbi:SharebasedPaymentArrangementOptionOutstandingMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if92afe08e0b947e0be3caee47bcadd7f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">bbi:A2020OmnibusPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8c46b385c9d410ba351bdf9a1cdef7b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e88d5581f8e4804aad93370dab97ef2_D20211001-20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">bbi:October2021OfferingMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-10-01</xbrli:startdate><xbrli:enddate>2021-10-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib3e388c0a38f49509a73e0978de43e31_I20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">bbi:October2021OfferingMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9b014fe7a35425989332f53b3651fe6_D20210701-20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">bbi:July2021PublicOfferingMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-07-01</xbrli:startdate><xbrli:enddate>2021-07-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7ed3b097161541adbe2daf684ed51058_I20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">bbi:July2021PublicOfferingMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i333296f159d743428ccdb664f0b26e4b_D20201001-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">bbi:October2020OfferingMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-10-01</xbrli:startdate><xbrli:enddate>2020-10-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iaa5e28b085f6467a8e8d5bd976dcc8e5_I20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">bbi:October2020OfferingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">bbi:CommonStockWarrantsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica27d249a23a4d56a3605dc92d05102f_I20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">bbi:October2020OfferingMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4933a0c944f3461aaef8817a358a0cca_I20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">bbi:October2020OfferingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">bbi:PreFundedWarrantMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f99c116b43947219d9f8eaf304dc70f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">bbi:CommonStockWarrantsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12fa54e463454aa7be2e64acbb078508_D20201001-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2020-10-01</xbrli:startdate><xbrli:enddate>2020-10-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2312571183384deb9159863e35bb9953_I20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">bbi:PreFundedWarrantMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied7da0ab5f3b4186bc770b0c713ddbe6_D20201001-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">bbi:October2020OfferingMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-10-01</xbrli:startdate><xbrli:enddate>2020-10-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i22405a7c372c4b70bda99cefeae4041e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">bbi:October2020OfferingMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i952c7982750142b5bb99a11d3b7bcc20_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">bbi:October2020OfferingMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id906d2a122b44e3daf1cf3704aa16a1a_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">bbi:CommonStockPublicOfferingMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieca34758531d4cd3bab0f67953c7f21d_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">bbi:CommonStockPublicOfferingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">bbi:PreFundedWarrantMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0763bbc1436649ac90db8b150740aa77_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">bbi:CommonStockPublicOfferingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">bbi:AccompanyingCommonWarrantMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24c191d998ef4179bc97fb022772f42f_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">bbi:PreFundedWarrantMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3b123870412497ba1f76e8e916224f0_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">bbi:CommonStockPublicOfferingMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-06-01</xbrli:startdate><xbrli:enddate>2020-06-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9317bd693e35453081407aad2ce3614f_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2020-06-01</xbrli:startdate><xbrli:enddate>2020-06-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic895a0f669dc41aebf0a3cbd34b88f1e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">bbi:CommonStockPublicOfferingMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie594e0c68fbb4c8a8664ea18c0e16f0b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">bbi:CommonStockPublicOfferingMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if7a9a60a17784350b175e1c4cd31f629_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">bbi:A2021AtMarketIssuanceSalesAgreementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id91cf804b976420eac12ee8c22f79102_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">bbi:A2021AtMarketIssuanceSalesAgreementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">bbi:PreFundedWarrantMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0362be51f9a54d76944d6aaa03e140f2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">bbi:A2021AtMarketIssuanceSalesAgreementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iab543560d5bc450b9a82e51ea2a6693b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">bbi:A2021AtMarketIssuanceSalesAgreementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfeb25fc4b5243e2a3a71ccaf8adc620_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">bbi:A2020AtMarketIssuanceSalesAgreementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23924d399b4848e0b9118cadf9c441ae_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">bbi:A2020AtMarketIssuanceSalesAgreementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i38418f7003a944819239bc331a3a2a94_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">bbi:A2020AtMarketIssuanceSalesAgreementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ifcbfe54310a844789ff68ad2cab988b4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">bbi:A2020AtMarketIssuanceSalesAgreementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ddf087d66c84f47a439f27661dd7001_I20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">bbi:PrivatePlacementOfferingsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4388918a81944717a6d159c056d08f96_I20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">bbi:PrivatePlacementOfferingsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b9f1dc5762f4d95957aa0f1550ec49e_I20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">bbi:PrivatePlacementOfferingsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i185b75e367b244df8844419e000cb28f_D20200201-20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">bbi:PrivatePlacementOfferingsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-02-01</xbrli:startdate><xbrli:enddate>2020-02-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if9fdf17822f8410583b96c2fb69f9183_I20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">bbi:LincolnParkMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff50bf3d85134fa6a29a20b378b5aa09_D20200201-20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">bbi:LincolnParkMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-02-01</xbrli:startdate><xbrli:enddate>2020-02-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8edf6096dea6465f96e3e0a94ab4e412_D20200201-20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">bbi:LincolnParkMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">bbi:PurchaseAgreementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-02-01</xbrli:startdate><xbrli:enddate>2020-02-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic8633634722843ffb8a237ecfa10d7ed_I20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">bbi:LincolnParkMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">bbi:PurchaseAgreementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b4ac58c8c514f56a81a0ae074fd90bc_D20200201-20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">bbi:LincolnParkMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">bbi:RegularPurchaseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-02-01</xbrli:startdate><xbrli:enddate>2020-02-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i58c0fb1ded3442bdbd8c1c72b8deb167_I20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">bbi:LincolnParkMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">bbi:RegularPurchaseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icea6541707c34696b90754dab441301f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">bbi:LincolnParkMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">bbi:PurchaseAgreementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i97a4f7600692420d84883467663d2f32_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">bbi:EquityIncentivePlan2009Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee299f936e4b4f6493db6a9c1edb92ad_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">bbi:VicalStockIncentivePlanMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib00fa4ecddfb408a8f6206ac1c5747b8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">bbi:A2020OmnibusPlanMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4d84a77f18f406b80dcc553f8680d1f_D20200831-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">bbi:A2020OmnibusPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-08-31</xbrli:startdate><xbrli:enddate>2020-08-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i99d487ee0b254f3787e06b5e936fbe3a_D20210419-20210419"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">bbi:A2020OmnibusPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-04-19</xbrli:startdate><xbrli:enddate>2021-04-19</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib9d3171439f046d18bb63ac1889442a5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic09f0cb7e935412bbc1991742a83d05e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id18f7e3519f74098b48becbf7a48145c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4fca80887a6747448ce1c3ce12b39a4d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3764ec9cafc742c88cf1c0d565bb6379_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60a3b4ccd49e4dd19777488e4f48d5f0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29cf34bcc25e40cb820c6d1976855b2f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51f8d7f1fbd74f8f984824ea54416009_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i536b401f49be405b870ac402e75bb048_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39a3ed5ab3674ef8a5d3562bc4955a3b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">bbi:EmployeeStockPurchasePlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ibeb42d5fcd6b44c7bf55d0f49eaa5cc1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">bbi:EmployeeStockPurchasePlanMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9b104686d0234f5b80fa09d742216b81_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i13107484a8a144969c7fbd351687ace2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8f0337209ceb487e9346447e0c16e3a6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if0ffa5e709694f368ca08366889ace83_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i35c489743bbd40648d43e3752f9e88fb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1206f2f7b6e948c8bf5cb270308ddcab_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if069865715654e2f9cb3c0fe326b768a_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec4608c916754d509543ef637b768f07_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ef51a60951147c688025855b9f5d94e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TaxCreditCarryforwardAxis">bbi:FederalResearchAndDevelopmentCreditsAndOrphanDrugCreditMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida3cc67b545b49469682a9e8d3a9e6da_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TaxCreditCarryforwardAxis">bbi:FederalResearchAndDevelopmentCreditsAndOrphanDrugCreditMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74d9a9e7131a4ebe8b34298a8a4575aa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifaaa1052eae2429ca6be054fc2faa42b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia377f4b4864f4191994d91d3152ca408_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TaxPeriodAxis">bbi:TaxYear2022Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92e0bb7447214495bd04667d15186df7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TaxPeriodAxis">bbi:TaxYear2022Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54d116e3b680474ebfebb6cc1da9fa04_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TaxCreditCarryforwardAxis">bbi:FederalResearchAndDevelopmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TaxPeriodAxis">bbi:TaxYear2022Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bfca4cc8bba4d5e9724f98399c5231a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TaxCreditCarryforwardAxis">bbi:FederalOrphanDrugMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TaxPeriodAxis">bbi:TaxYear2022Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9162577024e474bbb8ef516a461528a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TaxCreditCarryforwardAxis">bbi:StateResearchAndDevelopmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TaxPeriodAxis">bbi:TaxYear2022Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i055e8d473e5f460088db865a971a2e90_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TaxPeriodAxis">bbi:TaxYear2023Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bbe926f88884d4e854c2e429801b32f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TaxPeriodAxis">bbi:TaxYear2023Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49e62605df6747c6ad4117475d1fb987_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TaxCreditCarryforwardAxis">bbi:FederalResearchAndDevelopmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TaxPeriodAxis">bbi:TaxYear2023Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88decd1b1a234431a2bfe501b616ec2e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TaxPeriodAxis">bbi:TaxYear2023Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TaxCreditCarryforwardAxis">bbi:FederalOrphanDrugMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if015fe594d1f45d68fd0d5b29b7e029d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TaxCreditCarryforwardAxis">bbi:StateResearchAndDevelopmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TaxPeriodAxis">bbi:TaxYear2023Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief836506794f4fb4ac09c658d878fb63_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TaxPeriodAxis">bbi:TaxYear2024Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2fd9a0736ed4d1699213bd8e7662e31_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TaxPeriodAxis">bbi:TaxYear2024Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6a33dddb3224c30a28ed87c7a88e87b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TaxCreditCarryforwardAxis">bbi:FederalResearchAndDevelopmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TaxPeriodAxis">bbi:TaxYear2024Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf114d19233c49ecb4a3a0bdff3b4730_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TaxPeriodAxis">bbi:TaxYear2024Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TaxCreditCarryforwardAxis">bbi:FederalOrphanDrugMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccf7a6c422244f209239a5cceb1fd0e1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TaxCreditCarryforwardAxis">bbi:StateResearchAndDevelopmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TaxPeriodAxis">bbi:TaxYear2024Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icba3d25c77924f07b976d8ed0d1f674d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TaxPeriodAxis">bbi:TaxYear2025Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ed137c836424891ae89e0522e0531bd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TaxPeriodAxis">bbi:TaxYear2025Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99e282fca2d6495aa43c86ffa521681a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TaxPeriodAxis">bbi:TaxYear2025Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TaxCreditCarryforwardAxis">bbi:FederalResearchAndDevelopmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefaa5c4a7c97470ca20fbb972d15809c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TaxPeriodAxis">bbi:TaxYear2025Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TaxCreditCarryforwardAxis">bbi:FederalOrphanDrugMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75390603508c4979a7101c91da59e41c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TaxCreditCarryforwardAxis">bbi:StateResearchAndDevelopmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TaxPeriodAxis">bbi:TaxYear2025Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27c3cd712f364388b6f58cda40a050e9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TaxPeriodAxis">bbi:TaxYear2026AndThereafterMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0ee826e5fdc4ad191c11eec2cd9704b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TaxPeriodAxis">bbi:TaxYear2026AndThereafterMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bad8ed177f24dea9d15095e335759e4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TaxCreditCarryforwardAxis">bbi:FederalResearchAndDevelopmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TaxPeriodAxis">bbi:TaxYear2026AndThereafterMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icaa1655b26314906b0ae1a0f7373c717_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TaxPeriodAxis">bbi:TaxYear2026AndThereafterMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TaxCreditCarryforwardAxis">bbi:FederalOrphanDrugMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21637a81f1f649a2bb7c8c62210df99f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TaxCreditCarryforwardAxis">bbi:StateResearchAndDevelopmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TaxPeriodAxis">bbi:TaxYear2026AndThereafterMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e7c32c46b4347a380789e24ffa11089_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TaxPeriodAxis">bbi:IndefiniteMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2226ff53aa6a47f7bba1d2bafb644439_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TaxPeriodAxis">bbi:IndefiniteMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia893a09aeca64349aec659edad8bb1ef_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TaxPeriodAxis">bbi:IndefiniteMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TaxCreditCarryforwardAxis">bbi:FederalResearchAndDevelopmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i123e03f06e61449ba99dfad20ff96163_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TaxPeriodAxis">bbi:IndefiniteMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TaxCreditCarryforwardAxis">bbi:FederalOrphanDrugMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66ddca61491244439bcf9e0d19cbfb1e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TaxCreditCarryforwardAxis">bbi:StateResearchAndDevelopmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TaxPeriodAxis">bbi:IndefiniteMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a502aca50a64ba18b73ea0ce99d6515_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TaxCreditCarryforwardAxis">bbi:FederalResearchAndDevelopmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32fa7409baf340ddbe1255d4f16f1f40_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TaxCreditCarryforwardAxis">bbi:FederalOrphanDrugMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e43190ff0834525a23e0adddd8a0b6b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000819050</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TaxCreditCarryforwardAxis">bbi:StateResearchAndDevelopmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ie1e15c78f2af410c8f1490215e82bdbe_166"></div><div style="min-height:49.5pt;width:100%"><div><span><br></span></div></div><div style="text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="dei:DocumentType" id="fact-identifier-4" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8xNjYvZnJhZzpjYTQ1MDJmOWIzOGI0NWY0YTY3YmMzNzFmZjk4OTI4Yy90ZXh0cmVnaW9uOmNhNDUwMmY5YjM4YjQ1ZjRhNjdiYzM3MWZmOTg5MjhjXzM1MzQ_9b375a09-a46c-4969-82b6-45926b9043f4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="dei:DocumentType" id="fact-identifier-5" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8xNjYvZnJhZzpjYTQ1MDJmOWIzOGI0NWY0YTY3YmMzNzFmZjk4OTI4Yy90ZXh0cmVnaW9uOmNhNDUwMmY5YjM4YjQ1ZjRhNjdiYzM3MWZmOTg5MjhjXzM1MzQ_dd6e4238-1fd2-48ff-ac56-5cb6df5e38cf" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10-K</ix:nonnumeric></span></ix:nonnumeric></span> </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.977%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="fact-identifier-6" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8xNjYvZnJhZzpjYTQ1MDJmOWIzOGI0NWY0YTY3YmMzNzFmZjk4OTI4Yy90YWJsZTowOWNkMzYyMjE1NmU0Y2NkOGI4OTQwNDBhZjZlYmI1ZS90YWJsZXJhbmdlOjA5Y2QzNjIyMTU2ZTRjY2Q4Yjg5NDA0MGFmNmViYjVlXzAtMC0xLTEtMTYzNTE_8bd4092a-a32b-473b-ac02-783bbb24f29e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">☒</ix:nonnumeric></span></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></tbody></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For the fiscal year ended <span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="fact-identifier-7" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8xNjYvZnJhZzpjYTQ1MDJmOWIzOGI0NWY0YTY3YmMzNzFmZjk4OTI4Yy90ZXh0cmVnaW9uOmNhNDUwMmY5YjM4YjQ1ZjRhNjdiYzM3MWZmOTg5MjhjXzExNg_596b03df-407f-40ea-b045-c6f624931459" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="fact-identifier-8" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8xNjYvZnJhZzpjYTQ1MDJmOWIzOGI0NWY0YTY3YmMzNzFmZjk4OTI4Yy90ZXh0cmVnaW9uOmNhNDUwMmY5YjM4YjQ1ZjRhNjdiYzM3MWZmOTg5MjhjXzExNg_f9908312-f65d-45b0-a7c4-9dd72f202a46" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">December 31</ix:nonnumeric></span>, 2021</ix:nonnumeric></span> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">or</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.977%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="fact-identifier-9" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8xNjYvZnJhZzpjYTQ1MDJmOWIzOGI0NWY0YTY3YmMzNzFmZjk4OTI4Yy90YWJsZTpkMWY1NDE2YTBmY2E0YzBhOGE0YWNkODljMmMxNDJlOS90YWJsZXJhbmdlOmQxZjU0MTZhMGZjYTRjMGE4YTRhY2Q4OWMyYzE0MmU5XzAtMC0xLTEtMTYzNTE_a88df27c-d13d-4e3e-96d2-85794011d6e2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">☐</ix:nonnumeric></span></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></tbody></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For the transition period from         to </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commission File Number: <span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="dei:EntityFileNumber" id="fact-identifier-10" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8xNjYvZnJhZzpjYTQ1MDJmOWIzOGI0NWY0YTY3YmMzNzFmZjk4OTI4Yy90ZXh0cmVnaW9uOmNhNDUwMmY5YjM4YjQ1ZjRhNjdiYzM3MWZmOTg5MjhjXzM1MzU_ef8aa930-2170-4c00-8235-277d376722ec" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="dei:EntityFileNumber" id="fact-identifier-11" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8xNjYvZnJhZzpjYTQ1MDJmOWIzOGI0NWY0YTY3YmMzNzFmZjk4OTI4Yy90ZXh0cmVnaW9uOmNhNDUwMmY5YjM4YjQ1ZjRhNjdiYzM3MWZmOTg5MjhjXzM1MzU_f0f613fa-bdca-44cd-992c-69d3e0b9305d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">000-21088</ix:nonnumeric></span></ix:nonnumeric></span> </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="dei:EntityRegistrantName" id="fact-identifier-12" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8xNjYvZnJhZzpjYTQ1MDJmOWIzOGI0NWY0YTY3YmMzNzFmZjk4OTI4Yy90ZXh0cmVnaW9uOmNhNDUwMmY5YjM4YjQ1ZjRhNjdiYzM3MWZmOTg5MjhjXzM1NDM_1b38761b-dc7d-4e51-91b0-3487f00db9dc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">BRICKELL BIOTECH, INC.</ix:nonnumeric></span> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:5.186%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.530%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="fact-identifier-13" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8xNjYvZnJhZzpjYTQ1MDJmOWIzOGI0NWY0YTY3YmMzNzFmZjk4OTI4Yy90YWJsZTphMmZhYTVkMDBiZjQ0MGVkYTdkMTQ1YzI0NWJiN2E0YS90YWJsZXJhbmdlOmEyZmFhNWQwMGJmNDQwZWRhN2QxNDVjMjQ1YmI3YTRhXzAtMS0xLTEtMTYzNTE_24cb6dbc-a975-43f6-b8d9-99a2a9619d8a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Delaware</ix:nonnumeric></span></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="dei:EntityTaxIdentificationNumber" id="fact-identifier-14" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8xNjYvZnJhZzpjYTQ1MDJmOWIzOGI0NWY0YTY3YmMzNzFmZjk4OTI4Yy90YWJsZTphMmZhYTVkMDBiZjQ0MGVkYTdkMTQ1YzI0NWJiN2E0YS90YWJsZXJhbmdlOmEyZmFhNWQwMGJmNDQwZWRhN2QxNDVjMjQ1YmI3YTRhXzAtNi0xLTEtMTYzNTE_405eab27-e1f5-4be4-a88d-5208b4959fea" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">93-0948554</ix:nonnumeric></span></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="dei:EntityAddressAddressLine1" id="fact-identifier-15" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8xNjYvZnJhZzpjYTQ1MDJmOWIzOGI0NWY0YTY3YmMzNzFmZjk4OTI4Yy90YWJsZTphMmZhYTVkMDBiZjQ0MGVkYTdkMTQ1YzI0NWJiN2E0YS90YWJsZXJhbmdlOmEyZmFhNWQwMGJmNDQwZWRhN2QxNDVjMjQ1YmI3YTRhXzMtMS0xLTEtMTYzNTE_47fd047d-9a2a-4998-beb1-9d81fd45064d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5777 Central Avenue, Suite 102,</ix:nonnumeric></span></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&nbsp;<span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="dei:EntityAddressCityOrTown" id="fact-identifier-16" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8xNjYvZnJhZzpjYTQ1MDJmOWIzOGI0NWY0YTY3YmMzNzFmZjk4OTI4Yy90YWJsZTphMmZhYTVkMDBiZjQ0MGVkYTdkMTQ1YzI0NWJiN2E0YS90YWJsZXJhbmdlOmEyZmFhNWQwMGJmNDQwZWRhN2QxNDVjMjQ1YmI3YTRhXzMtMi0xLTEtMTYzNTE_e20d110c-c1cd-4d02-aae1-a07e861e61bc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Boulder,</ix:nonnumeric></span></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="dei:EntityAddressStateOrProvince" id="fact-identifier-17" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8xNjYvZnJhZzpjYTQ1MDJmOWIzOGI0NWY0YTY3YmMzNzFmZjk4OTI4Yy90YWJsZTphMmZhYTVkMDBiZjQ0MGVkYTdkMTQ1YzI0NWJiN2E0YS90YWJsZXJhbmdlOmEyZmFhNWQwMGJmNDQwZWRhN2QxNDVjMjQ1YmI3YTRhXzMtMy0xLTEtMTYzNTE_51208e39-53b2-4ac5-8a68-3e9a351439d0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">CO</ix:nonnumeric></span></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="dei:EntityAddressPostalZipCode" id="fact-identifier-18" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8xNjYvZnJhZzpjYTQ1MDJmOWIzOGI0NWY0YTY3YmMzNzFmZjk4OTI4Yy90YWJsZTphMmZhYTVkMDBiZjQ0MGVkYTdkMTQ1YzI0NWJiN2E0YS90YWJsZXJhbmdlOmEyZmFhNWQwMGJmNDQwZWRhN2QxNDVjMjQ1YmI3YTRhXzMtNi0xLTEtMTYzNTE_c1aa44ac-1e3f-4a3a-b3b7-93be117d0d4e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">80301</ix:nonnumeric></span></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Zip Code)</span></td><td colspan="3" style="padding:0 1pt"></td></tr></tbody></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Registrant’s telephone number, including area code: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="dei:CityAreaCode" id="fact-identifier-19" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8xNjYvZnJhZzpjYTQ1MDJmOWIzOGI0NWY0YTY3YmMzNzFmZjk4OTI4Yy90ZXh0cmVnaW9uOmNhNDUwMmY5YjM4YjQ1ZjRhNjdiYzM3MWZmOTg5MjhjXzM1Mzc_91758901-bf29-4360-801a-be1ba4265394" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="dei:CityAreaCode" id="fact-identifier-20" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8xNjYvZnJhZzpjYTQ1MDJmOWIzOGI0NWY0YTY3YmMzNzFmZjk4OTI4Yy90ZXh0cmVnaW9uOmNhNDUwMmY5YjM4YjQ1ZjRhNjdiYzM3MWZmOTg5MjhjXzM1Mzc_a0305cb8-6ac3-4ebb-a77b-268f166c5585" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">720</ix:nonnumeric></span></ix:nonnumeric></span>) <span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="dei:LocalPhoneNumber" id="fact-identifier-21" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8xNjYvZnJhZzpjYTQ1MDJmOWIzOGI0NWY0YTY3YmMzNzFmZjk4OTI4Yy90ZXh0cmVnaW9uOmNhNDUwMmY5YjM4YjQ1ZjRhNjdiYzM3MWZmOTg5MjhjXzM1Mzg_12d65777-3c7c-4ff3-9d16-9ffe770bf16f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="dei:LocalPhoneNumber" id="fact-identifier-22" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8xNjYvZnJhZzpjYTQ1MDJmOWIzOGI0NWY0YTY3YmMzNzFmZjk4OTI4Yy90ZXh0cmVnaW9uOmNhNDUwMmY5YjM4YjQ1ZjRhNjdiYzM3MWZmOTg5MjhjXzM1Mzg_d3833e42-793e-4f10-a501-cfc708c7cbe9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">505-4755</ix:nonnumeric></span></ix:nonnumeric></span> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.683%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.328%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trading symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="dei:Security12bTitle" id="fact-identifier-23" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8xNjYvZnJhZzpjYTQ1MDJmOWIzOGI0NWY0YTY3YmMzNzFmZjk4OTI4Yy90YWJsZTplYzYyMWYwZGYxYzU0ODUyOWM5OWYwMmUwMDBhNmU2OC90YWJsZXJhbmdlOmVjNjIxZjBkZjFjNTQ4NTI5Yzk5ZjAyZTAwMGE2ZTY4XzEtMC0xLTEtMTYzNTE_86bfd7b3-ef68-4d26-972c-374da9a0794e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Common stock, $0.01 par value per share</ix:nonnumeric></span></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="dei:TradingSymbol" id="fact-identifier-24" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8xNjYvZnJhZzpjYTQ1MDJmOWIzOGI0NWY0YTY3YmMzNzFmZjk4OTI4Yy90YWJsZTplYzYyMWYwZGYxYzU0ODUyOWM5OWYwMmUwMDBhNmU2OC90YWJsZXJhbmdlOmVjNjIxZjBkZjFjNTQ4NTI5Yzk5ZjAyZTAwMGE2ZTY4XzEtMS0xLTEtMTYzNTE_9447cd3c-3bbe-42d5-9734-a730a275c4b8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">BBI</ix:nonnumeric></span></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="fact-identifier-25" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8xNjYvZnJhZzpjYTQ1MDJmOWIzOGI0NWY0YTY3YmMzNzFmZjk4OTI4Yy90YWJsZTplYzYyMWYwZGYxYzU0ODUyOWM5OWYwMmUwMDBhNmU2OC90YWJsZXJhbmdlOmVjNjIxZjBkZjFjNTQ4NTI5Yzk5ZjAyZTAwMGE2ZTY4XzEtMi0xLTEtMTYzNTE_36ead859-7a8a-4420-be69-3e81c3798afa" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">The Nasdaq Stock Market LLC</ix:nonnumeric></span></span></td></tr></tbody></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to section 12(g) of the Act: None</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Yes ☐ <span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="dei:EntityWellKnownSeasonedIssuer" id="fact-identifier-26" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8xNjYvZnJhZzpjYTQ1MDJmOWIzOGI0NWY0YTY3YmMzNzFmZjk4OTI4Yy90ZXh0cmVnaW9uOmNhNDUwMmY5YjM4YjQ1ZjRhNjdiYzM3MWZmOTg5MjhjXzM1NDQ_9099f96e-d077-4017-a180-12812dad9a67" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="dei:EntityWellKnownSeasonedIssuer" id="fact-identifier-27" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8xNjYvZnJhZzpjYTQ1MDJmOWIzOGI0NWY0YTY3YmMzNzFmZjk4OTI4Yy90ZXh0cmVnaW9uOmNhNDUwMmY5YjM4YjQ1ZjRhNjdiYzM3MWZmOTg5MjhjXzM1NDQ_d7a07b0e-a1d0-473b-aa9e-ec19151bda68" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">No</ix:nonnumeric></span></ix:nonnumeric></span> ☒ </span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Yes ☐ <span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="dei:EntityVoluntaryFilers" id="fact-identifier-28" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8xNjYvZnJhZzpjYTQ1MDJmOWIzOGI0NWY0YTY3YmMzNzFmZjk4OTI4Yy90ZXh0cmVnaW9uOmNhNDUwMmY5YjM4YjQ1ZjRhNjdiYzM3MWZmOTg5MjhjXzM1Mzk_1789376e-2e38-40f2-bd1c-debb6b356a46" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="dei:EntityVoluntaryFilers" id="fact-identifier-29" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8xNjYvZnJhZzpjYTQ1MDJmOWIzOGI0NWY0YTY3YmMzNzFmZjk4OTI4Yy90ZXh0cmVnaW9uOmNhNDUwMmY5YjM4YjQ1ZjRhNjdiYzM3MWZmOTg5MjhjXzM1Mzk_b78eb7a3-e3ee-488a-8b8c-360942a7bbd0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">No</ix:nonnumeric></span></ix:nonnumeric></span> ☒ </span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="dei:EntityCurrentReportingStatus" id="fact-identifier-30" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8xNjYvZnJhZzpjYTQ1MDJmOWIzOGI0NWY0YTY3YmMzNzFmZjk4OTI4Yy90ZXh0cmVnaW9uOmNhNDUwMmY5YjM4YjQ1ZjRhNjdiYzM3MWZmOTg5MjhjXzM1NDA_0cfb002e-43a6-4333-9275-d7bbb0e60303" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="dei:EntityCurrentReportingStatus" id="fact-identifier-31" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8xNjYvZnJhZzpjYTQ1MDJmOWIzOGI0NWY0YTY3YmMzNzFmZjk4OTI4Yy90ZXh0cmVnaW9uOmNhNDUwMmY5YjM4YjQ1ZjRhNjdiYzM3MWZmOTg5MjhjXzM1NDA_489fb416-4961-4b8f-bb17-42514469ffc7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Yes</ix:nonnumeric></span></ix:nonnumeric></span> ☒ No ☐ </span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="dei:EntityInteractiveDataCurrent" id="fact-identifier-32" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8xNjYvZnJhZzpjYTQ1MDJmOWIzOGI0NWY0YTY3YmMzNzFmZjk4OTI4Yy90ZXh0cmVnaW9uOmNhNDUwMmY5YjM4YjQ1ZjRhNjdiYzM3MWZmOTg5MjhjXzM1MzM_d3bb7bc2-c276-435c-9b3d-75d64773602e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="dei:EntityInteractiveDataCurrent" id="fact-identifier-33" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8xNjYvZnJhZzpjYTQ1MDJmOWIzOGI0NWY0YTY3YmMzNzFmZjk4OTI4Yy90ZXh0cmVnaW9uOmNhNDUwMmY5YjM4YjQ1ZjRhNjdiYzM3MWZmOTg5MjhjXzM1MzM_e349d759-e732-48f4-bc68-082ef84fe230" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Yes</ix:nonnumeric></span></ix:nonnumeric></span> ☒  No ☐</span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:22.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.727%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">☐</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">☐</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="fact-identifier-34" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8xNjYvZnJhZzpjYTQ1MDJmOWIzOGI0NWY0YTY3YmMzNzFmZjk4OTI4Yy90YWJsZTo0NmM3NjE4OTI2ZTY0YzA4YjdmNGMxYWFhODhjMTFjOC90YWJsZXJhbmdlOjQ2Yzc2MTg5MjZlNjRjMDhiN2Y0YzFhYWE4OGMxMWM4XzEtMC0xLTEtMTYzNTE_3e50dcae-cbce-4e24-a22f-44874fd0f5be" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Non-accelerated filer</ix:nonnumeric></span></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">☒</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="fact-identifier-35" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8xNjYvZnJhZzpjYTQ1MDJmOWIzOGI0NWY0YTY3YmMzNzFmZjk4OTI4Yy90YWJsZTo0NmM3NjE4OTI2ZTY0YzA4YjdmNGMxYWFhODhjMTFjOC90YWJsZXJhbmdlOjQ2Yzc2MTg5MjZlNjRjMDhiN2Y0YzFhYWE4OGMxMWM4XzEtMy0xLTEtMTYzNTE_3a790fcb-9455-41aa-9fbd-e842a46fd4b1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">☒</ix:nonnumeric></span></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="fact-identifier-36" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8xNjYvZnJhZzpjYTQ1MDJmOWIzOGI0NWY0YTY3YmMzNzFmZjk4OTI4Yy90YWJsZTo0NmM3NjE4OTI2ZTY0YzA4YjdmNGMxYWFhODhjMTFjOC90YWJsZXJhbmdlOjQ2Yzc2MTg5MjZlNjRjMDhiN2Y0YzFhYWE4OGMxMWM4XzItMy0xLTEtMTYzNTE_5aa71477-5b0f-4a24-b665-3e8a40208738" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">☐</ix:nonnumeric></span></span></td><td colspan="3" style="padding:0 1pt"></td></tr></tbody></table></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">☐</span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox" id="fact-identifier-37" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8xNjYvZnJhZzpjYTQ1MDJmOWIzOGI0NWY0YTY3YmMzNzFmZjk4OTI4Yy90ZXh0cmVnaW9uOmNhNDUwMmY5YjM4YjQ1ZjRhNjdiYzM3MWZmOTg5MjhjXzM1NDE_7a6e5ca3-2f95-4e05-aee1-8923580d3be9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox" id="fact-identifier-38" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8xNjYvZnJhZzpjYTQ1MDJmOWIzOGI0NWY0YTY3YmMzNzFmZjk4OTI4Yy90ZXh0cmVnaW9uOmNhNDUwMmY5YjM4YjQ1ZjRhNjdiYzM3MWZmOTg5MjhjXzM1NDE_97b3cfbb-44f9-4fc8-ac30-9a60a096a609" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">☐</ix:nonnumeric></span></ix:nonnumeric></span></span></div><div style="margin-top:7pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Yes <span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="fact-identifier-39" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8xNjYvZnJhZzpjYTQ1MDJmOWIzOGI0NWY0YTY3YmMzNzFmZjk4OTI4Yy90ZXh0cmVnaW9uOmNhNDUwMmY5YjM4YjQ1ZjRhNjdiYzM3MWZmOTg5MjhjXzM1NDU_735674b8-25e8-4f82-874c-befeffdc94fa" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="fact-identifier-40" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8xNjYvZnJhZzpjYTQ1MDJmOWIzOGI0NWY0YTY3YmMzNzFmZjk4OTI4Yy90ZXh0cmVnaW9uOmNhNDUwMmY5YjM4YjQ1ZjRhNjdiYzM3MWZmOTg5MjhjXzM1NDU_75a2ee58-4db4-47ca-aac2-eae2f6e319ae" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">☐</ix:nonnumeric></span></ix:nonnumeric></span> No ☒ </span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The aggregate market value of the voting and non-voting stock held by non-affiliates of the registrant, based upon the closing sale price of the registrant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">’s</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> common stock on June&nbsp;30, 2021, as reported on The Nasdaq Capital Market, was $<span><ix:nonfraction unitref="usd" contextref="ia7070bb639334130a8409ffe339a5e23_I20210630" decimals="-5" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-41" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8xNjYvZnJhZzpjYTQ1MDJmOWIzOGI0NWY0YTY3YmMzNzFmZjk4OTI4Yy90ZXh0cmVnaW9uOmNhNDUwMmY5YjM4YjQ1ZjRhNjdiYzM3MWZmOTg5MjhjXzI3MDc_bdc10254-d236-4a66-9373-1f094ff3105c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">66.3</ix:nonfraction></span> million. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Shares of common stock held by each executive officer and director and by each person who owns 10% or more of the outstanding common stock have been excluded in that such persons may be deemed to be affiliates. This determination of affiliate status is not necessarily a conclusive determination for other purposes.</span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of March&nbsp;3, 2022, there were <span><ix:nonfraction unitref="shares" contextref="i21044c37daf646e383d7678e3b757019_I20220303" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-42" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8xNjYvZnJhZzpjYTQ1MDJmOWIzOGI0NWY0YTY3YmMzNzFmZjk4OTI4Yy90ZXh0cmVnaW9uOmNhNDUwMmY5YjM4YjQ1ZjRhNjdiYzM3MWZmOTg5MjhjXzMwNDg_52243eb3-0e58-4b3c-9dc8-5b055d5edcf4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">119,377,286</ix:nonfraction></span> shares of the registrant’s common stock outstanding.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="fact-identifier-43" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8xNjYvZnJhZzpjYTQ1MDJmOWIzOGI0NWY0YTY3YmMzNzFmZjk4OTI4Yy90ZXh0cmVnaW9uOmNhNDUwMmY5YjM4YjQ1ZjRhNjdiYzM3MWZmOTg5MjhjXzM1NDI_377c30d0-442e-475d-88ef-fdbab6ab2a39" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Portions of the registrant’s definitive proxy statement relating to its&nbsp;2022&nbsp;annual meeting of shareholders (the “2022&nbsp;Proxy Statement”) are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. The&nbsp;2022&nbsp;Proxy Statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.</ix:nonnumeric></span></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div></div></div><div id="ie1e15c78f2af410c8f1490215e82bdbe_169"></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BRICKELL BIOTECH, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM 10-K</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div style="text-align:center"><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:14.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:68.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.734%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_172" tabindex="18">PART I</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_175" tabindex="18">ITEM 1.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_175" tabindex="18">Business</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_175" tabindex="18">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_139" tabindex="18">ITEM 1A.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_139" tabindex="18">Risk Factors</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_139" tabindex="18">24</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_178" tabindex="18">ITEM 1B.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_178" tabindex="18">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_178" tabindex="18">57</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_181" tabindex="18">ITEM 2.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_181" tabindex="18">Properties</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_181" tabindex="18">57</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_136" tabindex="18">ITEM 3.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_136" tabindex="18">Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_136" tabindex="18">57</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_151" tabindex="18">ITEM 4.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_151" tabindex="18">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_151" tabindex="18">57</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_184" tabindex="18">PART II</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_187" tabindex="18">ITEM 5.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_187" tabindex="18">Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_187" tabindex="18">58</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_190" tabindex="18">ITEM 6.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_190" tabindex="18">[Reserved]</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_190" tabindex="18">58</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_103" tabindex="18">ITEM 7.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_103" tabindex="18">Management’s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_103" tabindex="18">58</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_121" tabindex="18">ITEM 7A.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_121" tabindex="18">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_121" tabindex="18">74</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_193" tabindex="18">ITEM 8.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_193" tabindex="18">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_193" tabindex="18">75</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_199" tabindex="18">ITEM 9.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_199" tabindex="18">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_199" tabindex="18">101</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_127" tabindex="18">ITEM 9A.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_127" tabindex="18">Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_127" tabindex="18">101</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_154" tabindex="18">ITEM 9B.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_154" tabindex="18">Other Information</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_154" tabindex="18">102</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_2224" tabindex="18">ITEM 9C.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_2224" tabindex="18">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_2224" tabindex="18">102</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_202" tabindex="18">PART III</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_205" tabindex="18">ITEM 10.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_205" tabindex="18">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_205" tabindex="18">103</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_208" tabindex="18">ITEM 11.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_208" tabindex="18">Executive Compensation</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_208" tabindex="18">103</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_211" tabindex="18">ITEM 12.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_211" tabindex="18">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_211" tabindex="18">103</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_214" tabindex="18">ITEM 13.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_214" tabindex="18">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_214" tabindex="18">103</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_217" tabindex="18">ITEM 14.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_217" tabindex="18">Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_217" tabindex="18">103</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_220" tabindex="18">PART IV</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_157" tabindex="18">ITEM 15.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_157" tabindex="18">Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_157" tabindex="18">104</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_223" tabindex="18">ITEM 16.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_223" tabindex="18">Form 10-K Summary</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_223" tabindex="18">107</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_226" tabindex="18">SIGNATURES</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_226" tabindex="18">108</a></span></div></td></tr></tbody></table></div><div><span><br></span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="ie1e15c78f2af410c8f1490215e82bdbe_13"></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISK FACTORS SUMMARY</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business, financial condition, and operating results may be affected by a number of factors, whether currently known or unknown. Any one or more of such factors could directly or indirectly cause our actual results of operations and financial condition to vary materially from past or anticipated future results of operations and financial condition. Any of these factors, in whole or in part, let alone combined with any of the others, could materially and adversely affect our business, financial condition, results of operations, and stock price. We have provided a summary of some of these risks below, with a more detailed explanation of those and other risks applicable to the Company in Part I, Item 1A. “Risk Factors” in this Annual Report. </span></div><div style="margin-bottom:12pt;padding-left:10.8pt;text-align:justify;text-indent:-10.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.3pt">Our business depends on the successful continued financing, clinical development, regulatory approval, and commercialization of our pipeline assets.</span></div><div style="margin-bottom:12pt;padding-left:10.8pt;text-align:justify;text-indent:-10.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.3pt">Clinical drug development for our pipeline assets is expensive, time-consuming, and uncertain. Specifically, with BBI-02, our lead DYRK1A inhibitor candidate, for which a Phase 1 trial in Canada is planned for the second quarter of 2022, we may not be able to obtain approval from Health Canada to start the trial or could be delayed in obtaining such approval. Any data resulting from such trial may not be favorable for further development.</span></div><div style="margin-bottom:12pt;padding-left:10.8pt;text-align:justify;text-indent:-10.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.3pt">Kaken Pharmaceutical Co., Ltd. (“Kaken”) substantially controls the development and commercialization of sofpironium bromide in Japan and certain other Asian countries and may make decisions regarding product development, regulatory strategy, and commercialization that may not be in our best interests. Kaken may be unable to secure an appropriate local business partner (if desirable) and/or obtain approval of the drug in the ex-Japan Asian markets over which it has rights. Kaken also provides certain support to us for our United States (“U.S.”) new drug application (“NDA”) submission and potential launch of sofpironium bromide.</span></div><div style="margin-bottom:12pt;padding-left:10.8pt;text-align:justify;text-indent:-10.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.3pt">Even if sofpironium bromide obtains regulatory approval outside Japan, and despite our partner Kaken launching the drug as ECCLOCK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Japan in 2020, it may fail to achieve the broad degree of physician and patient adoption and use necessary for commercial success.</span></div><div style="margin-bottom:12pt;padding-left:10.8pt;text-align:justify;text-indent:-10.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.3pt">We currently have limited marketing capabilities and no sales organization. If we are unable to generate adequate financing, establish sales and marketing capabilities on our own or through third parties, or are delayed in establishing these capabilities, we will be unable to successfully commercialize our product candidates, if approved, or generate meaningful product revenue. </span></div><div style="margin-bottom:12pt;padding-left:10.8pt;text-align:justify;text-indent:-10.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.3pt">Major public health issues, and specifically the pandemic caused by the spread of COVID-19 and COVID-19 variants, and the impact as certain markets emerge from the pandemic, especially in terms of constraints on supply chains and human resource availability, and different degrees of success various countries experience in rolling out their vaccine campaigns, could have an adverse impact on our financial condition and results of operations and other aspects of our business and that of our suppliers, contractors, and business partners.</span></div><div style="margin-bottom:12pt;padding-left:10.8pt;text-align:justify;text-indent:-10.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.3pt">We may never obtain regulatory approval to commercialize any of our product candidates in the U.S., or anywhere else in the world other than Japan for sofpironium bromide, and any products approved for sale will be subject to continued regulatory review and compliance obligations and there could be further restrictions on post-approval activities, including commercialization efforts. In obtaining regulatory approval, we will need to negotiate an appropriate product label (aka package insert) with the regulators, which will determine the extent of our allowed promotional activities, and this label could be restrictive or prohibitory with regard to subject matter we believe is necessary to maximize the commercial success of the products that are approved.</span></div><div style="margin-bottom:12pt;padding-left:10.8pt;text-align:justify;text-indent:-10.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.3pt">We have sponsored or supported and expect in the future sponsor or support clinical trials for our product candidates outside the U.S. and Japan, and the Food and Drug Administration (“FDA”), Japan’s </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:10.8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceuticals and Medical Devices Agency (“PMDA”), and applicable foreign regulatory authorities may not accept data from such trials; in addition, we may not be allowed alone or with local country business partners to obtain regulatory approval for our product candidates without first conducting clinical trials in each of these other countries.</span></div><div style="margin-bottom:12pt;padding-left:10.8pt;text-align:justify;text-indent:-10.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.3pt">Healthcare reform measures, including price controls or restricted access, could hinder or prevent the commercial success of our product candidates in any country. </span></div><div style="margin-bottom:12pt;padding-left:10.8pt;text-align:justify;text-indent:-10.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.3pt">We rely completely on third-party contractors to supply, manufacture, and distribute clinical drug supplies and to help prepare for a possible launch for our product candidates, including certain sole-source suppliers and manufacturers, both inside and outside the U.S.; we intend to rely on third parties for commercial supply, manufacturing, and distribution, and possibly sales and promotion, if any of our product candidates receive regulatory approval; and we expect to rely on third parties for supply, manufacturing, and distribution of preclinical, clinical, and commercial supplies, and possibly sales and promotion, of any future product candidates. </span></div><div style="margin-bottom:12pt;padding-left:10.8pt;text-align:justify;text-indent:-10.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.3pt">We may not be able to obtain, afford, maintain, enforce, or protect our intellectual property rights covering our product candidates, including sofpironium bromide, our autoimmune and inflammatory portfolio, and related technologies that are of sufficient type, breadth, and term throughout the world.</span></div><div style="margin-bottom:12pt;padding-left:10.8pt;text-align:justify;text-indent:-10.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.3pt">If we fail to comply with our obligations under our intellectual property and related license agreements, we could lose license rights that are important to our business. Additionally, these agreements may be subject to disagreement over contract interpretation, which could narrow the scope of our rights to the relevant intellectual property or technology, or other key aspects of product development and/or commercialization, or increase our financial or other obligations to our licensors. </span></div><div style="margin-bottom:12pt;padding-left:10.8pt;text-align:justify;text-indent:-10.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.3pt">Our failure to regain compliance with continued listing requirements of The Nasdaq Stock Market LLC (“Nasdaq”), including if we are unable to increase the closing bid price of our common stock to at least $1.00 per share for a minimum of 10 consecutive business days by June&nbsp;13, 2022, could result in the delisting of our common stock.</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="ie1e15c78f2af410c8f1490215e82bdbe_172"></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I.</span></div><div><span><br></span></div><div id="ie1e15c78f2af410c8f1490215e82bdbe_10"></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K (“Annual Report”) contains forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements contained in this Annual Report other than statements of historical fact, including statements relating to future financial, business, and/or research and clinical performance, conditions, plans, prospects, trends, or strategies and other such matters, including without limitation, our strategy; future operations; future financial position; future liquidity; future revenue; projected expenses; results of operations; the anticipated timing, scope, design, progress, results, and/or reporting of data of ongoing and future nonclinical and clinical trials; intellectual property rights, including the validity, term, and enforceability of such; the expected timing and/or results of regulatory submissions and approvals; and prospects for commercializing any of Brickell’s product candidates, or research or other business or license collaborations with, or actions of, its partners, including in Japan, South Korea, the U.S., or any other country, or business development activities with other potential partners. The words “may,” “could,” “should,” “might,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict,” “potential,” “will,” evaluate,” “advance,” “aim,” “strive,” “help,” “progress,” “select,” “initiate,” “looking forward,” “promise,” and similar expressions and their variants, are intended to identify forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors. Unless otherwise mentioned or unless the context requires otherwise, all references in this Annual Report to “Brickell,” “Brickell Subsidiary,” “Company,” “we,” “us,” and “our,” or similar references, refer to Brickell Biotech, Inc. and its consolidated subsidiaries.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy and business development activities, pipeline legal status, short-term and long-term business operations and objectives, employees, and financial needs. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described in Part I, Item 1A, “Risk Factors” in this Annual Report,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and under a similar heading in any other periodic or current report we may file with the U.S. Securities and Exchange Commission (the “SEC”) in the future. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge quickly and from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business and operations or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties, and assumptions, the future events and trends discussed in this Annual Report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. We undertake no obligation to revise or publicly release the results of any revision to these forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should read carefully the factors described in Part I, Item 1A, “Risk Factors” in this Annual Report to better understand the risks and uncertainties inherent in our business and underlying any forward-looking statements. You are advised to consult any further disclosures we make on related subjects in our future public filings and on our website.</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span><br></span></div><div id="ie1e15c78f2af410c8f1490215e82bdbe_175"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. BUSINESS</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases. Our pipeline combines several development-stage candidates and a cutting-edge platform with broad potential in autoimmune and inflammatory disorders with a potential best-in-class, late-stage program for the treatment of primary axillary hyperhidrosis. Our executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Taltz</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Gemzar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Prozac</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Cymbalta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Juvederm</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our strategy is to leverage this experience to in-license, acquire, develop, and commercialize innovative pharmaceutical products that we believe can meaningfully benefit patients who are suffering from chronic, debilitating diseases in the foregoing target disease areas and that are underserved by available therapies.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our product development programs: </span></div><div style="text-align:center"><img alt="bbi-20211231_g1.jpg" style="height:267px;margin-bottom:5pt;vertical-align:text-bottom;width:600px" data-src="https://www.sec.gov/Archives/edgar/data/819050/000081905022000016/bbi-20211231_g1.jpg" src="https://www.sec.gov/Archives/edgar/data/819050/000081905022000016/bbi-20211231_g1.jpg"></div><div style="text-align:center"><span><br></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research &amp; Development Programs</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BBI-02: A Potential First-in-Class Oral DYRK1A Inhibitor for the Treatment of Autoimmune and Inflammatory Diseases </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 27, 2021, we entered into a License and Development Agreement (the “Voronoi License Agreement”) with Voronoi Inc. (“Voronoi”), pursuant to which we acquired exclusive, worldwide rights to research, develop, and commercialize BBI-02, a potential first-in-class oral DYRK1A inhibitor, and other novel DYRK1A therapeutics developed from Voronoi’s proprietary kinase inhibitor platform. These novel DYRK1A inhibitors aim to restore immune balance in patients whose immune system has become dysregulated. Based on the promising preclinical efficacy data generated to date with BBI-02, we believe these drug candidates have the potential to offer first-in-class, potent therapies to treat a wide array of debilitating autoimmune and inflammatory diseases.</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead development-stage program, BBI-02, is a Phase 1-ready, highly selective, and orally bioavailable DYRK1A inhibitor that has demonstrated promising results in various preclinical models, including atopic dermatitis (“AD”) and rheumatoid arthritis (“RA”). In these models, BBI-02 showed encouraging decreases in disease severity and reduction of pro-inflammatory cytokines compared to current standard-of-care agents, such as Janus kinase (“JAK”) inhibitors and anti-tumor necrosis factor (“TNF”) biologics. Notably, many current therapies for autoimmune disorders are broadly immunosuppressant, which may lead to severe side effects, such as increased infection risk. Preclinical data have shown BBI-02 to drive regulatory T-cell differentiation while dampening pro-inflammatory T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">H</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17 cells and MyD88/IRAK4-related signaling pathways. Regulatory T cells serve to maintain tolerance and keep the autoreactive, pro-inflammatory T cells in check, thus inhibiting autoimmune disease and limiting chronic inflammation. The myeloid differentiation primary response 88 (“MyD88”) protein is normally spliced into a long form and a short form. DYRK1A inhibition shifts the balance to produce more MyD88 short form, which leads to IRAK4, a protein kinase involved in signaling immune responses from toll-like receptors, not being phosphorylated and so appears to deactivate downstream cascades of certain pro-inflammatory cytokines. Based on current understanding, this inhibition of the release of excess cytokines can be achieved by re-establishing the role of MyD88 short form as a negative regulator of this pathway. Unlike many existing therapies, as well as those currently being investigated, BBI-02 may have the ability to target both the adaptive and innate immune imbalance simultaneously, potentially resulting in, or substantially achieving, restoration of immune homeostasis that, if proven, would represent a paradigm shift in the treatment of certain autoimmune and inflammatory diseases.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are on track to progress BBI-02 into a Phase 1 clinical trial in Canada in the second quarter of 2022. This Phase 1 study is expected to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BBI-02 in both healthy volunteers and subjects with AD and will include a preliminary assessment of efficacy. Part 1A of the Phase 1 trial will be a single ascending dose (“SAD”) assessment in healthy volunteers, Part 1B will be a multiple ascending dose (“MAD”) assessment in healthy volunteers, and Part 2 will compare BBI-02 to placebo in moderate-to-severe AD patients. Topline results from the Phase 1 SAD and MAD trials (Parts 1A and 1B) are anticipated year-end 2022. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BBI-02 is covered by a composition of matter patent issued in the U.S., Japan, China, and other key countries through at least 2038, subject to patent term extensions and adjustments that may be available depending on how this early-stage asset is developed, as well as a pending Patent Cooperation Treaty (“PCT”) application, and other foreign and U.S. applications for BBI-02, as of the date of this Annual Report. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BBI-10: A Covalent STING Inhibitor for the Potential Treatment of Autoinflammatory and Rare Genetic Diseases</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&nbsp;2, 2022, we entered into an Exclusive License Agreement (the “Carna License Agreement”) with Carna Biosciences, Inc. (“Carna”), pursuant to which we acquired exclusive, worldwide rights to research, develop, and commercialize Carna’s portfolio of novel Stimulator of Interferon Genes (“STING”) inhibitors. STING is a well-known mediator of innate immune responses. Excessive signaling through STING is linked to numerous high unmet need diseases, ranging from autoimmune disorders, such as systemic lupus erythematosus and RA, to interferonopathies, which are a set of rare genetic conditions characterized by interferon overproduction and could have orphan drug potential.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">STING is a key component of the cyclic GMP-AMP synthase (“cGAS”)-STING pathway, which plays an important role in the activation of innate immunity. cGAS acts as a DNA sensor, detecting DNA from sources such as invading bacteria, viruses, and cellular debris that can arise from aging and tissue damage. Upon DNA binding, cGAS produces the secondary messenger molecule cyclic GMP-AMP (“cGAMP”), which binds to STING. STING then undergoes the post-translational modification called palmitoylation, a step essential to the activation of STING. Activated STING then in turn activates the recruitment of kinases that phosphorylate IRF3 and IκBα. Phosphorylated IRF3 leads to activation of the type I interferon response, while phosphorylated IκBα activates NFκB and increases the secretion of pro-inflammatory cytokines such as IL-6 and TNFα, resulting in </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inflammation. While the innate immune response is an important defense mechanism, a dysregulated type I interferon response and overproduction of pro-inflammatory cytokines also represents a driving cause for multiple autoimmune and inflammatory diseases. As such, targeting the cGAS-STING pathway may be a novel approach to treating these diseases. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BBI-10, our lead early-stage STING inhibitor candidate, is a novel, potent, and orally available covalent STING inhibitor that specifically targets the palmitoylation site of STING, which allows it to inhibit both wild-type STING and gain-of-function mutants without competing with cGAMP binding, thus deactivating downstream signaling through IRF3 and IκBα and ultimately suppressing inflammation. BBI-10 has exhibited strong proof-of mechanism and a promising profile in initial pharmacokinetics, toxicology, and safety pharmacology studies. In addition, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> studies show that BBI-10 more potently blocks the STING pathway compared to other known STING palmitoylation inhibitors, and that mice treated with BBI-10 demonstrate significant decreases in pro-inflammatory cytokine production following stimulation of STING. Nonclinical development activities for BBI-10 are currently underway, and we expect to conduct experimental characterization of the STING inhibitor library throughout 2022.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For BBI-10, as of the date of this Annual Report, we currently have one pending PCT application and one pending priority patent application. We possess an exclusive license directed to a library of compounds targeting/inhibiting STING, pharmaceutical compositions containing the same, and methods of their use, which are being evaluated. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Next-Generation Kinase Inhibitors: A Cutting-Edge Platform with Potential to Produce Treatments for Autoimmune, Inflammatory, and Other Debilitating Diseases</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Voronoi License Agreement, in August 2021 we acquired exclusive global rights to a cutting-edge platform of next-generation kinase inhibitors, in addition to BBI-02. This library of new chemical entities includes next-generation DYRK1A inhibitors, as well as other molecules that specifically inhibit Leucine Rich Repeat Kinase 2 (“LRRK2”), TTK (also known as Monopolar spindle 1 (Mps1)), and CDC2-like kinase (“CLK”) kinases. A number of these drug candidates have the potential to penetrate the blood brain barrier, presenting an opportunity to address neuroinflammatory conditions of high unmet need such as Down Syndrome, Alzheimer’s Disease, and Parkinson’s Disease, while other peripherally acting novel LRRK2, TTK, and CLK kinase inhibitors could be developed in additional therapeutic areas within autoimmunity, inflammation, and oncology. We are currently engaged in research to identify both brain penetrant and non-brain penetrant new chemical entities from this next-generation kinase inhibitor platform.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compounds from the next-generation kinase inhibitor platform are covered by U.S. and foreign composition of matter patent applications, as well as other applications, that are currently pending in global prosecution based on our exclusive license from Voronoi related to DYRK1A, LRRK2, TTK, and CLK kinases. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sofpironium Bromide</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> A Potential Best-in-Class Investigational Product for the Treatment of Primary Axillary Hyperhidrosis</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sofpironium bromide is a new chemical entity that belongs to a class of medications called anticholinergics. Anticholinergics block the action of acetylcholine, a chemical that transmits signals within the nervous system that are responsible for a range of bodily functions, including activation of the sweat glands. Sofpironium bromide was retrometabolically designed. Retrometabolic drugs are designed to exert their action locally and are potentially rapidly metabolized into a less active form once absorbed into the blood. We have developed sofpironium bromide gel, 15% as a potential best-in-class, self-administered, once daily, topical therapy for the treatment of primary axillary hyperhidrosis, also known as excessive underarm sweating. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hyperhidrosis is a debilitating, life-altering medical condition of sweating beyond what is physiologically required for thermoregulation of the body. Primary axillary hyperhidrosis is believed to be caused by an </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">overactive cholinergic response of the sweat glands and affects an estimated 15.3 million, or 4.8%, of the U.S. population, and 12.76% of the population in Japan. According to a 2016 update on the prevalence and severity of hyperhidrosis in the U.S., axillary hyperhidrosis, which is the targeted first potential indication for sofpironium bromide, is the most common occurrence of hyperhidrosis, affecting approximately 65% of patients, or an estimated 10 million individuals, in the U.S.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sofpironium bromide gel, 15% has completed a U.S. Phase 3 pivotal clinical program (also referred to as our “Cardigan Studies”) for the treatment of primary axillary hyperhidrosis, and sofpironium bromide gel, 5% is approved in Japan for the same indication under the brand name ECCLOCK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Following a pre-NDA meeting with the FDA held in the first quarter of 2022, we remain on track to file an NDA for sofpironium bromide gel, 15% in mid-2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the significant cost to obtain FDA approval of an NDA and, if approved, to launch sofpironium bromide successfully in the U.S., we are presently evaluating different options that include: (i) commercializing sofpironium bromide alone; (ii) partnering with a contract sales organization that has an embedded sales force and other commercial capabilities in which to share costs and profits; or (iii) assigning/selling our rights to sofpironium bromide to another third party pharmaceutical company or investment entity to commercialize on its own. No decision on our strategic direction for sofpironium bromide has been finalized as of the date of this Annual Report.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&nbsp;31, 2021, regarding our patent portfolio for sofpironium bromide, we owned or possessed an exclusive license to 18 issued U.S. patents and 137 patents granted, registered, or allowed in foreign countries, including validations in member states of the European Patent Organisation. For sofpironium bromide, for the same time period, we owned or possessed an exclusive license to eight pending U.S. patent applications, 87 pending foreign patent applications, and two pending international patent applications to be nationalized in 2022, which, if issued, may provide patent term coverage to 2041 in certain cases and countries, and even further subject to availability of patent term extension or adjustments. We continue to prosecute pending applications for sofpironium bromide globally as of the date of this Annual Report. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Phase 3 Pivotal Cardigan Studies</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our U.S. Phase 3 pivotal clinical program for sofpironium bromide gel, 15% was comprised of two pivotal clinical studies. The Cardigan I and Cardigan II studies enrolled 350 subjects and 351 subjects, respectively, who were nine years of age and older with primary axillary hyperhidrosis. The Cardigan Studies were multicenter, randomized, double-blinded, vehicle (placebo)-controlled, evaluating the efficacy and safety of topically applied sofpironium bromide gel, 15%. Subjects applied sofpironium bromide gel, 15% or placebo to their underarms once daily at bedtime for six consecutive weeks, with a two-week post-treatment follow-up. The co-primary efficacy endpoints of the Cardigan Studies included the proportion of subjects achieving at least a 2-point</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">improvement on the Hyperhidrosis Disease Severity Measure-Axillary</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">©</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (HSDM-Ax) scale, a proprietary and validated patient-reported outcome measure, and change in gravimetric sweat production (“GSP”), each from baseline to end of treatment (“EOT”). </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, we reported positive topline results from both Cardigan Studies, which achieved statistical significance on all primary and secondary efficacy endpoints. In the Cardigan I and II Studies, sofpironium bromide gel, 15% was generally well-tolerated. </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardigan Studies Efficacy Results</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">*</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All primary and secondary efficacy endpoints demonstrated statistically significant differences between sofpironium bromide gel, 15% (SB) and vehicle (or placebo), as follows:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:40.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.902%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Cardigan I</span></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Cardigan II</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Co-Primary Efficacy Endpoints</span></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">SB<br>(n=173)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Vehicle<br>(n=177)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">p-value</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">SB<br>(n=180)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Vehicle<br>(n=171)</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">p-value</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:117%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:117%;padding-left:14.5pt">Proportion of subjects achieving at least a 2-point improvement in the HDSM-Ax score from baseline to EOT</span></div></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">49.3%</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">29.4%</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">p&lt;0.001</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">63.9%</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">47.0%</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">p=0.003</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:117%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:117%;padding-left:14.5pt">Change in GSP from baseline to EOT (in mg)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-129.5</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-99.3</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">p=0.002</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-145.9</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-131.7</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">p=0.030</span></td></tr></tbody></table></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:40.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.902%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Cardigan I</span></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Cardigan II</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Secondary Efficacy Endpoints</span></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">SB<br>(n=173)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Vehicle<br>(n=177)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">p-value</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">SB<br>(n=180)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Vehicle<br>(n=171)</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">p-value</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:117%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:117%;padding-left:14.5pt">Proportion of subjects achieving at least a 1-point improvement in the HDSM-Ax score from baseline to EOT</span></div></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">82.8%</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">69.5%</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">p=0.005</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">89.9%</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">80.8%</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">p=0.020</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:117%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:117%;padding-left:14.5pt">Proportion of subjects achieving at least a 2‑point improvement in the HDSM-Ax score and at least a 70% reduction in GSP from baseline to EOT</span></div></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">32.1%</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.2%</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">p&lt;0.0001</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">35.5%</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">21.4%</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">p=0.006</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:117%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:117%;padding-left:14.5pt">Proportion of subjects achieving at least a 1‑point improvement in the HDSM-Ax score and at least a 50% reduction in GSP from baseline to EOT</span></div></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">54.3%</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">33.3%</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">p&lt;0.001</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">68.7%</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">54.6%</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">p=0.014</span></td></tr></tbody></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">* Intent-to-Treat analysis population</span></div><div style="text-align:justify"><span><br></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardigan Studies Safety Results </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the Cardigan Studies, sofpironium bromide gel, 15% was generally well-tolerated. The Treatment-Emergent Adverse Events (“TEAEs”) were mild or moderate in severity and transient in nature. Overall, 89% of patients who were randomized to sofpironium gel, 15% in the studies completed the full six weeks of treatment. Common adverse events (incidence ≥2%) observed in the sofpironium bromide gel, 15% treatment group in the Cardigan I and II studies were dry mouth (11.6%, 17.2%), blurred vision (5.2%, 11.7%), application site pain (6.4%, 10.0%), application site erythema (5.2%, 7.8%), mydriasis (7.5%, 5.0%), application site pruritis (6.4%, 2.2%), application site dermatitis (5.8%, 5.6%), urinary retention (1.2%, 3.3%), application site irritation (1.2%, 3.3%), dry eye (0.6%, 3.3%), headache (1.2%, 2.2%), constipation (0.6%, 2.2%) and urinary hesitation (0.6%, 2.2%), respectively. Five (2.9%) and nine (5.0%) subjects who received sofpironium bromide gel, 15%, discontinued the Cardigan I and II studies, respectively, due to a TEAE. No treatment-related serious adverse events were reported.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration with Kaken in Asia</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our License, Development, and Commercialization Agreement with Kaken, dated March 31, 2015 (as amended, the “Kaken Agreement”), we and Kaken have completed multiple clinical trials of sofpironium bromide gel involving over 1,690 subjects in the U.S. and Japan. These trials evaluated the potential safety, tolerability, pharmacokinetics, and efficacy of sofpironium bromide gel in adult and pediatric patients with primary axillary hyperhidrosis and healthy adult subjects. </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, Kaken received regulatory approval in Japan to manufacture and market sofpironium bromide gel, 5% under the brand name ECCLOCK for the once-daily treatment of primary axillary hyperhidrosis. Japan is the first country to approve sofpironium bromide, which also marks the first approval of a topical prescription product for the treatment of primary axillary hyperhidrosis in Japan. This approval was based on the results of Kaken’s Japanese pivotal Phase 3 registration study of sofpironium bromide gel, 5% in 281 patients with primary axillary hyperhidrosis. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, Kaken launched commercial sales of ECCLOCK in Japan. This marked the first commercialization of sofpironium bromide for any indication worldwide. Under the Kaken Agreement, we are entitled to receive commercial milestone payments, as well as tiered royalties based on a percentage of net sales of ECCLOCK in Japan. As a result, beginning in the fourth quarter of 2020, we have recognized royalty revenue earned on a percentage of net sales of ECCLOCK in Japan. In addition to Japan, Kaken has rights to develop and commercialize sofpironium bromide in South Korea, China, and certain other Asian countries, and we are entitled to receive royalties based on a percentage of Kaken’s net sales in these countries.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our industry is highly competitive and subject to rapid and significant change. While we believe that our team’s extensive pharmaceutical development and commercialization experience, scientific knowledge, and global industry relationships provide us with competitive advantages, we face competition from other pharmaceutical and biotechnology companies, specialty pharmaceutical companies, generic drug companies, over-the-counter (“OTC”) companies, academic institutions, government agencies, and research institutions. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our competitors have significantly greater financial, technical, and human resources than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated amongst a smaller number of our competitors. Our success will be based in part on our ability to identify, develop, and manage a patented portfolio of product candidates that are safer and more effective than competing products.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in large part upon our ability to secure proprietary protection for our products and technologies, including those in development, and to operate without infringing the proprietary rights of others. We seek to avoid the latter by monitoring patents and publications that may affect our business, and to the extent we identify such threats, evaluate and take appropriate courses of action. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents extend for varying periods according to the date of patent filing or grant, applicable laws allowing for patent term extension, and the legal term of patents in various countries where patent protection is obtained. The actual protection afforded by a patent can vary from country to country and depends on the type of patent, the scope of its coverage, and the availability of legal remedies in the country. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also intend to use regulatory exclusivity (also called data package exclusivity), or depending on eligibility, orphan drug designation, as a means of acquiring intellectual property protections that are separate and distinct to patents as appropriate for eligible pipeline candidates. These kinds of rights involve being given exclusivity for varying periods of time depending on the country to incentivize innovators who invest significant funds in and conduct clinical trials to produce necessary data to demonstrate a drug is safe and effective for its intended use(s) and, as such, the data package in an NDA for the FDA (or similar regulatory filings in other countries) should receive some degree of protection even if no patent is available, or exclusivity given to produce a treatment for a disease that otherwise would not realistically be invested in without such incentive. In addition, there are other forms of intellectual property protection we may seek worldwide, including but not limited to trademarks, copyrights, trade secrets, pediatric exclusivity and the like, where available and appropriate for our business interests.</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We further protect our proprietary information by requiring our directors, officers, employees, consultants, contractors, and other advisors to execute nondisclosure and assignment of invention agreements upon commencement of their respective employment or engagement. Agreements with our employees also prevent them from bringing the proprietary rights of third parties to our company without adequate permission to do so. In addition, we require confidentiality or service agreements from third parties that receive our confidential information or materials. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We aim to take advantage of a broad range of the intellectual property rights that are available to us and believe that this comprehensive approach will provide us with proprietary exclusive positions for our product candidates, where available. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">In-Licensing and Other Agreements</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exclusive License and Development Agreement with Carna</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&nbsp;2, 2022, we entered into the Carna License Agreement with Carna, pursuant to which we acquired exclusive, worldwide rights to research, develop, and commercialize </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Carna’s portfolio of novel STING inhibitors.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In accordance with the terms of the Carna License Agreement, in exchange for the licensed rights, we made a one-time cash payment of $2.0 million. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Carna License Agreement provides that we will make success-based payments to Carna of up to $258.0 million in the aggregate contingent upon achievement of specified development, regulatory, and commercial milestones. Further, the Carna License Agreement provides that we will pay Carna tiered royalty payments ranging from mid-single digits up to 10% of net sales. All of the contingent payments and royalties are payable in cash in U.S. Dollars. Under the terms of the Carna License Agreement, we will be responsible for, and bear the future costs of, all development and commercialization activities, including patenting, related to all the licensed compounds.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License and Development Agreement with Voronoi</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 27, 2021, we entered into the Voronoi License Agreement with Voronoi, pursuant to which we acquired exclusive, worldwide rights to research, develop, and commercialize BBI-02, a novel, Phase 1-ready, potential first-in-class DYRK1A inhibitor, and other next-generation therapeutics developed from Voronoi’s proprietary kinase inhibitor platform. In accordance with the terms of the Voronoi License Agreement, in exchange for the license rights, we made a one-time payment of $2.5&nbsp;million in cash and issued $2.0 million, or 2,816,901 shares, of our common stock to Voronoi.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to BBI-02, the Voronoi License Agreement provides that we will make payments to Voronoi of up to $211.0 million in the aggregate contingent upon achievement of specified development, regulatory, and commercial milestones. With respect to the next-generation compounds arising from the novel kinase inhibitor platform, we will make payments to Voronoi of up to $107.5 million in the aggregate contingent upon achievement of specified development, regulatory, and commercial milestones. Further, the Voronoi License Agreement provides that we will pay Voronoi tiered royalty payments ranging from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">low-single digits up to</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 10% of net sales of products arising from the in-licensed DYRK1A inhibitor programs and next-generation kinase inhibitor platform. All of the contingent payments and royalties are payable in cash in U.S. Dollars, except for $1.0 million of the development and regulatory milestone payments, which amount is payable in equivalent shares of our common stock. Under the terms of the Voronoi License Agreement, we will </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be responsible for, and bear the future costs of, all development and commercialization activities, including patenting, related to all the licensed compounds.</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amended and Restated License Agreement with Bodor</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, we, together with Brickell Subsidiary and Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor (collectively, “Bodor”) entered into an amended and restated license agreement (the “Amended and Restated License Agreement”), which supersedes the License Agreement, dated December 15, 2012, entered into between Brickell Subsidiary and Bodor, as amended by Amendment No. 1 to License Agreement, effective as of October 21, 2013, and Amendment No. 2 to License Agreement, effective as of March 31, 2015.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended and Restated License Agreement retains with us a worldwide, exclusive license to develop, manufacture, market, sell, and sublicense products containing the proprietary compound sofpironium bromide based upon the patents referenced in the Amended and Restated License Agreement for a defined field of use. As of December&nbsp;31, 2021, under the original License Agreement and the Amended and Restated License Agreement, we had remaining obligations to pay Bodor (i) a royalty on sales of product outside Kaken’s territory, including a low single-digit royalty on sales of certain product not covered by the patent estate licensed from Bodor; (ii) approximately 50 to 55% of all royalties we receive from Kaken for sales of product within its territory; (iii) a percentage of non-royalty sublicensing income we receive from Kaken or other sublicensees; and (iv) up to an aggregate of $0.8 million (plus an additional $0.1 million for approvals of additional products) in cash payments and $1.0 million of shares of our common stock upon the achievement of certain regulatory milestones. Under the terms of the Amended and Restated License Agreement, we made a $0.5 million milestone payment to Bodor following the closing of a public offering in June 2020 and accrued an additional $1.0 million related to our plan to initiate our U.S. Phase 3 pivotal program in the fourth quarter of 2020.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AnGes Collaboration Agreement</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we entered into a collaboration agreement with AnGes, Inc. (“AnGes”) relating to the development and potential commercialization of AnGes’ proprietary investigational adjuvanted plasmid DNA vaccine intended to prevent COVID-19. While AnGes has conducted a Phase 1/2 study and a Phase 2/3 clinical study with its vaccine candidate in Japan, many other COVID-19 vaccines are already approved or have received emergency use authorization from regulatory authorities, and the demand for new vaccines may be limited. As a result, at this time, our agreement with AnGes is not a strategic priority for us.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing and Supply</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently contract with third parties for the manufacture of drug substances and drug products for use in nonclinical and clinical studies, and would expect to do so for any potential future commercial supply, and we intend to continue to do so in the future. To our knowledge, all of our clinical drug substance and drug product manufacturing activities are in compliance with current good manufacturing practice (“cGMP”) and other applicable laws. We have assembled a team of experienced employees and consultants to provide the necessary technical, quality, and regulatory oversight over the contract manufacturing organizations (“CMOs”) with which we contract. We rely on third-party cGMP manufacturers for scale-up and process development work and to produce sufficient quantities of development product candidates for use in nonclinical and clinical studies. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FDA Drug Approval Process</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., prescription human drugs are subject to extensive regulation by the FDA. The Federal Food, Drug, and Cosmetic Act and other federal and state statutes and regulations govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, advertising, promotion and marketing, distribution, post-approval monitoring and reporting, sampling and import and export of pharmaceutical products, which apply to our pipeline of products. Failure to comply with applicable U.S. </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requirements may subject a company to a variety of administrative or judicial sanctions, such as FDA refusal to approve pending NDAs, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties, corporate integrity agreements, and criminal prosecution. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical product development for a new product or certain changes to an approved product in the U.S. typically involves nonclinical laboratory and animal tests, the submission to the FDA of an Investigational New Drug Exemption (“IND”), which must become effective before clinical testing may commence, and adequate and well-controlled clinical trials to establish the safety and effectiveness of the drug for each indication for which FDA approval is sought. In addition, other tests on the chemistry, manufacturing, and controls (“CMC”) of producing the drug and its various formulations to establish the shelf life, stability, storage conditions, and quality parameters and specifications must be conducted, submitted, and approved by the FDA. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Satisfaction of FDA pre-market approval requirements typically takes many years at significant cost and the actual time required may vary substantially based upon the type, complexity, and novelty of the product or disease. Nonclinical tests include laboratory evaluation of product chemistry, formulation, and toxicity, as well as animal trials to assess the characteristics and potential safety and efficacy of the product. The conduct of the nonclinical tests must comply with federal regulations and requirements, including current good laboratory practice (“GLP”) regulation. The results of nonclinical testing are submitted to the FDA as part of an IND along with other information, including information about product CMC described above and a proposed clinical trial protocol. Long-term nonclinical tests, such as animal tests of reproductive toxicity and carcinogenicity, may continue after the IND is submitted. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A 30-day waiting period after the submission of each IND is required prior to the commencement of clinical testing in humans. If the FDA has neither commented on nor questioned the IND within this 30-day period, the IND is considered in effect, and the clinical trial proposed in the IND may begin. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials involve the initial administration of the investigational new drug to healthy subjects or patients, with subsequent trials involving patients with the disease or disorder for which the investigational drug is being studied to treat, all under the supervision of qualified physician investigator(s). Clinical trials must be conducted (1) in compliance with federal and state regulations; (2) in compliance with current good clinical practice (“cGCP”) regulations, an international standard (as adopted by FDA) meant to protect the rights and health of patients and to define the roles of clinical trial sponsors, administrators, and monitors; and (3) under protocols detailing the objectives of the trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated as well as the actual primary and secondary endpoints of the study to be evaluated. Each protocol involving testing on U.S. patients and subsequent protocol amendments must be submitted to the FDA as part of the IND. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may order the temporary, or permanent, discontinuation of a clinical trial at any time, or impose other sanctions, if it believes that the clinical trial either is not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical trial participants. The study protocol and informed consent information for patients in clinical trials must also be submitted to a local or central institutional review board (“IRB”) (outside the U.S., these are called Ethics Committees) for approval and oversight. An IRB may also require the clinical trial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB’s requirements, or may impose other conditions. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials to support NDAs for marketing approval are typically conducted in three sequential phases, but the phases may overlap or in rarer cases early phases may be skipped depending on the amount and quality of data that exists. In Phase 1, the initial introduction of the drug into healthy human subjects or patients, the drug is tested to assess pharmacological actions, metabolism, pharmacokinetics, adverse effects associated with administration of the investigational drug and, if possible, early evidence of effectiveness. Phase 2 usually involves trials in a limited patient population to determine the effectiveness of the drug for a particular </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">indication, dosage tolerance, and optimum dosage, and to identify common adverse effects and safety risks. If a compound demonstrates evidence of effectiveness and an acceptable safety profile in Phase 2 evaluations, Phase 3 clinical trials are undertaken to obtain the additional information about clinical efficacy and safety in a larger number of patients with the targeted disease or disorder, typically at geographically dispersed clinical trial sites, to permit the FDA to evaluate the overall benefit-risk relationship of the drug and to provide adequate information for the labeling of the drug. In most cases, the FDA requires two adequate and well-controlled prospective Phase 3 clinical trials with statistically significant results to demonstrate the efficacy of the drug by comparing a treatment arm against a control (placebo or best supportive care) arm. A single Phase 3 clinical trial with other confirmatory evidence may be sufficient in limited instances for FDA registration where the study is a large multicenter trial demonstrating internal consistency and a statistically very persuasive finding of an effect on mortality, irreversible morbidity, or prevention of a disease with a potentially serious outcome and confirmation of the result in a second trial would be practically impossible or ethically problematic. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After completion of required clinical testing, applicable law requires that an NDA be prepared and submitted to the FDA. We have completed all FDA-required clinical trials of sofpironium bromide for the treatment of primary axillary hyperhidrosis that are expected to be part of an NDA submission by us to the FDA. In the first quarter of 2022, we held a pre-NDA meeting with the FDA, in which we discussed our plans for the content and organization of the NDA. The FDA provided comments and recommendations on the data to be included in the NDA. We agreed with the FDA’s suggestions and are on track to file an NDA for sofpironium bromide in mid-2022 consistent with the outcome of the pre-NDA meeting.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDA approval of an NDA is required before marketing of the product may begin in the U.S., which will be the case for sofpironium bromide, as well for any other pipeline products being developed by us. The NDA must include the results of all nonclinical, clinical, and other testing and a compilation of data relating to the product’s efficacy, safety, quality, and manufacturing. The cost of preparing and submitting an NDA is substantial. The submission of most NDAs is additionally subject to a substantial application user fee, and the manufacturer and sponsor under an approved NDA are also subject to annual product and establishment user fees. These fees are typically increased annually. In the case of sofpironium bromide, payment of a user fee is not expected to be required for filing of an initial NDA, because FDA guidance waives, or reduces, user fees for, among other things, a small business applicant, like us, submitting its first NDA. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has 60 calendar days from its receipt of an NDA submission to determine whether the application will be accepted for filing based on the agency’s threshold determination that it is sufficiently complete to permit substantive review. Once the submission is accepted for filing, the FDA begins an in-depth review. The FDA has agreed with Congress to certain performance goals in the review of NDAs. Priority review can be applied to drugs that treat a serious condition and, if approved, would provide a significant improvement in safety or effectiveness. In addition, the FDA provides an accelerated approval mechanism applied to investigational drugs for serious or life-threatening diseases. Sofpironium bromide is not eligible for priority review or accelerated approval, based on the present criteria. The review process for both standard and priority review may be extended by the FDA for three additional months to consider certain late-submitted information, or information intended to clarify information already provided in the submission. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA also may refer applications for novel drug products, or drug products that present difficult questions of safety or efficacy, to an advisory committee, typically a panel that includes independent clinicians and other experts in the targeted disease, for review, evaluation, and a recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations. It is not known at this time whether the FDA will require an advisory committee for review of any NDA that may be submitted for sofpironium bromide, and that decision will be made by the FDA during the NDA review. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before approving an NDA, the FDA will typically inspect one or more of the sponsor’s clinical sites to assure compliance with cGCPs. Additionally, the FDA will generally inspect the facility or the facilities at which the </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">drug is manufactured. As of the date of this Annual Report, it is not known what, if any, inspections the FDA may require related to the NDA for sofpironium bromide. The FDA will not approve an investigational product unless compliance with cGMP is satisfactory and the NDA contains data sufficient to support the labeled shelf life and to demonstrate that the drug can be manufactured reliably in a stable, controlled manner.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the FDA evaluates the NDA and potentially the manufacturing facilities, it issues either an approval letter or a complete response letter. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing, or information in order for the FDA to reconsider the application. If, or when, those deficiencies have been addressed to the FDA’s satisfaction in a resubmission of the NDA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of information required. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An approval letter authorizes commercial marketing of the drug in the U.S. with specific prescribing information for specific indications and may contain certain post-marketing requirements, including additional surveillance of how the drug is used. The approval letter may contain safety information that limits the ability of the drug to be marketed (e.g., black box warning; although these are not expected for sofpironium bromide) or contains contraindications, warnings, and/or precautions that limit the potential of the drug’s desirability (these are standard for most approved drugs). As another potential condition of NDA approval, the FDA may require a risk evaluation and mitigation strategy (“REMS”) for drugs that are effective but also have potentially significant safety concerns. REMS can include medication guides, communication plans for healthcare professionals, and elements to assure safe use (“ETASU”). ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the use of patient registries. The requirement for a REMS can materially affect the potential market and profitability of the drug. At the pre-NDA meeting held in the first quarter of 2022, the FDA stated that the need for a REMS is unlikely but a final decision will be made during the NDA review. As stated, product approval may require post-approval testing and surveillance to monitor the drug’s safety or efficacy, which could be substantial. Once granted, product approvals may be withdrawn if compliance by the drug’s sponsor with regulatory standards is not maintained or problems are identified following initial marketing and/or manufacturing by the sponsor or in how the drug is being used in the marketplace.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to some of the conditions established in an approved application, including changes in indications, labeling, or manufacturing processes or facilities, require submission and FDA approval of a new NDA or NDA supplement before the change can be implemented. Also, an NDA supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures and actions in reviewing NDA supplements as it does in reviewing NDAs.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Post-Approval Requirements</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once an NDA is approved, a product will be subject to certain post-approval requirements. For instance, the FDA closely regulates, in part, the post-approval marketing and promotion of drugs, including standards and regulations for direct-to-consumer advertising, social media, off-label promotion, formulary and reimbursement presentations, product sampling, sales force activities including dissemination of peer-reviewed journal articles, marketing items and detailing practices with prescribers, health care practitioner interactions, industry-sponsored scientific and educational activities, other promotional activities involving the internet and to certain other press, publicity and media communications initiated by us, while other parts of the government regulate, among other things, against false claims, foreign corrupt practices, trade sanctions, and anti-kickbacks. States often impose strict legal requirements and prohibitions on a variety of post-approval drug marketing practices. We may market drugs holding an approved NDA only for the permitted indications and in accordance with the provisions of the approved labeling. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse event reporting, pharmacovigilance, and submission of periodic reports are required of the NDA holder following FDA approval of that NDA. The FDA also may require post-marketing testing, known as Phase 4 </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">testing, the aforementioned REMS, and/or surveillance to monitor the effects of an approved product, or the FDA may place conditions on an approval that could restrict the distribution or use of the product, especially in the U.S. In addition, quality-control, drug manufacture, packaging, and labeling procedures must continue to conform to cGMPs after approval. Drug manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies. Registration with the FDA subjects entities to periodic unannounced inspections by the FDA, during which the agency inspects manufacturing facilities to assess compliance with cGMPs. Accordingly, manufacturers must continue to expend time, money, and effort in the areas of production and quality-control to maintain compliance with cGMPs or risk being sanctioned by the FDA from supplying the drugs they manufacture or facing partial or complete product recalls. Regulatory authorities may withdraw product approvals or request such product recalls if a company fails to comply with applicable regulatory standards, if we encounter problems following initial marketing and supply, or if previously unrecognized problems with the drug being prescribed subsequently are discovered. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Hatch-Waxman Act</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In seeking approval for a drug through an NDA, applicants are required to list with the FDA each eligible patent whose claims cover the applicant’s product. Upon approval of a drug, each of the patents listed in the application for the drug is then published in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the “Orange Book.” Drugs listed in the Orange Book can, in turn, be cited by potential generic competitors in support of approval of an abbreviated new drug application (“ANDA”). An ANDA provides for marketing of a drug product that has the same active ingredients in the same strengths and dosage form as the listed drug and has been shown through bioequivalence testing to be therapeutically equivalent to the listed drug. Other than the requirement for bioequivalence testing, ANDA applicants are not required to conduct, or submit results of, nonclinical or clinical studies to prove the safety or effectiveness of their drug product. Drugs approved in this way are commonly referred to as “generic equivalents” to the listed drug and can often be substituted by pharmacists under prescriptions written for the original listed drug and may be required to be switched to from the original listed drug by certain laws or insurance and formulary practices, which can affect the profitability of the original listed drug adversely. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To proceed forward, the ANDA applicant is required to certify to the FDA concerning any patents listed for the approved product in the FDA’s Orange Book. Specifically, the applicant must certify either that (1) the required patent information has not been filed; (2) the listed patent has expired; (3) the listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration; or (4) the listed patent is invalid or will not be infringed by the new product. The ANDA applicant also may elect to submit a section viii statement certifying that its proposed ANDA label does not contain (or carves out) any language regarding the patented method-of-use rather than certify to a listed method-of-use patent. If the applicant does not challenge the listed patents, the ANDA will not be approved until all the listed patents, if valid, claiming the referenced product expire. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A certification that the new product will not infringe the already approved product’s listed patents, or that such patents are invalid, is called a Paragraph IV certification. If the ANDA applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph IV certification to the NDA and patent holders once the ANDA has been accepted for filing by the FDA. The NDA and patent holders may then commence a patent infringement lawsuit in response to the notice of the Paragraph IV certification. The filing of a patent infringement lawsuit within 45 calendar days of the receipt of a Paragraph IV certification automatically prevents the FDA from approving the ANDA until the earlier of (i) 30 months; (ii) expiration of the patent; (iii) settlement of the lawsuit; or (iv) a decision in the infringement case that is favorable to the ANDA applicant. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ANDA also will not be approved until any applicable non-patent exclusivity listed in the Orange Book for the referenced product expires.</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is not known at this time whether and to what extent, or when, an ANDA applicant may emerge with respect to sofpironium bromide, or any other pipeline product in our portfolio, nor have the patents that will be listed in the NDA for sofpironium bromide and later the Orange Book been fully decided or evolved to date. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Exclusivity</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon NDA approval of a new chemical entity (“NCE”), which is a drug that contains no active molecule that has been approved by the FDA in any other NDA, that drug receives five years of marketing exclusivity in the U.S. during which the FDA cannot receive any ANDA seeking approval of a generic version of that drug. Certain changes to a drug, such as the addition of a new indication to the package insert, are associated with a three-year period of exclusivity during which the FDA cannot approve an ANDA for a generic drug that includes the change. Other countries may, and do, have different periods for regulatory exclusivity.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An ANDA may be submitted one year before NCE exclusivity expires if a Paragraph IV certification is filed. If there is no listed patent in the Orange Book, there may not be a Paragraph IV certification and, thus, no ANDA may be filed before the expiration of the exclusivity period; however, it is expected that the NDA for sofpironium bromide will list one or more patents.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent Term Extension</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After NDA approval, owners of relevant drug patents may apply for up to a five-year patent term extension in the U.S. The allowable patent term extension is calculated as half of the drug’s testing phase, the time between IND application and NDA submission, and all of the review phase, the time between NDA submission and approval, up to a maximum of five years. Only one patent may be extended for a regulatory review period for any product. If more than one application for extension of the same patent is filed, the certificate of extension of patent term, if appropriate, will be issued based upon the first filed application for extension. The time can be shortened if the FDA determines that the applicant did not pursue approval with due diligence. The total patent term after the extension may not exceed 14 years. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For patents that might expire during the application phase, the patent owner may request an interim patent extension. An interim patent extension increases the patent term by one year and may be renewed up to four times. For each interim patent extension granted, the post-approval patent extension is reduced by one year. The director of the USPTO must determine that approval of the drug covered by the patent for which a patent extension is being sought is likely. Interim patent extensions are not available for a drug for which an NDA has not been submitted.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is premature to know what, and if any, patent term extension that may be allowed in the U.S. would be at this time, or which patent an extension may be triggered from.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pediatric Information</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Pediatric Research Equity Act, NDAs or supplements to NDAs must contain data to assess the safety and effectiveness of the investigational drug for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration in each pediatric subpopulation for which the drug is safe and effective. The FDA may grant full or partial waivers, or deferrals, for submission of data. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Best Pharmaceuticals for Children Act (“BPCA”) provides NDA holders a six-month extension of any exclusivity, patent or non-patent, for a drug if certain conditions are met. Conditions for exclusivity include the FDA’s determination that information relating to the use of a new drug in the pediatric population may produce health benefits in that population, the FDA making a written request for pediatric studies, and the applicant agreeing to perform, and report on, the requested studies within the statutory timeframe. We are expected to see if we can obtain additional exclusivity based on the pediatric data it obtained and application of the BPCA.</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disclosure of Clinical Trial Information</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sponsors of clinical trials of FDA-regulated products, including drugs, are required to register and disclose certain clinical trial information, including when a clinical trial is initiated (often on www.clintrials.gov); information for certain Company studies, including several involving sofpironium bromide, can be accessed at this website. Information related to the product, patient population, phase, type and scope of investigation, study sites and investigators, and other aspects of the clinical trial is then made public as part of the registration process. Sponsors are obligated also to discuss the results of their clinical trials after completion and industry trade association ethics guidelines require publication of both favorable and unfavorable study results, which can affect the potential market for a drug. Disclosure of the results of these trials can be delayed until the new product or new indication being studied has been approved. Competitors may use this publicly available information to gain knowledge regarding the progress and intent of development programs. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulation Outside of the U.S.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to regulations in the U.S., we will be subject to regulations of other countries governing any clinical trials and commercial sales and distribution of our product candidates, as well as extent, scope, and enforceability of intellectual property rights associated with the product candidate introduced in these other countries. Whether or not we obtain FDA approval for a product, we, or our local partners, must obtain approval by the comparable regulatory authorities of countries outside of the U.S. before it can commence clinical trials in such countries and approval of the regulators of such countries or economic areas, such as the European Union, before we may market products in those countries or areas. Certain countries outside of the U.S. have a process similar to the FDA’s that requires the submission of a clinical trial application (“CTA”), much like the IND prior to the commencement of human clinical trials. In the European Union, for example, a CTA must be submitted to each country’s national health authority and an independent ethics committee, much like the FDA and IRB, respectively. Once the CTA is approved in accordance with a country’s requirements, clinical trial development may proceed. The approval process and requirements governing the conduct of clinical trials, product licensing, pricing, and reimbursement vary greatly from place to place, and the time may be longer or shorter than that required for FDA approval. In some cases, once the investigational drug is approved by a regulatory agency in certain established markets, like the FDA in the U.S., other countries will allow a sponsor to rely on that other country’s approval and extend it, with the same terms and conditions, in the foreign country and this may accelerate the introduction of the drug in foreign markets, where applicable (often called a free sales certificate (“FSC”), or also a CPP, process). </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under European Union regulatory systems, a company may submit marketing authorization applications either under a centralized or decentralized procedure. The centralized procedure, which is compulsory for medicines produced by biotechnology or those medicines intended to treat AIDS, cancer, neurodegenerative disorders, or diabetes and is optional for those medicines which are highly innovative, provides for the grant of a single marketing authorization that is valid for all European Union member states. The decentralized procedure provides for mutual recognition of national approval decisions. Under this procedure, the holder of a national marketing authorization may submit an application to the remaining member states. Within 90 calendar days of receiving the applications and assessments report, each member state must decide whether to recognize the national marketing authorization of a different member state.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of this Annual Report, there is only one regulatory submission pending outside the U.S. for any of our pipeline products, which is for BBI-02.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-Kickback, False Claims Laws</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to FDA restrictions on marketing of pharmaceutical products, several other types of state and federal laws in the U.S. have been applied to restrict or prohibit certain marketing practices in the pharmaceutical industry. These laws include, among others, anti-kickback statutes, false claims statutes and other statutes </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pertaining to healthcare fraud and abuse, and anticorruption. The federal healthcare program anti-kickback statute prohibits, among other things, knowingly and willfully offering, paying, soliciting, or receiving remuneration to induce, or in return for, purchasing, leasing, ordering, or arranging for the purchase, lease or order of any healthcare item or service reimbursable under Medicare, Medicaid, or other federally financed healthcare programs. The Patient Protection and Affordable Care Act, as amended (“PPACA”), amended the intent element of the federal anti-kickback statute so that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers, and formulary managers on the other. Although there are a number of statutory exceptions and regulatory safe harbors protecting certain common activities from prosecution or other regulatory sanctions, the exceptions and safe harbors are drawn narrowly, and practices that involve remuneration intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal false claims laws prohibit any person or entity from, among other things, knowingly presenting, or causing to be presented, a false claim for payment to the federal government, or knowingly making, or causing to be made, a false statement to have a false claim paid. This includes claims made to programs where the federal government reimburses, such as Medicaid, as well as programs where the federal government is a direct purchaser, such as when it purchases off the Federal Supply Schedule. Pharmaceutical and other healthcare companies have been prosecuted under these laws for, among other things, allegedly inflating drug prices they report to pricing services, which in turn were used by the government to set Medicare and Medicaid reimbursement rates, and for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. In addition, certain marketing practices, including off-label promotion, also may violate federal false claims laws. Additionally, PPACA amended the federal healthcare program anti-kickback statute such that a violation of that statute can serve as a basis for liability under certain federal false claims laws. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of U.S. states also have statutes or regulations similar to the federal anti-kickback law and false claims laws, which apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other federal statutes pertaining to healthcare fraud and abuse include the civil monetary penalties statute, which prohibits, among other things, the offer or payment of remuneration to a Medicaid or Medicare beneficiary that the offeror or payor knows or should know is likely to influence the beneficiary to order or receive a reimbursable item or service from a particular supplier, and the healthcare fraud and false statements statutes, which prohibit, among other things, knowingly and willfully executing or attempting to execute a scheme to defraud any healthcare benefit program or obtain by means of false or fraudulent pretenses, representations, or promises any money or property owned by or under the control of any healthcare benefit program in connection with the delivery of or payment for healthcare benefits, items, or services. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Violations of these federal healthcare fraud and abuse laws are punishable in the U.S. by imprisonment, criminal fines, civil monetary penalties, and exclusion from participation in federal healthcare programs. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Federal and State Regulatory Requirements </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Open Payments Rule, the Centers for Medicare &amp; Medicaid Services requires certain manufacturers of prescription drugs to annually collect and report information on payments or transfers of value to certain health care professionals, including physicians, and teaching hospitals, as well as certain ownership and investment interests held by physicians and their immediate family members. Failure to submit required information may result in civil monetary penalties. Other countries require similar reporting, including France and Belgium, if the product is approved and marketed there. In addition, several states now require prescription drug companies to report expenses relating to the marketing and promotion of drug products and to report gifts and payments to individual healthcare practitioners and entities in these states. Other states prohibit various </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other marketing-related activities. Still, other states require the posting of information relating to clinical studies and their outcomes. In addition, California, Connecticut, Nevada, and Massachusetts require pharmaceutical companies to implement compliance programs and marketing codes. Several additional states are considering similar proposals. Some of the state laws are broader in scope than federal laws. Compliance with these laws is difficult and time-consuming, and companies that do not comply with these state laws face civil or other penalties. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coverage and Reimbursement</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of our product candidates, if approved, by us or any potential commercial partners will depend, in part, on the extent to which such products will be covered by third-party payors, such as government healthcare programs, commercial insurance, and managed healthcare organizations. These third-party payors are increasingly limiting coverage or reducing reimbursements for medical products and services. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our products. Sales of any products for which we receive regulatory approval for commercial sale will therefore depend, in part, on the availability of coverage and adequate reimbursement from third-party payors. Third-party payors include government authorities, managed care plans, private health insurers, and other organizations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process for determining whether a third-party payor will provide coverage for a drug typically is separate from the process for setting the price of such product or for establishing the reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the FDA-approved products for a particular indication. A decision by a third-party payor not to cover our product candidates could reduce a physician’s willingness to prescribe our products once approved and have a material adverse effect on our sales, results of operations, and financial condition. Moreover, a third-party payor’s decision to provide coverage for a drug does not imply that an adequate reimbursement rate will be approved. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. Additionally, coverage and reimbursement for products can differ significantly from payor to payor. One third-party payor’s decision to cover a particular medical product or service does not ensure that other payors will also provide coverage for the medical product or service or will provide coverage at an adequate reimbursement rate.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the U.S. government, state legislatures, and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on reimbursement, and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our net revenue and results. Third-party payors are increasingly challenging the prices charged for medical products and services, examining the medical necessity and reviewing the cost-effectiveness of drugs, in addition to questioning safety and efficacy. If these third-party payors do not consider our products to be cost-effective compared to other available therapies, they may not cover our products after FDA approval or, if they do, the level of payment may not be sufficient to allow us to sell our products at a profit.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employees</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&nbsp;31, 2021, we had 16 regular full-time employees. From time to time, we retain independent contractors. None of our employees is represented by a labor union or covered by a collective bargaining agreement. We have not experienced any work stoppages, and we consider our relations with our employees to be excellent. </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate History</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vical Incorporated (“Vical”) was incorporated in Delaware in 1987. On August 31, 2019, the Delaware corporation formerly known as “Vical Incorporated” completed a reverse merger transaction in accordance with the terms and conditions of the Agreement and Plan of Merger and Reorganization, dated June 2, 2019, as further amended on August 20, 2019 and August 30, 2019, by and among Vical, Brickell Biotech, Inc. (“Private Brickell”) and Victory Subsidiary, Inc. (“Merger Sub”), pursuant to which Merger Sub merged with and into Private Brickell, with Private Brickell surviving the merger as a wholly-owned subsidiary of Vical (the “Merger”). Additionally, on August 31, 2019, immediately after the completion of the Merger, the Company changed its name from “Vical Incorporated” to “Brickell Biotech, Inc.” The Company’s common stock is listed on The Nasdaq Capital Market under the trading symbol “BBI” and is represented by CUSIP number 10802T 105.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Information</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters are in Boulder, Colorado, where we occupy facilities totaling approximately 3,000 square feet under a lease agreement that expires in December 2022 and includes two additional three-year renewal options. We use our current facilities primarily for research and development and general and administrative personnel. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report contains references to our trademarks and trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this Annual Report, including logos, artwork, and other visual displays, may appear without the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other companies’ trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other company.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Information about our Executive Officers</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth information concerning our executive officers. Executive officers are elected annually by the Board of Directors and serve at the Board of Directors’ discretion.</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:28.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Name</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Age</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Title</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Robert B. Brown</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">60</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Executive Officer and Director</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Andrew D. Sklawer</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">38</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Operating Officer and Secretary</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Albert N. Marchio, II</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">69</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deepak Chadha</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">52</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Research and Development Officer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Monica Luchi</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">61</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Medical Officer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Jose Breton</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">33</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Controller and Chief Accounting Officer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">David McAvoy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">59</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">General Counsel and Chief Compliance Officer</span></td></tr></tbody></table></div><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Robert B. Brown, Chief Executive Officer and Director</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Brown joined Private Brickell as its Chief Executive Officer and Director in January 2019, after having spent over 30 years at Eli Lilly and Company (NYSE: LLY), where he most recently served as the Chief Marketing Officer and Senior Vice President of Marketing from 2009 through 2018. As Chief Marketing Officer, Mr. Brown was responsible for building and leading marketing capabilities across Eli Lilly and Company’s pharmaceutical business units, including diabetes, oncology, emerging markets, and Lilly-BioMedicines, a business area focused on treatments for debilitating diseases. Prior to his role as Chief Marketing Officer, Mr. Brown held the position of Vice President and Chief Marketing Officer for Lilly USA from 2007 to 2009, in which he partnered with the business units to ensure Eli Lilly and Company continued to </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">develop industry leading marketing capabilities, streamline and improve marketing processes, and transform marketing by building a consumer marketing center of excellence. From 2003 to 2007, Mr. Brown was the executive director of marketing for the Intercontinental region, including responsibility for Europe. As the head marketer for Eli Lilly and Company’s international operations, Mr. Brown was responsible for the marketing of all Eli Lilly and Company’s products outside the U.S. Mr. Brown joined Eli Lilly and Company in 1985, after receiving a B.S. in economics from DePauw University and an M.S. in business administration from Indiana University. Mr. Brown currently serves on the board of trustees of Franklin College.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Andrew D. Sklawer, Co-Founder, Chief Operating Officer, and Secretary</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Sklawer co-founded Private Brickell and has served as its Chief Operating Officer and Secretary since 2009. Prior to 2009, Mr. Sklawer served as the Head of Operations at Concordia Pharmaceuticals, Inc., an oncology drug development company that was acquired by Kadmon Corporation in 2011. Prior to joining Concordia, Mr. Sklawer held various positions at Verid, Inc., a developer of security technology prior to its acquisition by EMC Corporation. Mr. Sklawer holds a B.A. in marketing from the University of Florida and earned his M.B.A. from the University of Miami. Mr. Sklawer currently serves as a board member for StartUp FIU, a Florida International University platform that supports researchers, inventors, innovators, and entrepreneurs to conceive, launch, and scale solutions, is a member of the Advisory Committee of Advancing Innovation in Dermatology Accelerator Fund, and is a board member of the Colorado BioScience Association.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Albert N. Marchio, II, Chief Financial Officer</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Marchio has been with Danforth Advisors since May 2019, providing financial consulting services on a project/interim basis for public (CytomX Therapeutics (CTMX)) and various private life sciences companies. Previously, Mr. Marchio served in various finance and accounting roles at Edge Therapeutics, Inc. (now known as PDS Biotechnology Corporation), a clinical-stage biopharmaceutical company, including Chief Accounting and Administrative Officer from October 2016 to November 2018, Interim Chief Financial Officer from March 2017 to October 2017, Chief Accounting and Operations Officer from March 2014 to October 2016, and Chief Financial Officer from December 2011 through March 2014. Mr. Marchio was a Managing Operating Partner with Three Fields Capital, a multi-strategy healthcare-focused investment firm, and provided consulting services to life science companies through Rockabye Valley Consulting from January 2009 to May 2013. Previously, Mr. Marchio served as the Executive Vice President, Chief Financial Officer of Informed Medical Communications from February 2008 to October 2009, and as the Vice President, Treasurer of MedPointe Pharmaceuticals from 2006 to January 2008. He began his career in life sciences as the Vice President, Treasurer of Alpharma, Inc. from 1992 to 2005. Mr. Marchio holds a B.A. in Economics from Muhlenberg College, an M.B.A. in Professional Accounting from Rutgers Graduate School of Business, and a Post-M.B.A. Certificate in Taxation from Bernard Baruch College of the City University of New York.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deepak Chadha, Chief Research and Development Officer</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Chadha joined Private Brickell in 2016 and has served as its Chief Research and Development Officer and as its Chief Regulatory, Pre-clinical, and Quality Compliance Officer from 2016 to 2018. Mr. Chadha served from 2014 to 2016 as Vice President, Global Regulatory Affairs at Suneva Medical, Inc. (“Suneva”), a medical technology company that develops, manufactures, and commercializes aesthetic products for the dermatology, plastic, and cosmetic surgery markets. During his time at Suneva, Mr. Chadha led the regulatory approval for BELLAFILL</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> dermal filler for acne scar correction and supported the company’s commercial products life cycle management. Prior to joining Suneva, Mr. Chadha worked at Allergan plc (f.k.a. KYTHERA Biopharmaceuticals, Inc.) from 2007 to 2014, where Mr. Chadha led the development of their product, KYBELLA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, from an early clinical phase to an NDA stage, and also supported the ex-U.S. regulatory activities. Mr. Chadha also served as Vice President of Global Regulatory Affairs at Allergan Medical (f.k.a. Inamed Corporation) from 2004 to 2007, where he assisted in building the organization’s Global Regulatory Affairs department and was involved with the approval for JUVEDERM</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Bioenterics</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, LAP-BAND</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Silicone </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">gel-filled breast implants. Mr. Chadha holds a B.S. in pharmaceutical sciences from Berhampur University in Orissa, India, an M.S. in pharmaceutics from Hamdard University in New Delhi, India, and an M.B.A. in international business from California State University, Dominguez Hills.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Monica Luchi, Chief Medical Officer</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. Luchi joined Brickell in 2021 and has served as its Chief Medical Officer. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Monica most recently served from November 2020 to August 2021 as interim Chief Medical Officer and Clinical Development consultant for The Bracken Group, a life sciences provider of highly experienced consultative support for the development of products by pharma, biotech, and companies across a broad spectrum of healthcare industries. Dr. Luchi began her career in an academic practice focused on Rheumatology and Immunology before moving to the pharmaceutical industry. She has held positions of increasing responsibility at Novartis, Incyte, Mesoblast, Immune Pharmaceuticals, Celularity and Sorrento Therapeutics, Inc. in clinical development, translational medicine, and strategic planning, as well as key business development roles. Her experience in the biotech/pharmaceutical industry ranges across all stages of development, from exploratory phase 1 through phase 3, in multiple therapeutic indications, and includes several regulatory filings. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. Luchi earned a B.A, Biology, Health Sciences Policy from University of Maryland, an M.D. from Northeastern Ohio Universities College of Medicine, an M.B.A. from George Washington University, and an Innovation and Entrepreneurship program certificate from Stanford University. Dr. Luchi is a practicing rheumatologist with an adjunct appointment at the University of Pennsylvania. She also serves on the Board of Trustees for the Children’s Village, NYC. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Jose Breton, Controller and Chief Accounting Officer</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Breton joined Private Brickell in 2013 and has served as its Controller and Chief Accounting Officer. Mr. Breton was an auditor from 2014 to 2015 at Deloitte LLP. Mr. Breton began his career in 2012 as a Client Manager at Global Resource Partners, Inc., an accounting and business advisory firm. In this role, Mr. Breton had overall responsibility for clients’ financial reporting, planning and budgeting, systems of internal controls, corporate and benefits accounting, and equity administration. Mr. Breton holds a B.B.A. degree in accounting and finance and a master’s degree in taxation from the University of Miami.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">David McAvoy, General Counsel and Chief Compliance Officer</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. McAvoy joined Private Brickell in 2019 and has served since then as its General Counsel and Chief Compliance Officer. He previously served as General Counsel, Vice President, and Chief Compliance Officer for Endocyte, Inc., a publicly traded nuclear medicine and oncology biotech company that was subsequently acquired by Novartis AG, from 2017 to 2018. Prior to joining Endocyte, Inc., Mr. McAvoy was at Eli Lilly and Company for 27 years serving in various leadership positions, including as General Counsel of Lilly Emerging Markets and in an executive management business role running strategic alliances for the food animal production group at Eli Lilly and Company’s former Elanco Animal Health subsidiary. While at Eli Lilly and Company, Mr. McAvoy was lead counsel for and helped launch several blockbuster medicines, including Prozac</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for depression, Gemzar</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for pancreatic and lung cancers, and ReoPro</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, one of the first interventional cardiology agents. Mr. McAvoy earned a J.D. and M.S. in environmental science from Indiana University and a B.A. in political science from the University of Notre Dame. He serves on the board of directors for The Villages of Indiana, Inc., championing families for abandoned and abused children.</span></div><div style="margin-bottom:12pt;text-align:justify"><span><br></span></div><div id="ie1e15c78f2af410c8f1490215e82bdbe_139"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A. RISK FACTORS</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business, financial condition, and operating results may be affected by a number of factors, whether currently known or unknown, including but not limited to those described below. Any one or more of such factors could directly or indirectly cause our actual results of operations and financial condition to vary </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">materially from past or anticipated future results of operations and financial condition. Any of these factors, in whole or in part, could materially and adversely affect our business, financial condition, results of operations, and stock price. The following information should be read in conjunction with Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and the consolidated financial statements and related notes in Part II, Item 8, “Financial Statements and Supplementary Data” of this&nbsp;Annual Report.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business Operations</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business depends on the successful continued financing, clinical development, regulatory approval, and commercialization of our pipeline assets. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The successful development, regulatory approval, and commercialization of our pipeline assets will require significant additional financing and depend on a number of factors, including but not limited to the following: </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">timely and successful initiation and completion of clinical trials for our product candidate portfolio, which may be significantly costlier than we currently anticipate, especially in a pandemic, and/or produce results that do not achieve the endpoints of the trials or which are ultimately deemed not to be clinically meaningful; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to receive regulatory approval for our proposed clinical trials, including our planned BBI-02 Phase 1 trial in Canada that Health Canada must approve;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether we are required by the FDA or similar foreign regulatory agencies to conduct additional clinical trials, including in the case of sofpironium bromide, beyond the recently completed U.S. Phase 3 pivotal clinical program to support our submission of an NDA with the FDA for that drug candidate;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">achieving and maintaining, and, where applicable, ensuring that our third-party contractors achieve and maintain, compliance with our and their contractual obligations and with all regulatory and legal requirements applicable to them and to our pipeline assets; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ability of third parties with which we contract to manufacture consistently adequate commercial supplies of sofpironium bromide and/or potential clinical trial supplies for development of our other pipeline assets, to remain in good standing with regulatory agencies and to develop, validate, and maintain or supervise commercially viable manufacturing processes that are compliant with FDA-regulated cGMPs and other applicable legal requirements, to hire and retain a sufficient and qualified workforce, and to manage their own supply chain(s) to comply with their contractual obligations to us, which supply chains and workforce availability have been constrained during the ongoing COVID-19 pandemic;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a continued acceptable safety and tolerability profile during clinical development of our pipeline assets and especially following any commercial approval of sofpironium bromide;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ability to obtain favorable labeling for sofpironium bromide through regulators that allows for successful commercialization, given the drug may be marketed only to the extent approved by these regulatory authorities (unlike with most other industries); </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ability to commercialize sofpironium bromide successfully in the U.S. and outside Japan, if approved for marketing, sale, and distribution in such countries and territories, whether alone or in collaboration with Kaken or others; </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ability of Kaken to commercialize sofpironium bromide successfully in Japan now that it has been approved and is being marketed;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance by physicians, insurers and payors, and patients of the quality, benefits, safety, and efficacy of our pipeline assets, if and where approved, including relative to alternative and competing treatments and the next best standard of care;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">existence of a regulatory, pricing and reimbursement, and legal environment conducive to the success of our pipeline assets; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ability to price our pipeline assets to recover our development costs and generate a satisfactory profit margin;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to commercialize sofpironium bromide alone or with other partners, including the ability to raise adequate capital to do so, and/or to find a suitable partner to commercialize sofpironium bromide in lieu of us;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability and our partners’ ability to establish and enforce intellectual property rights in and to our pipeline assets, including but not limited to patents, regulatory exclusivity rights, trademarks, copyrights, and licenses; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to raise capital to commercialize sofpironium bromide and advance our other pipeline assets, which will be limited if our common stock price does not appreciate.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not achieve one or more of these factors, many of which are beyond our reasonable control, in a timely manner or at all, we could experience significant delays or an inability to obtain regulatory approvals or commercialize sofpironium bromide or our other pipeline assets. Although we anticipate submitting an NDA for sofpironium bromide gel, 15% to the FDA in mid-2022, there can be no assurance that it will receive the necessary approvals. If approval is denied or delayed, it would have a material adverse impact on us.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if regulatory approvals are obtained, we may never be able to successfully commercialize sofpironium bromide or any of our other pipeline assets, especially if we attempt to do so without a partner. Accordingly, we cannot assure that we will be able to launch sofpironium bromide in any market or, if we do, that we will be able to generate sufficient revenue from the sale of sofpironium bromide, or any other asset, to continue our business. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical drug development for our pipeline assets is expensive, time-consuming, and uncertain. Specifically, with BBI-02, our lead DYRK1A inhibitor candidate, for which a Phase 1 trial in Canada is planned for the second quarter of 2022, we may not be able to obtain approval from Health Canada to start the trial or could be delayed in obtaining such approval. Any data resulting from such trial may not be favorable for further development.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical development for our pipeline assets is expensive, time-consuming, difficult to design and implement, and its outcome is inherently uncertain. Most product candidates that commence clinical trials are never approved by regulatory authorities for commercialization, and of those that are approved, many do not cover their costs of development or ever generate a profit. In addition, we, any partner with which we currently or may in the future collaborate, the FDA, a local or central institutional review board, or other regulatory authorities, including state and local agencies and counterpart agencies in foreign countries, may suspend, delay, extend, require modifications, or add additional requirements to or terminate our clinical trials at any time. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our pipeline targets autoimmune and inflammatory diseases and is still too early in clinical development to know whether they will progress past Phase 1 clinical trials. In addition, we are required to </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">obtain approval from regulatory authorities to initiate Phase 1 clinical trials, including our planned trial for BBI-02 in Canada in the second quarter of 2022. We may not be able to obtain approval from Health Canada to start the trial, as and when planned or at all. Any data resulting from such trial may not be favorable for further development.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently do not have in place a commercial supply agreement with Kaken or any other party and our inability to execute one in a timely manner could have a material adverse impact on our business even if sofpironium bromide is approved for use by the FDA in the U.S.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At this time, we do not have a commercial supply agreement for drug substance and product components, including the bottles and/or other container requirements, for sofpironium bromide with Kaken or other suppliers, and we may not be able to enter into such an agreement with acceptable terms, on a timely basis, or at all. Our inability to enter into an adequate commercial supply agreement at the right time for sofpironium bromide for the U.S. and other markets outside of Japan and certain other Asian countries would materially impact our business.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Kaken substantially controls the development and commercialization of sofpironium bromide in Japan and certain other Asian countries and may make decisions regarding product development, regulatory strategy, and commercialization that may not be in our best interests. Kaken may be unable to secure an appropriate local business partner (if desirable) and/or obtain approval of the drug in the ex-Japan Asian markets over which it has rights. Kaken also provides certain support to us for our U.S. NDA submission and potential launch of sofpironium bromide.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Kaken Agreement granted Kaken an exclusive license in Japan and certain rights to additional Asian countries to develop and commercialize sofpironium bromide. Under the terms of the Kaken Agreement, as amended, we received an upfront payment, development milestones, and research and development payments and have received and are eligible to receive future milestones and royalties based on a percentage of net sales.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kaken has final decision-making authority for the overall regulatory, development, and commercialization strategy for sofpironium bromide, market access activities, pricing and reimbursement activities, promotion, distribution, packaging, sales, and safety and pharmacovigilance in Japan and certain other Asian countries. In exercising its final decision-making authority in such territories, Kaken may make decisions regarding product development or regulatory strategy based on its determination of how best to preserve and extend regulatory approvals in these territories for sofpironium bromide, which may delay or prevent achieving regulatory approval for sofpironium bromide in Kaken’s territories, as well as by us in the U.S. and the other territories where we maintain exclusive rights. Additionally, Kaken is responsible for conducting certain active pharmaceutical ingredients (“API”) related activities (chemistry, manufacturing, and controls) that will be required for FDA approval in the U.S., and as a result, we are reliant on Kaken to execute successfully, in a timely, compliant, and efficient manner, such activities on our behalf. To the extent Kaken experiences delays and/or difficulties in performing its development activities, this could prevent or cause substantial delays in our ability to seek approval for sofpironium bromide gel in the U.S. and other territories in which we maintain exclusive rights. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September&nbsp;2020, Kaken received approval of an NDA in Japan for the manufacturing and marketing of sofpironium bromide gel, 5% under the brand name ECCLOCK for the treatment of primary axillary hyperhidrosis, and in November 2020, Kaken launched commercial sales of ECCLOCK in Japan. Despite Kaken receiving regulatory approval and commencing commercial activities in Japan, we cannot provide any assurance that an NDA in any other Asian markets will be approved or that regulatory approvals in other Asian countries will occur. We will not receive additional milestone or other payments from Kaken if Kaken does not continue to be successful in its development, regulatory, or commercial activities, if the approval is withdrawn for any reason, or if Kaken is unable to maintain an adequate price for ECCLOCK in Japan.</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely on Kaken to provide us with certain key regulatory information that will be used for our NDA submission to the FDA for sofpironium bromide, and also to supply us with certain components of the finished drug product we will need for any eventual U.S. commercial launch of this drug candidate. Kaken’s inability to meet its requirements for the foregoing would negatively impact our ability to obtain regulatory approval for sofpironium bromide and/or successfully commercialize sofpironium bromide in the U.S.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or any partners with which we may collaborate to market and sell sofpironium bromide are unable to achieve and maintain medical insurance coverage and adequate levels of reimbursement for this late-stage compound following its regulatory approval and usage by patients, our commercial success may be hindered severely. Kaken may not be able to maintain adequate pricing in Japan for sofpironium bromide given that country’s more restrictive price controls than the U.S.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If sofpironium bromide only becomes available by prescription, successful sales by us or by any partners with which we collaborate may depend on managed care approvals and the availability of adequate reimbursement from third-party payors, as patients would then be forced to pay for the drug out-of-pocket if coverage and associated reimbursement are denied. Patients who are prescribed medicine for the treatment of their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their prescription drugs. The availability of coverage and adequate reimbursement from governmental healthcare programs, such as Medicare and Medicaid in the U.S., and private third-party payors is often critical to new product acceptance regardless of how well the product works. Coverage decisions may depend on clinical and economic standards that disfavor new drug products when more established or lower-cost therapeutic alternatives are already available or subsequently become available, even if these alternatives are not as safe and effective or may be affected by the budgets and demands on the various entities responsible for providing health insurance to patients who will use sofpironium bromide. If insurers and payors decide that hyperhidrosis itself is not a disease they are willing to extend coverage to, which could happen if they only think the treatment improves quality of life, then coverage and reimbursement for sofpironium bromide may be denied, or at least severely restricted. In this case, patients would be forced to pay for sofpironium bromide out-of-pocket for cash, which they may not be willing or able to do. Even if we obtain coverage for sofpironium bromide, the resulting reimbursement payment rates might not be adequate or may require co-payments that patients find unacceptably high. Patients may not use sofpironium bromide unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of sofpironium bromide. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the market for sofpironium bromide will depend significantly on access to third-party payors’ drug formularies or lists of medications for which third-party payors provide coverage and reimbursement. The industry competition to be included in such formularies often leads to downward pricing pressures on pharmaceutical companies and there may be time limitations on when a new drug may even be eligible for formulary inclusion. Also, third-party payors may refuse to include sofpironium bromide in their formularies or otherwise restrict patient access to sofpironium bromide when a less costly generic equivalent or other treatment alternative is available in the discretion of the formulary. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party payors, whether foreign or domestic, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs. In the U.S., although private third-party payors tend to follow Medicare and Medicaid practices, no uniform or consistent policy of coverage and reimbursement for drug products exists among third-party payors. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor as well as state to state. Consequently, the coverage determination process is often uncertain and a time-consuming and costly process that must be played out across many jurisdictions and different entities and which will require us to provide scientific, clinical, and health economics support for the use of sofpironium bromide compared to current alternatives and do so to each payor separately, with no assurance that coverage and adequate reimbursement will be obtained and in what amount or time frame.</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, we believe that future coverage and reimbursement likely will be subject to increased restrictions both in the U.S. and in international markets, potentially based on changes in law and/or payor practices. Third-party coverage and reimbursement for sofpironium bromide may not be available or adequate in either the U.S. or international markets, which could harm our business, financial condition, operating results, and prospects. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After receiving regulatory approval in 2020 for ECCLOCK from Japanese regulators, Kaken applied for and received pricing approval in Japan, which is required by law to do before selling. On November 18, 2020, ECCLOCK was placed on Japan’s National Health Insurance drug reimbursement price list. To curb increasing healthcare expenditures, Japanese regulators require a biennial drug price review process. The nature of this review is highly regulated, with downward pricing pressures, and could adversely impact the pricing of ECCLOCK over time in Japan and the resulting royalties payable to us. If Kaken is unable to maintain the current price for ECCLOCK, or is unable to increase the price in future years, this would have a negative impact on sales in Japan.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if sofpironium bromide obtains regulatory approval outside Japan, and despite our partner Kaken launching the drug as ECCLOCK in Japan in 2020, it may fail to achieve the broad degree of physician and patient adoption and use necessary for commercial success.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercial success of sofpironium bromide, if and as approved, will depend significantly on the broad adoption and use of it by physicians and patients for approved indications, and may not be commercially successful even though the drug is shown to be safe and effective. The degree and rate of physician and patient adoption of sofpironium bromide, if approved, especially in the U.S., will depend on a number of factors, including but not limited to: </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patient demand for approved products that treat hyperhidrosis; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to market and sell the drug, including through direct-to-consumer advertising and non-traditional sales strategies;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to manage the ongoing COVID-19 pandemic to supply/manufacture sofpironium bromide commercially, and otherwise market and sell sofpironium bromide while the pandemic continues in effect, and the short- and long-term consequences of such pandemic if and as certain markets improve;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the safety and effectiveness of sofpironium bromide, and ease of use, compared to other available hyperhidrosis therapies, whether approved or used by physicians off-label; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of coverage and adequate reimbursement from managed care plans and other healthcare payors for sofpironium bromide; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of treatment with sofpironium bromide in relation to alternative hyperhidrosis treatments and willingness to pay for sofpironium bromide, if approved, on the part of patients; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">overcoming physician or patient biases toward particular therapies for the treatment of hyperhidrosis and achieving acceptance by physicians, major operators of clinics and patients of sofpironium bromide as a safe, effective, and economical hyperhidrosis treatment; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patients’ perception of hyperhidrosis as a disease and one for which medical treatment may be appropriate and a prescription therapy may be available; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">insurers’ and physicians’ willingness to see hyperhidrosis as a disease worth treating and for which reimbursement will be made available for treatment, or, if limited or no reimbursement is available, the degree to which patients will be willing to purchase sofpironium bromide treatment out-of-pocket; </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">proper administration of sofpironium bromide; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patient satisfaction with the results and administration of sofpironium bromide and overall treatment experience; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations or contraindications, warnings, precautions, or approved indications for use different than those sought by us that are contained in any final FDA-approved labeling for sofpironium bromide; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any FDA requirement to undertake a REMS, or results from any post-marketing surveillance studies that FDA may require as a condition of product approval; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effectiveness of our sales, marketing, pricing, reimbursement and access, government affairs, legal, medical, public relations, compliance, chemistry, manufacturing and controls, and distribution efforts; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse publicity about sofpironium bromide or favorable publicity about competitive products; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">new government regulations and programs, including price controls and/or public or private institutional limits or prohibitions on ways to commercialize drugs, such as increased scrutiny on direct-to-consumer advertising of pharmaceuticals or restrictions on sales representatives to market pharmaceuticals; and </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential product liability claims or other product-related litigation or litigation related to licensing and or other commercial matters associated with sofpironium bromide.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If sofpironium bromide is approved for use but fails to achieve the broad degree of physician and patient adoption necessary for commercial success, or our stock price does not increase to adequate levels to allow for financing of a commercial launch and we are unable to secure necessary funds from other sources, then our operating results and financial condition will be adversely affected, which may delay, prevent, or limit our ability to generate revenue and continue our business. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Major public health issues, and specifically the pandemic caused by the spread of COVID-19 and COVID-19 variants, and the impact as certain markets emerge from the pandemic, especially in terms of constraints on supply chains and human resource availability, and different degrees of success various countries experience in rolling out their vaccine campaigns,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">could have an adverse impact on our financial condition and results of operations and other aspects of our business and that of our suppliers, contractors, and business partners. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which COVID-19 impacts our business and operating results will depend on future developments that are highly uncertain and cannot be accurately predicted, including any new information that may emerge on COVID-19 variants and the actions to contain COVID-19 or treat its impact, especially for variants, among others, and even as or after the pandemic subsides, how long it takes for global supply chains to handle the pent-up demand for goods and services and the shutdowns associated around the world with those supply chains, and worker eagerness to return to the workforce and/or change employment patterns. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effects of the COVID-19 pandemic could delay or interrupt our business operations. Ongoing materials required for an eventual NDA for submission to the FDA, study monitoring, and data analysis may be paused or delayed due to changes in hospital or university policies, federal, state, or local regulations, prioritization of hospital resources toward pandemic efforts, worker and supplier patterns, or other reasons related to, or as a consequence of, the pandemic. Some participants and clinical investigators may not be able to comply with clinical trial protocols. For example, quarantines or other travel limitations (whether voluntary or required) may impede participant movement, affect sponsor access to study sites, or interrupt healthcare services, and we may be unable to complete our clinical trials. Further, if our operations are adversely impacted, we risk a delay, default, and/or nonperformance under existing agreements, which may increase our costs. These cost increases </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may not be fully recoverable or adequately covered by insurance. Infections and deaths related to the pandemic may disrupt the U.S.’ and other countries’ healthcare and healthcare regulatory systems. Such disruptions could divert healthcare resources away from, or materially delay FDA or other regulatory review and/or approval with respect to, our clinical trials. It is unknown how long these disruptions could continue, were they to occur. Any elongation or de-prioritization of our clinical trials or delay in regulatory review resulting from such disruptions could materially affect the development and study of our product candidates. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently rely on third parties, such as contract laboratories, contract research organizations, medical institutions, and clinical investigators to conduct studies and clinical trials for our pipeline assets. If these third parties themselves are adversely impacted by restrictions or disruptions resulting from the COVID-19 pandemic, we will likely experience delays, and/or realize additional costs. As a result, our efforts to obtain regulatory approvals for, and to commercialize, our therapeutic candidates may be delayed or otherwise adversely impacted. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The spread of COVID-19 and its variants, which has caused a broad impact globally, including restrictions on travel and quarantine policies put into place by businesses and governments, negative supply chain impacts, and worker unavailability, may have a material economic effect on our business. While the potential economic impact brought by, and the duration of, the pandemic may be difficult to assess or predict, it has already caused, and is likely to result in further, significant disruption of global financial and distribution markets, which may reduce our ability to access capital either at all or on favorable terms. In addition, a recession, depression, or other sustained adverse market event resulting from the spread of COVID-19 could materially and adversely affect our business and the value of our common stock. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ultimate impact of the current pandemic, or any other health epidemic, is highly uncertain and subject to change. We cannot predict the full extent of potential delays or impacts on our business and that of our key partners like Kaken, our clinical trials, our research programs, healthcare systems, or the global economy as a whole. However, these effects could have a material adverse effect on our business, financial condition, results of operations, and cash flows.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face significant competition in our industry, and our pipeline assets, if approved, may not be able to compete effectively or achieve significant market penetration.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical industry is characterized by rapidly advancing technologies, intense competition, less effective patent terms, and a strong emphasis on developing newer, fast-to-market proprietary therapeutics. Numerous companies are engaged in the development, patenting, manufacturing, and marketing of healthcare products competitive with those that we are developing. We face competition from a number of sources, such as pharmaceutical companies, generic drug companies, biotechnology companies, and academic and research institutions, many of which have greater financial resources, marketing capabilities, sales forces, manufacturing capabilities, research and development capabilities, regulatory expertise, clinical trial expertise, intellectual property portfolios, more international reach, experience in obtaining patents and regulatory approvals for product candidates and other resources than us. Some of the companies that offer competing products also have a broad range of other product offerings, large direct sales forces, and long-term customer relationships with our target physicians, which could inhibit our market penetration efforts. In addition, sofpironium bromide, where approved, may compete with other dermatological products, including OTC treatments, for a share of some patients’, or payors’, discretionary budgets and for physicians’ attention within their clinical practices. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that sofpironium bromide would compete with other therapies currently used for hyperhidrosis, including but not limited to: </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Self-Administered Treatments. Self-administered treatments, such as OTC and prescription topical antiperspirants, and Qbrexza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (glycopyrronium) 2.4% topical cloth. Oral and compounded topical anticholinergics also may be used off-label. </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Non-Surgical Office-Based Procedures. Office-based procedures have been approved by the FDA for certain uses and which may be used, on-or off-label, to treat hyperhidrosis, including intradermal injections of BOTOX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, marketed by Allergan plc, and MiraDry</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a microwave-based treatment marketed by Miramar Labs, Inc. </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Surgical Treatments. Surgical treatments include techniques for the removal of sweat glands, such as excision, curettage, and liposuction. Surgical procedures, such as endoscopic thoracic sympathectomy, are also used to destroy nerves that transmit activating signals to sweat glands. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To compete successfully in this market, we will have to provide an attractive and cost-effective alternative to these existing and other new therapies. Such competition could lead to reduced market share for sofpironium bromide and contribute to downward pressure on the pricing of sofpironium bromide, which could harm our business, financial condition, operating results, and prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., Qbrexza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is approved and is being commercialized for the same indication sought for sofpironium bromide, and we expect to face substantial competition being second to market. In Japan, where Kaken was the first to launch a product to treat primary axillary hyperhidrosis, there are attempts now underway to obtain regulatory approval for Qbrexza from the PDMA, which could negatively impact Kaken’s sales and thus our related royalty income.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some international markets, due to different regulatory requirements than in the U.S., there may be more dermatological products available for use than in the U.S., and there may be fewer limitations on the claims that our competitors can make about the effectiveness of their products and the manner in which they can market them. As a result, we could face more competition in these markets than in the U.S.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may face generic competition for sofpironium bromide, which could expose us to litigation or adversely affect our business, financial condition, operating results, and prospects. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon expiration of patent protection (including applicable extensions) in the U.S. (and any other countries where patent coverage exists, such as Japan) for sofpironium bromide, we could lose a significant portion of then-existing sales of sofpironium bromide in a short period of time from generic competition, which would reduce existing sales and could expose us to litigation, adversely affecting our business, financial condition, operating results, and prospects. Further, other therapies used for hyperhidrosis that would compete with sofpironium bromide could lose their patent protection at any time, increasing the risk of generic competition, which could reduce existing sales and adversely affect our business, financial condition, operating results, and prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we could face what is known as a paragraph IV filing as part of a generic drug manufacturer’s ANDA. ANDAs allow generic drug manufacturers to gain approval for generic drugs without completing their own costly clinical trials by showing that the generic form shares “bio-equivalence” with the branded drug (in this example, sofpironium bromide) under patent protection. In a paragraph IV filing, the applicant asserts that the patent they are targeting is (i) invalid; (ii) not infringed by their product; or (iii) not enforceable as written. Once an ANDA is filed, the patent holder has a defined period in which to respond and bring a counterclaim against the generic drug manufacturer if it wishes to challenge the filing. Should we be subject to a paragraph IV filing for sofpironium bromide, we could lose our existing patent protection for sofpironium bromide significantly earlier than expected, which would have a negative impact on our business, financial condition, operating results, and prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If clinical research organizations (“CROs”) and other third parties do not meet our requirements or otherwise conduct clinical trials for our pipeline assets as required or are unable to staff or supply our trials,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">we may not be able to satisfy our contractual obligations or obtain regulatory approval for, or commercialize, our pipeline assets at all or in the time frames currently planned for.</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have in the past relied, and expect to continue to rely, on third-party CROs to conduct and oversee our clinical trials for pipeline assets and other aspects of product development. We also rely on various medical institutions, clinical investigators, and contract laboratories to conduct our trials in accordance with our clinical protocols and all applicable regulatory requirements, including the FDA’s regulations and good clinical practice (“GCP”) requirements, which are an international standard meant to protect the rights and health of patients and to define the roles of clinical trial sponsors, administrators and monitors, and state regulations governing the handling, storage, security and recordkeeping for drug and biologic products. These CROs and other third parties play a significant role in the conduct of these trials and the subsequent collection and analysis of data from the clinical trials. We rely heavily on these parties for the execution of our clinical trials and preclinical studies and control only certain aspects of their activities. We and our CROs and other third-party contractors are required to comply with GCP and current GLP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities. Regulatory authorities enforce these GCP and GLP requirements through periodic inspections of trial sponsors, principal investigators, and trial sites. If we or any of these third parties fail to comply with applicable GCP and GLP requirements, or reveal noncompliance from an audit or inspection, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or other regulatory authorities may require us to perform additional clinical trials before approving our or our partners’ marketing applications. We cannot assure that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical or preclinical trials comply with applicable GCP and GLP requirements, or that our CROs and other third-party contractors are otherwise compliant with applicable laws despite their contractual assurances to us. In addition, our clinical trials generally must be conducted with product produced under cGMP regulations. Our failure, or the failure by our CROs and other third-party contractors, to comply with these regulations and policies, or to obtain supply of key items in sufficient quantities, in a timely manner or at all, may require us to extend or repeat clinical trials, which would delay or halt the regulatory approval process, or could cause us to fail to meet certain contractual obligations, including but not limited to milestone commitments, with licensors of our portfolio assets like Bodor, Voronoi, and Carna. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our CROs or clinical trial sites terminate their involvement in one of our clinical trials for any reason, including but not limited to impacts caused by the ongoing COVID-19 pandemic, we may not be able to enter into arrangements with alternative CROs or clinical trial sites, or do so on commercially reasonable terms, and in a satisfactory timeframe. If our relationship with clinical trial sites is terminated, we may experience the loss of follow-up information on patients enrolled in our clinical trials unless we are able to transfer the care of those patients to another qualified clinical trial site. In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and could receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, the integrity of the data generated at the applicable clinical trial site may be questioned by the FDA. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently have limited marketing capabilities and no sales organization. If we are unable to generate adequate financing, establish sales and marketing capabilities on our own or through third parties, or are delayed in establishing these capabilities, we will be unable to successfully commercialize our product candidates, if approved, or generate meaningful product revenue. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have limited marketing capabilities and no sales organization and limited cash runway. To commercialize our product candidates, if approved, in the U.S., Australia, Canada, the European Union, Latin America, Africa, the Middle East, and other jurisdictions we seek to enter, we must continue to obtain additional financing, build our marketing, sales, distribution, managerial, and other non-technical capabilities or make arrangements with third parties to perform these services, and we may not be successful in doing any of these. For sofpironium bromide, we may be unable to commercialize it in the U.S. or other countries without a partner, or we may seek a partner to commercialize it in lieu of us. As a company, we have no prior experience in the commercial launch, marketing, sale, and distribution of pharmaceutical products, and there are significant risks involved in building and managing a sales organization, including our ability to fund costs and expenses of a sales organization and its activities, hire, retain, and incentivize qualified individuals, generate sufficient sales </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">leads, or contract for a sales force and in either case, provide adequate training to sales and marketing personnel, and effectively manage a geographically dispersed sales and marketing team so they operate in an effective and compliant way. Any failure or delay in the development of our internal (or external contracted-for) sales, marketing, distribution, and pricing/reimbursement/access capabilities would impact adversely the commercialization of these products. In addition, we may need more than one approved and marketed product to sustain employing an internal sales force.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may choose to collaborate with third parties in various countries, including the U.S., that have direct sales forces, commercial and regulatory capacities, and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. We may not have sufficient financial resources to enter into and pay for such arrangements, and/or we may not be able to find adequate business partners in countries outside Japan. If we are unable to enter into such arrangements on acceptable terms or at all, we may not be able to successfully commercialize our product candidates, including sofpironium bromide and our other product candidates. The inability to commercialize successfully our product candidates, either on our own or through collaborations or partnerships with one or more third parties, would harm our business, financial condition, operating results, and prospects. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not achieve our projected development goals in the timeframes we announce and expect, our business and strategies may be adversely affected and, as a result, our stock price may decline.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we estimate the timing of the anticipated accomplishment of various scientific, clinical, regulatory, other product development, and commercial goals. These goals may include the commencement or completion of scientific studies and clinical trials and the submission of regulatory filings, as well as product launch. From time to time, we may publicly announce the expected timing of some of these goals. All of these goals are and will be based on numerous assumptions. The actual timing of these goals can vary dramatically compared to our estimates, in some cases for reasons beyond our control or that cannot be anticipated. If we do not meet these goals as publicly announced, or at all, our business and strategies may be adversely affected and, as a result, our stock price may decline.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business and operations would suffer in the event of system failures, illegal stock trading or manipulation by external parties, cyber-attacks, or a deficiency in or exploitation of our cyber-security.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on cloud-based software to provide the functionality necessary to operate our company, utilizing what is known as “software as a service” (“SaaS”). SaaS allows users like us to connect to and use cloud-based applications over the Internet, such as email, calendaring, and office tools. SaaS provides us with a complete software solution that we purchase on a subscription basis from a cloud service provider. Despite our efforts to protect confidential and sensitive information from unauthorized disclosure across all our platforms, and similar efforts by our cloud service provider(s) and our other third-party contractors, consultants and vendors, whether information technology (“IT”) providers or otherwise, including but not limited to our CROs, law firms, accountants, and even the government regulators who we rely on to advance our business, this information, and the systems used to store and transmit it, are vulnerable to damage from computer viruses, unauthorized access, computer hacking or breaches, natural disasters, epidemics and pandemics, terrorism, war, labor unrest, and telecommunication and electrical failures. The risk of a security breach or disruption, particularly through cyber-attacks or cyber-intrusion, or other illegal acts, including by computer hackers, foreign governments, and cyber-terrorists, has generally increased as the number, intensity, and sophistication of attempted attacks and intrusions from around the world have increased. Other emerging threats we face include: phishing, account takeover attacks, data breach or theft (no matter where the data are stored), loss of control, especially in SaaS applications, over which users have access to what data and level of access, new malware, zero-day threats, and threats within our own organization. In addition, and probably exacerbated by the COVID-19 pandemic and increased remote working arrangements, malicious cyber actors may increase malware and ransom campaigns and phishing emails targeting teleworkers as well as company systems, preying on the uncertainties surrounding COVID-19 or other world trends and events, which exposes us to additional cybersecurity risks, or may try to </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">illegally obtain inside information to manipulate our stock price. If such an event were to occur and cause interruptions in our operations, or substantial manipulation of our stock price, it could result in a material disruption of our development programs and our business operations. In addition, since we sponsor clinical trials, any breach that compromises patient data and identities, thereby causing a breach of privacy, could generate significant reputational damage and legal liabilities and costs to recover and repair, including affecting trust in us to recruit for future clinical trials. For example, the loss or theft of clinical trial data from completed, ongoing, or future clinical trials could result in delays in our regulatory approval efforts, stock manipulation, and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications or inappropriate disclosure of confidential or proprietary information, we could incur liability or suffer from stock price volatility or decline, and the further development and commercialization of our products and product candidates could be delayed.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be adversely affected by natural disasters and other catastrophic events and by man-made problems such as war or terrorism or labor disruptions that could disrupt our business operations, and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate office is located in Boulder, Colorado, near a major flood and blizzard zone and in an area prone to wildfires. If a disaster, power outage, or other event occurred that prevented us from using all or a significant portion of our office, that damaged critical infrastructure, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a period of time. Our contract manufacturers’ and suppliers’ facilities are located in multiple locations where other natural disasters or similar events, such as tornadoes, earthquakes, storms, fires, explosions or large-scale accidents or power outages, could severely disrupt our operations, could expose us to liability and could have a material adverse effect on our business, financial condition, operating results, and prospects. All of the aforementioned risks may be further increased if we do not implement an adequate disaster recovery plan or our partners’ or manufacturers’ disaster recovery plans prove to be inadequate. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Liquidity, Financial Matters, and Our Common Stock</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need to raise substantial additional financing in the future to fund our operations, which may not be available to us on favorable terms or at all. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will require substantial additional funds to develop and, if successful, commercialize our product candidates. Our future capital requirements will depend upon a number of factors, including but not limited to: the number and timing of future product candidates in the pipeline; progress with and results from preclinical testing and clinical trials; the ability to obtain sufficient drug supplies to complete preclinical and clinical trials; the costs involved in preparing, filing, acquiring, prosecuting, maintaining and enforcing patent and other intellectual property claims; compliance with our material contracts including the licensing agreements for sofpironium bromide and our autoimmune and inflammatory portfolio; the time and costs involved in obtaining regulatory approvals and favorable reimbursement or formulary acceptance for such product candidates; and overall stock market conditions, global business trends, our stock price performance, and our ability to generate funding under these and other conditions.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raising additional capital may be costly or difficult to obtain and could significantly dilute stockholders’ ownership interests or inhibit our ability to achieve our business objectives. If we raise additional funds through public or private equity offerings, the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Further, to the extent that we raise additional capital through the sale of common stock or securities convertible or exchangeable into common stock, our stockholders’ ownership interests in our company will be diluted. In addition, any debt financing may subject us to fixed payment obligations and covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. If we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances, or licensing </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">arrangements with third parties, we may have to relinquish certain valuable intellectual property or other rights to our product candidates, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable to us in one or more countries. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to raise additional funds is uncertain and is limited given our small market capitalization and current stock price. Due to the SEC’s “baby shelf rules,” which prohibit companies with a public float of less than $75 million from issuing securities under a shelf registration statement in excess of one-third of such company’s public float in a 12-month period, we are only able to issue a limited number of shares which aggregate to no more than one-third of our public float using our shelf registration statement at this time. Even if sufficient funding is available, there can be no assurance that it will be available on terms acceptable to us or our stockholders. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are currently operating in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability due to the ongoing military conflict between Russia and Ukraine. Our business, financial condition, and results of operations may be materially adversely affected by the negative impact on the global economy and capital markets resulting from the conflict in Ukraine or any other geopolitical tensions.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. and global markets are experiencing volatility and disruption following the escalation of geopolitical tensions and the start of the military conflict between Russia and Ukraine. On February&nbsp;24, 2022, a full-scale military invasion of Ukraine by Russian troops began. Although the length and impact of the ongoing military conflict is highly unpredictable, the conflict in Ukraine has led to market disruptions, including significant volatility in commodity prices, credit and capital markets, as well as supply chain disruptions. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, various of Russia’s actions have led to sanctions and other penalties being levied by the U.S., the European Union, and other countries, as well as other public and private actors and companies, against Russia and certain other geographic areas, including agreement to remove certain Russian financial institutions from the Society for Worldwide Interbank Financial Telecommunication payment system and restrictions on imports of Russian oil, liquified natural gas and coal. Additional potential sanctions and penalties have also been proposed and/or threatened. Russian military actions and the resulting sanctions could further adversely affect the global economy and financial markets and lead to instability and lack of liquidity in capital markets, potentially making it more difficult for us to obtain additional funds.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the above-mentioned factors could affect our business, prospects, financial condition, and operating results. The extent and duration of the military action, sanctions, and resulting market disruptions are impossible to predict, but could be substantial. Any such disruptions may also magnify the impact of other risks described in this Annual Report.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operating results and liquidity needs could be affected negatively by global market fluctuations and economic downturns. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating results and liquidity could be affected negatively by global economic conditions generally, both in the U.S. and elsewhere around the world, including but not limited to that related to the ongoing COVID-19 pandemic, the Russian invasion of Ukraine and related sanctions and global IT threats. The market for discretionary pharmaceutical products, medical devices, and procedures may be particularly vulnerable to unfavorable economic or other conditions. Some patients may consider sofpironium bromide as discretionary, and if full reimbursement for the product is not available, demand for the product may be tied to the discretionary, out-of-pocket cash-spending levels of our targeted patient populations. Domestic and international equity and debt markets have experienced and may in the future experience heightened volatility and turmoil based on domestic and international economic conditions and concerns. In the event these economic conditions and concerns continue or worsen and the markets again become volatile, or a bear market ensues in the U.S. stock market, including as a result of the COVID-19 pandemic, the Russian invasion of Ukraine and </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related sanctions or other stimulus, our operating results and liquidity could be affected adversely by those factors in many ways, including weakening demand for sofpironium bromide, making it more difficult for us to raise funds if necessary, and our stock price may decline. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our stock price and volume of shares traded have been and may continue to be highly volatile, and our common stock may continue to be illiquid. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock has been subject to significant fluctuations, including after reporting positive topline results of our U.S. Phase 3 pivotal clinical program for sofpironium bromide. The closing price of our common stock fluctuated from $4.69 per share as of September 3, 2019, the first trading date of our operating as a&nbsp;publicly-traded&nbsp;company, to $0.229 per share as of December&nbsp;31, 2021. Market prices for securities of biotechnology and other life sciences companies historically have been particularly volatile and subject even to large daily price swings. In addition, there has been limited liquidity in the trading market for our securities, which may adversely affect stockholders. Some of the factors that may cause the market price of our common stock to continue to fluctuate include, but are not limited to: </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">negative reaction by stockholders concerned about our ability to obtain sufficient funds to commercialize sofpironium bromide, if it is approved, given the positive results of the Phase 3 pivotal clinical program;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our need for additional potential financings to raise funds to further develop and commercialize our pipeline assets, which could result in significant additional share dilution; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">material developments in, or the conclusion of, any litigation to enforce or defend any intellectual property rights or defend against the intellectual property rights of others; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to increase our share price to at least $1.00 per share for the frequency and duration required by The Nasdaq Capital Market to stay listed on this stock exchange and the impact that this lower price may have on investors, including our inability to address the remedial conditions laid out by Nasdaq in our current notice of non-compliance in this regard;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the entry into, or termination of, or breach by us or our partners of material agreements, including key commercial partner or licensing agreements, including the Kaken, Voronoi, and/or Carna Agreements; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain timely regulatory approvals for sofpironium bromide or other product candidates, and delays or failures to obtain such approvals; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of sofpironium bromide, if approved in the U.S., to achieve commercial success; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issues in manufacturing or the supply chain for our product candidates; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of any future clinical trials of our pipeline assets; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of other product candidates, if approved, to achieve commercial success; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of any dilutive equity financings; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by commercial partners or competitors of new commercial products, clinical progress or the lack thereof, significant contracts, commercial relationships, or capital commitments; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the introduction of technological innovations or new therapies or formulations that compete with sofpironium bromide or our other pipeline assets; </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of commercial success of competitive products or products treating the same or similar indications;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to elicit meaningful stock analyst coverage and downgrades of our stock by analysts, or to obtain more institutional shareholders; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the loss of key employees and/or inability to recruit the necessary talent for new positions or to replace exiting employees. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, the stock markets in general have experienced substantial volatility in our industry, especially for microcap biotechnology companies, and such volatility has often been unrelated to the operating performance of individual companies or a certain industry segment, such as the ongoing reaction of global markets to the COVID-19 pandemic, the Russian invasion of Ukraine and related sanctions and other economic disruptions or concerns. These broad market fluctuations may also adversely affect the trading price of our common stock. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, following periods of volatility in the market price of a company’s securities, shareholders have often instituted class action securities litigation against those companies. Such litigation, if instituted, could result in substantial costs and diversion of management attention and resources, which could significantly harm our profitability and reputation and could expose us to liability or impact negatively our business, financial condition, operating results, and prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations to date have been limited primarily to business planning, raising capital, developing our pipeline assets, identifying and in-licensing product candidates, conducting clinical trials, and other research and development activities. Consequently, any predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history or approved products on the market. Our revenue and profitability will depend on development funding for our product portfolio, the achievement of sales milestones and royalties under the Kaken Agreement, our ability to satisfy the development and regulatory milestones under applicable in-license agreements, as well as our ability to do the same with regard to any potential future collaboration and license agreements, overall sales of any products, if approved, and our ability to maintain all of our product licenses. Any upfront and milestone payments either owed by or to us may vary significantly from product to product, period to period, and country to country, and any such variance could cause a significant fluctuation in our operating results from one period to the next. In addition, we measure compensation cost for stock-based awards made to employees at the grant date of the award, based on the fair value of the award, and recognize the cost as an expense over the employee’s requisite service period. As the variables that we use as a basis for valuing these awards change over time, including our underlying stock price and stock price volatility, the magnitude of the expense that we must recognize may vary significantly. Furthermore, our operating results may fluctuate due to a variety of other factors, many of which are outside of our control and may be difficult to predict. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are a “smaller reporting company” and the reduced disclosure and governance requirements applicable to smaller reporting companies may make our common stock less attractive to some investors.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We qualify as a “smaller reporting company” under Rule 12b-2 of the Exchange Act. As a smaller reporting company, we are entitled to rely on certain exemptions and reduced disclosure requirements, such as simplified executive compensation disclosures and reduced financial statement disclosure requirements, in our SEC filings. These exemptions and decreased disclosures in our SEC filings due to our status as a smaller reporting company may make it harder for investors to analyze our results of operations and financial prospects. We cannot predict if investors will find our common stock less attractive because we rely on these exemptions. If </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our common stock price may be more volatile.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the holders of our company’s stock options and warrants exercise their rights to purchase our common stock, the ownership of our stockholders will be diluted.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the holders of our outstanding stock options and warrants exercise their rights to acquire our common stock and service conditions related to restricted stock units are met, the percentage ownership of our stockholders existing prior to the exercise of such rights will be diluted. As of December&nbsp;31, 2021, we had outstanding warrants to purchase (i) one share of our common stock at an exercise price of $0.07 per share; (ii) 490,683 shares of our common stock at an exercise price of $10.36 per share; (iii) 9,005 shares of our common stock at an exercise price of $33.31 per share; (iv) 1,556,420 shares of our common stock at an exercise price of $1.16 per share; (v) 17,482,500 shares of our common stock at an exercise price of $1.25 per share; and (vi) 8,405,935 shares of our common stock at an exercise price of $0.72 per share. As of December&nbsp;31, 2021, we also had 7,059,842 options issued and outstanding to purchase our common stock at a weighted-average exercise price of $3.20 per share. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to access the full amounts available under the Purchase Agreement with Lincoln Park, which could prevent us from accessing the capital we need to continue our operations, which could have an adverse effect on our business.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 17, 2020, we entered into the Purchase Agreement with Lincoln Park pursuant to which Lincoln Park agreed to purchase from us up to an aggregate of $28.0 million of our common stock (subject to certain limitations) from time to time over the 36-month period commencing on August 14, 2020. As of December&nbsp;31, 2021, approximately $26.9&nbsp;million of shares of common stock were remaining, but had not yet been sold, under the Purchase Agreement. All remaining funds available under the Purchase Agreement are subject to the satisfaction of certain conditions specified in the Purchase Agreement, including that our common stock remains listed on The Nasdaq Capital Market, the effectiveness of a registration statement relating to the resale of the shares to be sold to Lincoln Park under the Purchase Agreement, and that no event of default has occurred under the Purchase Agreement. Additionally, depending upon the prevailing market price of our common stock, we may not be able to sell shares to Lincoln Park if such a sale would result in us issuing to Lincoln Park more than 9.99% of our shares outstanding prior to entering into the Purchase Agreement. In the event that we are unable to satisfy the conditions specified, the purchase commitment made by Lincoln Park will be unavailable to us and Lincoln Park will not be required to purchase any shares of our common stock. If obtaining funding from Lincoln Park were to prove unavailable, we will need to secure other sources of funding in order to continue with our proposed development activities and launch and commercialize any product candidates for which we receive regulatory approval. Additionally, even if we are able to sell all shares under the Purchase Agreement, we will still need additional capital to fully implement our business, operating, and development plans.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our failure to regain compliance with Nasdaq continued listing requirements, including if we are unable to increase the closing bid price of our common stock to at least $1.00 per share for a minimum of 10 consecutive business days by June&nbsp;13, 2022, could result in the delisting of our common stock.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is currently listed on The Nasdaq Capital Market. In order to maintain this listing, we must satisfy minimum financial and other requirements. On June&nbsp;17, 2021, we received a notice from the Listing Qualifications Department of the Nasdaq informing us that because the closing bid price for our common stock listed on Nasdaq was below $1.00 per share for 30 consecutive business days, we were not in compliance with the minimum closing bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Marketplace Rule 5550(a)(2) (the “Rule”). We initially had a period of 180 calendar days, or until December 13, 2021, to regain compliance with the Rule. In December 2021, Nasdaq provided notice that granted us an additional 180 calendar days, or until June&nbsp;13, 2022, to regain compliance with the Rule. If at any time during </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">this 180-day period, the closing bid price of our common stock is at least $1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide written confirmation that we have achieved compliance with the Rule, unless Nasdaq exercises its discretion to extend this 10-day period pursuant to Nasdaq Listing Rule 5810(c)(3). If compliance with the Rule cannot be demonstrated to Nasdaq’s satisfaction by June&nbsp;13, 2022, Nasdaq will provide written notification that the Company’s common stock will be delisted. At that time, the Company may appeal Nasdaq’s delisting determination to a Nasdaq Hearings Panel.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to continue to monitor the bid price for our common stock between now and June&nbsp;13, 2022, and plan to seek stockholder approval of a reverse split of our common stock, which would be intended to increase the trading price of our common stock in compliance with the Rule. There is no assurance, however, that we will receive stockholder approval for a reverse stock split, that such a reverse stock split would have the intended effect of increasing our stock price now or in the future, or that our common stock will not be delisted from Nasdaq. Even if we are not delisted, the perception among investors that we are at a heightened risk of delisting could negatively affect the market price and trading volume of our common stock.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our common stock is delisted from Nasdaq and we are unable to list our common stock on another national securities exchange, we expect our common stock would be quoted on an over-the-counter market. If this were to occur, we and our stockholders could face significant material adverse consequences, including limited availability of market quotations for our common stock; substantially decreased trading in our common stock; decreased market liquidity of our common stock as a result of the loss of market efficiencies associated with Nasdaq and the loss of federal preemption of state securities laws; an adverse effect on our ability to issue additional securities or obtain additional financing in the future on acceptable terms, if at all; potential loss of confidence by investors, suppliers, partners, and employees and fewer business development opportunities; and limited news and analyst coverage. Additionally, the market price of our common stock may decline further, and shareholders may lose some or all of their investment.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not anticipate paying any dividends in the foreseeable future. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current expectation is that we will retain any future earnings to fund the development and growth of our business. As a result, capital appreciation, if any, of our shares will be your sole source of gain, if any, for the foreseeable future. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use our net operating loss carryforwards and other tax assets to offset future taxable income may be subject to certain limitations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&nbsp;31, 2021, we had approximately $455.9&nbsp;million of federal and $429.0 million of state net operating loss (“NOL”) carryforwards available to offset future taxable income, of which $173.5 million will carryforward indefinitely and the remainder expiring in varying amounts beginning in 2022 for federal and state purposes if unused. Utilization of these NOLs depends on many factors, including our future income, which cannot be assured. Under the U.S. Tax Cuts and Jobs Acts (“Tax Act”), U.S. federal NOLs incurred in 2018 and later years may be carried forward indefinitely, but our ability to utilize such U.S. federal NOLs to offset taxable income is limited to 80% of the current-year taxable income. It is uncertain if and to what extent various states within the U.S. will conform to the Tax Act. In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986 and corresponding provisions of state law, if a corporation undergoes an “ownership change” (which is generally defined as a greater than 50 percentage points change (by value) in its equity ownership over a rolling three-year period), the corporation’s ability to use its pre-change NOL carryforwards and other pre-change tax attributes to offset its post-change income or taxes may be limited. We have not determined whether we have experienced Section 382 ownership changes in the past and if a portion of our NOLs is therefore subject to an annual limitation under Section 382. Therefore, we cannot provide any assurance that a change in ownership within the meaning of the Internal Revenue Code of 1986 and corresponding provisions of state law has not occurred in the past, and there is a risk that changes in ownership could have occurred. We may experience ownership changes as a result of subsequent changes in our stock </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ownership, as a result of offerings of our stock or subsequent shifts in our stock ownership, some of which may be outside of our control. In that case, the ability to use NOL carryforwards to offset future taxable income will be limited following any such ownership change and could be eliminated. If eliminated, the related asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance on our financial statements.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Legal, Regulatory, and Compliance Matters</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may never obtain regulatory approval to commercialize any of our product candidates in the U.S., or anywhere else in the world other than Japan for sofpironium bromide, and any products approved for sale will be subject to continued regulatory review and compliance obligations and there could be further restrictions on post-approval activities, including commercialization efforts. In obtaining regulatory approval, we will need to negotiate an appropriate product label (aka package insert) with the regulators, which will determine the extent of our allowed promotional activities, and this label could be restrictive or prohibitory with regard to subject matter we believe is necessary to maximize the commercial success of the products that are approved.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The research, testing, manufacturing, safety surveillance, efficacy, quality assurance and control, recordkeeping, labeling, packaging, storage, approval, sale, marketing, distribution, import, export, and reporting of safety and other post-market information related to our investigational drug products are subject to extensive regulation by the FDA and other regulatory authorities in the U.S. and foreign countries, and such regulations differ from country to country and frequently are revised. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we anticipate submitting an NDA for sofpironium bromide gel, 15% to the FDA in mid-2022, there can be no assurance that it will receive the necessary approvals. If approval is denied or delayed, it would have a material adverse impact on us.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even after we or our partners achieve regulatory approval for a product candidate, if any, we or our partners will be subject to continued regulatory review and compliance obligations, including on how the product is commercialized. For example, with respect to our product candidates for the U.S., the FDA may impose significant restrictions on the approved indicated use(s) for which the product may be marketed or on the conditions of approval. A product candidate’s approval may contain requirements for potentially costly post-approval studies and surveillance, including Phase&nbsp;4 clinical trials, to monitor the safety and efficacy of the product or include in the approved label restrictions on the product and how it may be used or sold. We also will be subject to ongoing FDA obligations and continued regulatory review with respect to, among other things, the manufacturing, processing, labeling, packaging, distribution, pharmacovigilance and adverse event reporting, storage, advertising, promotion, and recordkeeping for our product candidates. These requirements include submissions of safety and other post-marketing information and reports, registration, continued compliance with cGMP requirements and with the FDA’s GCP requirements and GLP requirements, which are regulations and guidelines enforced by the FDA for all of our product candidates in clinical and preclinical development, and for any clinical trials that we conduct post-approval, as well as continued compliance with the FDA’s laws governing commercialization of the approved product, including but not limited to the FDA’s Office of Prescription Drug Promotion’s regulation of promotional activities and direct-to-consumer advertising, fraud and abuse, antikickback, product sampling, debarment, scientific speaker engagements and activities, formulary interactions as well as interactions with healthcare practitioners, including various conflict-of-interest reporting requirements for any healthcare practitioners we may use as consultants, and laws relating to the pricing of drug products, including federal “best price” regulations that if not met can prohibit us from participating in federal reimbursement programs like Medicare or Medicaid. To the extent that a product candidate is approved for sale in other countries, we may be subject to similar or more onerous (e.g., prohibition on direct-to-consumer advertising and price controls that do not exist in the U.S.) restrictions and requirements imposed by laws and government regulators, and even private institutions, in those countries.</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, manufacturers of drug and biologic products and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMP regulations. If we or a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the manufacturing, processing, distribution, or storage facility where, or processes by which, the product is made, a regulatory agency may impose restrictions on that product or us, including requesting that we initiate a product recall, or requiring notice to physicians or the public, withdrawal of the product from the market, or suspension of manufacturing. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we, our partners, our product candidates, or the manufacturing facilities for our product candidates fail to comply with applicable regulatory requirements, a regulatory agency may: </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impose restrictions on the sale, marketing, advertising, or manufacturing of the product, or amend, suspend, or withdraw product approvals, or revoke necessary licenses; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">mandate modifications to or prohibit promotional and other product-specific materials or require us to provide corrective information to healthcare practitioners and other customers and/or patients, or in our advertising and promotion; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require us or our partners to enter into a consent decree, which can include imposition of various fines, reimbursements for inspection costs, required due dates for specific actions, penalties for noncompliance and, in extreme cases, require an independent compliance monitor to oversee our activities; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issue warning letters, bring enforcement actions, initiate surprise inspections, issue show cause notices or untitled letters describing alleged violations, which may be publicly available; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commence criminal investigations and prosecutions; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">debar certain healthcare professionals; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">exclude us from participating in or being eligible for government reimbursement and formulary inclusion;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">initiate audits, inspections, accounting and civil investigations, or litigation;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impose injunctions, suspensions, or revocations of necessary approvals or other licenses; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impose other civil or criminal penalties; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend or cancel any ongoing clinical trials; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">place restrictions on the kind of promotional activities that can be done; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delay or refuse to approve pending applications or supplements to approved applications filed by us or our potential partners; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refuse to permit drugs or precursor chemicals to be imported or exported to or from the U.S.;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend or impose restrictions on operations, including costly new manufacturing requirements;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">change or restrict our product labeling; or </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seize or detain products or require us or our partners to initiate a product recall. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulations, policies, or guidance of the FDA, Japan’s PMDA, and other applicable government agencies may change quickly, and new or additional statutes or government laws or regulations may be enacted, including at federal, state, and local levels, or case law may issue, which can differ by geography and could prevent or delay regulatory approval of our product candidates or further restrict or regulate post-approval activities, including commercialization efforts. We cannot predict the likelihood, nature, or extent of adverse government regulations that may arise from future legislation or administrative action, or judicial outcomes based on litigation, either in the U.S. or abroad. If we are not able to achieve and maintain regulatory or other legal compliance, we may not be permitted to commercialize our product candidates, which would adversely affect our ability to generate revenue and achieve or maintain profitability. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have sponsored or supported and expect in the future to sponsor or support clinical trials for our product candidates outside the U.S. and Japan, and the FDA, PMDA, and applicable foreign regulatory authorities may not accept data from such trials; in addition, we may not be allowed alone or with local country business partners to obtain regulatory approval for our product candidates without first conducting clinical trials in each of these other countries.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have sponsored or supported and expect in the future to sponsor or support one or more of our clinical trials outside of the U.S., including our planned Phase 1 clinical trial for BBI-02 in Canada. Although the FDA or applicable foreign regulatory authorities may accept data from clinical trials conducted outside the U.S. or the applicable jurisdiction, acceptance of such study data by the FDA or applicable foreign regulatory authorities may be subject to certain conditions or exclusions. Where data from foreign clinical trials are intended to serve as the basis for marketing approval in the U.S., the FDA will not approve the application on the basis of foreign data alone unless such data are applicable to the U.S. population and U.S. medical practice; the studies were performed by clinical investigators of recognized competence; and the data are considered valid without the need for an on-site inspection by the FDA or, if the FDA considers such an inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. Many foreign regulatory bodies have similar requirements. In addition, such foreign studies would be subject to the applicable local laws of the foreign jurisdictions where the studies are conducted. There can be no assurance the FDA or applicable foreign regulatory authorities will accept data from trials conducted outside of the U.S. or the applicable home country. If the FDA or applicable foreign regulatory authority does not accept such data, it would likely result in the need for additional clinical trials, which would be costly and time-consuming and delay aspects of our business plan. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may face product liability exposure, and if successful claims are brought against us, we may incur substantial liability if our insurance coverage for those claims is inadequate. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability or similar causes of action as a result of the clinical testing (and use) of our product candidates and will face an even greater risk if we commercialize any products. This risk exists even if a product is approved for commercial sale by the FDA and is manufactured in facilities licensed and regulated by the FDA or an applicable foreign regulatory authority and notwithstanding that we comply with applicable laws on promotional activity. Our products and product candidates are designed to affect important bodily functions and processes. Any side effects, manufacturing defects, misuse, or abuse associated with our product candidates could result in actual or perceived injury to a patient that may or may not be reversible or potentially even cause death. We cannot offer any assurance that we will not face product liability or other similar suits in the future or that we will be successful in defending them, nor can we assure that our insurance coverage will be sufficient to cover our liability under any such cases. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, a liability claim may be brought against us even if our product candidates merely appear to have caused an injury. Product liability claims may be brought against us by consumers, healthcare providers, pharmaceutical companies, or others selling or otherwise coming into contact with our product candidates, </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">among others, and under some circumstances even government agencies. If we cannot successfully defend against product liability or similar claims, we will incur substantial liabilities, reputational harm, and possibly injunctions and punitive actions. In addition, regardless of merit or eventual outcome, product liability claims may result in: </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal or delay of recruitment or decreased enrollment rates of clinical trial participants; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">termination or increased government regulation of clinical trial sites or entire trial programs; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to commercialize, or restrictions on commercializing, our product candidates; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased demand for our product candidates; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impairment of our business reputation; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product recall or withdrawal from the market or labeling, marketing, or promotional restrictions; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial costs of any related litigation or similar disputes; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">distraction of management’s attention and other resources from our primary business; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant delay in product launch; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">debarment of our clinical trial investigators or other related healthcare practitioners working with our company;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to patients or other claimants against us that may not be covered by insurance; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of reimbursement or formulary inclusion; or </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenue.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained product liability insurance coverage for our clinical trials. Large judgments have been awarded in class action or individual lawsuits based on drugs that had unanticipated side effects. Our insurance coverage may not be sufficient to cover all of our product liability-related expenses or losses and may not cover us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive, restrictive, and narrow, and, in the future, we may not be able to maintain adequate insurance coverage at a reasonable cost, or through self-insurance, in sufficient amounts or upon adequate terms to protect us against losses due to product liability or other similar legal actions. We will need to increase our product liability coverage if any of our product candidates receive regulatory approval, which will be costly, and we may be unable to obtain this increased product liability insurance on commercially reasonable terms or at all and for all geographies in which we wish to launch. A successful product liability claim or series of claims brought against us could, if judgments exceed our insurance coverage, decrease our cash, expose us to liability and harm our business, financial condition, operating results, and prospects. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to risks related to pre-approval promotion or off-label use, or unauthorized direct-to-consumer advertising, of our product candidates. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., the FDA strictly regulates the advertising and promotion of drug products, and drug products may only be marketed or promoted for their FDA-approved uses, consistent with the product’s approved labeling and to appropriate patient populations. Advertising and promotion of any product candidate that obtains </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approval in the U.S. will be heavily scrutinized by the FDA, the Department of Justice, the Office of Inspector General of the Department of Health and Human Services (“HHS”), state attorneys general, members of Congress, the public, and others. Violations, including promotion of our products for unapproved or off-label uses, or inappropriate direct-to-consumer advertising, are subject to enforcement letters, inquiries and investigations, and civil, criminal, and/or administrative sanctions by the FDA and other government agencies or tribunals and lawsuits by competitors, healthcare practitioners, consumers, investors, or other plaintiffs. Additionally, advertising and promotion of any product candidate that obtains approval outside of the U.S. will be heavily scrutinized by relevant foreign regulatory authorities. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we obtain regulatory approval for our product candidates, the FDA or comparable foreign regulatory authorities may require labeling changes or impose significant restrictions on a product’s indicated uses or marketing, or impose ongoing requirements for potentially costly post-approval studies or post-market surveillance. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., engaging in impermissible promotion of our product candidates for off-label uses, or engaging in pre-approval promotion of an unapproved drug candidate, also can subject us to false claims litigation under federal and state statutes, which can lead to civil, criminal and/or administrative penalties and fines and agreements, such as a corporate integrity agreement, that materially restrict the manner in which we promote or distribute our product candidates. If we do not lawfully promote our products once they have received regulatory approval, we may become subject to such litigation and, if we are not successful in defending against such actions, those actions could expose us to liability and could have a material adverse effect on our business, financial condition, operating results, and prospects and even result in having an independent compliance monitor assigned to audit our ongoing operations at our cost for a lengthy period of time. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare reform measures, including price controls or restricted access, could hinder or prevent the commercial success of our product candidates in any country.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The enactment of any new healthcare initiatives or pharmaceutical industry regulations could have significant impacts on our ability to advance the development of sofpironium bromide or other product candidates and eventually to commercialize them, if at all. Specifically, on September 9, 2021, the Biden White House released a Prescription Drug Pricing Plan (“Plan”) to reduce prescription drug prices and out-of-pocket costs for patients. This Plan highlights legislative policies that the White House supports to lower drug prices by allowing the Secretary of HHS to negotiate Medicare Part B (physician-administered) and Part D (outpatient) drug prices directly with pharmaceutical companies and make those prices available in the commercial market. However, to date, details are limited as to what these negotiations might look like. The Plan also pledges support for a redesign of the Medicare Part D program that would institute a lower cap on out-of-pocket spending to protect beneficiaries by shifting significantly more of the cost management burden onto payers and drug manufacturers after a Medicare beneficiary reaches his or her out-of-pocket spending limit. The Plan also aims to curb annual price increases of existing drugs covered by Medicare Parts B and D, imposing an inflationary rebate for those that exceed an unspecified inflation index (consumer or medical price inflation index). HHS also may pursue other administrative actions without Congress. While these proposals have not yet been enacted, we expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates if approved or additional pricing pressures. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are also calls to severely curtail or ban all direct-to-consumer advertising of pharmaceuticals or restrict activities by pharmaceutical sales representatives to have access to prescribers, which would limit our ability to market our product candidates. With regard to marketing directly to consumers and patients, the U.S. is in a minority of jurisdictions that even allow this kind of advertising, and its removal could limit the potential reach of a marketing campaign. </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are and may be subject to strict healthcare laws, regulation, and enforcement, and our failure to comply with those laws could expose us to liability or adversely affect our business, financial condition, operating results, and prospects. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain federal and state healthcare laws and regulations pertaining to fraud and abuse and patients’ rights and privacy are and will be applicable to our business. We are subject to regulation by both the federal government and the states in which we or our partners conduct business. The healthcare laws and regulations that may affect our ability to operate include: the Federal Food, Drug and Cosmetic Act, as amended; Title 21 of the Code of Federal Regulations Part 202 (21 CFR Part 202); the 21</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Century Cures Act, the federal Anti-Kickback Statute; federal civil and criminal false claims laws and civil monetary penalty laws; the federal Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act; the Prescription Drug Marketing Act (for sampling of drug product); the federal Best Price Act and Medicaid drug rebate program; the federal physician sunshine reporting requirements under the Affordable Care Act and state disclosure laws; the Foreign Corrupt Practices Act as it applies to activities both inside and outside of the U.S.; the federal Right-to-Try legislation; and state law equivalents of many of the above federal laws. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. In addition, healthcare reform legislation has strengthened these laws. For example, the Affordable Care Act, among other things, amended the intent requirement of the federal Anti-Kickback Statute and certain criminal healthcare fraud statutes. A person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it. In addition, the Affordable Care Act provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Achieving and sustaining compliance with these laws may prove costly. In addition, any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management’s attention from the operation of our business and result in reputational damage. If our operations are found to be in violation of any of the laws described above or any other governmental laws or regulations that apply to us, we may be subject to penalties, including administrative, civil, and criminal penalties, damages, including punitive damages, fines, disgorgement, the exclusion from participation in federal and state healthcare programs, individual imprisonment or corporate criminal liability, or the curtailment or restructuring of our operations, and injunctions, any of which could expose us to liability and could adversely affect our business, financial condition, operating results, and prospects. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may seek orphan drug exclusivity for some of our product candidates, and we may be unsuccessful.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a disease with a patient population of fewer than 200,000 individuals in the United States.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, if a product with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the European Medicines Agency (the “EMA”) or the FDA from approving another marketing application for the same drug for the same indication during the period of exclusivity. The applicable period is seven years in the United States and ten years in Europe. The European exclusivity period can be reduced to six years if a drug no longer meets the criteria for orphan drug designation or if the drug is sufficiently profitable so that market exclusivity is no longer justified. Orphan drug exclusivity may be lost if the FDA or EMA determines that the request for designation was materially defective, or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition.</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we obtain orphan drug exclusivity for a product candidate, that exclusivity may not effectively protect the product candidate from competition because different drugs can be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve a different drug for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, independent contractors, principal investigators, other clinical trial staff, consultants, vendors, CROs, and any partners with which we may collaborate may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk that our employees, officers, directors, independent contractors, principal investigators, other clinical trial staff, consultants, advisors, vendors, CROs, and any partners with which we may collaborate may engage in fraudulent or other illegal or unethical activity. Misconduct by these persons could include intentional, reckless, gross or negligent misconduct or unauthorized activity that violates: laws or regulations, including those laws requiring the reporting of true, complete, and accurate information to the FDA or foreign regulatory authorities; product sampling; manufacturing standards; federal, state and foreign healthcare fraud and abuse laws and data privacy; anticorruption laws, anti-kickback and Medicare/Medicaid rules, debarment laws, promotional laws, securities laws, and/or laws that require the true, complete and accurate reporting of financial information or data, books, and records. If any such or similar actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative and punitive penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid, and other federal or state healthcare programs, debarments, contractual damages, reputational harm, diminished profits and future earnings, injunctions, and curtailment or cessation of our operations, any of which could expose us to liability and adversely affect our business, financial condition, operating results, and prospects. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We incur costs and demands upon management as a result of complying with the laws and regulations affecting public companies. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incur significant legal, accounting, and other expenses to operate as a public company, including costs associated with public company reporting and other SEC requirements. We also incur costs associated with corporate governance requirements, including requirements under the Sarbanes-Oxley Act, as well as rules implemented by the SEC and Nasdaq. These rules and regulations have, and are expected to continue to, increase our legal and financial compliance costs and to make some activities more time-consuming and costly. These rules and regulations may also make it expensive for us to operate our business. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Strategic Matters</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We intend to continue to in-license and acquire product candidates and may engage in other strategic transactions, which could impact our liquidity, increase our expenses, and present significant distractions to our management. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One of our ongoing strategies is to in-license and acquire additional product candidates, and we may engage in other strategic transactions. Additional potential transactions that we may consider include a variety of different business arrangements, including mergers and acquisitions, spin-offs, strategic partnerships, joint ventures, co-marketing, co-promotion, distributorships, development and co-development, royalty monetization, restructurings, divestitures, business combinations, contract sales forces, out-licensing or divesture of existing products, and investments on a global basis. Any such transaction(s) may require us to incur non-recurring or other charges, may increase our near- and long-term expenditures, and may cause us to grow and expand rapidly, putting pressure on current resources and capabilities, and may pose significant integration challenges or disrupt our management or business, which could adversely affect our operations and financial results. Further, any such transaction(s) may require us to obtain additional financing, which may not be available to us </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on favorable terms or at all. Accordingly, there can be no assurance that we will undertake or successfully complete future transactions of the nature described above, and any transaction that we do complete could expose us to liability, delays, and implementation obstacles that could harm our business, financial condition, operating results, and prospects. We have no current commitment or obligation to enter into any transaction described above other than ones to which we are already committed.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may choose not to continue developing or commercializing any of our product candidates at any time during development or after approval, or we may sell and assign our rights, which would reduce or eliminate our potential return on investment for those product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At any time, we may decide to discontinue the development or commercialization of any of our early-stage or licensed rights to product candidates, or sell and assign our rights, for a variety of reasons, including the appearance of new technologies that make our product obsolete or significantly impact the ability to commercialize the affected product successfully, competition from a competing product including entry of generics, supply chain considerations, intellectual property right impacts, ability to price or changes in or failure to comply with applicable regulatory requirements, inability or difficulty to generate financing to commercialize a product, market reaction to the market potential for any product asset, or constraints on obtaining additional financing and capital. If we terminate, exit, or assign a program in which we have invested significant resources, we either likely will not receive any return, or only a partial return, on our investment, and we may have missed an opportunity to have allocated those resources to potentially more productive uses.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our failure to in-license, acquire, develop, and market successfully additional product candidates or approved products would impair our ability to grow our business. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have, and intend to continue to, in-license, acquire, develop, and market additional products and product candidates. Because our internal research and development capabilities are limited, we may be dependent on pharmaceutical or other companies, investment groups or funds, academic or government scientists, and other researchers to sell or license products or technology to us. The success of this strategy depends partly on our ability to identify and select promising pharmaceutical product candidates and products, negotiate licensing or acquisition agreements with their current owners, and finance these arrangements. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of proposing, negotiating, and implementing a license or acquisition of a product candidate or approved product is lengthy and complex. Other companies, including some with substantially greater financial, marketing, sales, legal and other resources, may compete with us for the license or acquisition of product candidates and approved products. We have limited resources to identify and execute the acquisition or in-licensing of third-party products, businesses, and technologies and integrate them into our current infrastructure. Moreover, we may devote resources to potential acquisitions or licensing opportunities that are never completed, or we may fail to realize the anticipated benefits of such efforts. We may not be able to acquire the rights to additional product candidates on terms that we find acceptable or at all. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, any product candidate that we maintain rights to or acquire may require (or, in the case of the pipeline assets we licensed from Voronoi and Carna, do require) additional development efforts prior to commercial sale, including preclinical or clinical testing and approval by the FDA and applicable foreign regulatory authorities for the targeted use(s), or present with significant integration issues. All product candidates are prone to significant risks of failure typical of pharmaceutical product development, including the possibility that a product candidate will not be shown to be sufficiently safe and effective for approval by regulatory authorities. In addition, we cannot provide assurance that any approved products that we acquire will be manufactured or sold profitably, obtain reimbursement, be subject to patents and other intellectual property rights that provide any form of market or regulatory exclusivity, sustain historical levels of performance that made the acquisition initially attractive, or achieve/maintain market acceptance.</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Dependence on Third Parties</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect to rely on our collaboration with third-party partners for the successful development and commercialization of our product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to rely upon the efforts of third-party partners for the successful development and commercialization of our current and future product candidates. The clinical, regulatory, and commercial success of our product candidates may depend upon maintaining successful relationships with third-party partners which are subject to a number of significant risks, including the following: </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our partners’ ability to execute their responsibilities in a timely, cost-efficient, and compliant manner and to maintain their supply chain systems and safeguard their IT operations and their and our data;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced control over supply, delivery, and manufacturing schedules; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">price increases and product reliability;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to attract and retain the right partners; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing deviations from internal or regulatory specifications; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">quality or integrity incidents; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the failure of partners to perform their obligations for technical, market, legal, or other reasons; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">misappropriation of our current or future product candidates; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ability of partners to comply with applicable laws or continue their own operations based on their unique situations; and </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other risks in potentially meeting our current and future product commercialization schedule or satisfying the requirements of our end-users. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot assure that we will be able to establish or maintain third-party partner relationships to successfully develop and commercialize our product candidates. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely completely on third-party contractors to supply, manufacture, and distribute clinical drug supplies and to help prepare for a possible launch for our product candidates, including certain sole-source suppliers and manufacturers, both inside and outside the U.S.; we intend to rely on third parties for commercial supply, manufacturing, and distribution, and possibly sales and promotion, if any of our product candidates receive regulatory approval; and we expect to rely on third parties for supply, manufacturing, and distribution of preclinical, clinical, and commercial supplies, and possibly sales and promotion, of any future product candidates. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently have, nor do we plan to acquire, the infrastructure or internal capability to supply, store, manufacture, or distribute preclinical, clinical, or commercial quantities of drug substances or products. Additionally, we have not entered into a long-term commercial supply agreement to provide us with such drug substances or products. As a result, our ability to develop our product candidates is dependent, and our ability to supply our products commercially will depend, in part, on our ability to obtain the APIs and other substances and materials used in our product candidates successfully from third parties and to have finished products manufactured by third parties in accordance with regulatory requirements and in sufficient quantities for preclinical and clinical testing and commercialization. If we fail to develop and maintain supply and other </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">technical relationships with these third parties, or global conditions like the coronavirus pandemic significantly and adversely impact such third parties, we may be unable to continue to develop or commercialize our products and product candidates. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have direct control over whether our contract suppliers and manufacturers will maintain current pricing terms, be willing (or able) to continue supplying us with APIs and finished products, or maintain adequate capacity and capabilities to serve our needs, including quality control, quality assurance, and qualified personnel. We are dependent on our contract suppliers and manufacturers for day-to-day compliance with applicable laws and cGMPs for production of both APIs and finished products. If the safety or quality of any product or product candidate or component is compromised due to a failure to adhere to applicable laws or for other reasons, we may not be able to commercialize or obtain regulatory approval for the affected product or product candidate successfully, and we may be held liable for injuries sustained as a result. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to conduct larger or late-stage clinical trials for our product candidates and supply sufficient commercial quantities of the resulting drug product and its components, if that product candidate is approved for sale, our contract manufacturers and suppliers will need to produce our drug substances and product candidates in larger quantities, more cost-effectively and, in certain cases, at higher yields than they currently achieve. If our third-party contractors are unable to scale up the manufacture of any of our product candidates successfully in sufficient quality and quantity and at commercially reasonable prices, or are shut down or put on clinical hold by government regulators, and we are unable to find one or more replacement suppliers or manufacturers capable of production at a substantially equivalent cost in substantially equivalent volumes and quality, and we are unable to transfer the processes successfully on a timely basis, the development of that product candidate and regulatory approval or commercial launch for any resulting products may be delayed, or there may be a shortage in supply, either of which could significantly harm our business, financial condition, operating results, and prospects. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to depend on third-party contract suppliers and manufacturers for the foreseeable future. Our supply and manufacturing agreements, if any, do not guarantee that a contract supplier or manufacturer will provide services adequate for our needs. In addition, inflation and/or global supply chain disruptions may have a negative impact on our third-party contract suppliers’ and manufacturers’ ability to acquire the materials necessary for our business, and we could incur higher costs for certain goods or services due to inflation or increased freight costs. Additionally, any damage to, destruction of, or threats to our third-party manufacturers’ or suppliers’ facilities, equipment, or systems, even by force majeure or by criminal acts, may significantly impair our ability to have our products and product candidates manufactured on a timely basis. Our reliance on contract manufacturers and suppliers further exposes us to the possibility that they, or third parties with access to their facilities and systems, will have access to and may misappropriate our trade secrets, clinical trial and other research data, or other proprietary information. In addition, the manufacturing facilities of certain of our suppliers may be located outside of the U.S. This may give rise to difficulties in importing our products or product candidates or their components into the U.S. or other countries, or otherwise protecting these assets. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Manufacturing and supply of the APIs and other substances and materials used in our product candidates and finished drug products is a complex and technically challenging undertaking, and there is potential for failure at many points in the manufacturing, testing, quality control and assurance, and distribution supply chain, as well as the potential for latent defects after products have been manufactured and distributed. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing and supply of APIs, other substances and materials, and finished drug products are technically challenging. Changes beyond our direct control can impact the quality, volume, price, and successful delivery of our products and product candidates and can impede, delay, limit, or prevent the successful development and commercialization of our products and product candidates. Mistakes and mishandling, and/or disruptions in the supply chain, are not uncommon despite reasonable best efforts and can affect successful production and supply. Some of these risks include but are not limited to: </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of our manufacturers to follow cGMP or other legal requirements or mishandling of or adulterating product while in production or in preparation for transit; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability of our contract suppliers and manufacturers to efficiently and cost-effectively increase and maintain high yields and batch quality, consistency, and stability; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulty in establishing optimal drug delivery substances and techniques, production and storage methods, and packaging and shipment processes; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">challenges in designing effective drug delivery substances and techniques especially in light of competitor options; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">transportation and import/export risk, particularly given the global nature of our supply chain; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in analytical results or failure of analytical techniques that we depend on for quality control/assurance and release of a product; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">natural disasters, strikes and labor disputes, epidemics or pandemics, war and terrorism, financial distress, lack of raw material supply, issues with facilities and equipment, third-party criminal threats such as IT malware and/or ransom attempts caused by holding systems hostage, or other forms of disruption to business operations of our contract manufacturers and suppliers; and </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">latent defects that may become apparent after a product has been released and even sold and used and that may result in recall and destruction of the product. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these factors could result in delays or higher costs in connection with our clinical trials, regulatory submissions, required approvals, or commercialization of our products, which could expose us to liability or harm our business, financial condition, operating results, and prospects. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to obtain, afford, maintain, enforce, or protect our intellectual property rights covering our product candidates, including sofpironium bromide, our autoimmune and inflammatory portfolio, and related technologies that are of sufficient type, breadth, and term throughout the world.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success with respect to sofpironium bromide, our autoimmune and inflammatory portfolio, and other product candidates will depend, in part, on our ability to protect patent and other intellectual property protections in both the U.S. and other countries, to preserve our trade secrets, and to prevent third parties from infringing on our proprietary rights. Our ability to prevent unauthorized or infringing use of sofpironium bromide, our autoimmune and inflammatory portfolio, and other product candidates by third parties depends in substantial part on our ability to leverage valid and enforceable patents and other intellectual property rights around the world. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent application process, also known as patent prosecution, is expensive and time-consuming, and we and our current or future licensors and licensees may not be able to prepare, file, and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner in all the countries that may be desirable. It is also possible that we or our current licensors and licensees, or any future licensors or licensees, will fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection by others on them. Therefore, these and any of our patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. Moreover, our competitors independently may develop equivalent knowledge, methods, and know-how or discover workarounds to our patents that would not constitute infringement. Our partners or licensees may </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inappropriately take or use our intellectual property and/or confidential information to infringe our patents or otherwise violate their contractual obligations as to us related to protection of our intellectual property. Any of these outcomes could impair our ability to enforce the exclusivity of our patents effectively, which may have an adverse impact on our business, financial condition, operating results, and prospects. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to constantly shifting global legal standards relating to patentability, validity, enforceability, and claim scope of patents covering pharmaceutical inventions, our ability to protect patents in any jurisdiction is uncertain and involves complex legal and factual questions, especially across countries. Accordingly, rights under any applicable patents that apply to us may not cover our product candidates or may not provide us with sufficient protection for our product candidates to afford a sustainable commercial advantage against competitive products or processes, including those from branded, generic, and OTC pharmaceutical companies. In addition, we cannot guarantee that any patents or other intellectual property rights will issue from any pending or future patent or other similar applications related to us. Even if patents or other intellectual property rights have issued or will issue, we cannot guarantee that the claims of these patents and other rights are or will be held valid or enforceable by the courts or other legal authorities, through injunction or otherwise, or will provide us with any significant protection against competitive products or otherwise be commercially valuable to us in every country of commercial significance that we may target, or that a legislative or executive branch of government may alter the rights and enforceability thereof at any time.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors in the therapeutic areas of our strategic focus have created a substantial amount of prior art, including scientific publications, abstracts, posters, presentations, patents and patent applications, and other public disclosures, including on the Internet and various social media. Our ability to protect valid and enforceable patents and other intellectual property rights depends on whether the differences between our proprietary technology and the prior art allow our technology to be patentable over the prior art. We do not have outstanding issued patents covering all of the recent developments in our technology and are unsure of the patent protection that we will be successful in securing, if any. Even if the patents do issue successfully, third parties may design around or challenge the validity, enforceability, or scope of such issued patents or any other issued patents or intellectual property that apply to us, which may result in such patents and/or other intellectual property being narrowed, invalidated, or held unenforceable. If the breadth or strength of protection provided by the patents and other intellectual property we hold or pursue with respect to our product candidates is challenged, regardless of our future success, it could dissuade companies from collaborating with us to develop, or threaten our ability to commercialize or finance, our product candidates. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The laws of some foreign jurisdictions do not provide intellectual property rights to the same extent or duration as in the U.S., and many companies have encountered significant difficulties in acquiring, maintaining, protecting, defending, and especially enforcing such rights in foreign jurisdictions. If we encounter such difficulties in protecting, or are otherwise precluded from effectively protecting, our intellectual property in foreign jurisdictions, our business prospects could be substantially harmed, especially internationally. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents have a limited lifespan. In the U.S., the natural expiration of a patent is generally 20 years after it is filed, with patent term extensions granted in certain instances to compensate for part of the period in which the drug was under development and could not be commercialized while under the patent. Without patent protection for sofpironium bromide and the rest of our product portfolio, we may be open to competition from generic versions of these assets. The issued U.S. patents relating to sofpironium bromide run through 2031, including expected extensions just described. Other patent rights we are seeking in the U.S. for sofpironium bromide would provide expected coverage through 2041, but only in the event of a grant of such rights. BBI-02 is covered by a composition of matter patent issued in the U.S., Japan, China, and other key countries through at least 2038, subject to patent term extensions and adjustments that may be available depending on how this early-stage asset is developed, as well as a pending PCT application, and other foreign and U.S. applications for BBI-02, as of the date of this Annual Report. We are evaluating the patent protection and strategy for the remainder of the assets in-licensed from Voronoi and Carna. </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proprietary trade secrets and unpatented know-how and confidential information are also important to our business. Although we have taken steps to protect our trade secrets, unpatented know-how, and confidential information by entering into confidentiality and nondisclosure agreements with third parties and intellectual property protection agreements with officers, directors, employees, and certain consultants and advisors, there can be no assurance that binding agreements will not be breached or enforced by courts or other legal authorities, that we would have adequate remedies for any breach, including injunctive and other equitable relief, or that our trade secrets, unpatented know-how, and confidential information will not otherwise become known, be inadvertently disclosed by us or our agents and representatives, or be independently discovered by our competitors. If trade secrets are independently discovered, we would not be able to prevent their use, and if we and our agents or representatives inadvertently disclose trade secrets, unpatented know-how, and/or confidential information, we may not be allowed to retrieve the inadvertently disclosed trade secret, unpatented know-how, and/or confidential information and maintain the exclusivity we previously enjoyed. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property rights meaningfully throughout the world. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting, and defending patents on our product candidates do not guarantee exclusivity. The requirements for patentability differ in certain countries, particularly developing countries, and can change over time in the same country. In addition, the laws of some other countries do not protect intellectual property rights to the same extent as laws in the U.S., especially when it comes to granting use and other kinds of patents and what kind of enforcement rights will be allowed, especially injunctive relief in a civil infringement proceeding. Consequently, we may not be able to prevent third parties from practicing our inventions in countries outside the U.S. and even in launching an identical version of our product notwithstanding us having a valid patent or other intellectual property rights in that country. Competitors may use our technologies in jurisdictions where we or our licensors have not obtained patent or other protections to develop their own products, or produce copy products, and, further, may export otherwise infringing products to territories where we have patent and other protections but enforcement against infringing activities is inadequate or where we have no patents or other intellectual property rights. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from commercialization or other uses.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly in developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to pharmaceuticals, and the judicial and government systems are often corrupt, apathetic, or ineffective, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our intellectual property rights generally. Proceedings to enforce our intellectual property rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our global patents and other rights at risk of being invalidated or interpreted narrowly and our global patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuit that we initiate or infringement action brought against us, and the damages or other remedies awarded, if any, may not be commercially meaningful when we are the plaintiff. When we are the defendant, we may be required to post large bonds to stay in the market while we defend ourselves from an infringement action. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, certain countries in Europe and certain developing countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties, especially if the patent owner does not enforce or use its patents over a protracted period of time. In some cases, the courts will force compulsory licenses on the patent holder even when finding the patentholder’s patents are valid if the court believes it is in the best interests of the country to have widespread access to an essential product covered by the patent. Further, there is no guarantee that any country will not adopt or impose compulsory licensing in the future. In these situations, the royalty the court requires to be paid by the licenseholder receiving the compulsory license may not be calculated at fair market value and can be inconsequential, thereby disaffecting the patentholder’s business. In these countries, we may have limited remedies if our patents are infringed or if we are compelled to </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">grant a license to our patents to a third party, which could also materially diminish the value of those patents. This would limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we own or license, especially in comparison to what we enjoy from enforcing our intellectual property rights in the U.S. Finally, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in both U.S. and foreign intellectual property laws, or changes to the policies in various government agencies in these countries, including but not limited to the patent office issuing patents and the health agency issuing pharmaceutical product approvals. For example, in Brazil, pharmaceutical patents require prior initial approval from the Brazilian health agency, ANVISA. Finally, many countries have large backlogs in patent prosecution, and in some countries in Latin America, it can take years, even decades, just to get a pharmaceutical patent application reviewed notwithstanding the merits of the application. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental patent and similar agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance, validation, and annuity fees on any issued patent are due to be paid to the U.S. Patent and Trademark Office (“USPTO”) and foreign patent agencies in several stages over the lifetime of a patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the patent application process. While an inadvertent lapse can, in many cases, be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction just for failure to know about and/or timely pay such fee. Noncompliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees in prescribed time periods, and failure to properly legalize and submit formal documents in the format and style the country requires. If we or our licensors fail to maintain the patents and patent applications covering our product candidates for any reason, our competitors might be able to otherwise enter the market, which would have an adverse effect on our business, financial condition, operating results, and prospects. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, countries continue to increase the fees that are charged to acquire, maintain, and enforce patents and other intellectual property rights, which may become prohibitive to initiate or continue paying in certain circumstances.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our obligations under our intellectual property and related license agreements, we could lose license rights that are important to our business. Additionally, these agreements may be subject to disagreement over contract interpretation, which could narrow the scope of our rights to the relevant intellectual property or technology, or other key aspects of product development and/or commercialization, or increase our financial or other obligations to our licensors. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into in-license arrangements with respect to all of our product candidates. These license agreements impose various diligence, milestone, royalty, insurance, reporting, and other obligations on us. If we fail to comply with these obligations, the respective licensors may have the right to terminate or modify the license, or trigger other more disadvantageous contract clauses, in which event we may not be able to finance, develop or market the affected product candidate. The loss of such rights could expose us to liability and could materially adversely affect our business, financial condition, operating results, and prospects. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends on our ability to develop, manufacture, market, and sell our product candidates and use our proprietary technologies without infringing the proprietary rights of third parties and do this in one or more countries. We cannot assure that marketing and selling such product candidates and using </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such technologies will not infringe existing or future patents or other intellectual property rights. Numerous U.S. and foreign-issued patents and pending patent applications owned by third parties exist in the fields relating to our product candidates. As the biotechnology and pharmaceutical industries expand and more patents and other intellectual property rights are issued, the risk increases that others may assert that our product candidates, technologies, or methods of delivery or use(s) infringe their patent or other intellectual property rights. Moreover, it is not always clear to industry participants, including us, which patents and other intellectual property rights cover various drugs, biologics, drug delivery systems and formulations, manufacturing processes, or their methods of use, and which of these patents may be valid and enforceable. Thus, because of the large number of patents issued and patent applications filed in our fields across many countries, there may be a risk that third parties may allege they have patent or other rights encompassing our product candidates, technologies, or methods. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there may be issued patents of third parties that are infringed or are alleged to be infringed by our product candidates or proprietary technologies notwithstanding the patents we may possess. Because some patent applications in the U.S. and other countries may be maintained in confidence until the patents are issued, because patent applications in the U.S. and many foreign jurisdictions are typically not published until eighteen (18) months or some other time after filing, and because publications in the scientific literature or other public disclosures often lag behind actual discoveries, we cannot be certain that others have not filed patent applications for technology covered by our patents or our pending applications. Our competitors may have filed, and may in the future file, patent applications covering our product candidates or technology similar to our technology. Any such patent application may have priority over our patent applications or patents, which could further require us to obtain rights to issued patents covering such technologies, which may mean paying significant licensing fees or royalties, or the like. If another party has filed a U.S. patent application on inventions similar to ours, we or the licensor may have to participate in the U.S. in an interference proceeding to determine priority of invention. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be exposed to, or threatened with, future litigation by third parties having patent or other intellectual property rights alleging that our product candidates or proprietary technologies infringe such third parties’ intellectual property rights, including litigation resulting from filing in the U.S. under Paragraph IV of the Hatch-Waxman Act or other countries’ laws similar to the Hatch-Waxman Act. These lawsuits could claim that there are existing patent rights for such drug, and this type of litigation can be costly and could adversely affect our operating results and divert the attention of managerial and technical personnel, even if we do not infringe such patents or the patents asserted against us are ultimately established as invalid. There is a risk that a court or other legal authority would decide that we are infringing the third party’s patents and would order us to stop the activities covered by the patents. In addition, there is a risk that a court or other legal authority will order us to pay the other party significant damages for having violated the other party’s patents or intellectual property rights.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we rely on certain third-party licensors, licensees, and partners and will continue to do so in the future, around the world, if one of our licensors, licensees, or partners is sued for infringing a third party’s intellectual property rights, this could expose us to liability, and our business, financial condition, operating results, and prospects could suffer in the same manner as if we were sued directly. In addition to facing litigation risks, we have agreed to indemnify certain third-party licensors, licensees, and partners against claims of infringement caused by our proprietary technologies, and we have entered or may enter into cost-sharing agreements with some of our licensors, licensees, and partners that could require us to pay some of the costs of patent or other intellectual property rights litigation brought against those third parties whether or not the alleged infringement is caused by our proprietary technologies. In certain instances, these cost-sharing agreements could also require us to assume greater responsibility for infringement damages than would be assumed just on the basis of our technology. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The occurrence of any of the foregoing could expose us to liability or adversely affect our business, financial condition, operating results, and prospects at any time. </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provisions of Delaware law and our restated certificate of incorporation and amended and restated bylaws may discourage another company from acquiring us and may prevent attempts by our stockholders to replace or remove our current management. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions of Delaware law and our restated certificate of incorporation and amended and restated bylaws may discourage, delay, or prevent a merger or acquisition that our stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace or remove our board of directors. These provisions include, but are not limited to: </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">authorizing the issuance of “blank check” preferred stock without any need for action by stockholders;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">providing for a classified board of directors with staggered terms; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requiring supermajority stockholder voting to effect certain amendments to our current certificate of incorporation and bylaws; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">eliminating the ability of stockholders to call special meetings of stockholders; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing advance notice requirements for nominations for election to our board of directors or for proposing matters that can be acted on by stockholders at stockholder meetings. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we believe these provisions collectively provide for an opportunity to receive higher bids by requiring potential acquirers to negotiate with our board of directors, they would apply even if an offer may be considered beneficial by some stockholders. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to attract and retain management and other key personnel and directors, we may be unable to continue to successfully develop or commercialize our product candidates or otherwise implement our business plan. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to compete in the highly competitive pharmaceuticals industry depends on our ability to attract and retain highly qualified managerial, scientific, medical, legal, regulatory and compliance, sales and marketing, business development, commercial and other personnel, and directors of our board of directors. We are highly dependent on our management, scientific personnel, and our directors. The loss of the services of any of these individuals could impede, delay, or prevent the regulatory approval of sofpironium bromide, successful development of the rest of our product pipeline, completion of our planned clinical trials, commercialization of our product candidates, or in-licensing or acquisition of new assets and could impact negatively our ability to implement successfully our business plan and in a way that complies with all applicable laws. If we lose the services of any of these individuals, we might not be able to find suitable diverse replacements on a timely basis or at all, and our business could be harmed as a result. We might not be able to attract or retain diverse qualified management and other key personnel or directors in the future due to the intense competition for qualified individuals among biotechnology, pharmaceutical, and other businesses. This risk is heightened recently for most employers by the global reaction to emergence from the COVID-19 pandemic and its impact on worker availability and government regulation of workplace practices associated with public health and other factors.</span></div><div style="margin-bottom:1pt;text-align:justify"><span><br></span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><div id="ie1e15c78f2af410c8f1490215e82bdbe_178"></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1B. UNRESOLVED STAFF COMMENTS</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br></span></div><div id="ie1e15c78f2af410c8f1490215e82bdbe_181"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. PROPERTIES</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters are in Boulder, Colorado, occupying approximately 3,000 square feet under a lease agreement that expires in December 2022 and includes two additional three-year renewal options. We use our current facilities primarily for research and development and general and administrative personnel. While we may seek to expand our current facilities or place certain operations in other states in the next 12 to 18 months, we believe that our existing facilities are adequate for our current needs.</span></div><div style="text-align:justify"><span><br></span></div><div id="ie1e15c78f2af410c8f1490215e82bdbe_136"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. LEGAL PROCEEDINGS</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. We are not presently a party to any legal proceedings that, if determined adversely to us, would individually or taken together have a material adverse effect on our company, nor is any such litigation threatened as of the date of this filing.</span></div><div style="text-align:justify"><span><br></span></div><div id="ie1e15c78f2af410c8f1490215e82bdbe_151"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. MINE SAFETY DISCLOSURES</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="text-align:justify"><span><br></span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><div id="ie1e15c78f2af410c8f1490215e82bdbe_184"></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II.</span></div><div style="text-align:justify"><span><br></span></div><div id="ie1e15c78f2af410c8f1490215e82bdbe_187"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market Information </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is traded on The Nasdaq Capital Market under the symbol “BBI.”</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Holders</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of&nbsp;March&nbsp;3, 2022, we had&nbsp;188&nbsp;registered holders of record of our common stock. A substantially greater number of holders of our common stock are “street name” or beneficial holders, whose shares of record are held by banks, brokers, other financial institutions, and registered clearing agencies.&nbsp;</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Repurchases</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were&nbsp;no&nbsp;repurchases&nbsp;made by us or on our behalf, or by any “affiliated purchaser,” of shares of our common stock during the year ended December&nbsp;31, 2021.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividend Policy</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We historically have not, and do not anticipate in the future, paying dividends on our common stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. We are not subject to any legal restrictions respecting the payment of dividends, except that we may not pay dividends if the payment would render us insolvent. Subject to these limitations, any future determination as to the payment of cash dividends on our common stock will be at our board of directors’ discretion and will depend on our financial condition, operating results, capital requirements, and other factors that our board of directors considers to be relevant.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 23, 2021, we issued 200,000 shares of our common stock to the FORCE Family Office, LLC (“Force”) pursuant to an agreement we entered into with Force on November&nbsp;23, 2021 for the provision of investor relations services from December&nbsp;1, 2021 through May&nbsp;31, 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such issuance was exempt from registration under Section 4(a)(2) of the Securities Act and Regulation D thereunder. Force has represented to us that it is an “accredited investor” as defined in Regulation D under the Securities Act and that the issued shares are being acquired for investment purposes and not with a view to resale or distribution.</span></div><div style="text-align:justify"><span><br></span></div><div id="ie1e15c78f2af410c8f1490215e82bdbe_190"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. [RESERVED]</span></div><div style="text-align:justify"><span><br></span></div><div id="ie1e15c78f2af410c8f1490215e82bdbe_103"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases. Our pipeline combines several development-stage candidates and a cutting-edge platform with broad potential in autoimmune and inflammatory disorders with a potential best-in-class, late-stage program for the treatment of primary axillary hyperhidrosis. Our executive management team and board of directors bring extensive experience in product development and global commercialization, having served in </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Taltz</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Gemzar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Prozac</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Cymbalta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Juvederm</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our strategy is to leverage this experience to in-license, acquire, develop, and commercialize innovative pharmaceutical products that we believe can meaningfully benefit patients who are suffering from chronic, debilitating diseases in the foregoing target disease areas and that are underserved by available therapies.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our product development programs: </span></div><div style="text-align:center"><img alt="bbi-20211231_g1.jpg" style="height:267px;margin-bottom:5pt;vertical-align:text-bottom;width:600px" data-src="https://www.sec.gov/Archives/edgar/data/819050/000081905022000016/bbi-20211231_g1.jpg" src="https://www.sec.gov/Archives/edgar/data/819050/000081905022000016/bbi-20211231_g1.jpg"></div><div style="text-align:center"><span><br></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research &amp; Development Programs</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BBI-02: A Potential First-in-Class Oral DYRK1A Inhibitor for the Treatment of Autoimmune and Inflammatory Diseases </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 27, 2021, we entered into the Voronoi License Agreement with Voronoi, pursuant to which we acquired exclusive, worldwide rights to research, develop, and commercialize BBI-02, a potential first-in-class oral DYRK1A inhibitor, and other novel DYRK1A therapeutics developed from Voronoi’s proprietary kinase inhibitor platform. These novel DYRK1A inhibitors aim to restore immune balance in patients whose immune system has become dysregulated. Based on the promising preclinical efficacy data generated to date with BBI-02, we believe these drug candidates have the potential to offer first-in-class, potent therapies to treat a wide array of debilitating autoimmune and inflammatory diseases.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead development-stage program, BBI-02, is a Phase 1-ready, highly selective, and orally bioavailable DYRK1A inhibitor that has demonstrated promising results in various preclinical models, including AD and RA. In these models, BBI-02 showed encouraging decreases in disease severity and reduction of pro-inflammatory cytokines compared to current standard-of-care agents, such as JAK inhibitors and TNF biologics. Notably, many current therapies for autoimmune disorders are broadly immunosuppressant, which may lead to severe side effects, such as increased infection risk. Preclinical data have shown BBI-02 to drive regulatory T-cell differentiation while dampening pro-inflammatory T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">H</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17 cells and MyD88/IRAK4-related signaling pathways. Regulatory T cells serve to maintain tolerance and keep the autoreactive, pro-inflammatory T cells in check, thus inhibiting autoimmune disease and limiting chronic inflammation. The MyD88 protein is normally spliced into a long form and a short form. DYRK1A inhibition shifts the balance to produce more MyD88 short form, which leads to IRAK4, a protein kinase involved in signaling immune responses from toll-like receptors, not being phosphorylated and so appears to deactivate downstream cascades of certain pro-inflammatory cytokines. Based on current understanding, this inhibition of the release of excess cytokines can be achieved by </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">re-establishing the role of MyD88 short form as a negative regulator of this pathway. Unlike many existing therapies, as well as those currently being investigated, BBI-02 may have the ability to target both the adaptive and innate immune imbalance simultaneously, potentially resulting in, or substantially achieving, restoration of immune homeostasis that, if proven, would represent a paradigm shift in the treatment of certain autoimmune and inflammatory diseases.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are on track to progress BBI-02 into a Phase 1 clinical trial in Canada in the second quarter of 2022. This Phase 1 study is expected to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BBI-02 in both healthy volunteers and subjects with AD and will include a preliminary assessment of efficacy. Part 1A of the Phase 1 trial will be a single ascending dose (SAD) assessment in healthy volunteers, Part 1B will be a multiple ascending dose (MAD) assessment in healthy volunteers, and Part 2 will compare BBI-02 to placebo in moderate-to-severe AD patients. Topline results from the Phase 1 SAD and MAD trials (Parts 1A and 1B) are anticipated year-end 2022. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BBI-02 is covered by a composition of matter patent issued in the U.S., Japan, China, and other key countries through at least 2038, subject to patent term extensions and adjustments that may be available depending on how this early-stage asset is developed, as well as a pending PCT application, and other foreign and U.S. applications for BBI-02, as of the date of this Annual Report.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BBI-10: A Covalent STING Inhibitor for the Potential Treatment of Autoinflammatory and Rare Genetic Diseases</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&nbsp;2, 2022, we entered into the Carna License Agreement with Carna, pursuant to which we acquired exclusive, worldwide rights to research, develop, and commercialize Carna’s portfolio of novel STING inhibitors. STING is a well-known mediator of innate immune responses. Excessive signaling through STING is linked to numerous high unmet need diseases, ranging from autoimmune disorders, such as systemic lupus erythematosus and RA, to interferonopathies, which are a set of rare genetic conditions characterized by interferon overproduction and could have orphan drug potential.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">STING is a key component of the cGAS-STING pathway, which plays an important role in the activation of innate immunity. cGAS acts as a DNA sensor, detecting DNA from sources such as invading bacteria, viruses, and cellular debris that can arise from aging and tissue damage. Upon DNA binding, cGAS produces the secondary messenger molecule cGAMP, which binds to STING. STING then undergoes the post-translational modification called palmitoylation, a step essential to the activation of STING. Activated STING then in turn activates the recruitment of kinases that phosphorylate IRF3 and IκBα. Phosphorylated IRF3 leads to activation of the type I interferon response, while phosphorylated IκBα activates NFκB and increases the secretion of pro- inflammatory cytokines such as IL-6 and TNFα, resulting in inflammation. While the innate immune response is an important defense mechanism, a dysregulated type I interferon response and overproduction of pro-inflammatory cytokines also represents a driving cause for multiple autoimmune and inflammatory diseases. As such, targeting the cGAS-STING pathway may be a novel approach to treating these diseases. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BBI-10, our lead early-stage STING inhibitor candidate, is a novel, potent, and orally available covalent STING inhibitor that specifically targets the palmitoylation site of STING, which allows it to inhibit both wild-type STING and gain-of-function mutants without competing with cGAMP binding, thus deactivating downstream signaling through IRF3 and IκBα and ultimately suppressing inflammation. BBI-10 has exhibited strong proof-of mechanism and a promising profile in initial pharmacokinetics, toxicology, and safety pharmacology studies. In addition, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> studies show that BBI-10 more potently blocks the STING pathway compared to other known STING palmitoylation inhibitors, and that mice treated with BBI-10 demonstrate significant decreases in pro-inflammatory cytokine production following stimulation of STING. Nonclinical development activities for BBI-10 are currently underway, and we expect to conduct experimental characterization of the STING inhibitor library throughout 2022.</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For BBI-10, as of the date of this Annual Report, we currently have one pending PCT application and one pending priority patent application. We possess an exclusive license directed to a library of compounds targeting/inhibiting STING, pharmaceutical compositions containing the same, and methods of their use, which are being evaluated. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Next-Generation Kinase Inhibitors: A Cutting-Edge Platform with Potential to Produce Treatments for Autoimmune, Inflammatory, and Other Debilitating Diseases</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Voronoi License Agreement, in August 2021 we acquired exclusive global rights to a cutting-edge platform of next-generation kinase inhibitors, in addition to BBI-02. This library of new chemical entities includes next-generation DYRK1A inhibitors, as well as other molecules that specifically inhibit LRRK2, TTK (also known as Monopolar spindle 1 (Mps1)), and CLK kinases. A number of these drug candidates have the potential to penetrate the blood brain barrier, presenting an opportunity to address neuroinflammatory conditions of high unmet need such as Down Syndrome, Alzheimer’s Disease, and Parkinson’s Disease, while other peripherally acting novel LRRK2, TTK, and CLK kinase inhibitors could be developed in additional therapeutic areas within autoimmunity, inflammation, and oncology. We are currently engaged in research to identify both brain penetrant and non-brain penetrant new chemical entities from this next-generation kinase inhibitor platform.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compounds from the next-generation kinase inhibitor platform are covered by U.S. and foreign composition of matter patent applications, as well as other applications, that are currently pending in global prosecution based on our exclusive license from Voronoi related to DYRK1A, LRRK2, TTK, and CLK kinases. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sofpironium Bromide</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> A Potential Best-in-Class Investigational Product for the Treatment of Primary Axillary Hyperhidrosis</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sofpironium bromide is a new chemical entity that belongs to a class of medications called anticholinergics. Anticholinergics block the action of acetylcholine, a chemical that transmits signals within the nervous system that are responsible for a range of bodily functions, including activation of the sweat glands. Sofpironium bromide was retrometabolically designed. Retrometabolic drugs are designed to exert their action locally and are potentially rapidly metabolized into a less active form once absorbed into the blood. We have developed sofpironium bromide gel, 15% as a potential best-in-class, self-administered, once daily, topical therapy for the treatment of primary axillary hyperhidrosis, also known as excessive underarm sweating.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hyperhidrosis is a debilitating, life-altering medical condition of sweating beyond what is physiologically required for thermoregulation of the body. Primary axillary hyperhidrosis is believed to be caused by an overactive cholinergic response of the sweat glands and affects an estimated 15.3 million, or 4.8%, of the U.S. population, and 12.76% of the population in Japan. According to a 2016 update on the prevalence and severity of hyperhidrosis in the U.S., axillary hyperhidrosis, which is the targeted first potential indication for sofpironium bromide, is the most common occurrence of hyperhidrosis, affecting approximately 65% of patients, or an estimated 10 million individuals, in the U.S. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sofpironium bromide gel, 15% has completed a U.S. Phase 3 pivotal clinical program (also referred to as our “Cardigan Studies”) for the treatment of primary axillary hyperhidrosis, and sofpironium bromide gel, 5% is approved in Japan for the same indication under the brand name ECCLOCK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Following a pre-NDA meeting with the FDA held in the first quarter of 2022, we remain on track to file an NDA for sofpironium bromide gel, 15% in mid-2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the significant cost to obtain FDA approval of an NDA and, if approved, to launch sofpironium bromide successfully in the U.S., we are presently evaluating different options that include: (i) commercializing sofpironium bromide alone; (ii) partnering with a contract sales organization that has an embedded sales force and other commercial capabilities in which to share costs and profits; or (iii) assigning/selling our rights to </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sofpironium bromide to another third party pharmaceutical company or investment entity to commercialize on its own. No decision on our strategic direction for sofpironium bromide has been finalized as of the date of this Annual Report.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&nbsp;31, 2021, regarding our patent portfolio for sofpironium bromide, we owned or possessed an exclusive license to 18 issued U.S. patents and 137 patents granted, registered, or allowed in foreign countries, including validations in member states of the European Patent Organisation. For sofpironium bromide, for the same time period, we owned or possessed an exclusive license to eight pending U.S. patent applications, 87 pending foreign patent applications, and two pending international patent applications to be nationalized in 2022, which, if issued, may provide patent term coverage to 2041 in certain cases and countries, and even further subject to availability of patent term extension or adjustments. We continue to prosecute pending applications for sofpironium bromide globally as of the date of this Annual Report. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Phase 3 Pivotal Cardigan Studies</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our U.S. Phase 3 pivotal clinical program for sofpironium bromide gel, 15% was comprised of two pivotal clinical studies. The Cardigan I and Cardigan II studies enrolled 350 subjects and 351 subjects, respectively, who were nine years of age and older with primary axillary hyperhidrosis. The Cardigan Studies were multicenter, randomized, double-blinded, vehicle (placebo)-controlled, evaluating the efficacy and safety of topically applied sofpironium bromide gel, 15%. Subjects applied sofpironium bromide gel, 15% or placebo to their underarms once daily at bedtime for six consecutive weeks, with a two-week post-treatment follow-up. The co-primary efficacy endpoints of the Cardigan Studies included the proportion of subjects achieving at least a 2-point</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">improvement on the HSDM-Ax scale, a proprietary and validated patient-reported outcome measure, and change in GSP, each from baseline to EOT. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, we reported positive topline results from both Cardigan Studies, which achieved statistical significance on all primary and secondary efficacy endpoints. In the Cardigan I and II Studies, sofpironium bromide gel, 15% was generally well-tolerated. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardigan Studies Efficacy Results</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">*</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All primary and secondary efficacy endpoints demonstrated statistically significant differences between sofpironium bromide gel, 15% (SB) and vehicle (or placebo), as follows:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:40.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.902%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Cardigan I</span></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Cardigan II</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Co-Primary Efficacy Endpoints</span></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">SB<br>(n=173)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Vehicle<br>(n=177)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">p-value</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">SB<br>(n=180)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Vehicle<br>(n=171)</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">p-value</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:117%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:117%;padding-left:14.5pt">Proportion of subjects achieving at least a 2-point improvement in the HDSM-Ax score from baseline to EOT</span></div></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">49.3%</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">29.4%</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">p&lt;0.001</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">63.9%</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">47.0%</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">p=0.003</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:117%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:117%;padding-left:14.5pt">Change in GSP from baseline to EOT (in mg)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-129.5</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-99.3</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">p=0.002</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-145.9</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-131.7</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">p=0.030</span></td></tr></tbody></table></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:40.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.902%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Cardigan I</span></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Cardigan II</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Secondary Efficacy Endpoints</span></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">SB<br>(n=173)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Vehicle<br>(n=177)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">p-value</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">SB<br>(n=180)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Vehicle<br>(n=171)</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">p-value</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:117%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:117%;padding-left:14.5pt">Proportion of subjects achieving at least a 1-point improvement in the HDSM-Ax score from baseline to EOT</span></div></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">82.8%</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">69.5%</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">p=0.005</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">89.9%</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">80.8%</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">p=0.020</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:117%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:117%;padding-left:14.5pt">Proportion of subjects achieving at least a 2‑point improvement in the HDSM-Ax score and at least a 70% reduction in GSP from baseline to EOT</span></div></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">32.1%</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.2%</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">p&lt;0.0001</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">35.5%</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">21.4%</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">p=0.006</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:117%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:117%;padding-left:14.5pt">Proportion of subjects achieving at least a 1‑point improvement in the HDSM-Ax score and at least a 50% reduction in GSP from baseline to EOT</span></div></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">54.3%</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">33.3%</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">p&lt;0.001</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">68.7%</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">54.6%</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">p=0.014</span></td></tr></tbody></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">* Intent-to-Treat analysis population</span></div><div style="text-align:justify"><span><br></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardigan Studies Safety Results </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the Cardigan Studies, sofpironium bromide gel, 15% was generally well-tolerated. The TEAEs were mild or moderate in severity and transient in nature. Overall, 89% of patients who were randomized to sofpironium gel, 15% in the studies completed the full six weeks of treatment. Common adverse events (incidence ≥2%) observed in the sofpironium bromide gel, 15% treatment group in the Cardigan I and II studies were dry mouth (11.6%, 17.2%), blurred vision (5.2%, 11.7%), application site pain (6.4%, 10.0%), application site erythema (5.2%, 7.8%), mydriasis (7.5%, 5.0%), application site pruritis (6.4%, 2.2%), application site dermatitis (5.8%, 5.6%), urinary retention (1.2%, 3.3%), application site irritation (1.2%, 3.3%), dry eye (0.6%, 3.3%), headache (1.2%, 2.2%), constipation (0.6%, 2.2%) and urinary hesitation (0.6%, 2.2%), respectively. Five (2.9%) and nine (5.0%) subjects who received sofpironium bromide gel, 15%, discontinued the Cardigan I and II studies, respectively, due to a TEAE. No treatment-related serious adverse events were reported.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration with Kaken in Asia</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Kaken Agreement, we and Kaken have completed multiple clinical trials of sofpironium bromide gel involving over 1,690 subjects in the U.S. and Japan. These trials evaluated the potential safety, tolerability, pharmacokinetics, and efficacy of sofpironium bromide gel in adult and pediatric patients with primary axillary hyperhidrosis and healthy adult subjects. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, Kaken received regulatory approval in Japan to manufacture and market sofpironium bromide gel, 5% under the brand name ECCLOCK for the once-daily treatment of primary axillary hyperhidrosis. Japan is the first country to approve sofpironium bromide, which also marks the first approval of a topical prescription product for the treatment of primary axillary hyperhidrosis in Japan. This approval was based on the results of Kaken’s Japanese pivotal Phase 3 registration study of sofpironium bromide gel, 5% in 281 patients with primary axillary hyperhidrosis. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, Kaken launched commercial sales of ECCLOCK in Japan. This marked the first commercialization of sofpironium bromide for any indication worldwide. Under the Kaken Agreement, we are entitled to receive commercial milestone payments, as well as tiered royalties based on a percentage of net sales of ECCLOCK in Japan. As a result, beginning in the fourth quarter of 2020, we have recognized royalty revenue earned on a percentage of net sales of ECCLOCK in Japan. In addition to Japan, Kaken has rights to develop and commercialize sofpironium bromide in South Korea, China, and certain other Asian countries, and we are entitled to receive royalties based on a percentage of Kaken’s net sales in these countries.</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Financing and Licensing Arrangements</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Public Offerings of Common Stock and Warrants </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, we completed the sale of 30,263,400 shares of our common stock (the “October 2021 Offering”). The October 2021 Offering resulted in net proceeds of approximately $10.3&nbsp;million, after deducting the underwriting discount and offering expenses payable by us. We are using the net proceeds from the October 2021 Offering for research and development, including clinical trials, working capital, business development, and general corporate purposes.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, we completed the sale of 12,983,871 shares of our common stock (the “July 2021 Offering”). The July 2021 Offering resulted in net proceeds of approximately $7.3&nbsp;million, after deducting underwriting discounts and commissions and offering expenses. We are using the net proceeds from the July 2021 Offering for research and development, including clinical trials, working capital, and general corporate purposes.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, we completed the sale of 19,003,510 shares of our common stock, and, to certain investors, pre-funded warrants to purchase 1,829,812 shares of our common stock, and accompanying common stock warrants to purchase up to an aggregate of 20,833,322 shares of our common stock (the “October 2020 Offering”). The October 2020 Offering resulted in net proceeds of approximately $13.7&nbsp;million to us after deducting underwriting commissions and discounts and other offering expenses of $1.3&nbsp;million and excluding the proceeds from the exercise of the warrants. During the year ended December&nbsp;31, 2021, 12,427,387 common warrants associated with the October 2020 Offering were exercised at a weighted-average exercise price of $0.72 per share, resulting in aggregate proceeds of approximately $8.9&nbsp;million. We are using the net proceeds from the October 2020 Offering for research and development, including clinical trials, working capital, and general corporate purposes.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, we completed the sale of 14,790,133 shares of our common stock, and, to certain investors, pre-funded warrants to purchase 2,709,867 shares of our common stock, and accompanying common warrants to purchase up to an aggregate of 17,500,000 shares of our common stock (the “June 2020 Offering”). The June 2020 Offering resulted in approximately $18.7&nbsp;million of net proceeds after deducting underwriting commissions and discounts and other offering expenses of $1.4&nbsp;million and excluding the proceeds from the exercise of the warrants. During the year ended December&nbsp;31, 2021, 17,500 common warrants associated with the June 2020 Offering were exercised at a weighted-average exercise price of $1.25 per share, resulting in aggregate proceeds of approximately $22&nbsp;thousand. We are using the net proceeds from the June 2020 Offering for research and development, including clinical trials, working capital, and general corporate purposes. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information regarding the offerings described above, see Note 7. “Capital Stock” of the notes to our consolidated financial statements included in this Annual Report.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">At Market Issuance Sales Agreements</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, we entered into an At Market Issuance Sales Agreement (the “2021 ATM Agreement”) with Oppenheimer &amp; Co. Inc. (“Oppenheimer”) and William Blair as our sales agents (the “Agents”). Pursuant to the terms of the 2021 ATM Agreement, we may sell from time to time through the Agents shares of our common stock having an aggregate offering price of up to $50.0&nbsp;million. Such shares are issued pursuant to our shelf registration statement on Form&nbsp;S-3 (Registration No.&nbsp;333-254037). Sales of shares are made by means of ordinary brokers’ transactions on The Nasdaq Capital Market at market prices or as otherwise agreed by us and the Agents. Under the terms of the 2021 ATM Agreement, we may also sell the shares from time to time to an Agent as principal for its own account at a price to be agreed upon at the time of sale. Any sale of the shares to an Agent as principal would be pursuant to the terms of a separate placement notice between us and such Agent. During the year ended December&nbsp;31, 2021, we sold 4,449,828 shares of our common stock under the 2021 ATM Agreement at a weighted-average price of $0.89 per share, for aggregate net proceeds of $3.8&nbsp;million, </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">after giving effect to a 3% commission to the Agents. As of December&nbsp;31, 2021, approximately $46.0&nbsp;million of shares of common stock were remaining, but had not yet been sold under the 2021 ATM Agreement.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we entered into an At Market Issuance Sales Agreement (the “2020 ATM Agreement” and, together with the 2021 ATM Agreement, the “ATM Agreements”) with Oppenheimer as our sales agent. Pursuant to the terms of the 2020 ATM Agreement, we may sell from time to time through Oppenheimer shares of our common stock having an aggregate offering price of up to $8.0 million. Such shares are issued pursuant to our shelf registration statement on Form S-3 (Registration No. 333-236353). Sales of the shares are made by means of ordinary brokers’ transactions on The Nasdaq Capital Market at market prices or as otherwise agreed by us and Oppenheimer. Under the terms of the 2020 ATM Agreement, we may also sell the shares from time to time to Oppenheimer as principal for its own account at a price to be agreed upon at the time of sale. Any sale of the shares to Oppenheimer as principal would be pursuant to the terms of a separate placement notice between us and Oppenheimer. During the year ended December&nbsp;31, 2021, we sold 1,089,048 shares of our common stock under the 2020 ATM Agreement at a weighted-average price of $1.55 per share, for aggregate net proceeds of approximately $1.6&nbsp;million, after giving effect to a 3% commission to Oppenheimer as agent. As of December&nbsp;31, 2021, approximately $2.6&nbsp;million of shares of common stock were remaining, but had not yet been sold under the 2020 ATM Agreement.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Private Placement Offerings</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, we and Lincoln Park Capital Fund, LLC (“Lincoln Park”) entered into (i) a securities purchase agreement (the “Securities Purchase Agreement”); (ii) a purchase agreement (the “Purchase Agreement”); and (iii) a registration rights agreement (the “Registration Rights Agreement”). Pursuant to the Securities Purchase Agreement, Lincoln Park purchased, and we sold, (i) an aggregate of 950,000 shares of common stock (the “Common Shares”); (ii) a warrant to initially purchase an aggregate of up to 606,420 shares of common stock at an exercise price of $0.01 per share (the “Series A Warrant”); and (iii) a warrant to initially purchase an aggregate of up to 1,556,420 shares of common stock at an exercise price of $1.16 per share (the “Series B Warrant” and, together with the Series A Warrant, the “Warrants”). The aggregate gross purchase price for the Common Shares and the Warrants was $2.0&nbsp;million.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms and subject to the conditions of the Purchase Agreement, we have the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase, up to $28.0&nbsp;million in the aggregate of shares of our common stock. In order to retain maximum flexibility to issue and sell up to the maximum of $28.0 million of our common stock under the Purchase Agreement, we sought and, at our annual meeting on April 19, 2021, received, stockholder approval for the sale and issuance of common stock in connection with the Purchase Agreement under Nasdaq Listing Rule 5635(d). Sales of common stock by us will be subject to certain limitations, and may occur from time to time, at our sole discretion, over the 36-month period commencing on August&nbsp;14,&nbsp;2020 (the “Commencement Date”). </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the Commencement Date, under the Purchase Agreement, on any business day selected by us, we may direct Lincoln Park to purchase up to 100,000 shares of our common stock on such business day (each, a “Regular Purchase”), provided, however, that (i) the Regular Purchase may be increased to up to 125,000 shares, provided that the closing sale price of the common stock is not below $3.00 on the purchase date; and (ii) the Regular Purchase may be increased to up to 150,000 shares, provided that the closing sale price of the common stock is not below $5.00 on the purchase date. In each case, Lincoln Park’s maximum commitment in any single Regular Purchase may not exceed $1,000,000. The purchase price per share for each such Regular Purchase will be based on prevailing market prices of common stock immediately preceding the time of sale. In addition to Regular Purchases, we may direct Lincoln Park to purchase other amounts as accelerated purchases or as additional accelerated purchases if the closing sale price of the common stock exceeds certain threshold prices as set forth in the Purchase Agreement. In all instances, we may not sell shares of our common stock to Lincoln Park under the Purchase Agreement if it would result in Lincoln Park beneficially owning more than 9.99% of the outstanding shares of our common stock. During the year ended December&nbsp;31, 2021, we sold to </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lincoln Park 1,300,000 shares under the Purchase Agreement at a weighted-average price of $0.81 per share, for aggregate net proceeds of $1.0&nbsp;million. As of December&nbsp;31, 2021, approximately $26.9&nbsp;million of shares of common stock were remaining, but had not yet been sold under the Purchase Agreement. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We agreed with Lincoln Park that we will not enter into any “variable rate” transactions with any third party, subject to certain exceptions, for a period defined in the Purchase Agreement. We have the right to terminate the Purchase Agreement at any time, at no cost or penalty. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exclusive License and Development Agreement with Carna</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&nbsp;2, 2022, we entered into the Carna License Agreement with Carna, pursuant to which we acquired exclusive, worldwide rights to research, develop, and commercialize Carna’s portfolio of novel STING inhibitors. In accordance with the terms of the Carna License Agreement, in exchange for the licensed rights, we made a one-time cash payment of $2.0 million. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Carna License Agreement provides that we will make success-based payments to Carna of up to $258.0 million in the aggregate contingent upon achievement of specified development, regulatory, and commercial milestones. Further, the Carna License Agreement provides that we will pay Carna tiered royalty payments ranging from mid-single digits up to 10% of net sales. All of the contingent payments and royalties are payable in cash in U.S. Dollars. Under the terms of the Carna License Agreement, we will be responsible for, and bear the future costs of, all development and commercialization activities, including patenting, related to all the licensed compounds. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License and Development Agreement with Voronoi</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 27, 2021, we entered into the Voronoi License Agreement with Voronoi, pursuant to which we acquired exclusive, worldwide rights to research, develop, and commercialize BBI-02, a novel, Phase 1-ready, potential first-in-class DYRK1A inhibitor, and other next-generation therapeutics developed from Voronoi’s proprietary kinase inhibitor platform. In accordance with the terms of the Voronoi License Agreement, in exchange for the license rights, we made a one-time payment of $2.5&nbsp;million in cash and issued $2.0 million, or 2,816,901 shares, of our common stock to Voronoi. As a result, we recorded $4.8&nbsp;million in research and development expenses during the year ended December&nbsp;31, 2021.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to BBI-02, the Voronoi License Agreement provides that we will make payments to Voronoi of up to $211.0 million in the aggregate contingent upon achievement of specified development, regulatory, and commercial milestones. With respect to the next-generation compounds arising from the novel kinase inhibitor platform, we will make payments to Voronoi of up to $107.5 million in the aggregate contingent upon achievement of specified development, regulatory, and commercial milestones. Further, the Voronoi License Agreement provides that we will pay Voronoi tiered royalty payments ranging from low-single digits up to 10% of net sales of products arising from the in-licensed DYRK1A inhibitor programs and next-generation kinase inhibitor platform. All of the contingent payments and royalties are payable in cash in U.S. Dollars, except for $1.0 million of the development and regulatory milestone payments, which amount is payable in equivalent shares of our common stock. Under the terms of the Voronoi License Agreement, we will be responsible for, and bear the future costs of, all development and commercialization activities, including patenting, related to all the licensed compounds.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amended and Restated License Agreement with Bodor</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, we, together with Brickell Subsidiary and Bodor, entered into the Amended and Restated License Agreement, which supersedes the License Agreement, dated December 15, 2012, entered into between Brickell Subsidiary and Bodor, as amended by Amendment No. 1 to License Agreement, effective as of October 21, 2013, and Amendment No. 2 to License Agreement, effective as of March 31, 2015.</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended and Restated License Agreement retains with us a worldwide, exclusive license to develop, manufacture, market, sell, and sublicense products containing the proprietary compound sofpironium bromide based upon the patents referenced in the Amended and Restated License Agreement for a defined field of use. As of December&nbsp;31, 2021, under the original License Agreement and the Amended and Restated License Agreement, we had remaining obligations to pay Bodor (i) a royalty on sales of product outside Kaken’s territory, including a low single-digit royalty on sales of certain product not covered by the patent estate licensed from Bodor; (ii) approximately 50 to 55% of all royalties we receive from Kaken for sales of product within its territory; (iii) a percentage of non-royalty sublicensing income we receive from Kaken or other sublicensees; and (iv) up to an aggregate of $0.8&nbsp;million (plus an additional $0.1&nbsp;million for approvals of additional products) in cash payments and $1.0&nbsp;million of shares of our common stock upon the achievement of certain regulatory milestones. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Amended and Restated License Agreement, we made a $0.5 million milestone payment to Bodor following the closing of a public offering in June 2020 and accrued an additional $1.0 million related to our plan to initiate our U.S. Phase 3 pivotal program in the fourth quarter of 2020. As a result, we recorded $1.5 million as research and development expenses in the consolidated statements of operations during the year ended December 31, 2020. No similar or associated research and development expense was incurred in the year ended December&nbsp;31, 2021, but we paid Bodor the applicable amount with respect to the royalties we received from Kaken for sales of ECCLOCK in Japan during those periods.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Overview</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations to date have been limited to business planning, raising capital, developing our pipeline assets, identifying and in-licensing product candidates, conducting clinical trials, and other research and development activities. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have financed operations primarily through funds received from the sale of common stock and warrants, convertible preferred stock, debt and convertible notes, and payments received under license and collaboration agreements. Other than through our sublicense of rights to sofpironium bromide to Kaken in Japan, we do not have any products approved for sale and have not generated any product sales. Since inception, we have incurred operating losses. We recorded a net loss of $39.5&nbsp;million and $20.9&nbsp;million for the years ended December&nbsp;31, 2021 and 2020, respectively. As of December&nbsp;31, 2021, we had an accumulated deficit of $145.4&nbsp;million. We expect to continue incurring significant expenses and operating losses for at least the next several years as we:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">initiate and execute a Phase 1 clinical trial, along with other nonclincial development activities, for BBI-02;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conduct preclinical development activities for BBI-10 and experimental characterization of the STING inhibitor library;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">engage in research to identify both brain penetrant and non-brain penetrant kinase inhibitors from the next-generation kinase inhibitor platform;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advance research and development-related activities to develop and expand our product pipeline;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prepare and submit an NDA for sofpironium bromide gel, 15% to the FDA;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conduct certain pre-commercialization activities related to sofpironium bromide gel, 15%;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain, expand, and protect our intellectual property portfolio for all our assets;</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">hire additional staff, including clinical, regulatory, quality, alliance management, scientific, and management personnel; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">add operational and finance personnel to support product and business development efforts.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not expect to generate significant revenue unless and until we successfully complete development of, obtain marketing approval for, and commercialize product candidates, either alone or in collaboration with third parties. We expect these activities may take several years and our success in these efforts is subject to significant uncertainty. We expect we will need to raise substantial additional capital prior to the regulatory approval and commercialization of any of our product candidates. Until such time, if ever, that we generate substantial product revenues, we expect to finance our operations through public or private equity or debt financings, collaborations or licenses, or other available financing transactions. However, we may be unable to raise additional funds through these or other means when needed.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Key Components of Operations</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue generally consists of revenue recognized under our strategic collaboration agreements for the development and commercialization of our product candidates. Our strategic collaboration agreements generally outline overall development plans and include payments we receive at signing, payments for the achievement of certain milestones, and royalties. For these activities and payments, we utilize judgment to assess the nature of the performance obligations to determine whether the performance obligations are satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. Prior to 2020, we had not recognized any royalty revenue from any collaboration arrangement. Beginning during the three months ended December 31, 2020, and continuing in 2021, pursuant to the Kaken Agreement, we recognized royalty revenue earned on a percentage of net sales of ECCLOCK in Japan, and we expect to continue to recognize such royalties going forward. Other than the revenue we may generate in connection with this agreement, we do not expect to generate any revenue from any product candidates that we develop unless and until we obtain regulatory approval and commercialize our products or enter into other collaboration agreements with third parties.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses principally consist of payments to third parties known as CROs and upfront in-licensing fees of development-stage assets. CROs help plan, organize, and conduct clinical and nonclinical studies under our direction. Personnel costs, including wages, benefits, and share-based compensation, related to our research and development staff in support of product development activities are also included, as well as costs incurred for supplies, preclinical studies and toxicology tests, consultants, and facility and related overhead costs.</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of our research and development expenses related to sofpironium bromide and our DYRK1A inhibitor program, including our next-generation kinase inhibitor platform, by categories of costs for the periods presented. </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:69.066%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.401%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="background-color:#ffffff;padding:2px 6.62pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended<br>December&nbsp;31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Direct program expenses related to</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sofpironium bromide (1)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,647&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,944&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other pipeline programs (2)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,355&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel and other expenses (3)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries, benefits, and stock-based compensation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,423&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,895&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regulatory and compliance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,322&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">484&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses (4)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,231&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,216&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">____________</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.34pt">Sofpironium bromide. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our research and development expenses related to sofpironium bromide to decrease in future periods given the end of our Phase 3 clinical trials for sofpironium bromide. </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.34pt">Other pipeline programs. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021 we acquired the DYRK1A inhibitor program targeting autoimmune and inflammatory diseases. To date, the expenses associated with our DYRK1A inhibitor program primarily relate to upfront in-licensing fees. We plan to progress BBI-02 into a Phase 1 clinical trial in Canada in the second quarter of 2022. We are also engaging in research to identify new chemical entities from our next-generation kinase inhibitor platform. As a result, in the following years, we expect to incur research and development expense for these programs at levels consistent with expenditures for development of early-stage assets. </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.34pt">Personnel and other expenses. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Personnel and other expenses include operational expenses not specifically attributable to a specific program. Other expenses include travel, lab and office supplies, clinical trial management software, license fees, and other miscellaneous expenses.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.34pt">STING inhibitor platform. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we acquired a portfolio of novel, potent, and orally available STING inhibitors that has broad potential in autoinflammatory diseases. Nonclinical development activities for our lead early-stage STING inhibitor candidate, BBI-10, are currently underway, and we expect to conduct experimental characterization of the STING inhibitor library throughout 2022. As a result, in the following years, we expect to incur research and development expense for this program at levels consistent with expenditures for development of early-stage assets.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of personnel costs, including wages, benefits, and share-based compensation, related to our executive, sales, marketing, finance, and human resources personnel, as well as professional fees, including legal, accounting, and sublicensing fees.</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income, Net</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net consists primarily of a gain on extinguishment of debt recognized in June 2021 as a result of the forgiveness of an outstanding loan that we received under the Paycheck Protection Program (the “PPP Loan”). Other income, net also consists of interest income, interest expense, and various income or expense items of a non-recurring nature. We earn interest income from interest-bearing accounts and money market funds. Interest expense is comprised of interest incurred related to the PPP Loan. Our interest income varies each reporting period depending on our average cash balances during the period and market interest rates. We expect interest income to fluctuate in the future with changes in average cash balances and market interest rates.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have prepared the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The preparation of these consolidated financial statements requires us to make estimates, assumptions, and judgments that affect the reported amounts of assets, liabilities, expenses, and related disclosures at the date of the consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. On an ongoing basis, management evaluates its critical estimates, including those related to revenue recognition and accrued research and development expenses. We base our estimates on our historical experience and on assumptions that we believe are reasonable; however, actual results may differ materially from these estimates under different assumptions or conditions.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information on our significant accounting policies, please refer to Note 2 of the notes to our consolidated financial statements included elsewhere in this Annual Report. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently recognize revenue primarily from licensing and royalty fees received under the Kaken Agreement. The terms of the agreement include non-refundable upfront fees, funding of research and development activities, payments based upon achievement of milestones, and royalties on net product sales.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized, we perform the following five steps: (i)&nbsp;identify the contract(s) with a customer; (ii)&nbsp;identify the performance obligations in the contract; (iii)&nbsp;determine the transaction price, including the constraint on variable consideration; (iv)&nbsp;allocate the transaction price to the performance obligations in the contract; and (v)&nbsp;recognize revenue when (or as) we satisfy the performance obligations. At contract inception, we assess the goods or services promised within each contract and assess whether each promised good or service is distinct and determine those that are performance obligations. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. To date, we have not received approval for any drug candidates from the FDA.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, we assess the goods or services promised within each contract, determine those that are performance obligations, and assess whether each promised good or service is distinct. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when or as the performance obligation is satisfied. We utilize judgment to assess the nature of the performance obligation to determine whether the performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses of Intellectual Property</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a license for our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer, and the customer can use and benefit from the license.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestones</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments (variable consideration), we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone (such as a regulatory submission) is included in the transaction price. Milestone payments that are not within our control or the control of our collaboration partner, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achievement of such development milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration, and other revenues and earnings in the period of adjustment and future periods through the end of the performance obligation period. To date, Kaken has paid us $10.0 million in milestone payments under the Kaken Agreement.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i)&nbsp;when the related sales occur or (ii)&nbsp;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). In September 2020, Kaken received regulatory approval in Japan to manufacture and market ECCLOCK for the treatment of primary axillary hyperhidrosis, and as a result, we began recognizing royalty revenue earned on a percentage of net sales of ECCLOCK in Japan of $27&nbsp;thousand during the fourth quarter of 2020. Prior to the fourth quarter of 2020, we had not recognized any royalty revenue from any collaboration arrangement. During the year ended December&nbsp;31, 2021, we recognized royalty revenue of $0.4&nbsp;million.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a complete discussion of accounting for collaboration licensing agreements, see Note 2 of the notes to our consolidated financial statements included elsewhere in this Annual Report. Our revenue to date has been generated primarily from licensing and development fees received under the Kaken Agreement.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are charged to expense when incurred and consist of costs incurred for independent and collaboration research and development activities. The major components of research and development costs include formulation development, nonclinical studies, clinical studies, clinical manufacturing costs, in-licensing fees for development-stage assets, salaries and employee benefits, and allocations of various overhead and occupancy costs. Research costs typically consist of applied research, preclinical, and toxicology work. Pharmaceutical manufacturing development costs consist of product formulation, chemical analysis, and the transfer and scale-up of manufacturing at contract manufacturers. Assets acquired (or in-licensed) that are utilized in research and development that have no alternative future use are expensed as incurred. Milestone payments related to our acquired (or in-licensed) assets are recorded as research and development expense when probable and can be reasonably estimated.</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expense accruals related to clinical trials are based on our estimates of services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on our behalf. The financial terms of these agreements vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing costs, we estimate the period over which services will be performed and the level of effort to be expended in each period based upon patient enrollment, clinical site activations, or information provided to us by our vendors on their actual costs incurred. Any estimates of the level of services performed or the costs of these services could differ from actual results.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not experienced significant changes in our estimates of accrued research and development expenses after a reporting period. However, due to the nature of estimates, we cannot assure that we will not make changes to our estimates in the future as we become aware of additional information about the status or conduct of our clinical trials and other research activities.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise discussed elsewhere in this Annual Report, we believe that the impact of recently issued guidance, whether adopted or to be adopted in the future, is not expected to have a material impact on our consolidated financial statements upon adoption. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comparison of the Years Ended December&nbsp;31, 2021 and 2020</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:69.733%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.068%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 6.62pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended<br>December&nbsp;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,822&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,231)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,216)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,417)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,582)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">770&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,474)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,913)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="text-align:justify"><span><br></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue decreased by $1.4 million for the year ended December&nbsp;31, 2021, compared to the year ended December&nbsp;31, 2020. Revenue in 2021 consisted of royalty revenue recognized related to sales of ECCLOCK in Japan by Kaken, while revenue in 2020 was driven primarily by collaboration revenue recognized for research and development activities under the Kaken Agreement pursuant to which Kaken provided research and development funding to us. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in royalty revenue recognized related to the regulatory approval in September 2020 for the manufacturing and marketing of ECCLOCK for the treatment of primary axillary hyperhidrosis. Prior to the fourth quarter of 2020, we had not recognized any royalty revenue from any collaboration arrangement. As a result of the regulatory approval, we began recognizing royalty revenue earned on a percentage of net sales of ECCLOCK in Japan of $27&nbsp;thousand during the fourth quarter of 2020. During the year ended December&nbsp;31, 2021, we recognized royalty revenue of $0.4&nbsp;million.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in collaboration revenue recognized was primarily attributable to our Phase&nbsp;3 open-label long-term safety study of sofpironium bromide gel and other ancillary clinical studies that were concluded or winding </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">down by the end of the first quarter of 2020. Conducting these studies was the basis for revenue recognition over time, through the third quarter of 2020, of a $15.6 million research and development payment received from Kaken in the second quarter of 2018.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased by $17.0 million for the year ended December&nbsp;31, 2021, compared to the year ended December&nbsp;31, 2020, which was primarily due to an increase of $10.7&nbsp;million in clinical costs related to our U.S. Phase 3 pivotal clinical program for sofpironium bromide gel, 15%, an increase of $5.4&nbsp;million in upfront costs and development expenses related to our DYRK1A inhibitor programs and next-generation kinase inhibitor platform, and an increase of $0.9&nbsp;million in personnel and other expenses.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses increased by $0.8 million for the year ended December&nbsp;31, 2021, compared to the year ended December&nbsp;31, 2020. The increase was primarily due to compensation and administrative expenses.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Total Other Income, Net</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other income, net increased by $0.7 million for the year ended December&nbsp;31, 2021 compared to the year ended December&nbsp;31, 2020. The increase was primarily due to a gain on extinguishment of debt of approximately $0.4 million that resulted from the forgiveness of the PPP Loan in June 2021 and other miscellaneous income of $0.3 million.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred significant operating losses and have an accumulated deficit as a result of ongoing efforts to in-license and develop our product candidates, including conducting preclinical and clinical trials and providing general and administrative support for these operations. For the years ended December&nbsp;31, 2021 and 2020, we had a net loss of $39.5&nbsp;million and $20.9&nbsp;million, respectively. As of December&nbsp;31, 2021, we had an accumulated deficit of $145.4&nbsp;million. As of December&nbsp;31, 2021, we had cash and cash equivalents of $26.9&nbsp;million compared to $30.1&nbsp;million as of December&nbsp;31, 2020. Since inception, we have financed our operations primarily through funds received from the sale of common stock and warrants, convertible preferred stock, debt, and convertible notes, and payments received under license and collaboration agreements.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our cash and cash equivalents as of December&nbsp;31, 2021 will be sufficient to fund our operations for at least the next 12 months, including through the receipt of the Phase 1 topline results for BBI-02, which is anticipated year-end 2022. Thereafter, we expect we will need additional funding to continue with our planned development and other activities. However, it is difficult to predict our spending for our product candidates prior to obtaining FDA approval. Moreover, changing circumstances may cause us to expend cash significantly faster than we currently anticipate, and we may need to spend more cash than currently expected because of circumstances beyond our control. We expect to continue to incur additional substantial losses in the foreseeable future as a result of our research and development activities.</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have primarily used our available cash to fund expenditures related to product discovery and development activities. The following table sets forth a summary of cash flows for the periods presented:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:69.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.401%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended<br>December&nbsp;31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 4.37pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,148)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,034)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,477&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,953&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,440&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,231)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,883&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="text-align:justify"><span><br></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Activities</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities of $36.1&nbsp;million during the year ended December&nbsp;31, 2021 increased compared to $20.0&nbsp;million during the year ended December&nbsp;31, 2020, which was primarily attributable to an increase in cash used to support our operating activities, including but not limited to, our clinical trials, an increase in research and development activities, and general working capital requirements. The $16.1&nbsp;million increase was impacted by an increase in net loss of $18.6&nbsp;million, partially offset by the net effect of changes in working capital of $1.1&nbsp;million and an increase in non-cash operating expenses of $1.4&nbsp;million, which primarily consisted of $2.0&nbsp;million in expense for the issuance of our common stock under the Voronoi License Agreement, net of a $0.4&nbsp;million gain on extinguishment of the PPP Loan.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing Activities</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities during the year ended December&nbsp;31, 2021 decreased by $4.5&nbsp;million compared to the year ended December&nbsp;31, 2020. The decrease in net cash provided by investing activities was primarily the result of a $4.5&nbsp;million reduction in maturities of marketable securities.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Activities</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities of $33.0&nbsp;million during the year ended December&nbsp;31, 2021 decreased compared to $38.4&nbsp;million during the year ended December&nbsp;31, 2020. The decrease was primarily related to a reduction of $16.7&nbsp;million in net proceeds from offerings of common stock and warrants and $0.4&nbsp;million in proceeds received from the PPP Loan in the year ended December&nbsp;31, 2020 that did not recur in the year ended December&nbsp;31, 2021, which was partially offset by higher net proceeds received of $8.9&nbsp;million from the exercise of warrants and $2.8&nbsp;million in sales of our common stock under the ATM Agreements and the Purchase Agreement.</span></div><div style="text-align:justify"><span><br></span></div><div id="ie1e15c78f2af410c8f1490215e82bdbe_121"></div><div style="margin-bottom:12pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and are not required to provide the information under this item.</span></div><div style="text-align:justify"><span><br></span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><div id="ie1e15c78f2af410c8f1490215e82bdbe_193"></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INDEX</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:83.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.400%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_196" tabindex="18">Report of Independent Registered Public Accounting Firm </a>(PCAOB ID No. <span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="dei:AuditorFirmId" id="fact-identifier-44" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8xOTMvZnJhZzo4YTI2ZjBhMWQyNjE0ZGRmODE3ZDUyMjcyNjgxMzc3NC90YWJsZTo0ZmQyMzE0ZTJmZDQ0MzMzOGM5YWNjNmU2OGIwZjI0NS90YWJsZXJhbmdlOjRmZDIzMTRlMmZkNDQzMzM4YzlhY2M2ZTY4YjBmMjQ1XzEtMC0xLTEtMzQyODQvdGV4dHJlZ2lvbjo5N2FlMjEwODU2M2Y0YThkYTMzM2EwZDgwNjM0MjZhOF8yMTk5MDIzMjU2MDQ4_b6949554-5c09-43f2-ad0e-2ce1d5ae130c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">42</ix:nonnumeric></span>)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_196" tabindex="18">76</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_22" tabindex="18">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_22" tabindex="18">78</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_25" tabindex="18">Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_25" tabindex="18">79</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_28" tabindex="18">Consolidated Statements of Comprehensive Loss</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_28" tabindex="18">80</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_31" tabindex="18">Consolidated Statements of Stockholders’ Equity</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_31" tabindex="18">81</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_37" tabindex="18">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_37" tabindex="18">82</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_43" tabindex="18">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_43" tabindex="18">83</a></span></div></td></tr></tbody></table></div><div style="text-align:center"><span><br></span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><div id="ie1e15c78f2af410c8f1490215e82bdbe_196"></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of Brickell Biotech, Inc.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Brickell Biotech, Inc. (the Company) as of December 31, 2021 and 2020, the related consolidated statements of operations, comprehensive loss, stockholders’ equity and cash flows for each of the two years in the period ended December 31, 2021, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2021, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matter</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:20.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.734%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Research and development costs</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Description of the Matter</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred $28.2&nbsp;million for research and development expenses for the year ended December 31, 2021, and accrued $0.8&nbsp;million and prepaid $1.4 million of research and development expenses at December 31, 2021. The completeness and valuation of certain clinical study fees incurred in the Company's accrued research and development costs are subject to risk of estimation uncertainty related to services received and efforts expended. As discussed in Note 2 of the Company’s consolidated financial statements, costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations or information provided to the Company by its vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Auditing research and development costs was complex and judgmental due to the significant estimation required by management in determining the time period over which services will be performed, enrollment of patients, number of sites activated and the level of effort to be expended in each period. The Company has contracts with multiple contract research organizations (“CROs”) that conduct and manage clinical studies on its behalf. The payment terms of these agreements vary from contract to contract and may result in uneven payment flows.</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">How We<br>Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To test the estimated research and development costs, we performed audit procedures that included, among others, assessing methodologies and testing the significant assumptions discussed above, testing the underlying data used by management, and assessing the historical accuracy of management’s estimates. We performed inquiries of clinical research managers to understand the status of significant trials, discussed any delays or new developments with the studies to understand the impact of the activity on the accounting for the studies, and confirmed directly with CROs the status of significant cost drivers, such as patient enrollment and site activation.</span></td></tr></tbody></table></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:3.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ </span></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="dei:AuditorName" id="fact-identifier-45" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8xOTYvZnJhZzozMWZhYTgyZDM4MGM0YzA5OWU2ZGQ2YTFiZTEwM2FiZC90YWJsZToyNGExMTQwNzM0MWY0MjQ4YjFlNjE2YjEzMWY1OGFlMy90YWJsZXJhbmdlOjI0YTExNDA3MzQxZjQyNDhiMWU2MTZiMTMxZjU4YWUzXzAtMi0xLTEtMjE2OTE_69fbe9d0-f729-4cb4-852b-18d8005e62db" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Ernst &amp; Young LLP</ix:nonnumeric></span></span></td></tr><tr style="height:14pt"><td colspan="15" style="padding:0 1pt"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We have served as the Company’s auditor since 2017.</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="dei:AuditorLocation" id="fact-identifier-46" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8xOTYvZnJhZzozMWZhYTgyZDM4MGM0YzA5OWU2ZGQ2YTFiZTEwM2FiZC90YWJsZToyNGExMTQwNzM0MWY0MjQ4YjFlNjE2YjEzMWY1OGFlMy90YWJsZXJhbmdlOjI0YTExNDA3MzQxZjQyNDhiMWU2MTZiMTMxZjU4YWUzXzMtMC0xLTEtMjE3NjI_70c6b6c2-d607-421d-bb9d-1455e544ea68" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Denver, Colorado</ix:nonnumeric></span></span></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 15, 2022</span></td></tr></tbody></table></div><div><span><br></span></div><div><span><br></span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><div id="ie1e15c78f2af410c8f1490215e82bdbe_22"></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BRICKELL BIOTECH, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:69.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i136a713ea34e4a3a8a8e3a24f4fa59ed_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-47" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMi9mcmFnOmQ5ZDVlOTEwODQ4ODQyNjFiNGJmZTg5NjBhNWQzMjQxL3RhYmxlOjY2YTA4MWJjNzI2YzQ3ZjU5OTA5Y2YyZDg4YTNhNzhkL3RhYmxlcmFuZ2U6NjZhMDgxYmM3MjZjNDdmNTk5MDljZjJkODhhM2E3OGRfNi0xLTEtMS0xNjM1MQ_b5f8ce41-ae20-4dfa-ba2a-bccd78c01e2e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">26,884</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i79b48cfc81254328ac1dae75e4c81c8f_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-48" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMi9mcmFnOmQ5ZDVlOTEwODQ4ODQyNjFiNGJmZTg5NjBhNWQzMjQxL3RhYmxlOjY2YTA4MWJjNzI2YzQ3ZjU5OTA5Y2YyZDg4YTNhNzhkL3RhYmxlcmFuZ2U6NjZhMDgxYmM3MjZjNDdmNTk5MDljZjJkODhhM2E3OGRfNi0zLTEtMS0xNjM1MQ_aa032dac-43b5-48e9-9e7c-f2e0a66d2a52" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">30,115</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i136a713ea34e4a3a8a8e3a24f4fa59ed_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-49" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMi9mcmFnOmQ5ZDVlOTEwODQ4ODQyNjFiNGJmZTg5NjBhNWQzMjQxL3RhYmxlOjY2YTA4MWJjNzI2YzQ3ZjU5OTA5Y2YyZDg4YTNhNzhkL3RhYmxlcmFuZ2U6NjZhMDgxYmM3MjZjNDdmNTk5MDljZjJkODhhM2E3OGRfOC0xLTEtMS0xNjM1MQ_eca2b3d9-9412-4974-aa79-535d353dbf7e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,716</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i79b48cfc81254328ac1dae75e4c81c8f_I20201231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-50" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMi9mcmFnOmQ5ZDVlOTEwODQ4ODQyNjFiNGJmZTg5NjBhNWQzMjQxL3RhYmxlOjY2YTA4MWJjNzI2YzQ3ZjU5OTA5Y2YyZDg4YTNhNzhkL3RhYmxlcmFuZ2U6NjZhMDgxYmM3MjZjNDdmNTk5MDljZjJkODhhM2E3OGRfOC0zLTEtMS0xNjM1MQ_72416992-7152-48a5-b2c3-115d94cdf69c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,415</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i136a713ea34e4a3a8a8e3a24f4fa59ed_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-51" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMi9mcmFnOmQ5ZDVlOTEwODQ4ODQyNjFiNGJmZTg5NjBhNWQzMjQxL3RhYmxlOjY2YTA4MWJjNzI2YzQ3ZjU5OTA5Y2YyZDg4YTNhNzhkL3RhYmxlcmFuZ2U6NjZhMDgxYmM3MjZjNDdmNTk5MDljZjJkODhhM2E3OGRfOS0xLTEtMS0xNjM1MQ_489483fb-2e37-4495-b974-8d71a29d6b2c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">29,600</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i79b48cfc81254328ac1dae75e4c81c8f_I20201231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-52" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMi9mcmFnOmQ5ZDVlOTEwODQ4ODQyNjFiNGJmZTg5NjBhNWQzMjQxL3RhYmxlOjY2YTA4MWJjNzI2YzQ3ZjU5OTA5Y2YyZDg4YTNhNzhkL3RhYmxlcmFuZ2U6NjZhMDgxYmM3MjZjNDdmNTk5MDljZjJkODhhM2E3OGRfOS0zLTEtMS0xNjM1MQ_cf96d5fe-eaf2-48e8-85fe-699c0a19e4a8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">33,530</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i136a713ea34e4a3a8a8e3a24f4fa59ed_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="fact-identifier-53" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMi9mcmFnOmQ5ZDVlOTEwODQ4ODQyNjFiNGJmZTg5NjBhNWQzMjQxL3RhYmxlOjY2YTA4MWJjNzI2YzQ3ZjU5OTA5Y2YyZDg4YTNhNzhkL3RhYmxlcmFuZ2U6NjZhMDgxYmM3MjZjNDdmNTk5MDljZjJkODhhM2E3OGRfMTAtMS0xLTEtMTYzNTE_237d2af6-1cc6-4d8a-bf6b-46d685fbead4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">58</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i79b48cfc81254328ac1dae75e4c81c8f_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="fact-identifier-54" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMi9mcmFnOmQ5ZDVlOTEwODQ4ODQyNjFiNGJmZTg5NjBhNWQzMjQxL3RhYmxlOjY2YTA4MWJjNzI2YzQ3ZjU5OTA5Y2YyZDg4YTNhNzhkL3RhYmxlcmFuZ2U6NjZhMDgxYmM3MjZjNDdmNTk5MDljZjJkODhhM2E3OGRfMTAtMy0xLTEtMTYzNTE_691169ad-bd12-41b4-a229-09d1be46b9a2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">30</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i136a713ea34e4a3a8a8e3a24f4fa59ed_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="fact-identifier-55" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMi9mcmFnOmQ5ZDVlOTEwODQ4ODQyNjFiNGJmZTg5NjBhNWQzMjQxL3RhYmxlOjY2YTA4MWJjNzI2YzQ3ZjU5OTA5Y2YyZDg4YTNhNzhkL3RhYmxlcmFuZ2U6NjZhMDgxYmM3MjZjNDdmNTk5MDljZjJkODhhM2E3OGRfMTEtMS0xLTEtMTYzNTE_f3b7e064-59ea-4d1b-b7a4-f44bcbc8a950" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">59</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i79b48cfc81254328ac1dae75e4c81c8f_I20201231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="fact-identifier-56" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMi9mcmFnOmQ5ZDVlOTEwODQ4ODQyNjFiNGJmZTg5NjBhNWQzMjQxL3RhYmxlOjY2YTA4MWJjNzI2YzQ3ZjU5OTA5Y2YyZDg4YTNhNzhkL3RhYmxlcmFuZ2U6NjZhMDgxYmM3MjZjNDdmNTk5MDljZjJkODhhM2E3OGRfMTEtMy0xLTEtMTYzNTE_34033a99-c19b-4b35-84fb-d59735b38fc2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">74</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i136a713ea34e4a3a8a8e3a24f4fa59ed_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-57" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMi9mcmFnOmQ5ZDVlOTEwODQ4ODQyNjFiNGJmZTg5NjBhNWQzMjQxL3RhYmxlOjY2YTA4MWJjNzI2YzQ3ZjU5OTA5Y2YyZDg4YTNhNzhkL3RhYmxlcmFuZ2U6NjZhMDgxYmM3MjZjNDdmNTk5MDljZjJkODhhM2E3OGRfMTMtMS0xLTEtMTYzNTE_bde65871-74ee-4468-a3b5-a9a62f5cc5f2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">29,717</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i79b48cfc81254328ac1dae75e4c81c8f_I20201231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-58" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMi9mcmFnOmQ5ZDVlOTEwODQ4ODQyNjFiNGJmZTg5NjBhNWQzMjQxL3RhYmxlOjY2YTA4MWJjNzI2YzQ3ZjU5OTA5Y2YyZDg4YTNhNzhkL3RhYmxlcmFuZ2U6NjZhMDgxYmM3MjZjNDdmNTk5MDljZjJkODhhM2E3OGRfMTMtMy0xLTEtMTYzNTE_c02e87a2-bd43-4b32-b119-6ea0687988cd" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">33,634</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> equity</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i136a713ea34e4a3a8a8e3a24f4fa59ed_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-59" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMi9mcmFnOmQ5ZDVlOTEwODQ4ODQyNjFiNGJmZTg5NjBhNWQzMjQxL3RhYmxlOjY2YTA4MWJjNzI2YzQ3ZjU5OTA5Y2YyZDg4YTNhNzhkL3RhYmxlcmFuZ2U6NjZhMDgxYmM3MjZjNDdmNTk5MDljZjJkODhhM2E3OGRfMTYtMS0xLTEtMTYzNTE_7d51e0b5-9ff4-4003-88a1-99b7769ee090" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,605</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i79b48cfc81254328ac1dae75e4c81c8f_I20201231" decimals="-3" name="us-gaap:AccountsPayableCurrent" scale="3" id="fact-identifier-60" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMi9mcmFnOmQ5ZDVlOTEwODQ4ODQyNjFiNGJmZTg5NjBhNWQzMjQxL3RhYmxlOjY2YTA4MWJjNzI2YzQ3ZjU5OTA5Y2YyZDg4YTNhNzhkL3RhYmxlcmFuZ2U6NjZhMDgxYmM3MjZjNDdmNTk5MDljZjJkODhhM2E3OGRfMTYtMy0xLTEtMTYzNTE_b0512f53-e810-438a-a20e-3d3fa584ef41" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">568</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i136a713ea34e4a3a8a8e3a24f4fa59ed_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-61" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMi9mcmFnOmQ5ZDVlOTEwODQ4ODQyNjFiNGJmZTg5NjBhNWQzMjQxL3RhYmxlOjY2YTA4MWJjNzI2YzQ3ZjU5OTA5Y2YyZDg4YTNhNzhkL3RhYmxlcmFuZ2U6NjZhMDgxYmM3MjZjNDdmNTk5MDljZjJkODhhM2E3OGRfMTctMS0xLTEtMTYzNTE_9d83ea2b-14d3-413e-86bb-e3698a846287" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,136</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i79b48cfc81254328ac1dae75e4c81c8f_I20201231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-62" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMi9mcmFnOmQ5ZDVlOTEwODQ4ODQyNjFiNGJmZTg5NjBhNWQzMjQxL3RhYmxlOjY2YTA4MWJjNzI2YzQ3ZjU5OTA5Y2YyZDg4YTNhNzhkL3RhYmxlcmFuZ2U6NjZhMDgxYmM3MjZjNDdmNTk5MDljZjJkODhhM2E3OGRfMTctMy0xLTEtMTYzNTE_df40317c-5a2a-4b3e-ab85-0b5a6deb4ffc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,420</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability, current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i136a713ea34e4a3a8a8e3a24f4fa59ed_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="fact-identifier-63" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMi9mcmFnOmQ5ZDVlOTEwODQ4ODQyNjFiNGJmZTg5NjBhNWQzMjQxL3RhYmxlOjY2YTA4MWJjNzI2YzQ3ZjU5OTA5Y2YyZDg4YTNhNzhkL3RhYmxlcmFuZ2U6NjZhMDgxYmM3MjZjNDdmNTk5MDljZjJkODhhM2E3OGRfMTgtMS0xLTEtMTYzNTE_7384983b-8374-4326-a5c5-a0ca4ce78c22" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">69</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i79b48cfc81254328ac1dae75e4c81c8f_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="fact-identifier-64" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMi9mcmFnOmQ5ZDVlOTEwODQ4ODQyNjFiNGJmZTg5NjBhNWQzMjQxL3RhYmxlOjY2YTA4MWJjNzI2YzQ3ZjU5OTA5Y2YyZDg4YTNhNzhkL3RhYmxlcmFuZ2U6NjZhMDgxYmM3MjZjNDdmNTk5MDljZjJkODhhM2E3OGRfMTgtMy0xLTEtMTYzNTE_751491fc-9088-4b9a-8c62-d467c6fcb260" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">74</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note payable, current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i136a713ea34e4a3a8a8e3a24f4fa59ed_I20211231" decimals="-3" name="us-gaap:NotesPayableCurrent" format="ixt:fixed-zero" scale="3" id="fact-identifier-65" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMi9mcmFnOmQ5ZDVlOTEwODQ4ODQyNjFiNGJmZTg5NjBhNWQzMjQxL3RhYmxlOjY2YTA4MWJjNzI2YzQ3ZjU5OTA5Y2YyZDg4YTNhNzhkL3RhYmxlcmFuZ2U6NjZhMDgxYmM3MjZjNDdmNTk5MDljZjJkODhhM2E3OGRfMjItMS0xLTEtMTYzNTE_76db2ecf-fa2b-43b3-8066-7eb12e610aac" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i79b48cfc81254328ac1dae75e4c81c8f_I20201231" decimals="-3" name="us-gaap:NotesPayableCurrent" scale="3" id="fact-identifier-66" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMi9mcmFnOmQ5ZDVlOTEwODQ4ODQyNjFiNGJmZTg5NjBhNWQzMjQxL3RhYmxlOjY2YTA4MWJjNzI2YzQ3ZjU5OTA5Y2YyZDg4YTNhNzhkL3RhYmxlcmFuZ2U6NjZhMDgxYmM3MjZjNDdmNTk5MDljZjJkODhhM2E3OGRfMjItMy0xLTEtMTYzNTE_49441401-21d4-485d-9a7f-8c1d4d2cce5b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">291</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i136a713ea34e4a3a8a8e3a24f4fa59ed_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-67" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMi9mcmFnOmQ5ZDVlOTEwODQ4ODQyNjFiNGJmZTg5NjBhNWQzMjQxL3RhYmxlOjY2YTA4MWJjNzI2YzQ3ZjU5OTA5Y2YyZDg4YTNhNzhkL3RhYmxlcmFuZ2U6NjZhMDgxYmM3MjZjNDdmNTk5MDljZjJkODhhM2E3OGRfMjQtMS0xLTEtMTYzNTE_1ce13111-b4c1-4e97-9474-a94c4d5d8396" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,810</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i79b48cfc81254328ac1dae75e4c81c8f_I20201231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-68" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMi9mcmFnOmQ5ZDVlOTEwODQ4ODQyNjFiNGJmZTg5NjBhNWQzMjQxL3RhYmxlOjY2YTA4MWJjNzI2YzQ3ZjU5OTA5Y2YyZDg4YTNhNzhkL3RhYmxlcmFuZ2U6NjZhMDgxYmM3MjZjNDdmNTk5MDljZjJkODhhM2E3OGRfMjQtMy0xLTEtMTYzNTE_c04dfa4f-e5b0-430a-bbdb-bea8bb9c6353" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,353</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note payable, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i136a713ea34e4a3a8a8e3a24f4fa59ed_I20211231" decimals="-3" name="us-gaap:LongTermNotesPayable" format="ixt:fixed-zero" scale="3" id="fact-identifier-69" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMi9mcmFnOmQ5ZDVlOTEwODQ4ODQyNjFiNGJmZTg5NjBhNWQzMjQxL3RhYmxlOjY2YTA4MWJjNzI2YzQ3ZjU5OTA5Y2YyZDg4YTNhNzhkL3RhYmxlcmFuZ2U6NjZhMDgxYmM3MjZjNDdmNTk5MDljZjJkODhhM2E3OGRfMzAtMS0xLTEtMTYzNTE_7dd17bbc-fa99-4421-8151-c73247adbd65" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i79b48cfc81254328ac1dae75e4c81c8f_I20201231" decimals="-3" name="us-gaap:LongTermNotesPayable" scale="3" id="fact-identifier-70" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMi9mcmFnOmQ5ZDVlOTEwODQ4ODQyNjFiNGJmZTg5NjBhNWQzMjQxL3RhYmxlOjY2YTA4MWJjNzI2YzQ3ZjU5OTA5Y2YyZDg4YTNhNzhkL3RhYmxlcmFuZ2U6NjZhMDgxYmM3MjZjNDdmNTk5MDljZjJkODhhM2E3OGRfMzAtMy0xLTEtMTYzNTE_80749be9-88b0-4e45-83c6-a4f3bc43f162" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">146</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i136a713ea34e4a3a8a8e3a24f4fa59ed_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-71" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMi9mcmFnOmQ5ZDVlOTEwODQ4ODQyNjFiNGJmZTg5NjBhNWQzMjQxL3RhYmxlOjY2YTA4MWJjNzI2YzQ3ZjU5OTA5Y2YyZDg4YTNhNzhkL3RhYmxlcmFuZ2U6NjZhMDgxYmM3MjZjNDdmNTk5MDljZjJkODhhM2E3OGRfMzEtMS0xLTEtMTYzNTE_ca704a23-50dc-481b-8f14-97cc0997559f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,810</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i79b48cfc81254328ac1dae75e4c81c8f_I20201231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-72" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMi9mcmFnOmQ5ZDVlOTEwODQ4ODQyNjFiNGJmZTg5NjBhNWQzMjQxL3RhYmxlOjY2YTA4MWJjNzI2YzQ3ZjU5OTA5Y2YyZDg4YTNhNzhkL3RhYmxlcmFuZ2U6NjZhMDgxYmM3MjZjNDdmNTk5MDljZjJkODhhM2E3OGRfMzEtMy0xLTEtMTYzNTE_d1ac18aa-e655-4e2f-bc22-b7f87d8cfa00" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,499</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 6)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><span><ix:nonfraction unitref="usd" contextref="i136a713ea34e4a3a8a8e3a24f4fa59ed_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="fact-identifier-73" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMi9mcmFnOmQ5ZDVlOTEwODQ4ODQyNjFiNGJmZTg5NjBhNWQzMjQxL3RhYmxlOjY2YTA4MWJjNzI2YzQ3ZjU5OTA5Y2YyZDg4YTNhNzhkL3RhYmxlcmFuZ2U6NjZhMDgxYmM3MjZjNDdmNTk5MDljZjJkODhhM2E3OGRfMzMtMS0xLTEtMTYzNTE_1cdfaa56-8044-4ff1-a1e1-8a3ad1e08e1c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><span><ix:nonfraction unitref="usd" contextref="i79b48cfc81254328ac1dae75e4c81c8f_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="fact-identifier-74" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMi9mcmFnOmQ5ZDVlOTEwODQ4ODQyNjFiNGJmZTg5NjBhNWQzMjQxL3RhYmxlOjY2YTA4MWJjNzI2YzQ3ZjU5OTA5Y2YyZDg4YTNhNzhkL3RhYmxlcmFuZ2U6NjZhMDgxYmM3MjZjNDdmNTk5MDljZjJkODhhM2E3OGRfMzMtMy0xLTEtMTYzNTE_b9e1a7d4-3f3d-481e-8ef2-4abe859faa52" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders’ equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<span><ix:nonfraction unitref="usdPerShare" contextref="i136a713ea34e4a3a8a8e3a24f4fa59ed_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="fact-identifier-75" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMi9mcmFnOmQ5ZDVlOTEwODQ4ODQyNjFiNGJmZTg5NjBhNWQzMjQxL3RhYmxlOjY2YTA4MWJjNzI2YzQ3ZjU5OTA5Y2YyZDg4YTNhNzhkL3RhYmxlcmFuZ2U6NjZhMDgxYmM3MjZjNDdmNTk5MDljZjJkODhhM2E3OGRfMzUtMC0xLTEtMTYzNTEvdGV4dHJlZ2lvbjozNTYyNDMzNTFmYTY0OGRiYTE1ZjBmNjJlZWNlNmUwMl8xOQ_930d92f4-cb7c-4317-a83e-0e2f7a372c62" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="usdPerShare" contextref="i79b48cfc81254328ac1dae75e4c81c8f_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="fact-identifier-76" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMi9mcmFnOmQ5ZDVlOTEwODQ4ODQyNjFiNGJmZTg5NjBhNWQzMjQxL3RhYmxlOjY2YTA4MWJjNzI2YzQ3ZjU5OTA5Y2YyZDg4YTNhNzhkL3RhYmxlcmFuZ2U6NjZhMDgxYmM3MjZjNDdmNTk5MDljZjJkODhhM2E3OGRfMzUtMC0xLTEtMTYzNTEvdGV4dHJlZ2lvbjozNTYyNDMzNTFmYTY0OGRiYTE1ZjBmNjJlZWNlNmUwMl8xOQ_a710f688-2816-4422-8aa3-5d92d7beb5ec" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.01</ix:nonfraction></span></ix:nonfraction></span> par value, <span><ix:nonfraction unitref="shares" contextref="i136a713ea34e4a3a8a8e3a24f4fa59ed_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-77" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMi9mcmFnOmQ5ZDVlOTEwODQ4ODQyNjFiNGJmZTg5NjBhNWQzMjQxL3RhYmxlOjY2YTA4MWJjNzI2YzQ3ZjU5OTA5Y2YyZDg4YTNhNzhkL3RhYmxlcmFuZ2U6NjZhMDgxYmM3MjZjNDdmNTk5MDljZjJkODhhM2E3OGRfMzUtMC0xLTEtMTYzNTEvdGV4dHJlZ2lvbjozNTYyNDMzNTFmYTY0OGRiYTE1ZjBmNjJlZWNlNmUwMl8zMw_26f20232-dae7-46e9-b19c-d98111aa5e2c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">300,000,000</ix:nonfraction></span> and <span><ix:nonfraction unitref="shares" contextref="i79b48cfc81254328ac1dae75e4c81c8f_I20201231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-78" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMi9mcmFnOmQ5ZDVlOTEwODQ4ODQyNjFiNGJmZTg5NjBhNWQzMjQxL3RhYmxlOjY2YTA4MWJjNzI2YzQ3ZjU5OTA5Y2YyZDg4YTNhNzhkL3RhYmxlcmFuZ2U6NjZhMDgxYmM3MjZjNDdmNTk5MDljZjJkODhhM2E3OGRfMzUtMC0xLTEtMTYzNTEvdGV4dHJlZ2lvbjozNTYyNDMzNTFmYTY0OGRiYTE1ZjBmNjJlZWNlNmUwMl80MA_014ebf40-61be-4253-b7de-459effd85546" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">100,000,000</ix:nonfraction></span> shares authorized as of December&nbsp;31, 2021 and 2020, respectively; <span><ix:nonfraction unitref="shares" contextref="i136a713ea34e4a3a8a8e3a24f4fa59ed_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-79" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMi9mcmFnOmQ5ZDVlOTEwODQ4ODQyNjFiNGJmZTg5NjBhNWQzMjQxL3RhYmxlOjY2YTA4MWJjNzI2YzQ3ZjU5OTA5Y2YyZDg4YTNhNzhkL3RhYmxlcmFuZ2U6NjZhMDgxYmM3MjZjNDdmNTk5MDljZjJkODhhM2E3OGRfMzUtMC0xLTEtMTYzNTEvdGV4dHJlZ2lvbjozNTYyNDMzNTFmYTY0OGRiYTE1ZjBmNjJlZWNlNmUwMl85Mg_1a4af5de-94bd-41e1-b40e-88111394ced9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="shares" contextref="i136a713ea34e4a3a8a8e3a24f4fa59ed_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-80" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMi9mcmFnOmQ5ZDVlOTEwODQ4ODQyNjFiNGJmZTg5NjBhNWQzMjQxL3RhYmxlOjY2YTA4MWJjNzI2YzQ3ZjU5OTA5Y2YyZDg4YTNhNzhkL3RhYmxlcmFuZ2U6NjZhMDgxYmM3MjZjNDdmNTk5MDljZjJkODhhM2E3OGRfMzUtMC0xLTEtMTYzNTEvdGV4dHJlZ2lvbjozNTYyNDMzNTFmYTY0OGRiYTE1ZjBmNjJlZWNlNmUwMl85Mg_89e155c4-535e-465e-93c9-a9a15d52f666" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">119,377,286</ix:nonfraction></span></ix:nonfraction></span> and <span><ix:nonfraction unitref="shares" contextref="i79b48cfc81254328ac1dae75e4c81c8f_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-81" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMi9mcmFnOmQ5ZDVlOTEwODQ4ODQyNjFiNGJmZTg5NjBhNWQzMjQxL3RhYmxlOjY2YTA4MWJjNzI2YzQ3ZjU5OTA5Y2YyZDg4YTNhNzhkL3RhYmxlcmFuZ2U6NjZhMDgxYmM3MjZjNDdmNTk5MDljZjJkODhhM2E3OGRfMzUtMC0xLTEtMTYzNTEvdGV4dHJlZ2lvbjozNTYyNDMzNTFmYTY0OGRiYTE1ZjBmNjJlZWNlNmUwMl85OQ_5461486f-f346-4921-9aa4-a108ec6f3f77" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="shares" contextref="i79b48cfc81254328ac1dae75e4c81c8f_I20201231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-82" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMi9mcmFnOmQ5ZDVlOTEwODQ4ODQyNjFiNGJmZTg5NjBhNWQzMjQxL3RhYmxlOjY2YTA4MWJjNzI2YzQ3ZjU5OTA5Y2YyZDg4YTNhNzhkL3RhYmxlcmFuZ2U6NjZhMDgxYmM3MjZjNDdmNTk5MDljZjJkODhhM2E3OGRfMzUtMC0xLTEtMTYzNTEvdGV4dHJlZ2lvbjozNTYyNDMzNTFmYTY0OGRiYTE1ZjBmNjJlZWNlNmUwMl85OQ_eade11c3-c8e0-417a-870a-5a25a37aad5e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">53,551,461</ix:nonfraction></span></ix:nonfraction></span> shares issued and outstanding as of December&nbsp;31, 2021 and 2020, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i136a713ea34e4a3a8a8e3a24f4fa59ed_I20211231" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-83" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMi9mcmFnOmQ5ZDVlOTEwODQ4ODQyNjFiNGJmZTg5NjBhNWQzMjQxL3RhYmxlOjY2YTA4MWJjNzI2YzQ3ZjU5OTA5Y2YyZDg4YTNhNzhkL3RhYmxlcmFuZ2U6NjZhMDgxYmM3MjZjNDdmNTk5MDljZjJkODhhM2E3OGRfMzUtMS0xLTEtMTYzNTE_941647eb-b714-4686-9a43-0789421d20e3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,194</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i79b48cfc81254328ac1dae75e4c81c8f_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="fact-identifier-84" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMi9mcmFnOmQ5ZDVlOTEwODQ4ODQyNjFiNGJmZTg5NjBhNWQzMjQxL3RhYmxlOjY2YTA4MWJjNzI2YzQ3ZjU5OTA5Y2YyZDg4YTNhNzhkL3RhYmxlcmFuZ2U6NjZhMDgxYmM3MjZjNDdmNTk5MDljZjJkODhhM2E3OGRfMzUtMy0xLTEtMTYzNTE_a3407cbd-92aa-4e0d-be0e-f6735a9c8ce7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">536</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i136a713ea34e4a3a8a8e3a24f4fa59ed_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-85" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMi9mcmFnOmQ5ZDVlOTEwODQ4ODQyNjFiNGJmZTg5NjBhNWQzMjQxL3RhYmxlOjY2YTA4MWJjNzI2YzQ3ZjU5OTA5Y2YyZDg4YTNhNzhkL3RhYmxlcmFuZ2U6NjZhMDgxYmM3MjZjNDdmNTk5MDljZjJkODhhM2E3OGRfMzYtMS0xLTEtMTYzNTE_cf2415d6-3edf-4286-bc6e-abe8774ed1ac" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">169,080</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i79b48cfc81254328ac1dae75e4c81c8f_I20201231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-86" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMi9mcmFnOmQ5ZDVlOTEwODQ4ODQyNjFiNGJmZTg5NjBhNWQzMjQxL3RhYmxlOjY2YTA4MWJjNzI2YzQ3ZjU5OTA5Y2YyZDg4YTNhNzhkL3RhYmxlcmFuZ2U6NjZhMDgxYmM3MjZjNDdmNTk5MDljZjJkODhhM2E3OGRfMzYtMy0xLTEtMTYzNTE_f00ee466-a6da-47f2-bcaf-44fc6e8abf37" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">132,492</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i136a713ea34e4a3a8a8e3a24f4fa59ed_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-87" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMi9mcmFnOmQ5ZDVlOTEwODQ4ODQyNjFiNGJmZTg5NjBhNWQzMjQxL3RhYmxlOjY2YTA4MWJjNzI2YzQ3ZjU5OTA5Y2YyZDg4YTNhNzhkL3RhYmxlcmFuZ2U6NjZhMDgxYmM3MjZjNDdmNTk5MDljZjJkODhhM2E3OGRfMzgtMS0xLTEtMTYzNTE_d0a1e2d3-edd7-4189-a38c-4c1d3868e80e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">145,367</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i79b48cfc81254328ac1dae75e4c81c8f_I20201231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-88" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMi9mcmFnOmQ5ZDVlOTEwODQ4ODQyNjFiNGJmZTg5NjBhNWQzMjQxL3RhYmxlOjY2YTA4MWJjNzI2YzQ3ZjU5OTA5Y2YyZDg4YTNhNzhkL3RhYmxlcmFuZ2U6NjZhMDgxYmM3MjZjNDdmNTk5MDljZjJkODhhM2E3OGRfMzgtMy0xLTEtMTYzNTE_07403d64-f5af-4e35-8136-4d4f183418c5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">105,893</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders’ equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i136a713ea34e4a3a8a8e3a24f4fa59ed_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-89" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMi9mcmFnOmQ5ZDVlOTEwODQ4ODQyNjFiNGJmZTg5NjBhNWQzMjQxL3RhYmxlOjY2YTA4MWJjNzI2YzQ3ZjU5OTA5Y2YyZDg4YTNhNzhkL3RhYmxlcmFuZ2U6NjZhMDgxYmM3MjZjNDdmNTk5MDljZjJkODhhM2E3OGRfMzktMS0xLTEtMTYzNTE_7a44961f-bcfc-4814-bd81-78cbef139635" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">24,907</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i79b48cfc81254328ac1dae75e4c81c8f_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-90" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMi9mcmFnOmQ5ZDVlOTEwODQ4ODQyNjFiNGJmZTg5NjBhNWQzMjQxL3RhYmxlOjY2YTA4MWJjNzI2YzQ3ZjU5OTA5Y2YyZDg4YTNhNzhkL3RhYmxlcmFuZ2U6NjZhMDgxYmM3MjZjNDdmNTk5MDljZjJkODhhM2E3OGRfMzktMy0xLTEtMTYzNTE_b8fa3d90-d84e-428d-830a-5fe5e6447ad5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">27,135</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders’ equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i136a713ea34e4a3a8a8e3a24f4fa59ed_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-91" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMi9mcmFnOmQ5ZDVlOTEwODQ4ODQyNjFiNGJmZTg5NjBhNWQzMjQxL3RhYmxlOjY2YTA4MWJjNzI2YzQ3ZjU5OTA5Y2YyZDg4YTNhNzhkL3RhYmxlcmFuZ2U6NjZhMDgxYmM3MjZjNDdmNTk5MDljZjJkODhhM2E3OGRfNDAtMS0xLTEtMTYzNTE_b52b2781-3b50-492d-9256-ed239a4041cb" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">29,717</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i79b48cfc81254328ac1dae75e4c81c8f_I20201231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-92" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMi9mcmFnOmQ5ZDVlOTEwODQ4ODQyNjFiNGJmZTg5NjBhNWQzMjQxL3RhYmxlOjY2YTA4MWJjNzI2YzQ3ZjU5OTA5Y2YyZDg4YTNhNzhkL3RhYmxlcmFuZ2U6NjZhMDgxYmM3MjZjNDdmNTk5MDljZjJkODhhM2E3OGRfNDAtMy0xLTEtMTYzNTE_d9b30ec7-4bc6-4202-93db-9c796da291ce" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">33,634</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to these consolidated financial statements.</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><div id="ie1e15c78f2af410c8f1490215e82bdbe_25"></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BRICKELL BIOTECH, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:69.066%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 6.62pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended<br>December&nbsp;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id87b073018e54ec8ac696cfa2b6026b5_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="fact-identifier-93" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yNS9mcmFnOjgxNzRjOGZiNzI2OTRiNmM4ZTA3NjYxMzU5OTFjZTgzL3RhYmxlOjYyMWY3ZDk0NjRhYjQ3NWQ4Mzk0ZmU2Zjk5YTNjYzA4L3RhYmxlcmFuZ2U6NjIxZjdkOTQ2NGFiNDc1ZDgzOTRmZTZmOTlhM2NjMDhfMy01LTEtMS0xNjM1MQ_1c815b4c-798c-4a5f-8801-54c8392a6c99" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ie3531b58557045488edaf451c2b00e9e_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-94" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yNS9mcmFnOjgxNzRjOGZiNzI2OTRiNmM4ZTA3NjYxMzU5OTFjZTgzL3RhYmxlOjYyMWY3ZDk0NjRhYjQ3NWQ4Mzk0ZmU2Zjk5YTNjYzA4L3RhYmxlcmFuZ2U6NjIxZjdkOTQ2NGFiNDc1ZDgzOTRmZTZmOTlhM2NjMDhfMy03LTEtMS0xNjM1MQ_1fbd4419-3519-4c9b-ba4f-fd4eb9ae87b0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,795</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i542b4f6af4e04f42a93210db56765f76_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="fact-identifier-95" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yNS9mcmFnOjgxNzRjOGZiNzI2OTRiNmM4ZTA3NjYxMzU5OTFjZTgzL3RhYmxlOjYyMWY3ZDk0NjRhYjQ3NWQ4Mzk0ZmU2Zjk5YTNjYzA4L3RhYmxlcmFuZ2U6NjIxZjdkOTQ2NGFiNDc1ZDgzOTRmZTZmOTlhM2NjMDhfNC01LTEtMS0xNjM1MQ_97bddbfa-b5d1-42d3-9d77-ad58387a6b67" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">404</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i1994e78f9c984a15a811ec9ab649aabf_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="fact-identifier-96" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yNS9mcmFnOjgxNzRjOGZiNzI2OTRiNmM4ZTA3NjYxMzU5OTFjZTgzL3RhYmxlOjYyMWY3ZDk0NjRhYjQ3NWQ4Mzk0ZmU2Zjk5YTNjYzA4L3RhYmxlcmFuZ2U6NjIxZjdkOTQ2NGFiNDc1ZDgzOTRmZTZmOTlhM2NjMDhfNC03LTEtMS0xNjM1MQ_1d6e76d2-25f9-4c07-964f-39b6596ac5ce" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">27</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="fact-identifier-97" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yNS9mcmFnOjgxNzRjOGZiNzI2OTRiNmM4ZTA3NjYxMzU5OTFjZTgzL3RhYmxlOjYyMWY3ZDk0NjRhYjQ3NWQ4Mzk0ZmU2Zjk5YTNjYzA4L3RhYmxlcmFuZ2U6NjIxZjdkOTQ2NGFiNDc1ZDgzOTRmZTZmOTlhM2NjMDhfNS01LTEtMS0xNjM1MQ_398eb4e1-fbfe-4c48-beed-57076f51d07c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">404</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-98" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yNS9mcmFnOjgxNzRjOGZiNzI2OTRiNmM4ZTA3NjYxMzU5OTFjZTgzL3RhYmxlOjYyMWY3ZDk0NjRhYjQ3NWQ4Mzk0ZmU2Zjk5YTNjYzA4L3RhYmxlcmFuZ2U6NjIxZjdkOTQ2NGFiNDc1ZDgzOTRmZTZmOTlhM2NjMDhfNS03LTEtMS0xNjM1MQ_c9e184f0-d296-42ac-9424-1e5b98669195" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,822</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-99" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yNS9mcmFnOjgxNzRjOGZiNzI2OTRiNmM4ZTA3NjYxMzU5OTFjZTgzL3RhYmxlOjYyMWY3ZDk0NjRhYjQ3NWQ4Mzk0ZmU2Zjk5YTNjYzA4L3RhYmxlcmFuZ2U6NjIxZjdkOTQ2NGFiNDc1ZDgzOTRmZTZmOTlhM2NjMDhfOC01LTEtMS0xNjM1MQ_14b0dc51-b634-4afa-ae20-e5c9587ba1c3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">28,231</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-100" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yNS9mcmFnOjgxNzRjOGZiNzI2OTRiNmM4ZTA3NjYxMzU5OTFjZTgzL3RhYmxlOjYyMWY3ZDk0NjRhYjQ3NWQ4Mzk0ZmU2Zjk5YTNjYzA4L3RhYmxlcmFuZ2U6NjIxZjdkOTQ2NGFiNDc1ZDgzOTRmZTZmOTlhM2NjMDhfOC03LTEtMS0xNjM1MQ_9418c062-5c2a-4187-9bf4-83ae2e63b459" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,216</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-101" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yNS9mcmFnOjgxNzRjOGZiNzI2OTRiNmM4ZTA3NjYxMzU5OTFjZTgzL3RhYmxlOjYyMWY3ZDk0NjRhYjQ3NWQ4Mzk0ZmU2Zjk5YTNjYzA4L3RhYmxlcmFuZ2U6NjIxZjdkOTQ2NGFiNDc1ZDgzOTRmZTZmOTlhM2NjMDhfOS01LTEtMS0xNjM1MQ_264ac8b0-4f9f-4ff8-94eb-b9b159dd2598" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12,417</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-102" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yNS9mcmFnOjgxNzRjOGZiNzI2OTRiNmM4ZTA3NjYxMzU5OTFjZTgzL3RhYmxlOjYyMWY3ZDk0NjRhYjQ3NWQ4Mzk0ZmU2Zjk5YTNjYzA4L3RhYmxlcmFuZ2U6NjIxZjdkOTQ2NGFiNDc1ZDgzOTRmZTZmOTlhM2NjMDhfOS03LTEtMS0xNjM1MQ_b54a96db-7f6a-4097-8ad5-a59b0e132249" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,582</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-103" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yNS9mcmFnOjgxNzRjOGZiNzI2OTRiNmM4ZTA3NjYxMzU5OTFjZTgzL3RhYmxlOjYyMWY3ZDk0NjRhYjQ3NWQ4Mzk0ZmU2Zjk5YTNjYzA4L3RhYmxlcmFuZ2U6NjIxZjdkOTQ2NGFiNDc1ZDgzOTRmZTZmOTlhM2NjMDhfMTAtNS0xLTEtMTYzNTE_416bb51d-575c-4c77-8371-4a9864685d38" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">40,648</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-104" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yNS9mcmFnOjgxNzRjOGZiNzI2OTRiNmM4ZTA3NjYxMzU5OTFjZTgzL3RhYmxlOjYyMWY3ZDk0NjRhYjQ3NWQ4Mzk0ZmU2Zjk5YTNjYzA4L3RhYmxlcmFuZ2U6NjIxZjdkOTQ2NGFiNDc1ZDgzOTRmZTZmOTlhM2NjMDhfMTAtNy0xLTEtMTYzNTE_3fe957f8-01ca-4c7c-9493-fb87e6c260bb" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">22,798</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-105" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yNS9mcmFnOjgxNzRjOGZiNzI2OTRiNmM4ZTA3NjYxMzU5OTFjZTgzL3RhYmxlOjYyMWY3ZDk0NjRhYjQ3NWQ4Mzk0ZmU2Zjk5YTNjYzA4L3RhYmxlcmFuZ2U6NjIxZjdkOTQ2NGFiNDc1ZDgzOTRmZTZmOTlhM2NjMDhfMTEtNS0xLTEtMTYzNTE_345489a5-73f9-4b2f-a5bf-31c638c28057" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">40,244</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-106" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yNS9mcmFnOjgxNzRjOGZiNzI2OTRiNmM4ZTA3NjYxMzU5OTFjZTgzL3RhYmxlOjYyMWY3ZDk0NjRhYjQ3NWQ4Mzk0ZmU2Zjk5YTNjYzA4L3RhYmxlcmFuZ2U6NjIxZjdkOTQ2NGFiNDc1ZDgzOTRmZTZmOTlhM2NjMDhfMTEtNy0xLTEtMTYzNTE_1c785d60-0129-41b3-a8e5-f600407ef304" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20,976</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment and other income, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="-3" name="us-gaap:InvestmentIncomeNet" scale="3" id="fact-identifier-107" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yNS9mcmFnOjgxNzRjOGZiNzI2OTRiNmM4ZTA3NjYxMzU5OTFjZTgzL3RhYmxlOjYyMWY3ZDk0NjRhYjQ3NWQ4Mzk0ZmU2Zjk5YTNjYzA4L3RhYmxlcmFuZ2U6NjIxZjdkOTQ2NGFiNDc1ZDgzOTRmZTZmOTlhM2NjMDhfMTItNS0xLTEtMTYzNTE_182ecdc9-9b9c-4aeb-b170-09689f8b15d3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">839</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="-3" name="us-gaap:InvestmentIncomeNet" scale="3" id="fact-identifier-108" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yNS9mcmFnOjgxNzRjOGZiNzI2OTRiNmM4ZTA3NjYxMzU5OTFjZTgzL3RhYmxlOjYyMWY3ZDk0NjRhYjQ3NWQ4Mzk0ZmU2Zjk5YTNjYzA4L3RhYmxlcmFuZ2U6NjIxZjdkOTQ2NGFiNDc1ZDgzOTRmZTZmOTlhM2NjMDhfMTItNy0xLTEtMTYzNTE_975ba26b-763f-4c08-b2a2-de9db224592a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">63</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="fact-identifier-109" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yNS9mcmFnOjgxNzRjOGZiNzI2OTRiNmM4ZTA3NjYxMzU5OTFjZTgzL3RhYmxlOjYyMWY3ZDk0NjRhYjQ3NWQ4Mzk0ZmU2Zjk5YTNjYzA4L3RhYmxlcmFuZ2U6NjIxZjdkOTQ2NGFiNDc1ZDgzOTRmZTZmOTlhM2NjMDhfMTQtNS0xLTEtMTYzNTE_8b8f4ced-b823-4ad3-9913-b08294586ce6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">69</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:fixed-zero" scale="3" id="fact-identifier-110" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yNS9mcmFnOjgxNzRjOGZiNzI2OTRiNmM4ZTA3NjYxMzU5OTFjZTgzL3RhYmxlOjYyMWY3ZDk0NjRhYjQ3NWQ4Mzk0ZmU2Zjk5YTNjYzA4L3RhYmxlcmFuZ2U6NjIxZjdkOTQ2NGFiNDc1ZDgzOTRmZTZmOTlhM2NjMDhfMTQtNy0xLTEtMTYzNTE_f5b7746c-866c-410a-8762-9dd27f4d8d1d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-111" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yNS9mcmFnOjgxNzRjOGZiNzI2OTRiNmM4ZTA3NjYxMzU5OTFjZTgzL3RhYmxlOjYyMWY3ZDk0NjRhYjQ3NWQ4Mzk0ZmU2Zjk5YTNjYzA4L3RhYmxlcmFuZ2U6NjIxZjdkOTQ2NGFiNDc1ZDgzOTRmZTZmOTlhM2NjMDhfMTktNS0xLTEtMTYzNTE_dfff9eb4-923e-49f5-b18e-4893a148765e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">39,474</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-112" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yNS9mcmFnOjgxNzRjOGZiNzI2OTRiNmM4ZTA3NjYxMzU5OTFjZTgzL3RhYmxlOjYyMWY3ZDk0NjRhYjQ3NWQ4Mzk0ZmU2Zjk5YTNjYzA4L3RhYmxlcmFuZ2U6NjIxZjdkOTQ2NGFiNDc1ZDgzOTRmZTZmOTlhM2NjMDhfMTktNy0xLTEtMTYzNTE_0a0a474f-abc2-4f47-a448-1121cbd85346" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20,913</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usdPerShare" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="fact-identifier-113" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yNS9mcmFnOjgxNzRjOGZiNzI2OTRiNmM4ZTA3NjYxMzU5OTFjZTgzL3RhYmxlOjYyMWY3ZDk0NjRhYjQ3NWQ4Mzk0ZmU2Zjk5YTNjYzA4L3RhYmxlcmFuZ2U6NjIxZjdkOTQ2NGFiNDc1ZDgzOTRmZTZmOTlhM2NjMDhfMjQtNS0xLTEtMTYzNTE_4284276c-0932-41f7-9d19-60ab2d6bab78" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="usdPerShare" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="fact-identifier-114" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yNS9mcmFnOjgxNzRjOGZiNzI2OTRiNmM4ZTA3NjYxMzU5OTFjZTgzL3RhYmxlOjYyMWY3ZDk0NjRhYjQ3NWQ4Mzk0ZmU2Zjk5YTNjYzA4L3RhYmxlcmFuZ2U6NjIxZjdkOTQ2NGFiNDc1ZDgzOTRmZTZmOTlhM2NjMDhfMjQtNS0xLTEtMTYzNTE_496d88fb-4d03-4fbb-be54-f443c84cfe5a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.49</ix:nonfraction></span></ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usdPerShare" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="fact-identifier-115" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yNS9mcmFnOjgxNzRjOGZiNzI2OTRiNmM4ZTA3NjYxMzU5OTFjZTgzL3RhYmxlOjYyMWY3ZDk0NjRhYjQ3NWQ4Mzk0ZmU2Zjk5YTNjYzA4L3RhYmxlcmFuZ2U6NjIxZjdkOTQ2NGFiNDc1ZDgzOTRmZTZmOTlhM2NjMDhfMjQtNy0xLTEtMTYzNTE_27121932-8236-4969-b5d2-f18973dec074" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="usdPerShare" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="fact-identifier-116" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yNS9mcmFnOjgxNzRjOGZiNzI2OTRiNmM4ZTA3NjYxMzU5OTFjZTgzL3RhYmxlOjYyMWY3ZDk0NjRhYjQ3NWQ4Mzk0ZmU2Zjk5YTNjYzA4L3RhYmxlcmFuZ2U6NjIxZjdkOTQ2NGFiNDc1ZDgzOTRmZTZmOTlhM2NjMDhfMjQtNy0xLTEtMTYzNTE_8cbae8f7-485a-45c6-8d65-97c69709754f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.85</ix:nonfraction></span></ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares used to compute net loss per share, basic and diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-117" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yNS9mcmFnOjgxNzRjOGZiNzI2OTRiNmM4ZTA3NjYxMzU5OTFjZTgzL3RhYmxlOjYyMWY3ZDk0NjRhYjQ3NWQ4Mzk0ZmU2Zjk5YTNjYzA4L3RhYmxlcmFuZ2U6NjIxZjdkOTQ2NGFiNDc1ZDgzOTRmZTZmOTlhM2NjMDhfMjYtNS0xLTEtMTYzNTE_17ef4374-8d8a-4dc0-b396-f7f3ab82b927" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="shares" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-118" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yNS9mcmFnOjgxNzRjOGZiNzI2OTRiNmM4ZTA3NjYxMzU5OTFjZTgzL3RhYmxlOjYyMWY3ZDk0NjRhYjQ3NWQ4Mzk0ZmU2Zjk5YTNjYzA4L3RhYmxlcmFuZ2U6NjIxZjdkOTQ2NGFiNDc1ZDgzOTRmZTZmOTlhM2NjMDhfMjYtNS0xLTEtMTYzNTE_3597e2b5-2654-438d-bde7-6e5595a32b12" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">80,315,595</ix:nonfraction></span></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-119" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yNS9mcmFnOjgxNzRjOGZiNzI2OTRiNmM4ZTA3NjYxMzU5OTFjZTgzL3RhYmxlOjYyMWY3ZDk0NjRhYjQ3NWQ4Mzk0ZmU2Zjk5YTNjYzA4L3RhYmxlcmFuZ2U6NjIxZjdkOTQ2NGFiNDc1ZDgzOTRmZTZmOTlhM2NjMDhfMjYtNy0xLTEtMTYzNTE_172118ba-d311-42f7-8898-17389c6309d0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="shares" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-120" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yNS9mcmFnOjgxNzRjOGZiNzI2OTRiNmM4ZTA3NjYxMzU5OTFjZTgzL3RhYmxlOjYyMWY3ZDk0NjRhYjQ3NWQ4Mzk0ZmU2Zjk5YTNjYzA4L3RhYmxlcmFuZ2U6NjIxZjdkOTQ2NGFiNDc1ZDgzOTRmZTZmOTlhM2NjMDhfMjYtNy0xLTEtMTYzNTE_5f2a5960-d170-4c46-abfd-ca76b0d86332" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">24,514,157</ix:nonfraction></span></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to these consolidated financial statements. </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><div id="ie1e15c78f2af410c8f1490215e82bdbe_28"></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BRICKELL BIOTECH, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands) </span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:69.066%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended<br>December&nbsp;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-121" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yOC9mcmFnOjI1ZmM0YmZmNTJiOTQ2YzViMTk4MzE2MDIxOTAwNTRiL3RhYmxlOmUzYThmYTVmOWU2MjQzYmNhN2RlOTA3ZjdkOWVmNjdlL3RhYmxlcmFuZ2U6ZTNhOGZhNWY5ZTYyNDNiY2E3ZGU5MDdmN2Q5ZWY2N2VfMi01LTEtMS0xNjM1MQ_9b77f60d-47cc-4359-8f29-693a1cf60bb9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">39,474</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-122" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yOC9mcmFnOjI1ZmM0YmZmNTJiOTQ2YzViMTk4MzE2MDIxOTAwNTRiL3RhYmxlOmUzYThmYTVmOWU2MjQzYmNhN2RlOTA3ZjdkOWVmNjdlL3RhYmxlcmFuZ2U6ZTNhOGZhNWY5ZTYyNDNiY2E3ZGU5MDdmN2Q5ZWY2N2VfMi03LTEtMS0xNjM1MQ_8583c6f3-082c-4f02-a0f1-b3ce0d7de970" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20,913</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on available-for-sale marketable securities arising during holding period, net of tax benefit of $<span><ix:nonfraction unitref="usd" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="3" id="fact-identifier-123" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yOC9mcmFnOjI1ZmM0YmZmNTJiOTQ2YzViMTk4MzE2MDIxOTAwNTRiL3RhYmxlOmUzYThmYTVmOWU2MjQzYmNhN2RlOTA3ZjdkOWVmNjdlL3RhYmxlcmFuZ2U6ZTNhOGZhNWY5ZTYyNDNiY2E3ZGU5MDdmN2Q5ZWY2N2VfNC0wLTEtMS0xNjM1MS90ZXh0cmVnaW9uOjc1OThjYjhmNTRmZDQ3Mzk5NzI4ZmRhNDUxZDhlMWFhXzExOA_7e000d4e-23e8-4822-af0b-c76c5fa4fdc1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="usd" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="3" id="fact-identifier-124" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yOC9mcmFnOjI1ZmM0YmZmNTJiOTQ2YzViMTk4MzE2MDIxOTAwNTRiL3RhYmxlOmUzYThmYTVmOWU2MjQzYmNhN2RlOTA3ZjdkOWVmNjdlL3RhYmxlcmFuZ2U6ZTNhOGZhNWY5ZTYyNDNiY2E3ZGU5MDdmN2Q5ZWY2N2VfNC0wLTEtMS0xNjM1MS90ZXh0cmVnaW9uOjc1OThjYjhmNTRmZDQ3Mzk5NzI4ZmRhNDUxZDhlMWFhXzExOA_8b126038-7372-4c8c-9ec3-2d3107fc5944" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0</ix:nonfraction></span></ix:nonfraction></span></span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:fixed-zero" scale="3" id="fact-identifier-125" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yOC9mcmFnOjI1ZmM0YmZmNTJiOTQ2YzViMTk4MzE2MDIxOTAwNTRiL3RhYmxlOmUzYThmYTVmOWU2MjQzYmNhN2RlOTA3ZjdkOWVmNjdlL3RhYmxlcmFuZ2U6ZTNhOGZhNWY5ZTYyNDNiY2E3ZGU5MDdmN2Q5ZWY2N2VfNC01LTEtMS0xNjM1MQ_2f5802bb-55eb-4ee2-bb22-41e50a0e02b4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="fact-identifier-126" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yOC9mcmFnOjI1ZmM0YmZmNTJiOTQ2YzViMTk4MzE2MDIxOTAwNTRiL3RhYmxlOmUzYThmYTVmOWU2MjQzYmNhN2RlOTA3ZjdkOWVmNjdlL3RhYmxlcmFuZ2U6ZTNhOGZhNWY5ZTYyNDNiY2E3ZGU5MDdmN2Q5ZWY2N2VfNC03LTEtMS0xNjM1MQ_0cdc51cd-7d5a-49ec-a1c7-a69e7f5e205a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">28</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total comprehensive loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-127" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yOC9mcmFnOjI1ZmM0YmZmNTJiOTQ2YzViMTk4MzE2MDIxOTAwNTRiL3RhYmxlOmUzYThmYTVmOWU2MjQzYmNhN2RlOTA3ZjdkOWVmNjdlL3RhYmxlcmFuZ2U6ZTNhOGZhNWY5ZTYyNDNiY2E3ZGU5MDdmN2Q5ZWY2N2VfNy01LTEtMS0xNjM1MQ_e9dc8a3c-cc9f-4b63-9233-b9337227729b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">39,474</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-128" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yOC9mcmFnOjI1ZmM0YmZmNTJiOTQ2YzViMTk4MzE2MDIxOTAwNTRiL3RhYmxlOmUzYThmYTVmOWU2MjQzYmNhN2RlOTA3ZjdkOWVmNjdlL3RhYmxlcmFuZ2U6ZTNhOGZhNWY5ZTYyNDNiY2E3ZGU5MDdmN2Q5ZWY2N2VfNy03LTEtMS0xNjM1MQ_785f9cd1-01e6-4d1d-a785-4bba09192546" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20,885</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div><span><br></span></div><div><span><br></span></div><div><span><br></span></div><div><span><br></span></div><div><span><br></span></div><div><span><br></span></div><div><span><br></span></div><div><span><br></span></div><div><span><br></span></div><div><span><br></span></div><div><span><br></span></div><div><span><br></span></div><div><span><br></span></div><div><span><br></span></div><div><span><br></span></div><div><span><br></span></div><div><span><br></span></div><div><span><br></span></div><div><span><br></span></div><div><span><br></span></div><div><span><br></span></div><div><span><br></span></div><div><span><br></span></div><div><span><br></span></div><div><span><br></span></div><div><span><br></span></div><div><span><br></span></div><div><span><br></span></div><div><span><br></span></div><div><span><br></span></div><div><span><br></span></div><div><span><br></span></div><div><span><br></span></div><div><span><br></span></div><div><span><br></span></div><div><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to these consolidated financial statements.</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><div id="ie1e15c78f2af410c8f1490215e82bdbe_31"></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BRICKELL BIOTECH, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share data)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.495%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.304%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.304%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.304%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.304%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.304%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.310%"></td><td style="width:0.1%"></td></tr><tr style="height:26pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional <br>Paid-In-Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Gain (Loss)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated <br>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total <br>Stockholders’ <br>Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Par&nbsp;Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="if68daead4a7e4b788c4551fd5f8f512f_I20191231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-129" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfMi01LTEtMS0xOTYwNw_68c54dc9-4c3c-4aec-bd4a-841c44c3ea9c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,480,968</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="if68daead4a7e4b788c4551fd5f8f512f_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="fact-identifier-130" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfMi03LTEtMS0xOTYwNw_4aa96d4b-7c9c-4c06-98cf-33be0568c22f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">85</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ie893733c265e4a34b51045c9d764a9a7_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-131" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfMi05LTEtMS0xOTYwNw_a020d576-42d6-42bf-8f6f-ace85d5bf884" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">92,497</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i2b69e5154f8c4a1ca56c0dd9a760bb9b_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="fact-identifier-132" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfMi0xMS0xLTEtMTk2MDc_8b3401d0-53ae-438a-b1f5-3c7ee5c1d1e6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">28</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="ic09a42f374cd48b88370d2716dd925ec_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-133" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfMi0xMy0xLTEtMTk2MDc_23d99534-3827-402a-b427-ff4cbfab2bf9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">84,980</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i1a7b0ff06cf34bf68b059f14a54eef1e_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-134" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfMi0xNS0xLTEtMTk2MDc_26f4aada-0f53-418a-bf4c-76205c8dcd67" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,574</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock and warrants issued, net of issuance costs of $<span><ix:nonfraction unitref="usd" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-135" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfNC0wLTEtMS0xNzExNi90ZXh0cmVnaW9uOmMyODdlNmFkZmZkZTQwMWFiNDk5OGMwM2FhMWNkNWZmXzYz_9811ff9d-1a31-4034-9f93-f30969ced371" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,840</ix:nonfraction></span></span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="icf376e7422e54e0e8bf0e84b0d5bfeb9_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-136" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfMy01LTEtMS0xOTYwNA_8f520c56-d973-478c-92ba-b8bec60aaf41" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">39,103,810</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="icf376e7422e54e0e8bf0e84b0d5bfeb9_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" scale="3" id="fact-identifier-137" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfMy03LTEtMS0xOTYwNA_d902306c-0845-47a4-9cdb-4bceb919fc64" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">391</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9fb02b6818044db5b8a5b172ab2d4f9d_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-138" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfMy05LTEtMS0xOTYwNA_85850510-bb71-4a04-a666-f0fb502b71ef" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">37,586</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-139" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfMy0xNS0xLTEtMTk2MDQ_ea0a2614-2b4f-4841-999d-387c1b7df19f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">37,977</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of warrants</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="icf376e7422e54e0e8bf0e84b0d5bfeb9_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-140" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfNC01LTEtMS0xOTYwOQ_23041fa9-cfdf-449f-b40d-54ea477f6f62" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,367,392</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="icf376e7422e54e0e8bf0e84b0d5bfeb9_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="fact-identifier-141" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfNC03LTEtMS0xOTYwOQ_ea46d578-0242-4861-85f1-2252826b665d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">54</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i9fb02b6818044db5b8a5b172ab2d4f9d_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="fact-identifier-142" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfNC05LTEtMS0xOTYwOQ_d1088a40-d80a-4366-b302-fb292d6d9df4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">28</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="fact-identifier-143" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfNC0xNS0xLTEtMTk2MDk_8deef47e-22eb-4ee8-a217-beda8e6949ad" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">26</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under license agreement</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="icf376e7422e54e0e8bf0e84b0d5bfeb9_D20200101-20201231" decimals="INF" name="bbi:StockIssuedDuringPeriodSharesLicenseAgreement" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-144" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfNS01LTEtMS0xOTYxMQ_b5bfe962-71c9-4b77-921e-7b3fe3c1654e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">480,769</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="icf376e7422e54e0e8bf0e84b0d5bfeb9_D20200101-20201231" decimals="-3" name="bbi:StockIssuedDuringPeriodValueLicenseAgreement" scale="3" id="fact-identifier-145" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfNS03LTEtMS0xOTYxMQ_6926eab4-8fb3-4072-88d9-7037d9c0011a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">5</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9fb02b6818044db5b8a5b172ab2d4f9d_D20200101-20201231" decimals="-3" name="bbi:StockIssuedDuringPeriodValueLicenseAgreement" scale="3" id="fact-identifier-146" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfNS05LTEtMS0xOTYxMQ_7a6e3f34-43b6-43bf-9523-f5cc7342d74e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">495</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="-3" name="bbi:StockIssuedDuringPeriodValueLicenseAgreement" scale="3" id="fact-identifier-147" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfNS0xNS0xLTEtMTk2MTE_4870592c-5dca-4607-a61d-d86d7a8e4372" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">500</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon restricted stock unit settlement, net of shares withheld for taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="icf376e7422e54e0e8bf0e84b0d5bfeb9_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-148" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfNi01LTEtMS0xOTYxMw_b7ffc857-986a-475f-becf-3537f8f95cdd" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">118,522</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="icf376e7422e54e0e8bf0e84b0d5bfeb9_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="fact-identifier-149" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfNi03LTEtMS0xOTYxMw_e324e3a7-e8cc-499f-9eb3-b9d296e7125a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i9fb02b6818044db5b8a5b172ab2d4f9d_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="fact-identifier-150" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfNi05LTEtMS0xOTYxMw_af0d8da6-90a8-475b-a9d1-f0b7143b2094" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">51</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="fact-identifier-151" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfNi0xNS0xLTEtMTk2MTM_a629e3b5-7c20-49ec-ad7c-42d221787969" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">50</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9fb02b6818044db5b8a5b172ab2d4f9d_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-152" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfNy05LTEtMS0xOTYxMw_c62d70e6-6603-4ebc-9f2c-f6b2c6327e04" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,993</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-153" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfNy0xNS0xLTEtMTk2MTM_e1e97af9-204f-4af0-8595-576629262037" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,993</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on available-for-sale marketable securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i08425205deea4f038db4f3d05c50394d_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" scale="3" id="fact-identifier-154" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfOC0xMS0xLTEtMTk2MTU_d250f3cb-8fca-4505-9d1f-b3278fa08dfc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">28</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" scale="3" id="fact-identifier-155" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfOC0xNS0xLTEtMTk2MTU_07c6b3f7-e6cb-45c3-9dad-6e9ee946847b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">28</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="ide39c4f1147c4fdd92395bc81230fc80_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-156" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfOS0xMy0xLTEtMTk2MTU_c35bcbd3-8b25-48a9-ab66-9602b2658824" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20,913</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-157" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfOS0xNS0xLTEtMTk2MTU_16d81285-f1cf-4ae2-b513-55cf1f83d919" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20,913</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i06899d50c5e947f3bd2f6c9185b7da79_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-158" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfMTAtNS0xLTEtMTk2MTc_ecb8867f-2e56-4d99-ad3f-ad1b0eb898ac" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">53,551,461</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i06899d50c5e947f3bd2f6c9185b7da79_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="fact-identifier-159" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfMTAtNy0xLTEtMTk2MTc_eb0b977e-58bb-4c30-ad1e-4d26fc50a143" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">536</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3fb7a10770e2462ab8aeb7d91d6b3938_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-160" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfMTAtOS0xLTEtMTk2MTc_b8467f4f-21e2-4f7d-825a-d346f1f8f7a6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">132,492</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8cd5bd44234c47dda5f055052702fa7c_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="fact-identifier-161" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfMTAtMTEtMS0xLTE5NjE3_3f9340e8-faa5-4ec0-89e6-522751888926" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="ic374ef00ae81457d854afc7e19d70628_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-162" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfMTAtMTMtMS0xLTE5NjE3_28473065-6882-47da-85d4-180d12bea311" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">105,893</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i79b48cfc81254328ac1dae75e4c81c8f_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-163" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfMTAtMTUtMS0xLTE5NjE3_5575ae93-c125-4493-8179-1d202602562b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">27,135</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock issued, net of issuance costs of $<span><ix:nonfraction unitref="usd" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-164" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfMTItMC0xLTEtMjIzMTIvdGV4dHJlZ2lvbjo3NWMyZWQzOTY1MDU0Y2ZiYWZjOGNkYzFhZGNiM2YzNF8xMDk5NTExNjI3ODM4_300169ad-12e3-48b3-b90e-c1291a2520c2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,246</ix:nonfraction></span></span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i145b5f02df19400f9409a9d7c1854861_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-165" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfMTItNS0xLTEtMjIzMTQ_67e4a183-5f59-4cf9-88b4-3a3a03c9e37a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">50,086,147</ix:nonfraction></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i145b5f02df19400f9409a9d7c1854861_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="fact-identifier-166" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfMTItNy0xLTEtMjIzMTQ_285e7288-129a-4d07-9c05-b16ad1fe263e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">501</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4a03ff97b4484593b0c0ab2fb78e1d93_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-167" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfMTItOS0xLTEtMjIzMTQ_68522490-1cd1-4f6d-a9c7-4cc2d9c62820" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">23,505</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-168" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfMTItMTUtMS0xLTIyMzE0_253cfa2c-8fae-42ed-98e2-9b31e5cd0c5d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">24,006</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of warrants</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i145b5f02df19400f9409a9d7c1854861_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-169" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfMTMtNS0xLTEtMjIzMzA_eeafd30b-2b55-40a1-9765-d415d71456ca" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12,444,887</ix:nonfraction></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i145b5f02df19400f9409a9d7c1854861_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="fact-identifier-170" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfMTMtNy0xLTEtMjIzMzA_a6de9fc3-3dbe-4a6e-be45-e270f4862ae5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">124</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4a03ff97b4484593b0c0ab2fb78e1d93_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-171" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfMTMtOS0xLTEtMjIzMzA_08869142-6704-4e3e-9cc5-1b7467418919" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,845</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-172" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfMTMtMTUtMS0xLTIyMzMw_5d91950a-dfcb-4335-b0da-e58dbc246f0b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,969</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under license agreement</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i145b5f02df19400f9409a9d7c1854861_D20210101-20211231" decimals="INF" name="bbi:StockIssuedDuringPeriodSharesLicenseAgreement" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-173" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfMTItNS0xLTEtMTg2OTY_f52e6d55-e951-4d47-84c9-a5e1ab267319" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,816,901</ix:nonfraction></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i145b5f02df19400f9409a9d7c1854861_D20210101-20211231" decimals="-3" name="bbi:StockIssuedDuringPeriodValueLicenseAgreement" scale="3" id="fact-identifier-174" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfMTItNy0xLTEtMTg2OTY_80cc4405-3c72-47ae-959b-c1c90cf5783b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">28</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4a03ff97b4484593b0c0ab2fb78e1d93_D20210101-20211231" decimals="-3" name="bbi:StockIssuedDuringPeriodValueLicenseAgreement" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-175" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfMTItOS0xLTEtMTg2OTY_d32c2e1c-2e94-4e1b-9074-54bf92d059ac" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,943</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="-3" name="bbi:StockIssuedDuringPeriodValueLicenseAgreement" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-176" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfMTItMTUtMS0xLTE4Njk2_b7fe976f-a84e-41aa-b57f-7817e3d629a4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,971</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock to settle accrued liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i145b5f02df19400f9409a9d7c1854861_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesOther" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-177" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfMTMtNS0xLTEtMTg2OTY_4278139b-34ed-444d-b493-4c95d9763406" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">200,000</ix:nonfraction></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i145b5f02df19400f9409a9d7c1854861_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" id="fact-identifier-178" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfMTMtNy0xLTEtMTg2OTY_117203a5-981a-497e-96dc-14507bdc9486" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4a03ff97b4484593b0c0ab2fb78e1d93_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" id="fact-identifier-179" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfMTMtOS0xLTEtMTg2OTY_03d3e41c-1010-4f1f-9b2d-19988e034d31" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">61</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" id="fact-identifier-180" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfMTMtMTUtMS0xLTE4Njk2_1396d956-1575-4325-97a3-42a9cbaaa3ed" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">63</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock for cash under employee stock purchase plan</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i145b5f02df19400f9409a9d7c1854861_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-181" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfMTYtNS0xLTEtMjIzMzc_fa6350de-afac-42af-9b00-ae675eeca527" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">149,285</ix:nonfraction></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i145b5f02df19400f9409a9d7c1854861_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="fact-identifier-182" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfMTYtNy0xLTEtMjIzMzc_1c9e2fd0-42e8-4afe-95fc-db8dc1742b2b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4a03ff97b4484593b0c0ab2fb78e1d93_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="fact-identifier-183" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfMTYtOS0xLTEtMjIzMzc_70135997-b06e-4870-9a23-1193e9128c46" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">28</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="fact-identifier-184" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfMTYtMTUtMS0xLTIyMzM3_1531186d-30c1-483f-8912-91443b8322e8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">29</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon restricted stock unit settlement, net of shares withheld for taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i145b5f02df19400f9409a9d7c1854861_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-185" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfMTQtNS0xLTEtMTg2OTY_c6d85035-ed47-4dd0-8e55-ccbc30a71202" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">128,605</ix:nonfraction></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i145b5f02df19400f9409a9d7c1854861_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="fact-identifier-186" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfMTQtNy0xLTEtMTg2OTY_f301e6b7-df42-409c-9df6-c2c757250de1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i4a03ff97b4484593b0c0ab2fb78e1d93_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="fact-identifier-187" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfMTQtOS0xLTEtMTg2OTY_8c65af19-9128-4939-90dd-191f5e394a50" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">57</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="fact-identifier-188" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfMTQtMTUtMS0xLTE4Njk2_14ed2b7f-f723-41c6-b101-e03a92863c9c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">55</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4a03ff97b4484593b0c0ab2fb78e1d93_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-189" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfMTYtOS0xLTEtMTg2OTY_da9a3908-6f9e-4754-a45d-42b1b6a46179" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,263</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-190" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfMTYtMTUtMS0xLTE4Njk2_02161bf6-b088-49bb-9553-15ac2dc64cc3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,263</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i22a3a87ba40a4de8864586d396c22c4f_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-191" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfMTgtMTMtMS0xLTE4Njk2_29125862-a2e5-4456-9a48-554beb2864f2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">39,474</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-192" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfMTgtMTUtMS0xLTE4Njk2_d58bd227-6994-45ce-a5a3-e1d06fbd616f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">39,474</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="ib3442e37cfcd4a1cbcfe38fd035ec774_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-193" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfMTktNS0xLTEtMTk2MTk_00680ab6-fc2f-4b4f-b0c3-0a32944aa5b1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">119,377,286</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ib3442e37cfcd4a1cbcfe38fd035ec774_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-194" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfMTktNy0xLTEtMTk2MTk_6b92b9ad-e5d5-4dbe-8091-21fa051e5c5c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,194</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ia8d854dbfb584e35a2eeedafaa5f9fb7_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-195" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfMTktOS0xLTEtMTk2MTk_3f873d3f-fb45-41ae-bc4f-92ff40999e63" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">169,080</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id3d32b10b3574141a67d2bc3a7c2ba6a_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="fact-identifier-196" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfMTktMTEtMS0xLTE5NjE5_56d1d584-8508-4773-b33b-f7100f0b082e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i2d2864ef02b045c08b23d62ca9064de4_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-197" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfMTktMTMtMS0xLTE5NjE5_0d4027f8-d312-4832-a8fd-36c15f8be0ed" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">145,367</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i136a713ea34e4a3a8a8e3a24f4fa59ed_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-198" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zMS9mcmFnOjhmNGQ3Zjk1M2VkYTQ4ZWQ5ZTI3NmE3NWI2NDQ0NmVlL3RhYmxlOjk5MDNmZDY3MWYxNTQ2ZGQ4Mjk4NTVkOTEzOTdjNGY2L3RhYmxlcmFuZ2U6OTkwM2ZkNjcxZjE1NDZkZDgyOTg1NWQ5MTM5N2M0ZjZfMTktMTUtMS0xLTE5NjE5_ab6f12c8-e601-4bfb-9bba-8d5bf8486635" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">24,907</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.376%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.304%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.304%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.304%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.304%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.310%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to these consolidated financial statements.</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><div id="ie1e15c78f2af410c8f1490215e82bdbe_37"></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BRICKELL BIOTECH, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands) </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:69.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended<br>December&nbsp;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CASH FLOWS FROM OPERATING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-199" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zNy9mcmFnOmU2ZjEwNjA0ODMxNTQ4ODY4OTQ3MGYwOGE5MWIyMzNmL3RhYmxlOjBkMGQ3OWY4ZmVlZjQ1ZTY5MDZjN2FlZDIyY2I2OTkwL3RhYmxlcmFuZ2U6MGQwZDc5ZjhmZWVmNDVlNjkwNmM3YWVkMjJjYjY5OTBfMy0xLTEtMS0xNjM1MQ_1761c278-dd42-4213-9cb2-2f1117b54c24" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">39,474</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-200" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zNy9mcmFnOmU2ZjEwNjA0ODMxNTQ4ODY4OTQ3MGYwOGE5MWIyMzNmL3RhYmxlOjBkMGQ3OWY4ZmVlZjQ1ZTY5MDZjN2FlZDIyY2I2OTkwL3RhYmxlcmFuZ2U6MGQwZDc5ZjhmZWVmNDVlNjkwNmM3YWVkMjJjYjY5OTBfMy0zLTEtMS0xNjM1MQ_0b9cfd4c-1a30-47da-8dcb-557d6f11a20b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20,913</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-201" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zNy9mcmFnOmU2ZjEwNjA0ODMxNTQ4ODY4OTQ3MGYwOGE5MWIyMzNmL3RhYmxlOjBkMGQ3OWY4ZmVlZjQ1ZTY5MDZjN2FlZDIyY2I2OTkwL3RhYmxlcmFuZ2U6MGQwZDc5ZjhmZWVmNDVlNjkwNmM3YWVkMjJjYjY5OTBfNS0xLTEtMS0yMjQzNw_dd5df6dd-f82f-49d4-b655-cbf234352207" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,263</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-202" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zNy9mcmFnOmU2ZjEwNjA0ODMxNTQ4ODY4OTQ3MGYwOGE5MWIyMzNmL3RhYmxlOjBkMGQ3OWY4ZmVlZjQ1ZTY5MDZjN2FlZDIyY2I2OTkwL3RhYmxlcmFuZ2U6MGQwZDc5ZjhmZWVmNDVlNjkwNmM3YWVkMjJjYjY5OTBfNS0zLTEtMS0yMjQzNw_d61058b7-ceb5-4160-9434-d186debedf75" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,993</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under license agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="-3" name="bbi:IssuanceOfStockUnderLicenseAgreement" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-203" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zNy9mcmFnOmU2ZjEwNjA0ODMxNTQ4ODY4OTQ3MGYwOGE5MWIyMzNmL3RhYmxlOjBkMGQ3OWY4ZmVlZjQ1ZTY5MDZjN2FlZDIyY2I2OTkwL3RhYmxlcmFuZ2U6MGQwZDc5ZjhmZWVmNDVlNjkwNmM3YWVkMjJjYjY5OTBfNS0xLTEtMS0xNjM1MQ_3808e7d6-534f-4eb1-88bb-2643c6ff9f5b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,971</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="-3" name="bbi:IssuanceOfStockUnderLicenseAgreement" scale="3" id="fact-identifier-204" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zNy9mcmFnOmU2ZjEwNjA0ODMxNTQ4ODY4OTQ3MGYwOGE5MWIyMzNmL3RhYmxlOjBkMGQ3OWY4ZmVlZjQ1ZTY5MDZjN2FlZDIyY2I2OTkwL3RhYmxlcmFuZ2U6MGQwZDc5ZjhmZWVmNDVlNjkwNmM3YWVkMjJjYjY5OTBfNS0zLTEtMS0xNjM1MQ_1728e20d-6c96-437a-b283-86db9fc94b03" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">500</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on loan extinguishment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="fact-identifier-205" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zNy9mcmFnOmU2ZjEwNjA0ODMxNTQ4ODY4OTQ3MGYwOGE5MWIyMzNmL3RhYmxlOjBkMGQ3OWY4ZmVlZjQ1ZTY5MDZjN2FlZDIyY2I2OTkwL3RhYmxlcmFuZ2U6MGQwZDc5ZjhmZWVmNDVlNjkwNmM3YWVkMjJjYjY5OTBfNy0xLTEtMS0xNjM1MQ_f8a33722-312f-4cae-afe1-8fa9b3628277" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">437</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="fact-identifier-206" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zNy9mcmFnOmU2ZjEwNjA0ODMxNTQ4ODY4OTQ3MGYwOGE5MWIyMzNmL3RhYmxlOjBkMGQ3OWY4ZmVlZjQ1ZTY5MDZjN2FlZDIyY2I2OTkwL3RhYmxlcmFuZ2U6MGQwZDc5ZjhmZWVmNDVlNjkwNmM3YWVkMjJjYjY5OTBfNy0zLTEtMS0xNjM1MQ_fb5eac65-dac7-4d14-919e-f858db89d40d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock to settle accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="-3" name="bbi:IssuanceOfCommonStockToSettleAccruedLiabilities" scale="3" id="fact-identifier-207" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zNy9mcmFnOmU2ZjEwNjA0ODMxNTQ4ODY4OTQ3MGYwOGE5MWIyMzNmL3RhYmxlOjBkMGQ3OWY4ZmVlZjQ1ZTY5MDZjN2FlZDIyY2I2OTkwL3RhYmxlcmFuZ2U6MGQwZDc5ZjhmZWVmNDVlNjkwNmM3YWVkMjJjYjY5OTBfOC0xLTEtMS0yMjQzMA_0c433b04-c218-40cb-b554-fd3d4fba32d4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">63</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="-3" name="bbi:IssuanceOfCommonStockToSettleAccruedLiabilities" format="ixt:fixed-zero" scale="3" id="fact-identifier-208" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zNy9mcmFnOmU2ZjEwNjA0ODMxNTQ4ODY4OTQ3MGYwOGE5MWIyMzNmL3RhYmxlOjBkMGQ3OWY4ZmVlZjQ1ZTY5MDZjN2FlZDIyY2I2OTkwL3RhYmxlcmFuZ2U6MGQwZDc5ZjhmZWVmNDVlNjkwNmM3YWVkMjJjYjY5OTBfOC0zLTEtMS0yMjQzMA_09719709-42b1-4e08-9c9b-3401d4909b5a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="-3" name="us-gaap:Depreciation" scale="3" id="fact-identifier-209" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zNy9mcmFnOmU2ZjEwNjA0ODMxNTQ4ODY4OTQ3MGYwOGE5MWIyMzNmL3RhYmxlOjBkMGQ3OWY4ZmVlZjQ1ZTY5MDZjN2FlZDIyY2I2OTkwL3RhYmxlcmFuZ2U6MGQwZDc5ZjhmZWVmNDVlNjkwNmM3YWVkMjJjYjY5OTBfOC0xLTEtMS0xNjM1MQ_c598a0f1-b221-458e-bc00-530b9f472f18" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">22</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="-3" name="us-gaap:Depreciation" scale="3" id="fact-identifier-210" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zNy9mcmFnOmU2ZjEwNjA0ODMxNTQ4ODY4OTQ3MGYwOGE5MWIyMzNmL3RhYmxlOjBkMGQ3OWY4ZmVlZjQ1ZTY5MDZjN2FlZDIyY2I2OTkwL3RhYmxlcmFuZ2U6MGQwZDc5ZjhmZWVmNDVlNjkwNmM3YWVkMjJjYjY5OTBfOC0zLTEtMS0xNjM1MQ_d2543006-9336-4d31-8d16-d44cc92d6a4e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of discount on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="-3" name="bbi:DebtSecuritiesAvailableforSaleAccretionOfDiscount" format="ixt:fixed-zero" scale="3" id="fact-identifier-211" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zNy9mcmFnOmU2ZjEwNjA0ODMxNTQ4ODY4OTQ3MGYwOGE5MWIyMzNmL3RhYmxlOjBkMGQ3OWY4ZmVlZjQ1ZTY5MDZjN2FlZDIyY2I2OTkwL3RhYmxlcmFuZ2U6MGQwZDc5ZjhmZWVmNDVlNjkwNmM3YWVkMjJjYjY5OTBfOS0xLTEtMS0xNjM1MQ_e5f24229-0c65-4958-9fe9-de9a4f232cc7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="-3" sign="-" name="bbi:DebtSecuritiesAvailableforSaleAccretionOfDiscount" scale="3" id="fact-identifier-212" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zNy9mcmFnOmU2ZjEwNjA0ODMxNTQ4ODY4OTQ3MGYwOGE5MWIyMzNmL3RhYmxlOjBkMGQ3OWY4ZmVlZjQ1ZTY5MDZjN2FlZDIyY2I2OTkwL3RhYmxlcmFuZ2U6MGQwZDc5ZjhmZWVmNDVlNjkwNmM3YWVkMjJjYjY5OTBfOS0zLTEtMS0xNjM1MQ_d2cf7735-0f38-487f-96d2-f7f37de7a1a7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">25</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="fact-identifier-213" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zNy9mcmFnOmU2ZjEwNjA0ODMxNTQ4ODY4OTQ3MGYwOGE5MWIyMzNmL3RhYmxlOjBkMGQ3OWY4ZmVlZjQ1ZTY5MDZjN2FlZDIyY2I2OTkwL3RhYmxlcmFuZ2U6MGQwZDc5ZjhmZWVmNDVlNjkwNmM3YWVkMjJjYjY5OTBfMjItMS0xLTEtMTYzNTE_a46b37ef-c72a-4104-af50-733e66bd7f66" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">709</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-214" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zNy9mcmFnOmU2ZjEwNjA0ODMxNTQ4ODY4OTQ3MGYwOGE5MWIyMzNmL3RhYmxlOjBkMGQ3OWY4ZmVlZjQ1ZTY5MDZjN2FlZDIyY2I2OTkwL3RhYmxlcmFuZ2U6MGQwZDc5ZjhmZWVmNDVlNjkwNmM3YWVkMjJjYjY5OTBfMjItMy0xLTEtMTYzNTE_79ef89e9-914a-4d46-97ba-2e26c2cdf69d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,833</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-215" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zNy9mcmFnOmU2ZjEwNjA0ODMxNTQ4ODY4OTQ3MGYwOGE5MWIyMzNmL3RhYmxlOjBkMGQ3OWY4ZmVlZjQ1ZTY5MDZjN2FlZDIyY2I2OTkwL3RhYmxlcmFuZ2U6MGQwZDc5ZjhmZWVmNDVlNjkwNmM3YWVkMjJjYjY5OTBfMjMtMS0xLTEtMTYzNTE_99a2eff6-2f3f-4906-8c68-16b6ebd21c66" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,023</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-216" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zNy9mcmFnOmU2ZjEwNjA0ODMxNTQ4ODY4OTQ3MGYwOGE5MWIyMzNmL3RhYmxlOjBkMGQ3OWY4ZmVlZjQ1ZTY5MDZjN2FlZDIyY2I2OTkwL3RhYmxlcmFuZ2U6MGQwZDc5ZjhmZWVmNDVlNjkwNmM3YWVkMjJjYjY5OTBfMjMtMy0xLTEtMTYzNTE_3b95167a-e236-4182-ac96-a4176e282883" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,677</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-217" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zNy9mcmFnOmU2ZjEwNjA0ODMxNTQ4ODY4OTQ3MGYwOGE5MWIyMzNmL3RhYmxlOjBkMGQ3OWY4ZmVlZjQ1ZTY5MDZjN2FlZDIyY2I2OTkwL3RhYmxlcmFuZ2U6MGQwZDc5ZjhmZWVmNDVlNjkwNmM3YWVkMjJjYjY5OTBfMjQtMS0xLTEtMTYzNTE_bd2861e8-35f4-44b8-8ed1-f0d6cf18b65c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,288</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-218" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zNy9mcmFnOmU2ZjEwNjA0ODMxNTQ4ODY4OTQ3MGYwOGE5MWIyMzNmL3RhYmxlOjBkMGQ3OWY4ZmVlZjQ1ZTY5MDZjN2FlZDIyY2I2OTkwL3RhYmxlcmFuZ2U6MGQwZDc5ZjhmZWVmNDVlNjkwNmM3YWVkMjJjYjY5OTBfMjQtMy0xLTEtMTYzNTE_67e23f05-70c7-4d22-9f3d-1908e9183293" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,010</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:fixed-zero" scale="3" id="fact-identifier-219" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zNy9mcmFnOmU2ZjEwNjA0ODMxNTQ4ODY4OTQ3MGYwOGE5MWIyMzNmL3RhYmxlOjBkMGQ3OWY4ZmVlZjQ1ZTY5MDZjN2FlZDIyY2I2OTkwL3RhYmxlcmFuZ2U6MGQwZDc5ZjhmZWVmNDVlNjkwNmM3YWVkMjJjYjY5OTBfMjgtMS0xLTEtMTYzNTE_4f33795a-1bd0-49b2-a053-9b02c795514c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-220" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zNy9mcmFnOmU2ZjEwNjA0ODMxNTQ4ODY4OTQ3MGYwOGE5MWIyMzNmL3RhYmxlOjBkMGQ3OWY4ZmVlZjQ1ZTY5MDZjN2FlZDIyY2I2OTkwL3RhYmxlcmFuZ2U6MGQwZDc5ZjhmZWVmNDVlNjkwNmM3YWVkMjJjYjY5OTBfMjgtMy0xLTEtMTYzNTE_e809c839-6c42-4480-99b4-1955f3d19bec" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,795</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-221" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zNy9mcmFnOmU2ZjEwNjA0ODMxNTQ4ODY4OTQ3MGYwOGE5MWIyMzNmL3RhYmxlOjBkMGQ3OWY4ZmVlZjQ1ZTY5MDZjN2FlZDIyY2I2OTkwL3RhYmxlcmFuZ2U6MGQwZDc5ZjhmZWVmNDVlNjkwNmM3YWVkMjJjYjY5OTBfMzAtMS0xLTEtMTYzNTE_bd70aeea-591c-4d2c-96e7-0e246f27f41e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">36,148</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-222" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zNy9mcmFnOmU2ZjEwNjA0ODMxNTQ4ODY4OTQ3MGYwOGE5MWIyMzNmL3RhYmxlOjBkMGQ3OWY4ZmVlZjQ1ZTY5MDZjN2FlZDIyY2I2OTkwL3RhYmxlcmFuZ2U6MGQwZDc5ZjhmZWVmNDVlNjkwNmM3YWVkMjJjYjY5OTBfMzAtMy0xLTEtMTYzNTE_630c8e7f-3ea0-40da-ad83-bc6a68693131" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20,034</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CASH FLOWS FROM INVESTING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="3" id="fact-identifier-223" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zNy9mcmFnOmU2ZjEwNjA0ODMxNTQ4ODY4OTQ3MGYwOGE5MWIyMzNmL3RhYmxlOjBkMGQ3OWY4ZmVlZjQ1ZTY5MDZjN2FlZDIyY2I2OTkwL3RhYmxlcmFuZ2U6MGQwZDc5ZjhmZWVmNDVlNjkwNmM3YWVkMjJjYjY5OTBfMzMtMS0xLTEtMTYzNTE_c4bd7cca-0811-4ed7-b841-38485f572db5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">36</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="3" id="fact-identifier-224" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zNy9mcmFnOmU2ZjEwNjA0ODMxNTQ4ODY4OTQ3MGYwOGE5MWIyMzNmL3RhYmxlOjBkMGQ3OWY4ZmVlZjQ1ZTY5MDZjN2FlZDIyY2I2OTkwL3RhYmxlcmFuZ2U6MGQwZDc5ZjhmZWVmNDVlNjkwNmM3YWVkMjJjYjY5OTBfMzMtMy0xLTEtMTYzNTE_b2c43ea5-3faf-499f-921a-7135bd637aab" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">23</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:fixed-zero" scale="3" id="fact-identifier-225" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zNy9mcmFnOmU2ZjEwNjA0ODMxNTQ4ODY4OTQ3MGYwOGE5MWIyMzNmL3RhYmxlOjBkMGQ3OWY4ZmVlZjQ1ZTY5MDZjN2FlZDIyY2I2OTkwL3RhYmxlcmFuZ2U6MGQwZDc5ZjhmZWVmNDVlNjkwNmM3YWVkMjJjYjY5OTBfMzQtMS0xLTEtMTYzNTE_2e19310e-8983-404f-8d17-c465ba2c6d67" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-226" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zNy9mcmFnOmU2ZjEwNjA0ODMxNTQ4ODY4OTQ3MGYwOGE5MWIyMzNmL3RhYmxlOjBkMGQ3OWY4ZmVlZjQ1ZTY5MDZjN2FlZDIyY2I2OTkwL3RhYmxlcmFuZ2U6MGQwZDc5ZjhmZWVmNDVlNjkwNmM3YWVkMjJjYjY5OTBfMzQtMy0xLTEtMTYzNTE_05adcc01-1001-4f50-9d07-6b2abe14cc70" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,500</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="fact-identifier-227" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zNy9mcmFnOmU2ZjEwNjA0ODMxNTQ4ODY4OTQ3MGYwOGE5MWIyMzNmL3RhYmxlOjBkMGQ3OWY4ZmVlZjQ1ZTY5MDZjN2FlZDIyY2I2OTkwL3RhYmxlcmFuZ2U6MGQwZDc5ZjhmZWVmNDVlNjkwNmM3YWVkMjJjYjY5OTBfMzYtMS0xLTEtMTYzNTE_4c449899-2da7-45af-8ede-ec3b528fc9c5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">36</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-228" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zNy9mcmFnOmU2ZjEwNjA0ODMxNTQ4ODY4OTQ3MGYwOGE5MWIyMzNmL3RhYmxlOjBkMGQ3OWY4ZmVlZjQ1ZTY5MDZjN2FlZDIyY2I2OTkwL3RhYmxlcmFuZ2U6MGQwZDc5ZjhmZWVmNDVlNjkwNmM3YWVkMjJjYjY5OTBfMzYtMy0xLTEtMTYzNTE_a6f59715-0faa-45b3-8e5e-ef503bca0aed" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,477</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CASH FLOWS FROM FINANCING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the issuance of common stock and warrants, net of offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-229" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zNy9mcmFnOmU2ZjEwNjA0ODMxNTQ4ODY4OTQ3MGYwOGE5MWIyMzNmL3RhYmxlOjBkMGQ3OWY4ZmVlZjQ1ZTY5MDZjN2FlZDIyY2I2OTkwL3RhYmxlcmFuZ2U6MGQwZDc5ZjhmZWVmNDVlNjkwNmM3YWVkMjJjYjY5OTBfNDEtMS0xLTEtMTYzNTE_6e874e74-6801-49d9-a210-950073bba0af" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">24,006</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-230" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zNy9mcmFnOmU2ZjEwNjA0ODMxNTQ4ODY4OTQ3MGYwOGE5MWIyMzNmL3RhYmxlOjBkMGQ3OWY4ZmVlZjQ1ZTY5MDZjN2FlZDIyY2I2OTkwL3RhYmxlcmFuZ2U6MGQwZDc5ZjhmZWVmNDVlNjkwNmM3YWVkMjJjYjY5OTBfNDEtMy0xLTEtMTYzNTE_89ce60b6-eba2-4614-a8b4-8c6b32a12832" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">37,977</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the exercise of warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-231" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zNy9mcmFnOmU2ZjEwNjA0ODMxNTQ4ODY4OTQ3MGYwOGE5MWIyMzNmL3RhYmxlOjBkMGQ3OWY4ZmVlZjQ1ZTY5MDZjN2FlZDIyY2I2OTkwL3RhYmxlcmFuZ2U6MGQwZDc5ZjhmZWVmNDVlNjkwNmM3YWVkMjJjYjY5OTBfNDItMS0xLTEtMTYzNTE_f31db069-90da-4782-a8a5-6ca87fbe4475" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,969</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="fact-identifier-232" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zNy9mcmFnOmU2ZjEwNjA0ODMxNTQ4ODY4OTQ3MGYwOGE5MWIyMzNmL3RhYmxlOjBkMGQ3OWY4ZmVlZjQ1ZTY5MDZjN2FlZDIyY2I2OTkwL3RhYmxlcmFuZ2U6MGQwZDc5ZjhmZWVmNDVlNjkwNmM3YWVkMjJjYjY5OTBfNDItMy0xLTEtMTYzNTE_18741bcb-a7d3-4481-8786-8990dfc8a37e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">26</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments of taxes related to net share settlement of equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="fact-identifier-233" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zNy9mcmFnOmU2ZjEwNjA0ODMxNTQ4ODY4OTQ3MGYwOGE5MWIyMzNmL3RhYmxlOjBkMGQ3OWY4ZmVlZjQ1ZTY5MDZjN2FlZDIyY2I2OTkwL3RhYmxlcmFuZ2U6MGQwZDc5ZjhmZWVmNDVlNjkwNmM3YWVkMjJjYjY5OTBfNDQtMS0xLTEtMzEzMjg_507373e8-c0dd-48fd-abb1-fcacadb21c33" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">51</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="fact-identifier-234" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zNy9mcmFnOmU2ZjEwNjA0ODMxNTQ4ODY4OTQ3MGYwOGE5MWIyMzNmL3RhYmxlOjBkMGQ3OWY4ZmVlZjQ1ZTY5MDZjN2FlZDIyY2I2OTkwL3RhYmxlcmFuZ2U6MGQwZDc5ZjhmZWVmNDVlNjkwNmM3YWVkMjJjYjY5OTBfNDQtMy0xLTEtMzEzMjg_f4bbe48d-1b27-4513-8f4c-c2eaafbad9f9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the issuance of commons stock under employee stock purchase program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="-3" name="bbi:ProceedsFromTheIssuanceOfEmployeeStock" scale="3" id="fact-identifier-235" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zNy9mcmFnOmU2ZjEwNjA0ODMxNTQ4ODY4OTQ3MGYwOGE5MWIyMzNmL3RhYmxlOjBkMGQ3OWY4ZmVlZjQ1ZTY5MDZjN2FlZDIyY2I2OTkwL3RhYmxlcmFuZ2U6MGQwZDc5ZjhmZWVmNDVlNjkwNmM3YWVkMjJjYjY5OTBfNDQtMS0xLTEtMjI0ODM_709c76a8-faec-46c4-9b6c-bec973be53cf" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">29</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="-3" name="bbi:ProceedsFromTheIssuanceOfEmployeeStock" format="ixt:fixed-zero" scale="3" id="fact-identifier-236" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zNy9mcmFnOmU2ZjEwNjA0ODMxNTQ4ODY4OTQ3MGYwOGE5MWIyMzNmL3RhYmxlOjBkMGQ3OWY4ZmVlZjQ1ZTY5MDZjN2FlZDIyY2I2OTkwL3RhYmxlcmFuZ2U6MGQwZDc5ZjhmZWVmNDVlNjkwNmM3YWVkMjJjYjY5OTBfNDQtMy0xLTEtMjI0ODM_00522f59-48de-4294-80fb-01f71b42833c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the issuance of note payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromNotesPayable" format="ixt:fixed-zero" scale="3" id="fact-identifier-237" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zNy9mcmFnOmU2ZjEwNjA0ODMxNTQ4ODY4OTQ3MGYwOGE5MWIyMzNmL3RhYmxlOjBkMGQ3OWY4ZmVlZjQ1ZTY5MDZjN2FlZDIyY2I2OTkwL3RhYmxlcmFuZ2U6MGQwZDc5ZjhmZWVmNDVlNjkwNmM3YWVkMjJjYjY5OTBfNDMtMS0xLTEtMTYzNTE_70c162a2-bb76-4a0a-baef-27eb26358c7f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromNotesPayable" scale="3" id="fact-identifier-238" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zNy9mcmFnOmU2ZjEwNjA0ODMxNTQ4ODY4OTQ3MGYwOGE5MWIyMzNmL3RhYmxlOjBkMGQ3OWY4ZmVlZjQ1ZTY5MDZjN2FlZDIyY2I2OTkwL3RhYmxlcmFuZ2U6MGQwZDc5ZjhmZWVmNDVlNjkwNmM3YWVkMjJjYjY5OTBfNDMtMy0xLTEtMTYzNTE_ca05fbda-d568-4e46-9b75-bcf636f5cfba" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">437</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-239" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zNy9mcmFnOmU2ZjEwNjA0ODMxNTQ4ODY4OTQ3MGYwOGE5MWIyMzNmL3RhYmxlOjBkMGQ3OWY4ZmVlZjQ1ZTY5MDZjN2FlZDIyY2I2OTkwL3RhYmxlcmFuZ2U6MGQwZDc5ZjhmZWVmNDVlNjkwNmM3YWVkMjJjYjY5OTBfNDgtMS0xLTEtMTYzNTE_6d10b6bc-eded-4165-bd95-bc247133f6c7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">32,953</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-240" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zNy9mcmFnOmU2ZjEwNjA0ODMxNTQ4ODY4OTQ3MGYwOGE5MWIyMzNmL3RhYmxlOjBkMGQ3OWY4ZmVlZjQ1ZTY5MDZjN2FlZDIyY2I2OTkwL3RhYmxlcmFuZ2U6MGQwZDc5ZjhmZWVmNDVlNjkwNmM3YWVkMjJjYjY5OTBfNDgtMy0xLTEtMTYzNTE_895aafaa-50ac-4c36-a754-1e3c2b5aeece" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">38,440</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-241" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zNy9mcmFnOmU2ZjEwNjA0ODMxNTQ4ODY4OTQ3MGYwOGE5MWIyMzNmL3RhYmxlOjBkMGQ3OWY4ZmVlZjQ1ZTY5MDZjN2FlZDIyY2I2OTkwL3RhYmxlcmFuZ2U6MGQwZDc5ZjhmZWVmNDVlNjkwNmM3YWVkMjJjYjY5OTBfNTAtMS0xLTEtMTYzNTE_acffc67a-d8e3-4506-b6b3-4921e366d384" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,231</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-242" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zNy9mcmFnOmU2ZjEwNjA0ODMxNTQ4ODY4OTQ3MGYwOGE5MWIyMzNmL3RhYmxlOjBkMGQ3OWY4ZmVlZjQ1ZTY5MDZjN2FlZDIyY2I2OTkwL3RhYmxlcmFuZ2U6MGQwZDc5ZjhmZWVmNDVlNjkwNmM3YWVkMjJjYjY5OTBfNTAtMy0xLTEtMTYzNTE_a7048525-48fd-44df-9f74-ef92f0205673" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">22,883</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CASH AND CASH EQUIVALENTS—BEGINNING</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i79b48cfc81254328ac1dae75e4c81c8f_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-243" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zNy9mcmFnOmU2ZjEwNjA0ODMxNTQ4ODY4OTQ3MGYwOGE5MWIyMzNmL3RhYmxlOjBkMGQ3OWY4ZmVlZjQ1ZTY5MDZjN2FlZDIyY2I2OTkwL3RhYmxlcmFuZ2U6MGQwZDc5ZjhmZWVmNDVlNjkwNmM3YWVkMjJjYjY5OTBfNTEtMS0xLTEtMTYzNTE_27670182-ca50-4154-99a4-7dc0ec2da0db" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">30,115</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i1a7b0ff06cf34bf68b059f14a54eef1e_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-244" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zNy9mcmFnOmU2ZjEwNjA0ODMxNTQ4ODY4OTQ3MGYwOGE5MWIyMzNmL3RhYmxlOjBkMGQ3OWY4ZmVlZjQ1ZTY5MDZjN2FlZDIyY2I2OTkwL3RhYmxlcmFuZ2U6MGQwZDc5ZjhmZWVmNDVlNjkwNmM3YWVkMjJjYjY5OTBfNTEtMy0xLTEtMTYzNTE_4926a9bf-8eaa-4c60-a4e1-7e9f13e94a7e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,232</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CASH AND CASH EQUIVALENTS—ENDING</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i136a713ea34e4a3a8a8e3a24f4fa59ed_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-245" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zNy9mcmFnOmU2ZjEwNjA0ODMxNTQ4ODY4OTQ3MGYwOGE5MWIyMzNmL3RhYmxlOjBkMGQ3OWY4ZmVlZjQ1ZTY5MDZjN2FlZDIyY2I2OTkwL3RhYmxlcmFuZ2U6MGQwZDc5ZjhmZWVmNDVlNjkwNmM3YWVkMjJjYjY5OTBfNTItMS0xLTEtMTYzNTE_a6f9730f-bcb8-4b64-b11c-2bd147225696" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">26,884</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i79b48cfc81254328ac1dae75e4c81c8f_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-246" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zNy9mcmFnOmU2ZjEwNjA0ODMxNTQ4ODY4OTQ3MGYwOGE5MWIyMzNmL3RhYmxlOjBkMGQ3OWY4ZmVlZjQ1ZTY5MDZjN2FlZDIyY2I2OTkwL3RhYmxlcmFuZ2U6MGQwZDc5ZjhmZWVmNDVlNjkwNmM3YWVkMjJjYjY5OTBfNTItMy0xLTEtMTYzNTE_8ba2606f-72a6-4b40-874c-97345a2ae0f2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">30,115</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Disclosure of Non-Cash Investing and Financing Activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forgiveness of Paycheck Protection Program loan</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="-3" name="bbi:ForgivenessOfPaycheckProtectionProgramLoanNonCashInvestingAndFinancingActivitiesLoansForgivenCARESAct" scale="3" id="fact-identifier-247" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zNy9mcmFnOmU2ZjEwNjA0ODMxNTQ4ODY4OTQ3MGYwOGE5MWIyMzNmL3RhYmxlOjBkMGQ3OWY4ZmVlZjQ1ZTY5MDZjN2FlZDIyY2I2OTkwL3RhYmxlcmFuZ2U6MGQwZDc5ZjhmZWVmNDVlNjkwNmM3YWVkMjJjYjY5OTBfNTctMS0xLTEtMTYzNTE_279e259e-886d-4a34-87f5-84bbb4d8b8f8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">437</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="-3" name="bbi:ForgivenessOfPaycheckProtectionProgramLoanNonCashInvestingAndFinancingActivitiesLoansForgivenCARESAct" format="ixt:fixed-zero" scale="3" id="fact-identifier-248" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8zNy9mcmFnOmU2ZjEwNjA0ODMxNTQ4ODY4OTQ3MGYwOGE5MWIyMzNmL3RhYmxlOjBkMGQ3OWY4ZmVlZjQ1ZTY5MDZjN2FlZDIyY2I2OTkwL3RhYmxlcmFuZ2U6MGQwZDc5ZjhmZWVmNDVlNjkwNmM3YWVkMjJjYjY5OTBfNTctMy0xLTEtMTYzNTE_d1886e7b-9355-4143-a8cb-83dbd6fb860b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to these consolidated financial statements. </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><div id="ie1e15c78f2af410c8f1490215e82bdbe_43"></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BRICKELL BIOTECH, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div id="ie1e15c78f2af410c8f1490215e82bdbe_49"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 1. <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="fact-identifier-249" continuedat="ifbb979349e184a29b466c920a0bafa5d" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV80OS9mcmFnOmE2NDg3MzRkNGI4ZjRmYmE4MWFlOTIzZmNhODlkOGNjL3RleHRyZWdpb246YTY0ODczNGQ0YjhmNGZiYTgxYWU5MjNmY2E4OWQ4Y2NfMzAwNg_ddc1cce0-ceba-4c98-beb4-ba6948bd3cae" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">ORGANIZATION AND NATURE OF OPERATIONS </ix:nonnumeric></span></span></div><span><ix:continuation id="ifbb979349e184a29b466c920a0bafa5d" continuedat="i785133424985417fb4aad55b05accf9e" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Brickell Biotech, Inc. (the “Company” or “Brickell”) is a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases. The Company’s pipeline combines several development-stage candidates and a cutting-edge platform with broad potential in autoimmune and inflammatory disorders with a potential best-in-class, late-stage program for the treatment of primary axillary hyperhidrosis. Brickell’s executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Taltz</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Gemzar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Prozac</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Cymbalta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Juvederm</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company’s strategy includes leveraging this experience to in-license, acquire, develop, and commercialize innovative pharmaceutical products that it believes can meaningfully benefit patients who are suffering from chronic, debilitating diseases in the foregoing target disease areas and that are underserved by available therapies.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s operations to date have been limited to business planning, raising capital, developing its pipeline assets (in particular sofpironium bromide), identifying and in-licensing product candidates, conducting clinical trials, and other research and development.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Capital Resources </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred significant operating losses and has an accumulated deficit as a result of ongoing efforts to in-license and develop product candidates, including conducting preclinical and clinical trials and providing general and administrative support for these operations. For the year ended December&nbsp;31, 2021, the Company had a net loss of $<span><ix:nonfraction unitref="usd" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-251" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV80OS9mcmFnOmE2NDg3MzRkNGI4ZjRmYmE4MWFlOTIzZmNhODlkOGNjL3RleHRyZWdpb246YTY0ODczNGQ0YjhmNGZiYTgxYWU5MjNmY2E4OWQ4Y2NfMjI3MQ_46f3c3cf-7dc8-4aae-8669-dc05fb7a8f6a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">39.5</ix:nonfraction></span>&nbsp;million and net cash used in operating activities of $<span><ix:nonfraction unitref="usd" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-252" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV80OS9mcmFnOmE2NDg3MzRkNGI4ZjRmYmE4MWFlOTIzZmNhODlkOGNjL3RleHRyZWdpb246YTY0ODczNGQ0YjhmNGZiYTgxYWU5MjNmY2E4OWQ4Y2NfMjMxOQ_08064fea-aaa5-40d2-bb65-25eb10862c54" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">36.1</ix:nonfraction></span>&nbsp;million. As of&nbsp;December&nbsp;31, 2021, the Company had cash and cash equivalents of $<span><ix:nonfraction unitref="usd" contextref="i136a713ea34e4a3a8a8e3a24f4fa59ed_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-253" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV80OS9mcmFnOmE2NDg3MzRkNGI4ZjRmYmE4MWFlOTIzZmNhODlkOGNjL3RleHRyZWdpb246YTY0ODczNGQ0YjhmNGZiYTgxYWU5MjNmY2E4OWQ4Y2NfMjM3OA_67ce796b-0790-4af8-bd87-e368d15f5f11" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">26.9</ix:nonfraction></span>&nbsp;million&nbsp;and an accumulated deficit of $<span><ix:nonfraction unitref="usd" contextref="i136a713ea34e4a3a8a8e3a24f4fa59ed_I20211231" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-254" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV80OS9mcmFnOmE2NDg3MzRkNGI4ZjRmYmE4MWFlOTIzZmNhODlkOGNjL3RleHRyZWdpb246YTY0ODczNGQ0YjhmNGZiYTgxYWU5MjNmY2E4OWQ4Y2NfMjQxMQ_eb8f5167-62cb-4215-bb5f-39ad6bea068a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">145.4</ix:nonfraction></span>&nbsp;million.</span></div></ix:continuation></span><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span><ix:continuation id="i785133424985417fb4aad55b05accf9e" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false">The Company believes that its cash and cash equivalents as of December&nbsp;31, 2021 will be sufficient to fund its operations for at least the next 12 months from the issuance of these consolidated financial statements. The Company expects to continue to incur additional substantial losses in the foreseeable future as a result of the Company’s research and development activities. Additional funding will be required in the future to continue with the Company’s planned development and other activities.</ix:continuation></span> </span></div><div style="text-align:justify"><span><br></span></div><div id="ie1e15c78f2af410c8f1490215e82bdbe_55"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 2. <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="fact-identifier-256" continuedat="i542b3d9b22c34d7190d642df5e162aa0" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV81NS9mcmFnOjhkZTk3ZmI3Yjg4OTRkYzNiMWQ0OWU3ZGUwZGNjOWUzL3RleHRyZWdpb246OGRlOTdmYjdiODg5NGRjM2IxZDQ5ZTdkZTBkY2M5ZTNfMTgwOTY_fd1788b8-25e7-4921-80c0-3b614726e290" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonnumeric></span></span></div><span><ix:continuation id="i542b3d9b22c34d7190d642df5e162aa0" continuedat="i909b5918afa942f4b31979e876ce56e8" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="fact-identifier-258" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV81NS9mcmFnOjhkZTk3ZmI3Yjg4OTRkYzNiMWQ0OWU3ZGUwZGNjOWUzL3RleHRyZWdpb246OGRlOTdmYjdiODg5NGRjM2IxZDQ5ZTdkZTBkY2M5ZTNfMTgwOTA_f3a94afc-2f21-4685-bfb4-e3f122d06cc0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Brickell Subsidiary, Inc., and are presented in United States (“U.S.”) dollars and prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), which include all adjustments necessary for the fair presentation of the Company’s financial position, results of operations, and cash flows for the periods presented. All significant intercompany balances have been eliminated in consolidation. The Company operates in <span><ix:nonfraction unitref="segment" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="fact-identifier-259" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV81NS9mcmFnOjhkZTk3ZmI3Yjg4OTRkYzNiMWQ0OWU3ZGUwZGNjOWUzL3RleHRyZWdpb246OGRlOTdmYjdiODg5NGRjM2IxZDQ5ZTdkZTBkY2M5ZTNfMTA5OTUxMTY1NzQ2OA_0cf34747-d4d5-4065-8b85-b3038563831e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">one</ix:nonfraction></span> operating segment and, accordingly, no segment disclosures have been presented herein. The Company’s management performed an evaluation of its activities through the date of filing of these financial statements and concluded that there are no subsequent events requiring disclosure, other than as disclosed.</span></div></ix:nonnumeric></span></ix:continuation></span><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><span><ix:continuation id="i909b5918afa942f4b31979e876ce56e8" continuedat="i7d73531902de4a5197fa60628041f328" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="us-gaap:UseOfEstimates" id="fact-identifier-261" escape="true" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV81NS9mcmFnOjhkZTk3ZmI3Yjg4OTRkYzNiMWQ0OWU3ZGUwZGNjOWUzL3RleHRyZWdpb246OGRlOTdmYjdiODg5NGRjM2IxZDQ5ZTdkZTBkY2M5ZTNfMTgwOTE_f96537a4-4eac-4be4-a365-c8574597618c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s consolidated financial statements are prepared in accordance with U.S. GAAP, which requires it to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on the Company’s knowledge of current events and actions it may take in the future, actual results may ultimately differ from these estimates and assumptions.</span></div></ix:nonnumeric></span><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s business is subject to significant risks common to early-stage companies in the pharmaceutical industry including, but not limited to, the ability to develop appropriate formulations, scale up and produce the compounds; dependence on collaborative parties; uncertainties associated with obtaining and enforcing patents and other intellectual property rights; clinical implementation and success; the lengthy and expensive regulatory approval process; compliance with regulatory and other legal requirements; competition from other products; uncertainty of broad adoption of its approved products, if any, by physicians and patients; significant competition; ability to manage third-party manufacturers, suppliers, contract research organizations, business partners and other alliances; and obtaining additional financing to fund the Company’s efforts.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The product candidates developed by the Company require approvals from the U.S. Food and Drug Administration (“FDA”) and foreign regulatory agencies prior to commercial sales in the U.S. or foreign jurisdictions, respectively. There can be no assurance that the Company’s current and future product candidates will receive the necessary approvals. If the Company is denied approval or approval is delayed, it may have a material adverse impact on the Company’s business and its financial condition.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects to incur substantial operating losses for the next several years and will need to obtain additional financing in order to develop and, if successful, commercialize its product candidates. There can be no assurance that such financing will be available or will be at terms acceptable to the Company.</span></div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="fact-identifier-262" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV81NS9mcmFnOjhkZTk3ZmI3Yjg4OTRkYzNiMWQ0OWU3ZGUwZGNjOWUzL3RleHRyZWdpb246OGRlOTdmYjdiODg5NGRjM2IxZDQ5ZTdkZTBkY2M5ZTNfNzE0NjgyNTYxMjUzMQ_94c9f439-9f61-4ae6-93a7-eb6ce13eea64" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid debt instruments with an original maturity of three months or less from date of purchase to be cash equivalents. Cash equivalents, which are stated at cost, consist primarily of amounts held in short-term money market accounts with highly rated financial institutions.</span></div></ix:nonnumeric></span><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="us-gaap:ConcentrationRiskCreditRisk" id="fact-identifier-263" escape="true" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV81NS9mcmFnOjhkZTk3ZmI3Yjg4OTRkYzNiMWQ0OWU3ZGUwZGNjOWUzL3RleHRyZWdpb246OGRlOTdmYjdiODg5NGRjM2IxZDQ5ZTdkZTBkY2M5ZTNfNzE0NjgyNTYxMjUzMg_02eee6cc-99a3-4efc-9e4c-42ebe9db1dd1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains cash and cash equivalents balances in several accounts with one financial institution which, from time to time, are in excess of federally insured limits.</span></div></ix:nonnumeric></span><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="fact-identifier-264" continuedat="ib6929af7b3574ef4ae0c18c71b7dcfe3" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV81NS9mcmFnOjhkZTk3ZmI3Yjg4OTRkYzNiMWQ0OWU3ZGUwZGNjOWUzL3RleHRyZWdpb246OGRlOTdmYjdiODg5NGRjM2IxZDQ5ZTdkZTBkY2M5ZTNfNzE0NjgyNTYxMjUzMw_9d926fba-9ef7-428b-b900-3bbb2c372b41" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Property and Equipment</ix:nonnumeric></span></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span><ix:continuation id="ib6929af7b3574ef4ae0c18c71b7dcfe3" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false">Property and equipment is stated at cost, less accumulated depreciation. Expenditures for major betterments and additions are charged to the asset accounts, while replacements, maintenance, and repairs, which do not improve or extend the lives of the respective assets, are charged to expense as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between <span><ix:nonnumeric contextref="ife9a1b0f0d6646b6920f29eb20835875_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" id="fact-identifier-266" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV81NS9mcmFnOjhkZTk3ZmI3Yjg4OTRkYzNiMWQ0OWU3ZGUwZGNjOWUzL3RleHRyZWdpb246OGRlOTdmYjdiODg5NGRjM2IxZDQ5ZTdkZTBkY2M5ZTNfMTA5OTUxMTY1MzM0MQ_74452544-b033-40df-a5cf-2d60a0f1256b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">three</ix:nonnumeric></span> and <span><ix:nonnumeric contextref="i10aedd8fb2ac472d99e658bd782e2bd6_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" id="fact-identifier-267" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV81NS9mcmFnOjhkZTk3ZmI3Yjg4OTRkYzNiMWQ0OWU3ZGUwZGNjOWUzL3RleHRyZWdpb246OGRlOTdmYjdiODg5NGRjM2IxZDQ5ZTdkZTBkY2M5ZTNfMTA5OTUxMTY1MzM0OQ_4624c718-e622-465f-bf25-ea599b4baef6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">five</ix:nonnumeric></span> years.</ix:continuation></span> Depreciation expense amounted to $<span><ix:nonfraction unitref="usd" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-268" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV81NS9mcmFnOjhkZTk3ZmI3Yjg4OTRkYzNiMWQ0OWU3ZGUwZGNjOWUzL3RleHRyZWdpb246OGRlOTdmYjdiODg5NGRjM2IxZDQ5ZTdkZTBkY2M5ZTNfMTA5OTUxMTY2MDgwNQ_81e996cf-1d34-4dbc-b057-5f3a7fd23c61" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">22</ix:nonfraction></span> thousand and $<span><ix:nonfraction unitref="usd" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-269" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV81NS9mcmFnOjhkZTk3ZmI3Yjg4OTRkYzNiMWQ0OWU3ZGUwZGNjOWUzL3RleHRyZWdpb246OGRlOTdmYjdiODg5NGRjM2IxZDQ5ZTdkZTBkY2M5ZTNfMTA5OTUxMTY2MDgxNg_f15f5730-bb3e-485e-8868-a9929126fe09" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10</ix:nonfraction></span> thousand for the years ended December&nbsp;31, 2021 and 2020, respectively.</span></div></ix:continuation></span><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><span><ix:continuation id="i7d73531902de4a5197fa60628041f328" continuedat="i106b16927a474074b2f2b9ecf009227a" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="fact-identifier-271" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV81NS9mcmFnOjhkZTk3ZmI3Yjg4OTRkYzNiMWQ0OWU3ZGUwZGNjOWUzL3RleHRyZWdpb246OGRlOTdmYjdiODg5NGRjM2IxZDQ5ZTdkZTBkY2M5ZTNfMTgwOTM_ab9c6af9-4fc4-4ae4-9a2e-0646a37ac195" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is the price that the Company would receive to sell an asset or pay to transfer a liability in a timely transaction with an independent counterparty in the principal market, or in the absence of a principal market, the most advantageous market for the asset or liability. A three-tier hierarchy distinguishes between (1)&nbsp;inputs that reflect the assumptions market participants would use in pricing an asset or liability developed based on market data obtained from sources independent of the reporting entity (observable inputs) and (2)&nbsp;inputs that reflect the reporting entity’s own assumptions about the assumptions market participants would use in pricing an asset or liability developed based on the best information available in the circumstances (unobservable inputs). The hierarchy is summarized in the three broad levels listed below:</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level&nbsp;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—quoted prices in active markets for identical assets and liabilities</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level&nbsp;2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—other significant observable inputs (including quoted prices for similar assets and liabilities, interest rates, credit risk, etc.)</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level&nbsp;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—significant unobservable inputs (including the Company’s own assumptions in determining the fair value of assets and liabilities)</span></div></ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="fact-identifier-272" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV81NS9mcmFnOjhkZTk3ZmI3Yjg4OTRkYzNiMWQ0OWU3ZGUwZGNjOWUzL3RleHRyZWdpb246OGRlOTdmYjdiODg5NGRjM2IxZDQ5ZTdkZTBkY2M5ZTNfMTgxMDM_f3574be0-9413-4676-ba3d-d8d54a957e1f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the fair value of the Company’s financial assets measured at fair value on a recurring basis based on the three-tier fair value hierarchy (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:69.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.401%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&nbsp;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ie71093466047442fa4c12d9719470f93_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-273" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV81NS9mcmFnOjhkZTk3ZmI3Yjg4OTRkYzNiMWQ0OWU3ZGUwZGNjOWUzL3RhYmxlOjc0NmRhODc4MzcxYTRjNTU5Y2FhNzU1YWUzNTQyOTdjL3RhYmxlcmFuZ2U6NzQ2ZGE4NzgzNzFhNGM1NTljYWE3NTVhZTM1NDI5N2NfNi0xLTEtMS0xNjM1MQ_73e7dc64-4571-4f77-8bf1-152224da22e4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">25,875</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id0337d14e1f247559651c4c7555de919_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-274" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV81NS9mcmFnOjhkZTk3ZmI3Yjg4OTRkYzNiMWQ0OWU3ZGUwZGNjOWUzL3RhYmxlOjc0NmRhODc4MzcxYTRjNTU5Y2FhNzU1YWUzNTQyOTdjL3RhYmxlcmFuZ2U6NzQ2ZGE4NzgzNzFhNGM1NTljYWE3NTVhZTM1NDI5N2NfNi0zLTEtMS0xNjM1MQ_2712a1e1-1c2a-4656-913b-6d0723cf183e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">29,182</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&nbsp;&nbsp;&nbsp;&nbsp;No assets as of each respective date were identified as Level 2 or 3 based on the three-tier fair value hierarchy. The Company had no financial liabilities measured at fair value on a recurring basis as of each respective date.</span></div></ix:nonnumeric></span><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following methods and assumptions were used by the Company in estimating the fair values of each class of financial instrument disclosed herein:</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Money Market Funds—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts reported as cash and cash equivalents in the consolidated balance sheets approximate their fair values due to their short-term nature and/or market rates of interest (Level 1 of the fair value hierarchy).</span></div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="fact-identifier-275" continuedat="i6411841bdd0d4f5c897b07676407f33d" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV81NS9mcmFnOjhkZTk3ZmI3Yjg4OTRkYzNiMWQ0OWU3ZGUwZGNjOWUzL3RleHRyZWdpb246OGRlOTdmYjdiODg5NGRjM2IxZDQ5ZTdkZTBkY2M5ZTNfNzE0NjgyNTYxMjUzNA_9dc6e939-7926-49d6-a2d2-ad80f7b41a98" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at inception. Operating leases with a term greater than one year are recognized on the balance sheet as right-of-use assets, lease liabilities and, if applicable, long-term lease liabilities. The Company does not currently hold any financing leases. The Company has elected the practical expedient not to recognize on the balance sheet leases with terms of one year or less and not to separate lease components and non-lease components for long-term real estate leases. Lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company estimates the incremental borrowing rate based on industry peers in determining the present value of lease payments. Industry peers consist of several public companies in the biotechnology industry with </span></div></ix:nonnumeric></span></ix:continuation></span><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><span><ix:continuation id="i106b16927a474074b2f2b9ecf009227a" continuedat="i1edea3a32c114b89be18b0bfa1f35139" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span><ix:continuation id="i6411841bdd0d4f5c897b07676407f33d" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false">comparable characteristics. The Company’s facility operating lease has one single component. The lease component results in a right-of-use asset being recorded on the balance sheet, which is amortized as lease expense on a straight-line basis in the Company’s consolidated statements of operations.</ix:continuation></span></span></div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="fact-identifier-278" continuedat="i58a0212bc80c4562a03e9a5a2cf8a2e3" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV81NS9mcmFnOjhkZTk3ZmI3Yjg4OTRkYzNiMWQ0OWU3ZGUwZGNjOWUzL3RleHRyZWdpb246OGRlOTdmYjdiODg5NGRjM2IxZDQ5ZTdkZTBkY2M5ZTNfMTgwOTQ_51794080-1f53-439b-9a24-177356142c1d" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently recognizes revenue primarily from licensing and royalty fees received under the Kaken Agreement described in Note 3. “Strategic Agreements,” of which the terms of the agreement include non-refundable upfront fees, funding of research and development activities, payments based upon achievement of milestones, and royalties on net product sales.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized, the Company performs the following five steps: (i)&nbsp;identify the contract(s) with a customer; (ii)&nbsp;identify the performance obligations in the contract; (iii)&nbsp;determine the transaction price, including the constraint on variable consideration; (iv)&nbsp;allocate the transaction price to the performance obligations in the contract; and (v)&nbsp;recognize revenue when (or as) the Company satisfies the performance obligations. At contract inception, the Company assesses the goods or services promised within each contract and assesses whether each promised good or service is distinct and determines those that are&nbsp;performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes judgment to assess the nature of the performance obligation to determine whether the performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Revenue</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates collaboration arrangements to determine whether units of account within the collaboration arrangement exhibit the characteristics of a vendor and customer relationship. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses of Intellectual Property</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a license for the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer, and the customer can use and benefit from the license.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestones</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone (such as a regulatory submission) is included in the transaction price. Milestone payments that are not within the Company or the Company’s collaboration partner’s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjusts </span></div></ix:nonnumeric></span></ix:continuation></span><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><span><ix:continuation id="i1edea3a32c114b89be18b0bfa1f35139" continuedat="i1334ac50b1694fa7b84bc64fb338595a" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation id="i58a0212bc80c4562a03e9a5a2cf8a2e3" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company’s estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration, and other revenues and earnings in the period of adjustment and future periods through the end of the performance obligation period. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i)&nbsp;when the related sales occur or (ii)&nbsp;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div></ix:continuation></span><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="fact-identifier-281" escape="true" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV81NS9mcmFnOjhkZTk3ZmI3Yjg4OTRkYzNiMWQ0OWU3ZGUwZGNjOWUzL3RleHRyZWdpb246OGRlOTdmYjdiODg5NGRjM2IxZDQ5ZTdkZTBkY2M5ZTNfMTgwODk_c6d10ade-08c8-447a-96a1-950c3c64379c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are charged to expense when incurred and consist of costs incurred for independent and collaboration research and development activities. The major components of research and development costs include formulation development, nonclinical studies, clinical studies, clinical manufacturing costs, in-licensing fees for development-stage assets, salaries and employee benefits, and allocations of various overhead and occupancy costs. Research costs typically consist of applied research, preclinical, and toxicology work. Pharmaceutical manufacturing development costs consist of product formulation, chemical analysis, and the transfer and scale-up of manufacturing at contract manufacturers. Assets acquired (or in-licensed) that are utilized in research and development that have no alternative future use are expensed as incurred. Milestone payments related to the Company’s acquired (or in-licensed) assets are recorded as research and development expense when probable and can be reasonably estimated.</span></div></ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="bbi:ClinicalTrialAccrualsPolicyPolicyTextBlock" id="fact-identifier-282" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV81NS9mcmFnOjhkZTk3ZmI3Yjg4OTRkYzNiMWQ0OWU3ZGUwZGNjOWUzL3RleHRyZWdpb246OGRlOTdmYjdiODg5NGRjM2IxZDQ5ZTdkZTBkY2M5ZTNfMTgxMDQ_aa6a4631-95ef-4876-aec9-f255c118f012" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Trial Accruals</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expense accruals related to clinical trials are based on the Company’s estimates of services received and efforts expended pursuant to contracts with multiple research institutions and third-party clinical research organizations that conduct and manage clinical trials on the Company’s behalf. The financial terms of these agreements vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing costs, the Company estimates the period over which services will be performed and the level of effort to be expended in each period based upon patient enrollment, clinical site activations, or information provided to the Company by its vendors on their actual costs incurred. Any estimates of the level of services performed or the costs of these services could differ from actual results. As of December&nbsp;31, 2021, related to clinical trials, the Company recorded $<span><ix:nonfraction unitref="usd" contextref="i136a713ea34e4a3a8a8e3a24f4fa59ed_I20211231" decimals="-5" name="bbi:ClinicalTrialsAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-283" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV81NS9mcmFnOjhkZTk3ZmI3Yjg4OTRkYzNiMWQ0OWU3ZGUwZGNjOWUzL3RleHRyZWdpb246OGRlOTdmYjdiODg5NGRjM2IxZDQ5ZTdkZTBkY2M5ZTNfMTA5OTUxMTY3OTA3MA_e8158648-ab51-4dc2-bd9e-ce97bd6aff4a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.8</ix:nonfraction></span>&nbsp;million of accrued expenses and $<span><ix:nonfraction unitref="usd" contextref="i136a713ea34e4a3a8a8e3a24f4fa59ed_I20211231" decimals="-5" name="bbi:ClinicalTrialsPrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-284" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV81NS9mcmFnOjhkZTk3ZmI3Yjg4OTRkYzNiMWQ0OWU3ZGUwZGNjOWUzL3RleHRyZWdpb246OGRlOTdmYjdiODg5NGRjM2IxZDQ5ZTdkZTBkY2M5ZTNfNjA0NzMxNDAwNDQyNQ_53210f17-e85a-4cb3-8474-692d804b232e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1.4</ix:nonfraction></span>&nbsp;million of prepaid expenses, which are reported in the consolidated balance sheet as components of accrued liabilities and prepaid expenses and other current assets, respectively.</span></div></ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="fact-identifier-285" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV81NS9mcmFnOjhkZTk3ZmI3Yjg4OTRkYzNiMWQ0OWU3ZGUwZGNjOWUzL3RleHRyZWdpb246OGRlOTdmYjdiODg5NGRjM2IxZDQ5ZTdkZTBkY2M5ZTNfMTgxMDE_6db98251-a29b-4016-9cd8-5ac6b18d347f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding. When the effects are not anti-dilutive, diluted earnings per share is computed by dividing the Company’s net income by the weighted average number of common shares outstanding and the impact of all potentially dilutive common shares. Diluted net loss per share is the same as basic net loss per share, as the effects of potentially dilutive securities are anti-dilutive for all periods presented.</span></div></ix:nonnumeric></span></ix:continuation></span><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><span><ix:continuation id="i1334ac50b1694fa7b84bc64fb338595a" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="fact-identifier-287" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV81NS9mcmFnOjhkZTk3ZmI3Yjg4OTRkYzNiMWQ0OWU3ZGUwZGNjOWUzL3RleHRyZWdpb246OGRlOTdmYjdiODg5NGRjM2IxZDQ5ZTdkZTBkY2M5ZTNfMTgwOTg_9ed59532-70d2-452b-98e8-ee647d43c0df" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the potential common shares excluded from the calculation of diluted net loss per share because their inclusion would be anti-dilutive:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:69.066%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended<br>December&nbsp;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding warrants</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="ibefe7702458545ea8f5b2c0e3413b2b8_D20210101-20211231" decimals="INF" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-288" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV81NS9mcmFnOjhkZTk3ZmI3Yjg4OTRkYzNiMWQ0OWU3ZGUwZGNjOWUzL3RhYmxlOmM2ODIxYzdlMWRmOTRiNjFhMzIwY2NhMjRiNTQ5YjBjL3RhYmxlcmFuZ2U6YzY4MjFjN2UxZGY5NGI2MWEzMjBjY2EyNGI1NDliMGNfMi01LTEtMS0xNjM1MQ_cb486642-519f-4f2a-a65f-2a94b7f35b6a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">27,944,544</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i72ce39e4fc9c4f4fb4167626cfe366ad_D20200101-20201231" decimals="INF" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-289" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV81NS9mcmFnOjhkZTk3ZmI3Yjg4OTRkYzNiMWQ0OWU3ZGUwZGNjOWUzL3RhYmxlOmM2ODIxYzdlMWRmOTRiNjFhMzIwY2NhMjRiNTQ5YjBjL3RhYmxlcmFuZ2U6YzY4MjFjN2UxZGY5NGI2MWEzMjBjY2EyNGI1NDliMGNfMi03LTEtMS0xNjM1MQ_83d07e5a-38b4-40b9-b3b5-f9c1c2bebe93" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">40,389,431</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i73c721546b6043588c18a762c0b2f2fa_D20210101-20211231" decimals="INF" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-290" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV81NS9mcmFnOjhkZTk3ZmI3Yjg4OTRkYzNiMWQ0OWU3ZGUwZGNjOWUzL3RhYmxlOmM2ODIxYzdlMWRmOTRiNjFhMzIwY2NhMjRiNTQ5YjBjL3RhYmxlcmFuZ2U6YzY4MjFjN2UxZGY5NGI2MWEzMjBjY2EyNGI1NDliMGNfMy01LTEtMS0xNjM1MQ_86583c8c-805c-4fd1-88dc-e450546c2316" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,059,842</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i751d45db4c76499988f110b5325a83ac_D20200101-20201231" decimals="INF" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-291" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV81NS9mcmFnOjhkZTk3ZmI3Yjg4OTRkYzNiMWQ0OWU3ZGUwZGNjOWUzL3RhYmxlOmM2ODIxYzdlMWRmOTRiNjFhMzIwY2NhMjRiNTQ5YjBjL3RhYmxlcmFuZ2U6YzY4MjFjN2UxZGY5NGI2MWEzMjBjY2EyNGI1NDliMGNfMy03LTEtMS0xNjM1MQ_f7bb4dd2-6916-44e2-8252-f2d8c0af19fe" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,688,625</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="ibab54c3adead408687d6cbac3b5979dd_D20210101-20211231" decimals="INF" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="fact-identifier-292" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV81NS9mcmFnOjhkZTk3ZmI3Yjg4OTRkYzNiMWQ0OWU3ZGUwZGNjOWUzL3RhYmxlOmM2ODIxYzdlMWRmOTRiNjFhMzIwY2NhMjRiNTQ5YjBjL3RhYmxlcmFuZ2U6YzY4MjFjN2UxZGY5NGI2MWEzMjBjY2EyNGI1NDliMGNfNC01LTEtMS0xNjM1MQ_1792f678-3731-4d45-9aab-0dad5f801a2e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i070fe27d5536497092d9af2480ee02f4_D20200101-20201231" decimals="INF" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-293" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV81NS9mcmFnOjhkZTk3ZmI3Yjg4OTRkYzNiMWQ0OWU3ZGUwZGNjOWUzL3RhYmxlOmM2ODIxYzdlMWRmOTRiNjFhMzIwY2NhMjRiNTQ5YjBjL3RhYmxlcmFuZ2U6YzY4MjFjN2UxZGY5NGI2MWEzMjBjY2EyNGI1NDliMGNfNC03LTEtMS0xNjM1MQ_13f2b4bf-3ece-4bc1-b78a-8bd7f49e7491" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">143,000</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="INF" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-294" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV81NS9mcmFnOjhkZTk3ZmI3Yjg4OTRkYzNiMWQ0OWU3ZGUwZGNjOWUzL3RhYmxlOmM2ODIxYzdlMWRmOTRiNjFhMzIwY2NhMjRiNTQ5YjBjL3RhYmxlcmFuZ2U6YzY4MjFjN2UxZGY5NGI2MWEzMjBjY2EyNGI1NDliMGNfOC01LTEtMS0xNjM1MQ_b8e9bca9-835a-41e8-96ab-b42592f61881" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">35,004,386</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="INF" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-295" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV81NS9mcmFnOjhkZTk3ZmI3Yjg4OTRkYzNiMWQ0OWU3ZGUwZGNjOWUzL3RhYmxlOmM2ODIxYzdlMWRmOTRiNjFhMzIwY2NhMjRiNTQ5YjBjL3RhYmxlcmFuZ2U6YzY4MjFjN2UxZGY5NGI2MWEzMjBjY2EyNGI1NDliMGNfOC03LTEtMS0xNjM1MQ_b9f6dd05-a7df-48c6-8b2d-871677304f9f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">45,221,056</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div></ix:nonnumeric></span><div style="text-align:justify"><span><br></span></div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="us-gaap:IncomeTaxPolicyTextBlock" id="fact-identifier-296" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV81NS9mcmFnOjhkZTk3ZmI3Yjg4OTRkYzNiMWQ0OWU3ZGUwZGNjOWUzL3RleHRyZWdpb246OGRlOTdmYjdiODg5NGRjM2IxZDQ5ZTdkZTBkY2M5ZTNfMTgwOTU_494d8d03-bbf0-4afc-a556-184a7858c474" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes by using an asset and liability method of accounting for deferred income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is recorded to the extent it is more likely than not that a deferred tax asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s significant deferred tax assets are for net operating loss (“NOL”) carryforwards, tax credits, fixed assets, and intangible assets. The Company has provided a valuation allowance for its entire net deferred tax assets since inception as, due to its history of operating losses, the Company has concluded that it is more likely than not that its deferred tax assets will not be realized.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies interest and penalties arising from the underpayment of income taxes in the consolidated statements of operations and comprehensive loss as general and administrative expenses. No such expenses were recognized during the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">years ended December&nbsp;31, 2021 and 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="fact-identifier-297" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV81NS9mcmFnOjhkZTk3ZmI3Yjg4OTRkYzNiMWQ0OWU3ZGUwZGNjOWUzL3RleHRyZWdpb246OGRlOTdmYjdiODg5NGRjM2IxZDQ5ZTdkZTBkY2M5ZTNfMjE5OTAyMzI4OTIzOQ_0ac4c5f3-0df7-44a7-98ce-8e4d9e3d3960" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Data</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company’s singular focus is developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases. Management uses one measurement of profitability and does not segregate its business for internal reporting. All tangible assets are held in the U.S.</span></div></ix:nonnumeric></span><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="fact-identifier-298" continuedat="i181c3d2bf04d45e791f0dd1187a4ebf3" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV81NS9mcmFnOjhkZTk3ZmI3Yjg4OTRkYzNiMWQ0OWU3ZGUwZGNjOWUzL3RleHRyZWdpb246OGRlOTdmYjdiODg5NGRjM2IxZDQ5ZTdkZTBkY2M5ZTNfMTgxMDU_c5c3c722-25eb-400a-9a9e-2be9d1a5eef8" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">New Accounting Pronouncements</ix:nonnumeric></span></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span><ix:continuation id="i181c3d2bf04d45e791f0dd1187a4ebf3" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that the Company adopts as of the specified effective date. The Company does not believe that the adoption of recently issued standards has had or will have a material impact on the Company's consolidated financial statements or disclosures</ix:continuation></span>.</span></div></ix:continuation></span><div style="text-align:justify"><span><br></span></div><div id="ie1e15c78f2af410c8f1490215e82bdbe_2271"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 3. <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="fact-identifier-300" continuedat="i8ae801d453cc4d91945f9e882a09bd6a" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMjcxL2ZyYWc6MjJhNTQyMDc4ODVhNGIwNWEwM2FkNjgwNWYxMTY2YzcvdGV4dHJlZ2lvbjoyMmE1NDIwNzg4NWE0YjA1YTAzYWQ2ODA1ZjExNjZjN18yMTk5MDIzMjY0MDM2_a4e7f7a9-2d15-49d0-b290-8976a3cadf64" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">STRATEGIC AGREEMENTS</ix:nonnumeric></span></span></div><span><ix:continuation id="i8ae801d453cc4d91945f9e882a09bd6a" continuedat="i1a5880c7b6e740d389fff7341ea97fb3" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exclusive License and Development Agreement with Carna</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&nbsp;2, 2022, the Company entered into an </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exclusive License Agreement</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the “Carna License Agreement”) with Carna Biosciences, Inc. (“Carna”), pursuant to which the Company acquired exclusive, </span></div></ix:continuation></span><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><span><ix:continuation id="i1a5880c7b6e740d389fff7341ea97fb3" continuedat="ie011a33f9f434f4e9f4a5683980d145d" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">worldwide rights to research, develop, and comme</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rcialize Carna’s portfolio of novel Stimulator of Interferon Genes (“STING”) inhibitors. In</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> accordance with the terms of the Carna License Agreement, in exchange for the licensed rights, the Company made a one-time cash payment of $<span><ix:nonfraction unitref="usd" contextref="i79c757803c2946a984ceb18f7309e2d8_I20220222" decimals="-5" name="bbi:CollaborativeArrangementRightsAndObligationsOneTimeCashPayment" scale="6" id="fact-identifier-303" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMjcxL2ZyYWc6MjJhNTQyMDc4ODVhNGIwNWEwM2FkNjgwNWYxMTY2YzcvdGV4dHJlZ2lvbjoyMmE1NDIwNzg4NWE0YjA1YTAzYWQ2ODA1ZjExNjZjN18xMDk5NTExNjI4MjY5_7fb6e318-c883-4197-a0c7-a1c0a9ef9edc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2.0</ix:nonfraction></span> million. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Carna License Agreement provides that the Company will make success-based payments to Carna of up to $<span><ix:nonfraction unitref="usd" contextref="i79c757803c2946a984ceb18f7309e2d8_I20220222" decimals="-5" name="bbi:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments" scale="6" id="fact-identifier-304" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMjcxL2ZyYWc6MjJhNTQyMDc4ODVhNGIwNWEwM2FkNjgwNWYxMTY2YzcvdGV4dHJlZ2lvbjoyMmE1NDIwNzg4NWE0YjA1YTAzYWQ2ODA1ZjExNjZjN18xMDk5NTExNjI4Mzgw_c1f2d6f0-5aa4-4603-9a45-f625e07dd064" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">258.0</ix:nonfraction></span> million in the aggregate contingent upon achievement of specified development, regulatory, and commercial milestones. Further, the Carna License Agreement provides that the Company will pay Carna tiered royalty payments ranging from mid-single digits up to <span><ix:nonfraction unitref="number" contextref="i79c757803c2946a984ceb18f7309e2d8_I20220222" decimals="INF" name="bbi:CollaborativeArrangementRightsAndObligationsRoyaltyPaymentsPercentOfNetSales" scale="-2" id="fact-identifier-305" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMjcxL2ZyYWc6MjJhNTQyMDc4ODVhNGIwNWEwM2FkNjgwNWYxMTY2YzcvdGV4dHJlZ2lvbjoyMmE1NDIwNzg4NWE0YjA1YTAzYWQ2ODA1ZjExNjZjN18xMDk5NTExNjI4NjEz_fb54222d-cac1-4970-b0f9-ef215540bee0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">10</ix:nonfraction></span>% of net sales. All of the contingent payments and royalties are payable in cash in U.S. Dollars. Under the terms of the Carna License Agreement, the Company will be responsible for, and bear the future costs of, all development and commercialization activities, including patenting, related to all the licensed compounds.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License and Development Agreement with Voronoi</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 27, 2021, the Company entered into a License and Development Agreement (the “Voronoi License Agreement”) with Voronoi Inc. (“Voronoi”), pursuant to which the Company acquired exclusive, worldwide rights to research, develop, and commercialize BBI-02, a novel, Phase 1-ready, potential first-in-class DYRK1A inhibitor, and other next-generation therapeutics developed from Voronoi’s proprietary kinase inhibitor platform. In accordance with the terms of the Voronoi License Agreement, in exchange for the license rights, the Company made a one-time payment of $<span><ix:nonfraction unitref="usd" contextref="i8cc89a88f2c04531a3c91a0c43c75e3b_D20210827-20210827" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-306" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMjcxL2ZyYWc6MjJhNTQyMDc4ODVhNGIwNWEwM2FkNjgwNWYxMTY2YzcvdGV4dHJlZ2lvbjoyMmE1NDIwNzg4NWE0YjA1YTAzYWQ2ODA1ZjExNjZjN18xMDk5NTExNjI5NDk2_c6af459d-11c7-4b64-bd40-c9235d6429e9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.5</ix:nonfraction></span> million in cash and issued $<span><ix:nonfraction unitref="usd" contextref="i8cc89a88f2c04531a3c91a0c43c75e3b_D20210827-20210827" decimals="-5" name="bbi:StockIssuedDuringPeriodValueLicenseAgreement" scale="6" id="fact-identifier-307" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMjcxL2ZyYWc6MjJhNTQyMDc4ODVhNGIwNWEwM2FkNjgwNWYxMTY2YzcvdGV4dHJlZ2lvbjoyMmE1NDIwNzg4NWE0YjA1YTAzYWQ2ODA1ZjExNjZjN18xMDk5NTExNjI5NTE5_ffee19a1-e388-48ff-89c1-07cd32b0924f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2.0</ix:nonfraction></span> million, or <span><ix:nonfraction unitref="shares" contextref="i8cc89a88f2c04531a3c91a0c43c75e3b_D20210827-20210827" decimals="INF" name="bbi:StockIssuedDuringPeriodSharesLicenseAgreement" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-308" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMjcxL2ZyYWc6MjJhNTQyMDc4ODVhNGIwNWEwM2FkNjgwNWYxMTY2YzcvdGV4dHJlZ2lvbjoyMmE1NDIwNzg4NWE0YjA1YTAzYWQ2ODA1ZjExNjZjN18xMDk5NTExNjI5NTI3_11ebf2a9-1c12-4456-9c10-cf0935dfd501" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,816,901</ix:nonfraction></span> shares, of its common stock to Voronoi. As a result, the Company recorded $<span><ix:nonfraction unitref="usd" contextref="i72165e927c8d413c9a775a4ef5166aea_D20210101-20211231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-309" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMjcxL2ZyYWc6MjJhNTQyMDc4ODVhNGIwNWEwM2FkNjgwNWYxMTY2YzcvdGV4dHJlZ2lvbjoyMmE1NDIwNzg4NWE0YjA1YTAzYWQ2ODA1ZjExNjZjN183Njk2NTgxNDAyOTE3_af4d9649-f60b-4b2f-9e9c-6e526696f176" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4.8</ix:nonfraction></span>&nbsp;million in research and development expenses during the year ended December&nbsp;31, 2021.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to BBI-02, the Voronoi License Agreement provides that the Company will make payments to Voronoi of up to $<span><ix:nonfraction unitref="usd" contextref="i8cc89a88f2c04531a3c91a0c43c75e3b_D20210827-20210827" decimals="-5" name="bbi:ResearchAndDevelopmentExpenseFuturePaymentPaymentOne" scale="6" id="fact-identifier-310" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMjcxL2ZyYWc6MjJhNTQyMDc4ODVhNGIwNWEwM2FkNjgwNWYxMTY2YzcvdGV4dHJlZ2lvbjoyMmE1NDIwNzg4NWE0YjA1YTAzYWQ2ODA1ZjExNjZjN18xMDk5NTExNjI5ODUy_5c34bba6-d8cb-477d-a1dc-fbfcc416c953" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">211.0</ix:nonfraction></span> million in the aggregate contingent upon achievement of specified development, regulatory, and commercial milestones. With respect to the next-generation compounds arising from the novel kinase inhibitor platform, the Company will make payments to Voronoi of up to $<span><ix:nonfraction unitref="usd" contextref="if8a97fd31a9240d3aa4b18008191f7ec_D20210827-20210827" decimals="-5" name="bbi:ResearchAndDevelopmentExpenseFuturePaymentPaymentTwo" scale="6" id="fact-identifier-311" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMjcxL2ZyYWc6MjJhNTQyMDc4ODVhNGIwNWEwM2FkNjgwNWYxMTY2YzcvdGV4dHJlZ2lvbjoyMmE1NDIwNzg4NWE0YjA1YTAzYWQ2ODA1ZjExNjZjN18xMDk5NTExNjMwMTA5_d05f0f92-b242-452b-bda5-c357d4e0dfe0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">107.5</ix:nonfraction></span> million in the aggregate contingent upon achievement of specified development, regulatory, and commercial milestones. Further, the Voronoi License Agreement provides that the Company will pay Voronoi tiered royalty payments ranging from low-single digits up to 10% of net sales of products arising from the in-licensed DYRK1A inhibitor programs and next-generation kinase inhibitor platform. All of the contingent payments and royalties are payable in cash in U.S. Dollars, except for $<span><ix:nonfraction unitref="usd" contextref="if8a97fd31a9240d3aa4b18008191f7ec_D20210827-20210827" decimals="-3" name="bbi:MilestonePayment" scale="6" id="fact-identifier-312" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMjcxL2ZyYWc6MjJhNTQyMDc4ODVhNGIwNWEwM2FkNjgwNWYxMTY2YzcvdGV4dHJlZ2lvbjoyMmE1NDIwNzg4NWE0YjA1YTAzYWQ2ODA1ZjExNjZjN18xMDk5NTExNjMwNDk1_8787ab8c-94b3-436f-ad62-a107ba59ba63" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1.0</ix:nonfraction></span> million of the development and regulatory milestone payments, which amount is payable in equivalent shares of the Company’s common stock. Under the terms of the Voronoi License Agreement, the Company will be responsible for, and bear the future costs of, all development and commercialization activities, including patenting, related to all the licensed compounds.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amended and Restated License Agreement with Bodor</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, the Company, together with Brickell Subsidiary and Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor (collectively, “Bodor”) entered into an amended and restated license agreement (the “Amended and Restated License Agreement”), which supersedes the License Agreement, dated December 15, 2012, entered into between Brickell Subsidiary and Bodor, as amended by Amendment No. 1 to License Agreement, effective as of October 21, 2013, and Amendment No. 2 to License Agreement, effective as of March 31, 2015.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended and Restated License Agreement retains with the Company a worldwide, exclusive license to develop, manufacture, market, sell, and sublicense products containing the proprietary compound sofpironium bromide based upon the patents referenced in the Amended and Restated License Agreement for a defined field of use. As of December&nbsp;31, 2021, under the original License Agreement and the Amended and Restated License Agreement, the Company had remaining obligations to pay Bodor (i) a royalty on sales of product outside of Japan and certain other Asian countries (the “Territory”), including a low single-digit royalty on sales of certain product not covered by the patent estate licensed from Bodor; (ii) approximately 50 to 55% of all royalties the </span></div></ix:continuation></span><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><span><ix:continuation id="ie011a33f9f434f4e9f4a5683980d145d" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company receives from Kaken Pharmaceutical Co., Ltd. (“Kaken”) for sales of product within the Territory; (iii) a percentage of non-royalty sublicensing income the Company receives from Kaken or other sublicensees; and (iv) up to an aggregate of $<span><ix:nonfraction unitref="usd" contextref="ie765297f3b45432eb04ae5ca2c4c30d3_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsForRoyalties" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-314" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMjcxL2ZyYWc6MjJhNTQyMDc4ODVhNGIwNWEwM2FkNjgwNWYxMTY2YzcvdGV4dHJlZ2lvbjoyMmE1NDIwNzg4NWE0YjA1YTAzYWQ2ODA1ZjExNjZjN18yMTk5MDIzMjY0MDQw_35e7680c-cf17-4914-b2c7-6e6921d478dd" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.8</ix:nonfraction></span>&nbsp;million (plus an additional $<span><ix:nonfraction unitref="usd" contextref="ie765297f3b45432eb04ae5ca2c4c30d3_D20210101-20211231" decimals="-5" name="bbi:PaymentsForAdditionalProductApproval" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-315" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMjcxL2ZyYWc6MjJhNTQyMDc4ODVhNGIwNWEwM2FkNjgwNWYxMTY2YzcvdGV4dHJlZ2lvbjoyMmE1NDIwNzg4NWE0YjA1YTAzYWQ2ODA1ZjExNjZjN18yMTk5MDIzMjY0MDQ0_b627c465-f48e-4a71-9f99-e6cb0ef96d60" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.1</ix:nonfraction></span>&nbsp;million for approvals of additional products) in cash payments and $<span><ix:nonfraction unitref="usd" contextref="ie765297f3b45432eb04ae5ca2c4c30d3_D20210101-20211231" decimals="-5" name="us-gaap:StockIssued1" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-316" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMjcxL2ZyYWc6MjJhNTQyMDc4ODVhNGIwNWEwM2FkNjgwNWYxMTY2YzcvdGV4dHJlZ2lvbjoyMmE1NDIwNzg4NWE0YjA1YTAzYWQ2ODA1ZjExNjZjN18yMTk5MDIzMjY0MDQ4_a13397f8-e5d3-45b2-8c66-91d9a2eabb56" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.0</ix:nonfraction></span>&nbsp;million of shares of the Company’s common stock upon the achievement of certain regulatory milestones.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Amended and Restated License Agreement, the Company made a $<span><ix:nonfraction unitref="usd" contextref="ibbb989d10e29424aac8a88c70c5285d0_D20200101-20201231" decimals="-5" name="bbi:MilestonePayment" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-317" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMjcxL2ZyYWc6MjJhNTQyMDc4ODVhNGIwNWEwM2FkNjgwNWYxMTY2YzcvdGV4dHJlZ2lvbjoyMmE1NDIwNzg4NWE0YjA1YTAzYWQ2ODA1ZjExNjZjN18yMTk5MDIzMjY0MDUy_073ef690-fac2-4073-a4f5-493ba4f77047" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.5</ix:nonfraction></span>&nbsp;million milestone payment to Bodor following the closing of a public offering in June 2020 and accrued an additional $<span><ix:nonfraction unitref="usd" contextref="icc7525770f5b490db5692d1a694fcf2c_D20201001-20201231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-318" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMjcxL2ZyYWc6MjJhNTQyMDc4ODVhNGIwNWEwM2FkNjgwNWYxMTY2YzcvdGV4dHJlZ2lvbjoyMmE1NDIwNzg4NWE0YjA1YTAzYWQ2ODA1ZjExNjZjN18yMTk5MDIzMjY0MDU2_4ffea948-be8e-4a0b-bff2-cefe11a74b9e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.0</ix:nonfraction></span>&nbsp;million related to its plan to initiate its U.S. Phase 3 pivotal program in the fourth quarter of 2020. As a result, the Company recorded $<span><ix:nonfraction unitref="usd" contextref="ibbb989d10e29424aac8a88c70c5285d0_D20200101-20201231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-319" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMjcxL2ZyYWc6MjJhNTQyMDc4ODVhNGIwNWEwM2FkNjgwNWYxMTY2YzcvdGV4dHJlZ2lvbjoyMmE1NDIwNzg4NWE0YjA1YTAzYWQ2ODA1ZjExNjZjN18yMTk5MDIzMjY0MDYw_1762dbbf-08d3-4e8c-b0f4-a5a4e8be0199" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.5</ix:nonfraction></span>&nbsp;million as research and development expense in the consolidated statements of operations during the year ended</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2020. <span><ix:nonfraction unitref="usd" contextref="ie765297f3b45432eb04ae5ca2c4c30d3_D20210101-20211231" decimals="INF" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:fixed-zero" scale="0" id="fact-identifier-320" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMjcxL2ZyYWc6MjJhNTQyMDc4ODVhNGIwNWEwM2FkNjgwNWYxMTY2YzcvdGV4dHJlZ2lvbjoyMmE1NDIwNzg4NWE0YjA1YTAzYWQ2ODA1ZjExNjZjN18yMTk5MDIzMjY0MDY0_b7f7b2c7-9851-4e38-b186-51b7f8125dff" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">No</ix:nonfraction></span> similar or associated research and development expense was incurred in the year ended</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&nbsp;31, 2021, but the Company paid Bodor the applicable amount with respect to the royalties it received from Kaken for sales of ECCLOCK in Japan during those periods. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License, Development, and Commercialization Agreement with Kaken</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2015, the Company entered into a license, development, and commercialization agreement (as amended, the “Kaken Agreement”) with Kaken. Under the Kaken Agreement, the Company granted to Kaken an exclusive right to develop, manufacture, and commercialize the Company’s sofpironium bromide compound in the Territory. In exchange, Kaken paid the Company an upfront, non-refundable payment of $<span><ix:nonfraction unitref="usd" contextref="i35e59a3ab10c4639a54916140c1a0441_D20150301-20150331" decimals="-5" name="bbi:CollaborativeArrangementNonrefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-321" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMjcxL2ZyYWc6MjJhNTQyMDc4ODVhNGIwNWEwM2FkNjgwNWYxMTY2YzcvdGV4dHJlZ2lvbjoyMmE1NDIwNzg4NWE0YjA1YTAzYWQ2ODA1ZjExNjZjN18xMDk5NTExNjMzNjMy_7245ad16-3a61-48e2-91ec-9f2d2656d46b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">11.0</ix:nonfraction></span>&nbsp;million. In addition, the Company was entitled to receive aggregate payments of up to $<span><ix:nonfraction unitref="usd" contextref="i439ade89822b4df2858d9b0f7b2d949e_I20150331" decimals="-5" name="bbi:CollaborativeArrangementDevelopmentMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-322" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMjcxL2ZyYWc6MjJhNTQyMDc4ODVhNGIwNWEwM2FkNjgwNWYxMTY2YzcvdGV4dHJlZ2lvbjoyMmE1NDIwNzg4NWE0YjA1YTAzYWQ2ODA1ZjExNjZjN18xMDk5NTExNjMzNzE0_bd19a8bc-831e-49ef-a908-63a8d591ce99" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">10.0</ix:nonfraction></span>&nbsp;million&nbsp;upon the achievement of specified development milestones, and $<span><ix:nonfraction unitref="usd" contextref="i439ade89822b4df2858d9b0f7b2d949e_I20150331" decimals="-5" name="bbi:CollaborativeArrangementCommercializationMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-323" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMjcxL2ZyYWc6MjJhNTQyMDc4ODVhNGIwNWEwM2FkNjgwNWYxMTY2YzcvdGV4dHJlZ2lvbjoyMmE1NDIwNzg4NWE0YjA1YTAzYWQ2ODA1ZjExNjZjN18xMDk5NTExNjMzNzgw_bcd26b26-48f4-4499-842e-33fbdc4af2f3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">30.0</ix:nonfraction></span>&nbsp;million upon the achievement of commercial milestones, as well as tiered royalties based on a percentage of net sales of licensed products in the Territory. The Kaken Agreement further provides that Kaken will be responsible for funding all development and commercial costs for the program in the Territory. Kaken was also required to enter into negotiations with the Company, to supply the Company, at cost, with clinical supplies to perform Phase&nbsp;3 clinical trials in the U.S.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, the Company entered into an amendment to the Kaken Agreement, pursuant to which the Company received an upfront non-refundable fee of $<span><ix:nonfraction unitref="usd" contextref="i9393e64507a84944b92e7bd13ec71c90_D20180501-20180531" decimals="-5" name="bbi:CollaborativeArrangementNonrefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-324" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMjcxL2ZyYWc6MjJhNTQyMDc4ODVhNGIwNWEwM2FkNjgwNWYxMTY2YzcvdGV4dHJlZ2lvbjoyMmE1NDIwNzg4NWE0YjA1YTAzYWQ2ODA1ZjExNjZjN18xMDk5NTExNjM0NDAy_ae33a118-77dd-46cf-85f0-be72e4f7f82f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">15.6</ix:nonfraction></span>&nbsp;million (the “Kaken R&amp;D Payment”), which was initially recorded as deferred revenue, to provide the Company with research and development funds for the sole purpose of conducting&nbsp;certain clinical trials and other such research and development activities required to support the submission of a new drug application for sofpironium bromide. Upon receipt of the Kaken R&amp;D Payment on May&nbsp;31, 2018, a milestone payment originally due upon the first commercial sale in Japan was removed from the Kaken Agreement and all future royalties to the Company under the Kaken Agreement were reduced by <span><ix:nonfraction unitref="number" contextref="i7289f808102044a5acf122d6d9f65ba9_D20200101-20201231" decimals="INF" name="bbi:RevenueFromContractWithCustomerContractModificationBasisPointReduction" scale="-4" id="fact-identifier-325" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMjcxL2ZyYWc6MjJhNTQyMDc4ODVhNGIwNWEwM2FkNjgwNWYxMTY2YzcvdGV4dHJlZ2lvbjoyMmE1NDIwNzg4NWE0YjA1YTAzYWQ2ODA1ZjExNjZjN18xMDk5NTExNjM0OTg3_a4771c21-d41a-4e5c-b3bd-0ae0c3a09e05" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">150</ix:nonfraction></span> basis points. During the year ended December&nbsp;31, 2020, the Company recognized revenue of $<span><ix:nonfraction unitref="usd" contextref="i7289f808102044a5acf122d6d9f65ba9_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-326" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMjcxL2ZyYWc6MjJhNTQyMDc4ODVhNGIwNWEwM2FkNjgwNWYxMTY2YzcvdGV4dHJlZ2lvbjoyMmE1NDIwNzg4NWE0YjA1YTAzYWQ2ODA1ZjExNjZjN18xMDk5NTExNjM1MDU5_309ae037-4264-428c-bbb2-ea92ad95988b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.8</ix:nonfraction></span>&nbsp;million related to the Kaken R&amp;D Payment. The Kaken R&amp;D Payment was recognized in full by the end of the third quarter of 2020.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, Kaken received regulatory approval in Japan to manufacture and market sofpironium bromide gel, 5% (ECCLOCK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) for the treatment of primary axillary hyperhidrosis, and as a result, the Company began recognizing royalty revenue earned on a percentage of net sales of ECCLOCK in Japan of $<span><ix:nonfraction unitref="usd" contextref="ie8e9ad122fed497cab90ee40fd300cd7_D20201001-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-327" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMjcxL2ZyYWc6MjJhNTQyMDc4ODVhNGIwNWEwM2FkNjgwNWYxMTY2YzcvdGV4dHJlZ2lvbjoyMmE1NDIwNzg4NWE0YjA1YTAzYWQ2ODA1ZjExNjZjN18xMDk5NTExNjM1NDg3_e0b7dc36-5ab2-499c-87c7-42c8cee37017" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">27</ix:nonfraction></span>&nbsp;thousand during the fourth quarter of 2020. Prior to the fourth quarter of 2020, the Company had <span><ix:nonfraction unitref="usd" contextref="i6a6fa850e9df4db6a3ed2b43eacbee41_D20200101-20200930" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="fact-identifier-328" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMjcxL2ZyYWc6MjJhNTQyMDc4ODVhNGIwNWEwM2FkNjgwNWYxMTY2YzcvdGV4dHJlZ2lvbjoyMmE1NDIwNzg4NWE0YjA1YTAzYWQ2ODA1ZjExNjZjN18yMTk5MDIzMjY0MTAx_d0684cdf-1c84-4631-909e-504e588c3968" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">no</ix:nonfraction></span>t recognized any royalty revenue from any collaboration arrangement. During the year ended December&nbsp;31, 2021, the Company recognized royalty revenue of $<span><ix:nonfraction unitref="usd" contextref="id82b40dc002940bd9c7491e5b5dee885_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-329" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV8yMjcxL2ZyYWc6MjJhNTQyMDc4ODVhNGIwNWEwM2FkNjgwNWYxMTY2YzcvdGV4dHJlZ2lvbjoyMmE1NDIwNzg4NWE0YjA1YTAzYWQ2ODA1ZjExNjZjN18xMDk5NTExNjM1NzEz_91634c87-0f29-4041-afe2-6d33b2664e30" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.4</ix:nonfraction></span>&nbsp;million.</span></div></ix:continuation></span><div style="text-align:justify"><span><br></span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><div id="ie1e15c78f2af410c8f1490215e82bdbe_61"></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 4. <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="fact-identifier-330" continuedat="id0aa564778ba41aeba148638c3afc82e" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV82MS9mcmFnOjQ2YzRlZjQzZjA1NDQwYWRiZDIwMjFkNWJlNmZkMDk3L3RleHRyZWdpb246NDZjNGVmNDNmMDU0NDBhZGJkMjAyMWQ1YmU2ZmQwOTdfNzQ_440463e6-3c2a-43b4-a5bc-56861c7f03eb" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">ACCRUED LIABILITIES</ix:nonnumeric></span></span></div><span><ix:continuation id="id0aa564778ba41aeba148638c3afc82e" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="fact-identifier-332" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV82MS9mcmFnOjQ2YzRlZjQzZjA1NDQwYWRiZDIwMjFkNWJlNmZkMDk3L3RleHRyZWdpb246NDZjNGVmNDNmMDU0NDBhZGJkMjAyMWQ1YmU2ZmQwOTdfNzU_fe4fa4c7-903a-409f-8893-89cdd7bdc03a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:69.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i136a713ea34e4a3a8a8e3a24f4fa59ed_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-333" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV82MS9mcmFnOjQ2YzRlZjQzZjA1NDQwYWRiZDIwMjFkNWJlNmZkMDk3L3RhYmxlOjg1MWI2NGYwZDc5MDRkZjNiYWYzMmFmNjgwNzA0NGNkL3RhYmxlcmFuZ2U6ODUxYjY0ZjBkNzkwNGRmM2JhZjMyYWY2ODA3MDQ0Y2RfMy0xLTEtMS0xNjM1MQ_ade118ef-10d9-42db-b963-958be0a0e694" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,861</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i79b48cfc81254328ac1dae75e4c81c8f_I20201231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-334" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV82MS9mcmFnOjQ2YzRlZjQzZjA1NDQwYWRiZDIwMjFkNWJlNmZkMDk3L3RhYmxlOjg1MWI2NGYwZDc5MDRkZjNiYWYzMmFmNjgwNzA0NGNkL3RhYmxlcmFuZ2U6ODUxYjY0ZjBkNzkwNGRmM2JhZjMyYWY2ODA3MDQ0Y2RfMy0zLTEtMS0xNjM1MQ_f51e7d31-3966-46cc-8829-445756b4186f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,369</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued contracted research and development services </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i136a713ea34e4a3a8a8e3a24f4fa59ed_I20211231" decimals="-3" name="bbi:AccruedResearchAndDevelopmentFeesCurrent" scale="3" id="fact-identifier-335" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV82MS9mcmFnOjQ2YzRlZjQzZjA1NDQwYWRiZDIwMjFkNWJlNmZkMDk3L3RhYmxlOjg1MWI2NGYwZDc5MDRkZjNiYWYzMmFmNjgwNzA0NGNkL3RhYmxlcmFuZ2U6ODUxYjY0ZjBkNzkwNGRmM2JhZjMyYWY2ODA3MDQ0Y2RfNC0xLTEtMS0xNjM1MQ_d4b1c814-b7bb-495d-8da9-cf160df687e1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">823</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i79b48cfc81254328ac1dae75e4c81c8f_I20201231" decimals="-3" name="bbi:AccruedResearchAndDevelopmentFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-336" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV82MS9mcmFnOjQ2YzRlZjQzZjA1NDQwYWRiZDIwMjFkNWJlNmZkMDk3L3RhYmxlOjg1MWI2NGYwZDc5MDRkZjNiYWYzMmFmNjgwNzA0NGNkL3RhYmxlcmFuZ2U6ODUxYjY0ZjBkNzkwNGRmM2JhZjMyYWY2ODA3MDQ0Y2RfNC0zLTEtMS0xNjM1MQ_9324ed65-0f2c-4af2-908b-57a6aee06e44" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">3,733</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i136a713ea34e4a3a8a8e3a24f4fa59ed_I20211231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="fact-identifier-337" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV82MS9mcmFnOjQ2YzRlZjQzZjA1NDQwYWRiZDIwMjFkNWJlNmZkMDk3L3RhYmxlOjg1MWI2NGYwZDc5MDRkZjNiYWYzMmFmNjgwNzA0NGNkL3RhYmxlcmFuZ2U6ODUxYjY0ZjBkNzkwNGRmM2JhZjMyYWY2ODA3MDQ0Y2RfNi0xLTEtMS0xNjM1MQ_fd476f4c-628c-4fa7-82a3-4d6d44b64747" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">452</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i79b48cfc81254328ac1dae75e4c81c8f_I20201231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="fact-identifier-338" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV82MS9mcmFnOjQ2YzRlZjQzZjA1NDQwYWRiZDIwMjFkNWJlNmZkMDk3L3RhYmxlOjg1MWI2NGYwZDc5MDRkZjNiYWYzMmFmNjgwNzA0NGNkL3RhYmxlcmFuZ2U6ODUxYjY0ZjBkNzkwNGRmM2JhZjMyYWY2ODA3MDQ0Y2RfNi0zLTEtMS0xNjM1MQ_dcd55061-bc2d-401e-8186-4113dced9e5e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">318</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i136a713ea34e4a3a8a8e3a24f4fa59ed_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-339" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV82MS9mcmFnOjQ2YzRlZjQzZjA1NDQwYWRiZDIwMjFkNWJlNmZkMDk3L3RhYmxlOjg1MWI2NGYwZDc5MDRkZjNiYWYzMmFmNjgwNzA0NGNkL3RhYmxlcmFuZ2U6ODUxYjY0ZjBkNzkwNGRmM2JhZjMyYWY2ODA3MDQ0Y2RfMTAtMS0xLTEtMTYzNTE_601573c4-4dd2-4d95-ae82-20f0135dfb51" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,136</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i79b48cfc81254328ac1dae75e4c81c8f_I20201231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-340" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV82MS9mcmFnOjQ2YzRlZjQzZjA1NDQwYWRiZDIwMjFkNWJlNmZkMDk3L3RhYmxlOjg1MWI2NGYwZDc5MDRkZjNiYWYzMmFmNjgwNzA0NGNkL3RhYmxlcmFuZ2U6ODUxYjY0ZjBkNzkwNGRmM2JhZjMyYWY2ODA3MDQ0Y2RfMTAtMy0xLTEtMTYzNTE_187bf1a0-0138-46e7-b05a-23589361dfe7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,420</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div></ix:nonnumeric></span></ix:continuation></span><div style="text-align:justify"><span><br></span></div><div id="ie1e15c78f2af410c8f1490215e82bdbe_64"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 5. <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="us-gaap:OtherLiabilitiesDisclosureTextBlock" id="fact-identifier-341" continuedat="i10f3d59b3f124b5abd5b8f4b07b15f1a" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV82NC9mcmFnOjNlODMyZWE3NDZhNzQ4OWU5OWNhZjBlZGZmYjc3ZTViL3RleHRyZWdpb246M2U4MzJlYTc0NmE3NDg5ZTk5Y2FmMGVkZmZiNzdlNWJfODQy_87d18b93-8e6e-4f82-a52f-b7be1915666b" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">NOTE PAYABLE</ix:nonnumeric></span></span></div><div style="text-align:justify"><span><ix:continuation id="i10f3d59b3f124b5abd5b8f4b07b15f1a" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April&nbsp;15, 2020, the Company executed an unsecured promissory note to IberiaBank (the “PPP Loan”) pursuant to the U.S. Small Business Administration’s Paycheck Protection Program (the “PPP”) under Division A, Title I of the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company used the PPP Loan proceeds in the principal amount of $<span><ix:nonfraction unitref="usd" contextref="ied3898b760044f5fad97b15508cb4e05_I20200415" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-343" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV82NC9mcmFnOjNlODMyZWE3NDZhNzQ4OWU5OWNhZjBlZGZmYjc3ZTViL3RleHRyZWdpb246M2U4MzJlYTc0NmE3NDg5ZTk5Y2FmMGVkZmZiNzdlNWJfMzYw_daa8ca4e-83e4-41b3-bdaa-197c0e494fe7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.4</ix:nonfraction></span>&nbsp;million and bearing interest at a fixed rate of <span><ix:nonfraction unitref="number" contextref="ied3898b760044f5fad97b15508cb4e05_I20200415" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="fact-identifier-344" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV82NC9mcmFnOjNlODMyZWE3NDZhNzQ4OWU5OWNhZjBlZGZmYjc3ZTViL3RleHRyZWdpb246M2U4MzJlYTc0NmE3NDg5ZTk5Y2FmMGVkZmZiNzdlNWJfNDAz_83b3b767-369a-48d4-aa8f-8d2f59930b62" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.00</ix:nonfraction></span>% per annum to cover payroll costs and certain other permitted costs in accordance with the relevant terms and conditions of the CARES Act. In January 2021, the Company applied for forgiveness of the full amount of the PPP Loan, which was forgiven in full in June 2021. As a result, during the year ended December&nbsp;31, 2021, the Company recognized a gain on extinguishment of debt of approximately $<span><ix:nonfraction unitref="usd" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="-5" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-345" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV82NC9mcmFnOjNlODMyZWE3NDZhNzQ4OWU5OWNhZjBlZGZmYjc3ZTViL3RleHRyZWdpb246M2U4MzJlYTc0NmE3NDg5ZTk5Y2FmMGVkZmZiNzdlNWJfNzc4_f5394347-9213-4e80-99aa-05e87fa8e2b4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.4</ix:nonfraction></span>&nbsp;million in the consolidated statements of operations within the line “Investment and other income, net.”</span></ix:continuation></span></div><div style="text-align:justify"><span><br></span></div><div id="ie1e15c78f2af410c8f1490215e82bdbe_70"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 6. <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="fact-identifier-346" continuedat="i692b6285ad0145fcae2b876ce99c4919" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83MC9mcmFnOjg4YTNhYTNhMzJmYTRiZGM5NTIwOGViYWNmNjgwMjMxL3RleHRyZWdpb246ODhhM2FhM2EzMmZhNGJkYzk1MjA4ZWJhY2Y2ODAyMzFfNTU1MQ_a2aeff1d-f71e-4bba-9e41-2191c67b90aa" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">COMMITMENTS AND CONTINGENCIES</ix:nonnumeric></span></span></div><span><ix:continuation id="i692b6285ad0145fcae2b876ce99c4919" continuedat="ic7a9b36004b347d6b69d65153f710021" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Lease</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2016, the Company entered into a multi-year, noncancelable lease for its Colorado-based office space, which was amended in June 2021 to, among other things, extend the lease term to December&nbsp;31, 2022 (as amended, the “Boulder Lease”). Under the terms of the Boulder Lease, the Company may, at its option, renew the Boulder Lease for <span><ix:nonfraction unitref="renewalterm" contextref="i136a713ea34e4a3a8a8e3a24f4fa59ed_I20211231" decimals="INF" name="bbi:LesseeOperatingLeaseNumberOfRenewalTerms" format="ixt-sec:numwordsen" scale="0" id="fact-identifier-348" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83MC9mcmFnOjg4YTNhYTNhMzJmYTRiZGM5NTIwOGViYWNmNjgwMjMxL3RleHRyZWdpb246ODhhM2FhM2EzMmZhNGJkYzk1MjA4ZWJhY2Y2ODAyMzFfMzY5_2c09a203-7190-4d7f-8700-b4bc178a482e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">two</ix:nonfraction></span> additional terms of <span><ix:nonnumeric contextref="i136a713ea34e4a3a8a8e3a24f4fa59ed_I20211231" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="fact-identifier-349" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83MC9mcmFnOjg4YTNhYTNhMzJmYTRiZGM5NTIwOGViYWNmNjgwMjMxL3RleHRyZWdpb246ODhhM2FhM2EzMmZhNGJkYzk1MjA4ZWJhY2Y2ODAyMzFfMzky_b8f46aef-5820-45fc-bf50-9a1e7e02da3b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">three years</ix:nonnumeric></span> each, with monthly rent payments determined at the time of renewal at the lower of $<span><ix:nonfraction unitref="usd" contextref="i4d33a851a96040978ef2f9da670c66f4_I20220101" decimals="0" name="bbi:LesseeOperatingLeaseMonthlyPaymentThereafter" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-350" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83MC9mcmFnOjg4YTNhYTNhMzJmYTRiZGM5NTIwOGViYWNmNjgwMjMxL3RleHRyZWdpb246ODhhM2FhM2EzMmZhNGJkYzk1MjA4ZWJhY2Y2ODAyMzFfMTA5OTUxMTYzODc3MA_d41c95c1-b87b-41e1-b4f8-d7bb7d6fcfe8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">6,076</ix:nonfraction></span> per month or current market rental rates. The Company recognized a right-of-use asset and corresponding lease liability. Minimum base lease payments under the Boulder Lease are recognized on a straight-line basis over the full term of the lease. In addition to base rental payments included in the contractual obligations table below, the Company is responsible for its pro rata share of the operating expenses for the building, which includes common area maintenance, utilities, property taxes, and insurance.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon modification of the Boulder Lease, the Company reassessed classification of the lease and determined that the lease still met the criteria to be classified as an operating lease. Furthermore, the Company remeasured the lease liability as of the effective date by calculating the present value of the new lease payments, discounted at the Company’s updated incremental borrowing rate of <span><ix:nonfraction unitref="number" contextref="i136a713ea34e4a3a8a8e3a24f4fa59ed_I20211231" decimals="INF" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="fact-identifier-351" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83MC9mcmFnOjg4YTNhYTNhMzJmYTRiZGM5NTIwOGViYWNmNjgwMjMxL3RleHRyZWdpb246ODhhM2FhM2EzMmZhNGJkYzk1MjA4ZWJhY2Y2ODAyMzFfMjE5OTAyMzI2NjcyNQ_d58241ae-64ef-4321-b77c-f157cc1663e0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11.0</ix:nonfraction></span>%, over the extended term of <span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="bbi:LesseeOperatingLeaseExtendedLeaseTerm" format="ixt-sec:durmonth" id="fact-identifier-352" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83MC9mcmFnOjg4YTNhYTNhMzJmYTRiZGM5NTIwOGViYWNmNjgwMjMxL3RleHRyZWdpb246ODhhM2FhM2EzMmZhNGJkYzk1MjA4ZWJhY2Y2ODAyMzFfMjE5OTAyMzI2NzE3MQ_cb101a36-a0aa-4951-8afe-f03cbf9e90e1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">18</ix:nonnumeric></span> months. The operating expenses are variable and thus not included in the present value determination of the lease liability. Because the Company was not reasonably certain to exercise the renewal option, the option was not considered in determining the lease term, and associated potential additional payments were excluded from lease payments.</span></div></ix:continuation></span><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><span><ix:continuation id="ic7a9b36004b347d6b69d65153f710021" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="us-gaap:LeaseCostTableTextBlock" id="fact-identifier-354" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83MC9mcmFnOjg4YTNhYTNhMzJmYTRiZGM5NTIwOGViYWNmNjgwMjMxL3RleHRyZWdpb246ODhhM2FhM2EzMmZhNGJkYzk1MjA4ZWJhY2Y2ODAyMzFfMjE5OTAyMzI2NzE1Ng_3757dc74-4c2a-4354-b2b3-0bdea4eeecce" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents lease cost, cash paid for amounts included in the measurement of lease liabilities, the weighted-average remaining lease term, and the weighted-average discount rate for the Company’s operating leases (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:69.066%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended<br>December&nbsp;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="fact-identifier-355" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83MC9mcmFnOjg4YTNhYTNhMzJmYTRiZGM5NTIwOGViYWNmNjgwMjMxL3RhYmxlOjlkYzkwODhjNjM4ZTQyMGJhYjc3OTkwMTFlN2ZkOTY2L3RhYmxlcmFuZ2U6OWRjOTA4OGM2MzhlNDIwYmFiNzc5OTAxMWU3ZmQ5NjZfMy01LTEtMS0zMTg0MQ_26527f84-6b4f-4dfb-8591-49c03181d079" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">62</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="fact-identifier-356" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83MC9mcmFnOjg4YTNhYTNhMzJmYTRiZGM5NTIwOGViYWNmNjgwMjMxL3RhYmxlOjlkYzkwODhjNjM4ZTQyMGJhYjc3OTkwMTFlN2ZkOTY2L3RhYmxlcmFuZ2U6OWRjOTA4OGM2MzhlNDIwYmFiNzc5OTAxMWU3ZmQ5NjZfMy03LTEtMS0zMTg0MQ_d9ecf5ec-0bf6-411c-b47a-864a175b01e4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">53</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="fact-identifier-357" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83MC9mcmFnOjg4YTNhYTNhMzJmYTRiZGM5NTIwOGViYWNmNjgwMjMxL3RhYmxlOjlkYzkwODhjNjM4ZTQyMGJhYjc3OTkwMTFlN2ZkOTY2L3RhYmxlcmFuZ2U6OWRjOTA4OGM2MzhlNDIwYmFiNzc5OTAxMWU3ZmQ5NjZfNC01LTEtMS0zMTg0MQ_3eb5bda8-d8f0-496d-b66c-8d3998e1401b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">37</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="fact-identifier-358" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83MC9mcmFnOjg4YTNhYTNhMzJmYTRiZGM5NTIwOGViYWNmNjgwMjMxL3RhYmxlOjlkYzkwODhjNjM4ZTQyMGJhYjc3OTkwMTFlN2ZkOTY2L3RhYmxlcmFuZ2U6OWRjOTA4OGM2MzhlNDIwYmFiNzc5OTAxMWU3ZmQ5NjZfNC03LTEtMS0zMTg0MQ_070661f7-ac50-4d63-9fb7-d512288eeac8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">25</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash outflows from operating leases</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="fact-identifier-359" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83MC9mcmFnOjg4YTNhYTNhMzJmYTRiZGM5NTIwOGViYWNmNjgwMjMxL3RhYmxlOjlkYzkwODhjNjM4ZTQyMGJhYjc3OTkwMTFlN2ZkOTY2L3RhYmxlcmFuZ2U6OWRjOTA4OGM2MzhlNDIwYmFiNzc5OTAxMWU3ZmQ5NjZfNi01LTEtMS0zMTg0MQ_2cfe16fd-b4a1-40b4-a52b-919a718a7f2f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">88</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="fact-identifier-360" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83MC9mcmFnOjg4YTNhYTNhMzJmYTRiZGM5NTIwOGViYWNmNjgwMjMxL3RhYmxlOjlkYzkwODhjNjM4ZTQyMGJhYjc3OTkwMTFlN2ZkOTY2L3RhYmxlcmFuZ2U6OWRjOTA4OGM2MzhlNDIwYmFiNzc5OTAxMWU3ZmQ5NjZfNi03LTEtMS0zMTg0MQ_ea3d3f48-092c-4857-80ef-aff9a47c83f2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">84</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i136a713ea34e4a3a8a8e3a24f4fa59ed_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="fact-identifier-361" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83MC9mcmFnOjg4YTNhYTNhMzJmYTRiZGM5NTIwOGViYWNmNjgwMjMxL3RhYmxlOjlkYzkwODhjNjM4ZTQyMGJhYjc3OTkwMTFlN2ZkOTY2L3RhYmxlcmFuZ2U6OWRjOTA4OGM2MzhlNDIwYmFiNzc5OTAxMWU3ZmQ5NjZfOC01LTEtMS0zMTg0MQ_beb0bd1a-7b2c-42a3-99b4-095ce811efbb" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.0</ix:nonnumeric></span> year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i79b48cfc81254328ac1dae75e4c81c8f_I20201231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="fact-identifier-362" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83MC9mcmFnOjg4YTNhYTNhMzJmYTRiZGM5NTIwOGViYWNmNjgwMjMxL3RhYmxlOjlkYzkwODhjNjM4ZTQyMGJhYjc3OTkwMTFlN2ZkOTY2L3RhYmxlcmFuZ2U6OWRjOTA4OGM2MzhlNDIwYmFiNzc5OTAxMWU3ZmQ5NjZfOC03LTEtMS0zMTg0MQ_14f6ab19-1ac1-476e-a14f-2cb725fabfca" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.8</ix:nonnumeric></span> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i136a713ea34e4a3a8a8e3a24f4fa59ed_I20211231" decimals="INF" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="fact-identifier-363" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83MC9mcmFnOjg4YTNhYTNhMzJmYTRiZGM5NTIwOGViYWNmNjgwMjMxL3RhYmxlOjlkYzkwODhjNjM4ZTQyMGJhYjc3OTkwMTFlN2ZkOTY2L3RhYmxlcmFuZ2U6OWRjOTA4OGM2MzhlNDIwYmFiNzc5OTAxMWU3ZmQ5NjZfOS01LTEtMS0zMTg0MQ_51cd423d-09dc-48bf-9113-b794b12382ad" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i79b48cfc81254328ac1dae75e4c81c8f_I20201231" decimals="INF" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="fact-identifier-364" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83MC9mcmFnOjg4YTNhYTNhMzJmYTRiZGM5NTIwOGViYWNmNjgwMjMxL3RhYmxlOjlkYzkwODhjNjM4ZTQyMGJhYjc3OTkwMTFlN2ZkOTY2L3RhYmxlcmFuZ2U6OWRjOTA4OGM2MzhlNDIwYmFiNzc5OTAxMWU3ZmQ5NjZfOS03LTEtMS0zMTg0MQ_b8215a6d-6151-4d8b-91bc-0316d289df0c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></tbody></table></div></ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock" id="fact-identifier-365" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83MC9mcmFnOjg4YTNhYTNhMzJmYTRiZGM5NTIwOGViYWNmNjgwMjMxL3RleHRyZWdpb246ODhhM2FhM2EzMmZhNGJkYzk1MjA4ZWJhY2Y2ODAyMzFfNTU1Mg_c5fad943-ed0a-4e64-b106-f05760f21caa" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the contractual obligations related to operating lease commitments as of December&nbsp;31, 2021, and the effect such obligations are expected to have on the Company’s liquidity and cash flows in future periods (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:83.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total maturities, through December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i136a713ea34e4a3a8a8e3a24f4fa59ed_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="fact-identifier-366" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83MC9mcmFnOjg4YTNhYTNhMzJmYTRiZGM5NTIwOGViYWNmNjgwMjMxL3RhYmxlOjY2MDM2ZDhiMzVkOTQ1MDY4OTdjZjgxYzQwNzgxODk5L3RhYmxlcmFuZ2U6NjYwMzZkOGIzNWQ5NDUwNjg5N2NmODFjNDA3ODE4OTlfMy0yLTEtMS0xNjM1MQ_5bbc2006-3969-49ec-8adb-8a041e577d31" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">73</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i136a713ea34e4a3a8a8e3a24f4fa59ed_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="fact-identifier-367" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83MC9mcmFnOjg4YTNhYTNhMzJmYTRiZGM5NTIwOGViYWNmNjgwMjMxL3RhYmxlOjY2MDM2ZDhiMzVkOTQ1MDY4OTdjZjgxYzQwNzgxODk5L3RhYmxlcmFuZ2U6NjYwMzZkOGIzNWQ5NDUwNjg5N2NmODFjNDA3ODE4OTlfNC0yLTEtMS0xNjM1MQ_6513775e-693a-4227-9995-ee075622be16" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i136a713ea34e4a3a8a8e3a24f4fa59ed_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="fact-identifier-368" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83MC9mcmFnOjg4YTNhYTNhMzJmYTRiZGM5NTIwOGViYWNmNjgwMjMxL3RhYmxlOjY2MDM2ZDhiMzVkOTQ1MDY4OTdjZjgxYzQwNzgxODk5L3RhYmxlcmFuZ2U6NjYwMzZkOGIzNWQ5NDUwNjg5N2NmODFjNDA3ODE4OTlfNS0yLTEtMS0xNjM1MQ_14d67785-fcbd-4b6b-83ff-01c2fb5aafca" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">69</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div></ix:nonnumeric></span></ix:continuation></span><div style="text-align:justify"><span><br></span></div><div id="ie1e15c78f2af410c8f1490215e82bdbe_76"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 7. <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="fact-identifier-369" continuedat="i1897a3c623274a64acb2ef7799f0005b" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfMTI2NDE_51472372-63ae-4e89-b7eb-e7bae5177294" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">CAPITAL STOCK</ix:nonnumeric></span></span></div><span><ix:continuation id="i1897a3c623274a64acb2ef7799f0005b" continuedat="i9a55d2ff800545dca214ae530158549d" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 19, 2021, following approval by the Company’s stockholders, the Company filed an amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware that increased the number of the Company’s authorized shares of common stock, par value $<span><ix:nonfraction unitref="usdPerShare" contextref="i136a713ea34e4a3a8a8e3a24f4fa59ed_I20211231" decimals="2" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="fact-identifier-371" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfMzIx_a5182e9d-457c-40c1-ae97-f79d584fce87" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.01</ix:nonfraction></span> per share, from <span><ix:nonfraction unitref="shares" contextref="i79b48cfc81254328ac1dae75e4c81c8f_I20201231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-372" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfMzQw_3a749dad-ee27-4d8d-b9ee-1d0ce55ea38e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">100,000,000</ix:nonfraction></span> to <span><ix:nonfraction unitref="shares" contextref="i2e2ac66356654b37bd53ed713a163f86_I20210419" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-373" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfMzQ2_131a5b1f-26e2-4a19-bef2-f85510037b5d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">300,000,000</ix:nonfraction></span>. Each share of the Company’s common stock is entitled to one vote, and the holders of the Company’s common stock are entitled to receive dividends when and as declared or paid by its board of directors. <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="us-gaap:ScheduleOfStockByClassTextBlock" id="fact-identifier-374" continuedat="ia3def47d5d054143b53ab71f25d2acfc" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfMTI2NDA_d321d6c1-8237-4652-899c-f2bc6a1044b1" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">The Company had reserved authorized shares of common stock for future issuance at December&nbsp;31, 2021 as follows:</ix:nonnumeric></span></span></div><div><span><ix:continuation id="ia3def47d5d054143b53ab71f25d2acfc" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:82.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.067%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&nbsp;31,<br>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i7263d1bd71cd41cf83f618481b17ec62_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-376" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RhYmxlOmI3ODczYTQyYjcxYjQ5MjI4MjE5MGFlMTA1MzQwZGE0L3RhYmxlcmFuZ2U6Yjc4NzNhNDJiNzFiNDkyMjgyMTkwYWUxMDUzNDBkYTRfMS0xLTEtMS0xNjM1MQ_b61b5a6d-4717-4005-a4a7-ce462d461d44" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">27,944,544</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options outstanding </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i060d4bd2c05e4f3b8b6d111ec3f59f4d_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-377" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RhYmxlOmI3ODczYTQyYjcxYjQ5MjI4MjE5MGFlMTA1MzQwZGE0L3RhYmxlcmFuZ2U6Yjc4NzNhNDJiNzFiNDkyMjgyMTkwYWUxMDUzNDBkYTRfMi0xLTEtMS0xNjM1MQ_3b27acec-23e2-4d9b-a447-d6f80c6fb1bf" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,059,842</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for grant under the Omnibus Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="if92afe08e0b947e0be3caee47bcadd7f_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-378" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RhYmxlOmI3ODczYTQyYjcxYjQ5MjI4MjE5MGFlMTA1MzQwZGE0L3RhYmxlcmFuZ2U6Yjc4NzNhNDJiNzFiNDkyMjgyMTkwYWUxMDUzNDBkYTRfMy0xLTEtMS0xNjM1MQ_d65c2a47-14b2-4446-b2df-28f99ee7b0f7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,644,883</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for grant under the Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="ic8c46b385c9d410ba351bdf9a1cdef7b_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-379" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RhYmxlOmI3ODczYTQyYjcxYjQ5MjI4MjE5MGFlMTA1MzQwZGE0L3RhYmxlcmFuZ2U6Yjc4NzNhNDJiNzFiNDkyMjgyMTkwYWUxMDUzNDBkYTRfNC0xLTEtMS0xNjM1MQ_62a9c5a7-d0a6-49e3-9ef9-a7f43787e61f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,450,715</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i136a713ea34e4a3a8a8e3a24f4fa59ed_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-380" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RhYmxlOmI3ODczYTQyYjcxYjQ5MjI4MjE5MGFlMTA1MzQwZGE0L3RhYmxlcmFuZ2U6Yjc4NzNhNDJiNzFiNDkyMjgyMTkwYWUxMDUzNDBkYTRfOC0xLTEtMS0xNjM1MQ_5be452ab-c63e-4b76-90f8-e69f8ae61c91" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">41,099,984</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></ix:continuation></span></div><div><span><br></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may be limited in its ability to sell a certain number of shares of its common stock under the Purchase Agreement or ATM Agreements described below, depending on the availability at any given time of authorized and available shares of common stock.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Public Offerings of Common Stock and Warrants</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the Company completed a sale of <span><ix:nonfraction unitref="shares" contextref="i2e88d5581f8e4804aad93370dab97ef2_D20211001-20211031" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-381" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfMTY0OTI2NzQ1NjI2NQ_30a40c76-b111-4b10-997b-c735ef7db698" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">30,263,400</ix:nonfraction></span> shares of its common stock at a public offering price of $<span><ix:nonfraction unitref="usdPerShare" contextref="ib3e388c0a38f49509a73e0978de43e31_I20211031" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="fact-identifier-382" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfMTA5OTUxMTY0NTgwMA_38c43244-26bd-4c13-afd1-1f854406f5ed" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.38</ix:nonfraction></span> per share in an underwritten public offering (the “October 2021 Offering”). The October 2021 </span></div></ix:continuation></span><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><span><ix:continuation id="i9a55d2ff800545dca214ae530158549d" continuedat="ibf8c22d6bb0e456ab0f191981af1febf" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Offering resulted in net proceeds of approximately $<span><ix:nonfraction unitref="usd" contextref="i2e88d5581f8e4804aad93370dab97ef2_D20211001-20211031" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-384" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfMTY0OTI2NzQ1NjQ1OA_c5c43d9f-cf82-4fc7-8c17-a2089090ba02" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10.3</ix:nonfraction></span>&nbsp;million, after deducting the underwriting discount and offering expenses payable by the Company. The Company is using the net proceeds from the October 2021 Offering for research and development, including clinical trials, working capital, business development, and general corporate purposes.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the Company completed a sale of <span><ix:nonfraction unitref="shares" contextref="ia9b014fe7a35425989332f53b3651fe6_D20210701-20210731" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-385" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfNzQ0_455f50f4-d1b6-4fa8-8c95-d428d8b61751" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12,983,871</ix:nonfraction></span> shares of its common stock at a public offering price of $<span><ix:nonfraction unitref="usdPerShare" contextref="i7ed3b097161541adbe2daf684ed51058_I20210731" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="fact-identifier-386" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfODA0_14e667c9-f0c2-4a23-aeff-c0e235b33605" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.62</ix:nonfraction></span> per share in an underwritten public offering (the “July 2021 Offering”). The July 2021 Offering resulted in net proceeds of approximately $<span><ix:nonfraction unitref="usd" contextref="ia9b014fe7a35425989332f53b3651fe6_D20210701-20210731" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-387" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfOTQ1_9fa32384-f0ef-46c6-8578-ce54e90cc87b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.3</ix:nonfraction></span>&nbsp;million, after deducting underwriting discounts and commissions and offering expenses. The Company is using the net proceeds from the July 2021 Offering for research and development, including clinical trials, working capital, and general corporate purposes. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the Company completed a sale of <span><ix:nonfraction unitref="shares" contextref="i333296f159d743428ccdb664f0b26e4b_D20201001-20201031" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-388" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfMTI0OQ_9ea4af55-1c4a-41b0-b82d-a1984e13264d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">19,003,510</ix:nonfraction></span> shares of its common stock, and, to certain investors, pre-funded warrants to purchase <span><ix:nonfraction unitref="shares" contextref="iaa5e28b085f6467a8e8d5bd976dcc8e5_I20201031" decimals="INF" name="us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-389" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfMTMzOQ_1f81e1ab-cbe9-4777-a5d8-36877af9ebc6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,829,812</ix:nonfraction></span> shares of its common stock, and accompanying common stock warrants to purchase up to an aggregate of <span><ix:nonfraction unitref="shares" contextref="ica27d249a23a4d56a3605dc92d05102f_I20201031" decimals="INF" name="us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-390" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfMTQ0Mw_d63eb1c8-91fd-4146-807a-949245f74b41" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20,833,322</ix:nonfraction></span> shares of its common stock (the “October 2020 Offering”). Each share of common stock and pre-funded warrant to purchase one share of the Company’s common stock was sold together with a common warrant to purchase one share of the Company’s common stock. The public offering price of each share of the Company’s common stock and accompanying common warrant was $<span><ix:nonfraction unitref="usdPerShare" contextref="iaa5e28b085f6467a8e8d5bd976dcc8e5_I20201031" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="fact-identifier-391" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfMTgwNQ_d70ba215-bb93-4bb4-9573-88976f824954" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.72</ix:nonfraction></span> and $<span><ix:nonfraction unitref="usdPerShare" contextref="i4933a0c944f3461aaef8817a358a0cca_I20201031" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="fact-identifier-392" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfMTgxMg_b7c23dac-8f9e-43d5-ab86-5c1651005bae" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.719</ix:nonfraction></span> for each pre-funded warrant and accompanying common warrant, respectively. The shares of common stock and pre-funded warrants, and the accompanying common warrants, were issued separately and were immediately separable upon issuance. The common warrants are exercisable at a price of $<span><ix:nonfraction unitref="usdPerShare" contextref="i9f99c116b43947219d9f8eaf304dc70f_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="fact-identifier-393" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfMjA5OQ_c9b4d988-1eac-483b-8095-5ebff592bafc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.72</ix:nonfraction></span> per share of the Company’s common stock and will expire <span><ix:nonnumeric contextref="i12fa54e463454aa7be2e64acbb078508_D20201001-20201031" name="bbi:SaleOfStockExpirationTerm" format="ixt-sec:durwordsen" id="fact-identifier-394" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfMjE1OA_14eaa15a-4345-4c33-8c34-d25222e63336" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">five years</ix:nonnumeric></span> from the date of issuance. The pre-funded warrants were exercised in October 2020 at an exercise price of $<span><ix:nonfraction unitref="usdPerShare" contextref="i2312571183384deb9159863e35bb9953_I20201031" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="fact-identifier-395" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfMjI2Nw_76b123db-d9bb-4251-a238-b1af9f78549b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.001</ix:nonfraction></span> per share of the Company’s common stock. The October 2020 Offering resulted in net proceeds of approximately $<span><ix:nonfraction unitref="usd" contextref="ied7da0ab5f3b4186bc770b0c713ddbe6_D20201001-20201031" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-396" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfMjM3OQ_ec4f2c9f-1216-4606-ab0b-709fa6324f60" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">13.7</ix:nonfraction></span>&nbsp;million to the Company after deducting underwriting commissions and discounts and other offering expenses of $<span><ix:nonfraction unitref="usd" contextref="ied7da0ab5f3b4186bc770b0c713ddbe6_D20201001-20201031" decimals="-5" name="bbi:SaleOfStockCommissionsDiscountsAndOtherOfferingExpenses" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-397" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfMjQ4Mw_4e483de8-73be-41a8-8f41-cb6f5b53f09c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1.3</ix:nonfraction></span>&nbsp;million and excluding the proceeds from the exercise of the warrants. During the year ended December&nbsp;31, 2021, <span><ix:nonfraction unitref="shares" contextref="i22405a7c372c4b70bda99cefeae4041e_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-398" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfMjU2Ng_bf38e01a-98c6-4b82-84af-e154e6e5e205" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12,427,387</ix:nonfraction></span> common warrants associated with the October 2020 Offering were exercised at a weighted-average exercise price of $<span><ix:nonfraction unitref="usdPerShare" contextref="i22405a7c372c4b70bda99cefeae4041e_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="fact-identifier-399" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfMjY4Mg_a756fc95-9cd7-4c7e-ad72-fd8b741d96d7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.72</ix:nonfraction></span> per share, resulting in aggregate proceeds of approximately $<span><ix:nonfraction unitref="usd" contextref="i952c7982750142b5bb99a11d3b7bcc20_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-400" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfMjc0NQ_4f132acb-d401-477a-9873-a1c58c5bb93e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8.9</ix:nonfraction></span> million. The Company is using the net proceeds from the October 2020 Offering for research and development, including clinical trials, working capital, and general corporate purposes.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company completed a sale of <span><ix:nonfraction unitref="shares" contextref="id906d2a122b44e3daf1cf3704aa16a1a_I20200630" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-401" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfMjc5Ng_c5f9c5d9-e311-45cd-8860-fe78a7a3b3c0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">14,790,133</ix:nonfraction></span> shares of its common stock, and, to certain investors, pre-funded warrants to purchase <span><ix:nonfraction unitref="shares" contextref="ieca34758531d4cd3bab0f67953c7f21d_I20200630" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-402" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfMjg4Ng_8fd428b3-e3ba-4b33-99bb-bedf4b345a7b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,709,867</ix:nonfraction></span> shares of its common stock, and accompanying common stock warrants to purchase up to an aggregate of <span><ix:nonfraction unitref="shares" contextref="i0763bbc1436649ac90db8b150740aa77_I20200630" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-403" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfMjk5MA_641064a1-1425-421e-927e-539238391d4c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">17,500,000</ix:nonfraction></span> shares of its common stock (the “June 2020 Offering”). Each share of common stock and pre-funded warrant to purchase one share of common stock was sold together with a common warrant to purchase one share of common stock. The public offering price of each share of common stock and accompanying common warrant was $<span><ix:nonfraction unitref="usdPerShare" contextref="ieca34758531d4cd3bab0f67953c7f21d_I20200630" decimals="INF" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="fact-identifier-404" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfMzM3NQ_294198fa-4205-486c-91d5-8e6622f00cd9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.15</ix:nonfraction></span> and $<span><ix:nonfraction unitref="usdPerShare" contextref="i0763bbc1436649ac90db8b150740aa77_I20200630" decimals="INF" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="fact-identifier-405" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfMzM4Mg_f89293bd-a906-49cb-9f7e-4c585e95d912" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.149</ix:nonfraction></span> for each pre-funded warrant and accompanying common warrant, respectively. The shares of common stock and pre-funded warrants, and the accompanying common warrants, were issued separately and were immediately separable upon issuance. The pre-funded warrants were exercised in the third quarter of 2020 at an exercise price of $<span><ix:nonfraction unitref="usdPerShare" contextref="i24c191d998ef4179bc97fb022772f42f_I20200630" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="fact-identifier-406" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfMzcxMQ_6bf63fb0-73a7-4769-a3f8-611a55468dc3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.001</ix:nonfraction></span> per share of common stock. The common warrants were immediately exercisable at a price of $<span><ix:nonfraction unitref="usdPerShare" contextref="id906d2a122b44e3daf1cf3704aa16a1a_I20200630" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="fact-identifier-407" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfMzgwNA_f2f2e554-314d-4147-97af-8446aa1b7a0c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.25</ix:nonfraction></span> per share of common stock and will expire <span><ix:nonnumeric contextref="ic3b123870412497ba1f76e8e916224f0_D20200601-20200630" name="bbi:SaleOfStockExpirationTerm" format="ixt-sec:durwordsen" id="fact-identifier-408" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfMzg0OQ_e347d4dd-4c09-4765-9451-14583835c74b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">five years</ix:nonnumeric></span> from the date of issuance. The June 2020 Offering resulted in approximately $<span><ix:nonfraction unitref="usd" contextref="ic3b123870412497ba1f76e8e916224f0_D20200601-20200630" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfWarrants" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-409" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfMzkyOA_95da2007-16d9-4bfe-91a3-862fecc8ea5a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">18.7</ix:nonfraction></span>&nbsp;million of net proceeds to the Company after deducting underwriting commissions and discounts and other offering expenses of $<span><ix:nonfraction unitref="usd" contextref="ic3b123870412497ba1f76e8e916224f0_D20200601-20200630" decimals="-5" name="bbi:UnderwritingCommissionsDiscountsAndOtherOfferingExpenses" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-410" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfNDA0OA_67c559bc-eafa-4abd-887f-229c3e8309f7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1.4</ix:nonfraction></span>&nbsp;million and excluding the proceeds from the exercise of the warrants. Certain officers of the Company participated in the June 2020 Offering by purchasing an aggregate purchase price of $<span><ix:nonfraction unitref="usd" contextref="i9317bd693e35453081407aad2ce3614f_D20200601-20200630" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfWarrants" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-411" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfNDIyOQ_f3cbdf92-8179-4290-aa40-22a17881230d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.2</ix:nonfraction></span>&nbsp;million of the Company's common stock and warrants. During the year ended December&nbsp;31, 2021, <span><ix:nonfraction unitref="shares" contextref="ic895a0f669dc41aebf0a3cbd34b88f1e_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-412" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfNDI5NA_d3e08e3f-ca7e-49ed-bc81-cf94133e7ba5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">17,500</ix:nonfraction></span> common warrants associated with the June 2020 Offering were exercised at a weighted-average exercise price of $<span><ix:nonfraction unitref="usdPerShare" contextref="ic895a0f669dc41aebf0a3cbd34b88f1e_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="fact-identifier-413" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfNDQwNw_fd53d3f4-00ef-42c5-bbe2-099c6117cea8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.25</ix:nonfraction></span> per share, resulting in aggregate proceeds of approximately $<span><ix:nonfraction unitref="usd" contextref="ie594e0c68fbb4c8a8664ea18c0e16f0b_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-414" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfNDQ3MA_c8456271-4240-47ca-8be1-0a1ea97882de" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">22</ix:nonfraction></span>&nbsp;thousand. The Company is using the net proceeds from the June 2020 Offering for research and development, including clinical trials, working capital, and general corporate purposes.</span></div></ix:continuation></span><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><span><ix:continuation id="ibf8c22d6bb0e456ab0f191981af1febf" continuedat="i4c177f76247944ed8e5bb491f73c904e" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">At Market Issuance Sales Agreements</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, the Company entered into an At Market Issuance Sales Agreement (the “2021 ATM Agreement”) with Oppenheimer &amp; Co. Inc. (“Oppenheimer”) and William Blair &amp; Company, L.L.C. as the Company’s sales agents (the “Agents”). Pursuant to the terms of the 2021 ATM Agreement, the Company may sell from time to time through the Agents shares of its common stock having an aggregate offering price of up to $<span><ix:nonfraction unitref="usd" contextref="if7a9a60a17784350b175e1c4cd31f629_I20210331" decimals="-5" name="bbi:CommonStockValueAggregateOfferingPrice" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-416" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfNTEwNQ_f27349fe-6318-4cec-a5eb-d571e98b884d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">50.0</ix:nonfraction></span>&nbsp;million. Such shares are issued pursuant to the Company’s shelf registration statement on Form&nbsp;S-3 (Registration No.&nbsp;333-254037). Sales of the shares are made by means of ordinary brokers’ transactions on The Nasdaq Capital Market at market prices or as otherwise agreed by the Company and the Agents. Under the terms of the 2021 ATM Agreement, the Company may also sell the shares from time to time to an Agent as principal for its own account at a price to be agreed upon at the time of sale. Any sale of the shares to an Agent as principal would be pursuant to the terms of a separate placement notice between the Company and such Agent. During the year ended December&nbsp;31, 2021, the Company sold <span><ix:nonfraction unitref="shares" contextref="id91cf804b976420eac12ee8c22f79102_D20210101-20211231" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-417" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfNTk5OQ_88f0e424-8c29-4958-b519-e71b27c66400" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,449,828</ix:nonfraction></span> shares of its common stock under the 2021 ATM Agreement at a weighted-average price of $<span><ix:nonfraction unitref="usdPerShare" contextref="i0362be51f9a54d76944d6aaa03e140f2_D20210101-20211231" decimals="2" name="bbi:SaleOfStockWeightedAveragePricePerShare" scale="0" id="fact-identifier-418" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfNjA4NQ_557669da-99a4-442d-bc6e-9c3af635b99c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.89</ix:nonfraction></span> per share, for aggregate net proceeds of $<span><ix:nonfraction unitref="usd" contextref="i0362be51f9a54d76944d6aaa03e140f2_D20210101-20211231" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-419" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfNjEyOQ_4bd0c3b6-7bac-41ee-a376-71319635f42f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.8</ix:nonfraction></span>&nbsp;million, after giving effect to a <span><ix:nonfraction unitref="number" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="INF" name="bbi:SaleOfStockPercentageOfCommission" scale="-2" id="fact-identifier-420" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfNjE1OA_bb9668a3-2497-4e69-8a85-c3ec0d7224bd" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">3</ix:nonfraction></span>% commission to the Agents. As of December&nbsp;31, 2021, approximately $<span><ix:nonfraction unitref="usd" contextref="iab543560d5bc450b9a82e51ea2a6693b_I20211231" decimals="-5" name="bbi:SaleOfStockAdditionalSharesAuthorizedAmount" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-421" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfNjIxMQ_b8cecf88-6228-4cc3-bd11-ece21795a86e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">46.0</ix:nonfraction></span>&nbsp;million of shares of common stock were remaining, but had not yet been sold by the Company under the 2021 ATM Agreement.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the Company entered into an At Market Issuance Sales Agreement (the “2020 ATM Agreement” and, together with the 2021 ATM Agreement, the “ATM Agreements”) with Oppenheimer as the Company’s sales agent. Pursuant to the terms of the 2020 ATM Agreement, the Company may sell from time to time through Oppenheimer shares of its common stock having an aggregate offering price of up to $<span><ix:nonfraction unitref="usd" contextref="ibfeb25fc4b5243e2a3a71ccaf8adc620_I20200430" decimals="-5" name="bbi:CommonStockValueAggregateOfferingPrice" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-422" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfNjY1OA_3b41ee55-7cea-4458-bde9-0d1f6e0e1307" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">8.0</ix:nonfraction></span>&nbsp;million. Such shares are issued pursuant to the Company’s shelf registration statement on Form&nbsp;S-3 (Registration No.&nbsp;333-236353). Sales of the shares are made by means of ordinary brokers’ transactions on The Nasdaq Capital Market at market prices or as otherwise agreed by the Company and Oppenheimer. Under the terms of the 2020 ATM Agreement, the Company may also sell the shares from time to time to Oppenheimer as principal for its own account at a price to be agreed upon at the time of sale. Any sale of the shares to Oppenheimer as principal would be pursuant to the terms of a separate placement notice between the Company and Oppenheimer. During the year ended December&nbsp;31, 2021, the Company sold <span><ix:nonfraction unitref="shares" contextref="i23924d399b4848e0b9118cadf9c441ae_D20210101-20211231" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-423" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfNzQxOQ_7288bc57-96f3-46c9-86c4-bc774e348c34" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,089,048</ix:nonfraction></span> shares of its common stock under the 2020 ATM Agreement at a weighted-average price of $<span><ix:nonfraction unitref="usdPerShare" contextref="i38418f7003a944819239bc331a3a2a94_D20210101-20211231" decimals="2" name="bbi:SaleOfStockWeightedAveragePricePerShare" scale="0" id="fact-identifier-424" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfNzUwNQ_5ef13553-4b60-49c8-b166-b1b03be2e70a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1.55</ix:nonfraction></span> per share, for aggregate net proceeds of approximately $<span><ix:nonfraction unitref="usd" contextref="i38418f7003a944819239bc331a3a2a94_D20210101-20211231" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-425" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfNzU2Mw_393eebd3-c8ae-4174-b1e2-e510d8c079d2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.6</ix:nonfraction></span>&nbsp;million, after giving effect to a <span><ix:nonfraction unitref="number" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="INF" name="bbi:SaleOfStockPercentageOfCommission" scale="-2" id="fact-identifier-426" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfNzU5Mg_bb9668a3-2497-4e69-8a85-c3ec0d7224bd" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">3</ix:nonfraction></span>% commission to Oppenheimer as agent. As of December&nbsp;31, 2021, approximately $<span><ix:nonfraction unitref="usd" contextref="ifcbfe54310a844789ff68ad2cab988b4_I20211231" decimals="-5" name="bbi:SaleOfStockAdditionalSharesAuthorizedAmount" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-427" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfNzY1NQ_28950edd-9768-4b21-9000-12ebf982beea" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2.6</ix:nonfraction></span>&nbsp;million of shares of common stock were remaining, but had not yet been sold by the Company under the 2020 ATM Agreement.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Private Placement Offerings</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, the Company and Lincoln Park Capital Fund, LLC (“Lincoln Park”) entered into (i) a securities purchase agreement (the “Securities Purchase Agreement”); (ii) a purchase agreement (the “Purchase Agreement”); and (iii) a registration rights agreement (the “Registration Rights Agreement”). Pursuant to the Securities Purchase Agreement, Lincoln Park purchased, and the Company sold, (i) an aggregate of <span><ix:nonfraction unitref="shares" contextref="i2ddf087d66c84f47a439f27661dd7001_I20200229" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-428" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfODIxNw_e7d01252-44c7-46ee-bf5a-8679e2784be5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">950,000</ix:nonfraction></span> shares of common stock (the “Common Shares”); (ii) a warrant to initially purchase an aggregate of up to <span><ix:nonfraction unitref="shares" contextref="i4388918a81944717a6d159c056d08f96_I20200229" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-429" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfODMyNQ_0f445b33-4b9b-4953-aae6-0fe9134de4be" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">606,420</ix:nonfraction></span> shares of common stock at an exercise price of $<span><ix:nonfraction unitref="usdPerShare" contextref="i4388918a81944717a6d159c056d08f96_I20200229" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="fact-identifier-430" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfODM3NQ_00adb897-e133-445a-8fb1-ea9ee1a7cea7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.01</ix:nonfraction></span> per share (the “Series A Warrant”); and (iii) a warrant to initially purchase an aggregate of up to <span><ix:nonfraction unitref="shares" contextref="i6b9f1dc5762f4d95957aa0f1550ec49e_I20200229" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-431" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfODQ3OA_eca484ef-fcd3-421e-87fa-d44ba00d42ad" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,556,420</ix:nonfraction></span> shares of common stock at an exercise price of $<span><ix:nonfraction unitref="usdPerShare" contextref="i6b9f1dc5762f4d95957aa0f1550ec49e_I20200229" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="fact-identifier-432" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfODUyOA_652ffb42-ce66-4801-a35f-8e9d1d90ab01" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.16</ix:nonfraction></span> per share (the “Series B Warrant,” and together with the Series A Warrant, the “Warrants”). The aggregate gross purchase price for the Common Shares and the Warrants was $<span><ix:nonfraction unitref="usd" contextref="i185b75e367b244df8844419e000cb28f_D20200201-20200229" decimals="-5" name="bbi:ProceedsFromIssuanceOfCommonStockAndWarrants" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-433" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfODcwMQ_6b9d46ed-4741-4564-991d-eed864fc388a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2.0</ix:nonfraction></span>&nbsp;million.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms and subject to the conditions of the Purchase Agreement, the Company has the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase, up to $<span><ix:nonfraction unitref="usd" contextref="if9fdf17822f8410583b96c2fb69f9183_I20200229" decimals="-5" name="us-gaap:PurchaseObligation" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-434" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfODkwMw_3544c179-c5d8-4226-aedb-a46b302c244c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">28.0</ix:nonfraction></span>&nbsp;million in the aggregate of shares of common stock. In order to retain maximum flexibility to issue and sell up to the maximum of $<span><ix:nonfraction unitref="usd" contextref="if9fdf17822f8410583b96c2fb69f9183_I20200229" decimals="-5" name="us-gaap:PurchaseObligation" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-435" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfOTAyOA_abefec05-a906-446f-8d6c-ff0f84795a7c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">28.0</ix:nonfraction></span>&nbsp;million of the Company’s common stock under the Purchase Agreement, the Company sought and, at its annual meeting on April 19, 2021, received, stockholder approval for the sale and issuance of common stock in connection with the Purchase Agreement under Nasdaq Listing Rule 5635(d). Sales of </span></div></ix:continuation></span><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><span><ix:continuation id="i4c177f76247944ed8e5bb491f73c904e" continuedat="i6e21dbdbd4ed4945aa71da66eadb392b" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">common stock by the Company will be subject to certain limitations, and may occur from time to time, at the Company’s sole discretion, over the <span><ix:nonnumeric contextref="iff50bf3d85134fa6a29a20b378b5aa09_D20200201-20200229" name="bbi:PurchaseObligationTerm" format="ixt-sec:durmonth" id="fact-identifier-437" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfOTQ1OQ_2ef96fad-e780-46dc-9e3f-b9835e174e77" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">36</ix:nonnumeric></span>-month period commencing on August&nbsp;14,&nbsp;2020 (the “Commencement Date”). </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the Commencement Date, under the Purchase Agreement, on any business day selected by the Company, the Company may direct Lincoln Park to purchase up to <span><ix:nonfraction unitref="shares" contextref="i8edf6096dea6465f96e3e0a94ab4e412_D20200201-20200229" decimals="INF" name="bbi:SaleOfStockMaximumSharesPurchased" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-438" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfOTY5NQ_e67c50c1-f82b-4a19-880b-d4731beb7c85" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">100,000</ix:nonfraction></span> shares of common stock on such business day (each, a “Regular Purchase”), provided, however, that (i) the Regular Purchase may be increased to up to <span><ix:nonfraction unitref="shares" contextref="i8edf6096dea6465f96e3e0a94ab4e412_D20200201-20200229" decimals="INF" name="bbi:SaleOfStockMaximumShareIncreaseAmount" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-439" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfOTg0Nw_57aecaaa-4b0f-4b5a-baf0-ea41b1ffd84f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">125,000</ix:nonfraction></span> shares, provided that the closing sale price of the common stock is not below $<span><ix:nonfraction unitref="usdPerShare" contextref="ic8633634722843ffb8a237ecfa10d7ed_I20200229" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="fact-identifier-440" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfOTkyOA_2226bfd3-c62e-4a0d-94e8-e9bb3d26dbaf" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.00</ix:nonfraction></span> on the purchase date; and (ii) the Regular Purchase may be increased to up to <span><ix:nonfraction unitref="shares" contextref="i4b4ac58c8c514f56a81a0ae074fd90bc_D20200201-20200229" decimals="INF" name="bbi:SaleOfStockMaximumShareIncreaseAmount" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-441" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfMTAwMDk_1aff410f-3ed9-416c-938c-74dea883efb0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">150,000</ix:nonfraction></span> shares, provided that the closing sale price of the common stock is not below $<span><ix:nonfraction unitref="usdPerShare" contextref="i58c0fb1ded3442bdbd8c1c72b8deb167_I20200229" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="fact-identifier-442" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfMTAwOTA_20cf7fea-4d22-4488-8072-0bedfebbedbb" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5.00</ix:nonfraction></span> on the purchase date. In each case, Lincoln Park’s maximum commitment in any single Regular Purchase may not exceed $<span><ix:nonfraction unitref="usd" contextref="iff50bf3d85134fa6a29a20b378b5aa09_D20200201-20200229" decimals="INF" name="bbi:SaleOfStockMaximumCommitmentPurchaseAmount" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-443" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfMTAyMDk_804004ec-8d86-44b5-a5e0-9caa0226e618" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,000,000</ix:nonfraction></span>. The purchase price per share for each such Regular Purchase will be based on prevailing market prices of common stock immediately preceding the time of sale. In addition to Regular Purchases, the Company may direct Lincoln Park to purchase other amounts as accelerated purchases or as additional accelerated purchases if the closing sale price of the common stock exceeds certain threshold prices as set forth in the Purchase Agreement. In all instances, the Company may not sell shares of its common stock to Lincoln Park under the Purchase Agreement if it would result in Lincoln Park beneficially owning more than <span><ix:nonfraction unitref="number" contextref="iff50bf3d85134fa6a29a20b378b5aa09_D20200201-20200229" decimals="4" name="us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction" scale="-2" id="fact-identifier-444" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfMTA4MzA_0d31efc8-87c4-4b74-897d-511a1c174e4d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9.99</ix:nonfraction></span>% of the outstanding shares of common stock. During the year ended December&nbsp;31, 2021, the Company sold to Lincoln Park <span><ix:nonfraction unitref="shares" contextref="icea6541707c34696b90754dab441301f_D20210101-20211231" decimals="-3" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-445" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfMTEwOTY_25e8d916-6d6b-4f48-8f10-033459309e3b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,300,000</ix:nonfraction></span> shares under the Purchase Agreement at a weighted-average price of $<span><ix:nonfraction unitref="usdPerShare" contextref="icea6541707c34696b90754dab441301f_D20210101-20211231" decimals="2" name="bbi:SaleOfStockWeightedAveragePricePerShare" scale="0" id="fact-identifier-446" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfMTExNjY_85276bd5-fd5f-4b20-a783-cc4ec7504946" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.81</ix:nonfraction></span> per share, for aggregate net proceeds of $<span><ix:nonfraction unitref="usd" contextref="icea6541707c34696b90754dab441301f_D20210101-20211231" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-447" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfMTEyMTA_dd1b690e-d2d0-4fb0-bb7d-84ea9ee1c4ad" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.0</ix:nonfraction></span>&nbsp;million. As of December&nbsp;31, 2021, approximately $<span><ix:nonfraction unitref="usd" contextref="i136a713ea34e4a3a8a8e3a24f4fa59ed_I20211231" decimals="-5" name="bbi:SaleOfStockAdditionalSharesAuthorizedAmount" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-448" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfMTEyMzg_55c75162-6dfd-4f0f-bfb2-b5e12f6439aa" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">26.9</ix:nonfraction></span>&nbsp;million of shares of common stock were remaining, but had not yet been sold by the Company under the Purchase Agreement.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company agreed with Lincoln Park that it will not enter into any “variable rate” transactions with any third party,&nbsp;subject to certain exceptions, for a period defined in the Purchase Agreement. The Company has the right to terminate the Purchase Agreement at any time, at no cost or penalty.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Securities Purchase Agreement, the Purchase Agreement, and the Registration Rights Agreement contain customary representations, warranties, agreements, and conditions to completing future sale transactions, indemnification rights, and obligations of the parties.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div></ix:continuation></span><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span><ix:continuation id="i6e21dbdbd4ed4945aa71da66eadb392b" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false">Under the Company’s amended and restated certificate of incorporation, the Company’s board of directors has the authority&nbsp;to issue up to <span><ix:nonfraction unitref="shares" contextref="i136a713ea34e4a3a8a8e3a24f4fa59ed_I20211231" decimals="INF" name="us-gaap:TemporaryEquitySharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-450" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfMTIwNzE_8e31c139-77f0-4c6f-ad94-9c81e2dc97a7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,000,000</ix:nonfraction></span> shares of preferred stock with a par value of $<span><ix:nonfraction unitref="usdPerShare" contextref="i136a713ea34e4a3a8a8e3a24f4fa59ed_I20211231" decimals="INF" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="fact-identifier-451" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfMTIxMjA_f1f6de1e-a700-47a4-842e-e7741d06250d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.01</ix:nonfraction></span> per&nbsp;share, at its discretion, in one or more classes or series and to fix the powers, preferences and rights, and the qualifications, limitations, or restrictions thereof, including dividend rights, conversion rights, voting rights, terms of redemption, and liquidation preferences, without further vote or action by the Company’s stockholders. As of December&nbsp;31, 2021, the Company had <span><ix:nonfraction unitref="shares" contextref="i136a713ea34e4a3a8a8e3a24f4fa59ed_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="fact-identifier-452" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV83Ni9mcmFnOjljMWYxZGZmOGE0ZTQ1ZDA4MzM2OTZlMjg5OWU4NjZiL3RleHRyZWdpb246OWMxZjFkZmY4YTRlNDVkMDgzMzY5NmUyODk5ZTg2NmJfMTI0OTQ_143bbd44-3bf5-483d-a497-719fdff723ad" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">no</ix:nonfraction></span> shares of preferred stock outstanding and had not designated the rights, preferences, or privileges of any class or series of preferred stock.</ix:continuation></span> </span></div><div style="text-align:justify"><span><br></span></div><div id="ie1e15c78f2af410c8f1490215e82bdbe_82"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 8. <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="fact-identifier-453" continuedat="i018f6526baf44d13ab1516f7d7ff59d0" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RleHRyZWdpb246Y2Q2NTY3YjhkMjAyNDFkZTg1YmRiNTRkNDljMDgzMjdfMjU5OA_6b2e0cf0-f8e0-41a8-a88e-f9012667c1c9" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">STOCK-BASED COMPENSATION</ix:nonnumeric></span></span></div><span><ix:continuation id="i018f6526baf44d13ab1516f7d7ff59d0" continuedat="iaeb819bf045c4ef98c1072d2bd832a54" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Incentive Plans</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 20, 2020, the Company’s stockholders approved the 2020 Omnibus Long-Term Incentive Plan (the “Omnibus Plan”), which replaced, with respect to new award grants, the Company’s 2009 Equity Incentive Plan, as amended and restated (the “2009 Plan”), and the Vical Equity Incentive Plan (the “Vical Plan”) (collectively, the “Prior Plans”) that were previously in effect. Following the approval of the Omnibus Plan on April 20, 2020, no further awards were available to be issued under the Prior Plans, but awards outstanding under those plans as of that date remain outstanding in accordance with their terms. As of December&nbsp;31, 2021, <span><ix:nonfraction unitref="shares" contextref="i97a4f7600692420d84883467663d2f32_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-455" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RleHRyZWdpb246Y2Q2NTY3YjhkMjAyNDFkZTg1YmRiNTRkNDljMDgzMjdfMTA5OTUxMTYzODU4OQ_a10f95fe-eb03-42c5-b9a4-ff2a394ea781" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,247,497</ix:nonfraction></span> and <span><ix:nonfraction unitref="shares" contextref="iee299f936e4b4f6493db6a9c1edb92ad_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-456" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RleHRyZWdpb246Y2Q2NTY3YjhkMjAyNDFkZTg1YmRiNTRkNDljMDgzMjdfMTA5OTUxMTYzODcyOA_d4117b77-7908-4562-9416-f5731654435c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">117,180</ix:nonfraction></span> shares were subject to outstanding awards under the 2009 Plan and Vical Plan, respectively. </span></div></ix:continuation></span><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><span><ix:continuation id="iaeb819bf045c4ef98c1072d2bd832a54" continuedat="i7dd2a2feac7a44f58563e0d0a0a238f4" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&nbsp;31, 2021, <span><ix:nonfraction unitref="shares" contextref="ib00fa4ecddfb408a8f6206ac1c5747b8_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-458" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RleHRyZWdpb246Y2Q2NTY3YjhkMjAyNDFkZTg1YmRiNTRkNDljMDgzMjdfMTA5OTUxMTYzODg1MA_2a8839ad-ee1d-477f-9521-0c2cbb5f6011" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,125,000</ix:nonfraction></span> shares were authorized and <span><ix:nonfraction unitref="shares" contextref="if92afe08e0b947e0be3caee47bcadd7f_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-459" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RleHRyZWdpb246Y2Q2NTY3YjhkMjAyNDFkZTg1YmRiNTRkNDljMDgzMjdfMTA5OTUxMTYzODg4Mg_df006a25-4c75-4728-856d-9dbc8e9bb2ad" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,695,165</ix:nonfraction></span> shares were subject to outstanding awards under the Omnibus Plan. On August&nbsp;31,&nbsp;2020 and April 19, 2021, the Company’s stockholders approved increases in the number of shares of common stock authorized for issuance under the Omnibus Plan by <span><ix:nonfraction unitref="shares" contextref="ie4d84a77f18f406b80dcc553f8680d1f_D20200831-20200831" decimals="INF" name="bbi:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-460" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RleHRyZWdpb246Y2Q2NTY3YjhkMjAyNDFkZTg1YmRiNTRkNDljMDgzMjdfMTA5OTUxMTYzOTIxMQ_0a9f0ff7-1f32-428c-a740-5d591d32c595" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">4,500,000</ix:nonfraction></span> and <span><ix:nonfraction unitref="shares" contextref="i99d487ee0b254f3787e06b5e936fbe3a_D20210419-20210419" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-461" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RleHRyZWdpb246Y2Q2NTY3YjhkMjAyNDFkZTg1YmRiNTRkNDljMDgzMjdfMTA5OTUxMTYzOTIxOQ_c5038e17-ec2a-4c1d-938b-3c43da5c2d09" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,000,000</ix:nonfraction></span> shares, respectively. As of December&nbsp;31, 2021, <span><ix:nonfraction unitref="shares" contextref="if92afe08e0b947e0be3caee47bcadd7f_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-462" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RleHRyZWdpb246Y2Q2NTY3YjhkMjAyNDFkZTg1YmRiNTRkNDljMDgzMjdfMTA5OTUxMTYzODk2NQ_d65c2a47-14b2-4446-b2df-28f99ee7b0f7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,644,883</ix:nonfraction></span> shares remained available for grant under the Omnibus Plan. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Assumptions</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for share-based compensation expense for stock options granted to employees, members of its board of directors, and non-employees by estimating the fair value of each stock-based award on the date of grant using the Black-Scholes option pricing model. The Company recognizes share-based compensation expense on a straight-line basis over the vesting term.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of the fair value of stock-based awards on the date of grant using an option-pricing model is affected by the value of the Company’s stock price, as well as assumptions regarding subjective variables. These variables include expected stock price volatility over the term of the awards, actual and projected employee stock option exercise behaviors, risk-free interest rate, and expected dividends.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because the Company has a limited history of stock purchase and sale activity, the Company estimates expected volatility of the common stock by using the average share fluctuations of companies similar in size, operations, and life cycle. The expected term of stock options granted to employees, including members of the board of directors, is determined as the midpoint between the vesting date and the contractual end of the option grant. The expected term of all other stock options granted is based on the Company’s historical share option exercise experience, which approximates the midpoint between the vesting date and the contractual end of the option grant. The risk-free interest rates used in the valuation model are based on U.S. Treasury yield issues in effect at the time of grant for a period commensurate with the expected term of the grant. The Company does not anticipate paying any dividends in the foreseeable future and therefore uses an expected dividend yield of zero.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has estimated a forfeiture rate of <span><ix:nonfraction unitref="number" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="INF" name="bbi:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" scale="-2" id="fact-identifier-463" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RleHRyZWdpb246Y2Q2NTY3YjhkMjAyNDFkZTg1YmRiNTRkNDljMDgzMjdfMTA5OTUxMTYzMTk2Mw_6c688abd-3eb0-464e-a9c0-f903f41a1e9c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">11</ix:nonfraction></span>% based on past history, forfeiture rates, and the individuals receiving the options. The Company monitors actual forfeiture experience and periodically updates forfeiture estimates based on actual experience.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options granted by the Company have an exercise price per share equal to the closing sales price of the common stock on the day prior to the date of grant and expire <span><ix:nonnumeric contextref="ib9d3171439f046d18bb63ac1889442a5_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="fact-identifier-464" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RleHRyZWdpb246Y2Q2NTY3YjhkMjAyNDFkZTg1YmRiNTRkNDljMDgzMjdfMjE5OTAyMzI3OTk5OQ_d04345d4-d447-4634-880b-1a9307a6de14" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">ten years</ix:nonnumeric></span> from the date of grant. The vesting term of granted stock options is stated in each individual grant agreement, which is generally four years. During the years ended December&nbsp;31, 2021 and December&nbsp;31, 2020, the Company granted stock options with a weighted-average grant date fair value of $<span><ix:nonfraction unitref="usdPerShare" contextref="ib9d3171439f046d18bb63ac1889442a5_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="fact-identifier-465" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RleHRyZWdpb246Y2Q2NTY3YjhkMjAyNDFkZTg1YmRiNTRkNDljMDgzMjdfMTA5OTUxMTY1MTI5NQ_2268662d-31ff-44b2-a00d-1186d3e11d87" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.65</ix:nonfraction></span> per share and $<span><ix:nonfraction unitref="usdPerShare" contextref="ic09f0cb7e935412bbc1991742a83d05e_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="fact-identifier-466" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RleHRyZWdpb246Y2Q2NTY3YjhkMjAyNDFkZTg1YmRiNTRkNDljMDgzMjdfMTA5OTUxMTY1MTMyMA_820dcd84-d790-4ba9-80b2-5cf67bb14977" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.52</ix:nonfraction></span> per share, respectively. <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="fact-identifier-467" continuedat="i2d80eb6e419f4ce4b12fda8cc0042b20" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RleHRyZWdpb246Y2Q2NTY3YjhkMjAyNDFkZTg1YmRiNTRkNDljMDgzMjdfNjA0NzMxMzk2NTU3Mg_f39910ca-0441-4aed-aa2d-1da260b237f6" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">The assumptions used to calculate the fair value of stock options granted are as follows, presented on a weighted-average basis:</ix:nonnumeric></span></span></div><div style="margin-bottom:1pt;text-align:center"><span><ix:continuation id="i2d80eb6e419f4ce4b12fda8cc0042b20" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:69.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended<br>December&nbsp;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="id18f7e3519f74098b48becbf7a48145c_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="fact-identifier-469" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RhYmxlOmQ0ODllZTE4MGMyNTRlNzE4YjAxNGM0Mzg5NDlmNWUxL3RhYmxlcmFuZ2U6ZDQ4OWVlMTgwYzI1NGU3MThiMDE0YzQzODk0OWY1ZTFfMy0xLTEtMS0xNzk1Nw_e835afba-9aa9-47f0-a0d6-dbd675146b9f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.0</ix:nonnumeric></span> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i4fca80887a6747448ce1c3ce12b39a4d_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="fact-identifier-470" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RhYmxlOmQ0ODllZTE4MGMyNTRlNzE4YjAxNGM0Mzg5NDlmNWUxL3RhYmxlcmFuZ2U6ZDQ4OWVlMTgwYzI1NGU3MThiMDE0YzQzODk0OWY1ZTFfMy0zLTEtMS0xNzk1Nw_770c6c03-6f7d-45f6-9c0e-19c634566159" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.0</ix:nonnumeric></span> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="id18f7e3519f74098b48becbf7a48145c_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="fact-identifier-471" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RhYmxlOmQ0ODllZTE4MGMyNTRlNzE4YjAxNGM0Mzg5NDlmNWUxL3RhYmxlcmFuZ2U6ZDQ4OWVlMTgwYzI1NGU3MThiMDE0YzQzODk0OWY1ZTFfNC0xLTEtMS0xNzk1Nw_87f324c5-7438-4402-91ae-98d20196f860" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">99.3</ix:nonfraction></span>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i4fca80887a6747448ce1c3ce12b39a4d_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="fact-identifier-472" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RhYmxlOmQ0ODllZTE4MGMyNTRlNzE4YjAxNGM0Mzg5NDlmNWUxL3RhYmxlcmFuZ2U6ZDQ4OWVlMTgwYzI1NGU3MThiMDE0YzQzODk0OWY1ZTFfNC0zLTEtMS0xNzk1Nw_26f16991-e601-4691-93fc-bcdc18fd9f6f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">73.0</ix:nonfraction></span>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="id18f7e3519f74098b48becbf7a48145c_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="fact-identifier-473" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RhYmxlOmQ0ODllZTE4MGMyNTRlNzE4YjAxNGM0Mzg5NDlmNWUxL3RhYmxlcmFuZ2U6ZDQ4OWVlMTgwYzI1NGU3MThiMDE0YzQzODk0OWY1ZTFfNS0xLTEtMS0xNzk1Nw_1033f270-0004-4067-afb7-1781749b0c8a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.0</ix:nonfraction></span>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i4fca80887a6747448ce1c3ce12b39a4d_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="fact-identifier-474" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RhYmxlOmQ0ODllZTE4MGMyNTRlNzE4YjAxNGM0Mzg5NDlmNWUxL3RhYmxlcmFuZ2U6ZDQ4OWVlMTgwYzI1NGU3MThiMDE0YzQzODk0OWY1ZTFfNS0zLTEtMS0xNzk1Nw_6e342f54-5dda-4fea-83ac-72bddfdc2280" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.4</ix:nonfraction></span>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="id18f7e3519f74098b48becbf7a48145c_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="fact-identifier-475" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RhYmxlOmQ0ODllZTE4MGMyNTRlNzE4YjAxNGM0Mzg5NDlmNWUxL3RhYmxlcmFuZ2U6ZDQ4OWVlMTgwYzI1NGU3MThiMDE0YzQzODk0OWY1ZTFfNi0xLTEtMS0xNzk1Nw_44537ab2-a7c5-4b97-978b-ada131cd30d2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i4fca80887a6747448ce1c3ce12b39a4d_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="fact-identifier-476" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RhYmxlOmQ0ODllZTE4MGMyNTRlNzE4YjAxNGM0Mzg5NDlmNWUxL3RhYmxlcmFuZ2U6ZDQ4OWVlMTgwYzI1NGU3MThiMDE0YzQzODk0OWY1ZTFfNi0zLTEtMS0xNzk1Nw_7a4fd0db-ec97-4ece-9b51-6dc79af3db6b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>%</span></td></tr></tbody></table></ix:continuation></span></div></ix:continuation></span><div style="text-align:justify"><span><br></span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><span><ix:continuation id="i7dd2a2feac7a44f58563e0d0a0a238f4" continuedat="i763938f4ee6d4d0c9f737f2ffe5166b2" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="fact-identifier-478" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RleHRyZWdpb246Y2Q2NTY3YjhkMjAyNDFkZTg1YmRiNTRkNDljMDgzMjdfNjA0NzMxMzk2NTU3Mw_9022b17a-6e30-488c-8e8f-383744fce785" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity under the Company’s incentive plans is as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:49.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted <br>Average <br>Exercise <br>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br>Intrinsic <br>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted&nbsp;Average <br>Remaining <br>Contractual&nbsp;Life <br>(In&nbsp;Years)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i3764ec9cafc742c88cf1c0d565bb6379_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-479" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RhYmxlOmFmMDk3ZDQxMDI4ODRhMjc5MTRhMGIzNTY4NDIwODI1L3RhYmxlcmFuZ2U6YWYwOTdkNDEwMjg4NGEyNzkxNGEwYjM1Njg0MjA4MjVfMTEtMS0xLTEtMTc5NTc_d26cc1dc-f767-44a2-8eaa-ba4bddb2ef43" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,688,625</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i3764ec9cafc742c88cf1c0d565bb6379_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="fact-identifier-480" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RhYmxlOmFmMDk3ZDQxMDI4ODRhMjc5MTRhMGIzNTY4NDIwODI1L3RhYmxlcmFuZ2U6YWYwOTdkNDEwMjg4NGEyNzkxNGEwYjM1Njg0MjA4MjVfMTEtMy0xLTEtMTc5NTc_ae41c925-25b6-48cd-8fbc-79add20159f1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4.66</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3764ec9cafc742c88cf1c0d565bb6379_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:fixed-zero" scale="0" id="fact-identifier-481" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RhYmxlOmFmMDk3ZDQxMDI4ODRhMjc5MTRhMGIzNTY4NDIwODI1L3RhYmxlcmFuZ2U6YWYwOTdkNDEwMjg4NGEyNzkxNGEwYjM1Njg0MjA4MjVfMTEtNS0xLTEtMTc5NTc_ae235598-bd69-47aa-ab2b-861f8ce789ee" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="ic09f0cb7e935412bbc1991742a83d05e_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="fact-identifier-482" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RhYmxlOmFmMDk3ZDQxMDI4ODRhMjc5MTRhMGIzNTY4NDIwODI1L3RhYmxlcmFuZ2U6YWYwOTdkNDEwMjg4NGEyNzkxNGEwYjM1Njg0MjA4MjVfMTEtNy0xLTEtMTc5NTc_1e0bf3e7-1d29-4944-8cd8-1a01dc22f392" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9.04</ix:nonnumeric></span></span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="ib9d3171439f046d18bb63ac1889442a5_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-483" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RhYmxlOmFmMDk3ZDQxMDI4ODRhMjc5MTRhMGIzNTY4NDIwODI1L3RhYmxlcmFuZ2U6YWYwOTdkNDEwMjg4NGEyNzkxNGEwYjM1Njg0MjA4MjVfMTQtMS0xLTEtMTg0MDQ_712de6ed-d1d4-4b0e-9938-e8d82c34ffe5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,645,000</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="ib9d3171439f046d18bb63ac1889442a5_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="fact-identifier-484" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RhYmxlOmFmMDk3ZDQxMDI4ODRhMjc5MTRhMGIzNTY4NDIwODI1L3RhYmxlcmFuZ2U6YWYwOTdkNDEwMjg4NGEyNzkxNGEwYjM1Njg0MjA4MjVfMTQtMy0xLTEtMTg0MDQ_459b8969-97a9-4e01-bb65-6c95d44003ca" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.89</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 7.75pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 7.75pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="ib9d3171439f046d18bb63ac1889442a5_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="fact-identifier-485" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RhYmxlOmFmMDk3ZDQxMDI4ODRhMjc5MTRhMGIzNTY4NDIwODI1L3RhYmxlcmFuZ2U6YWYwOTdkNDEwMjg4NGEyNzkxNGEwYjM1Njg0MjA4MjVfMTUtMS0xLTEtMTg0MDQ_58367c59-a210-458e-8807-9735af067f9c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="ib9d3171439f046d18bb63ac1889442a5_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="fact-identifier-486" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RhYmxlOmFmMDk3ZDQxMDI4ODRhMjc5MTRhMGIzNTY4NDIwODI1L3RhYmxlcmFuZ2U6YWYwOTdkNDEwMjg4NGEyNzkxNGEwYjM1Njg0MjA4MjVfMTUtMy0xLTEtMTg0MDQ_9a4bf97a-77d7-4ec6-87c1-71b9c0513338" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 7.75pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 7.75pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="shares" contextref="ib9d3171439f046d18bb63ac1889442a5_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-487" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RhYmxlOmFmMDk3ZDQxMDI4ODRhMjc5MTRhMGIzNTY4NDIwODI1L3RhYmxlcmFuZ2U6YWYwOTdkNDEwMjg4NGEyNzkxNGEwYjM1Njg0MjA4MjVfMTYtMS0xLTEtMTg0MDQ_0e8bc54a-692a-4ea6-a464-a173c8839c58" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">219,731</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="ib9d3171439f046d18bb63ac1889442a5_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="fact-identifier-488" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RhYmxlOmFmMDk3ZDQxMDI4ODRhMjc5MTRhMGIzNTY4NDIwODI1L3RhYmxlcmFuZ2U6YWYwOTdkNDEwMjg4NGEyNzkxNGEwYjM1Njg0MjA4MjVfMTYtMy0xLTEtMTg0MDQ_dbb32187-3c97-406c-92f3-e8472ff8c788" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.57</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 7.75pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 7.75pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="shares" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-489" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RhYmxlOmFmMDk3ZDQxMDI4ODRhMjc5MTRhMGIzNTY4NDIwODI1L3RhYmxlcmFuZ2U6YWYwOTdkNDEwMjg4NGEyNzkxNGEwYjM1Njg0MjA4MjVfMTctMS0xLTEtMjQ5NTk_4a6863ee-31fb-498e-82f8-35de719cceee" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">54,052</ix:nonfraction></span>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="fact-identifier-490" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RhYmxlOmFmMDk3ZDQxMDI4ODRhMjc5MTRhMGIzNTY4NDIwODI1L3RhYmxlcmFuZ2U6YWYwOTdkNDEwMjg4NGEyNzkxNGEwYjM1Njg0MjA4MjVfMTctMy0xLTEtMjQ5NTk_4ad4d70a-b13f-4303-8040-11985713bdb8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">23.01</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i60a3b4ccd49e4dd19777488e4f48d5f0_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-491" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RhYmxlOmFmMDk3ZDQxMDI4ODRhMjc5MTRhMGIzNTY4NDIwODI1L3RhYmxlcmFuZ2U6YWYwOTdkNDEwMjg4NGEyNzkxNGEwYjM1Njg0MjA4MjVfMTctMS0xLTEtMTg0MDQ_3d925d7a-248e-45b3-9eeb-d23325260067" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,059,842</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i60a3b4ccd49e4dd19777488e4f48d5f0_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="fact-identifier-492" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RhYmxlOmFmMDk3ZDQxMDI4ODRhMjc5MTRhMGIzNTY4NDIwODI1L3RhYmxlcmFuZ2U6YWYwOTdkNDEwMjg4NGEyNzkxNGEwYjM1Njg0MjA4MjVfMTctMy0xLTEtMTg0MDQ_1534a6b7-941a-4531-94f2-8a12d542183d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.20</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 7.75pt 0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i60a3b4ccd49e4dd19777488e4f48d5f0_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:fixed-zero" scale="0" id="fact-identifier-493" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RhYmxlOmFmMDk3ZDQxMDI4ODRhMjc5MTRhMGIzNTY4NDIwODI1L3RhYmxlcmFuZ2U6YWYwOTdkNDEwMjg4NGEyNzkxNGEwYjM1Njg0MjA4MjVfMTctNS0xLTEtMTg0MDQ_6c149fce-818f-4711-8be9-48c9dae29fd7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 7.75pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="ib9d3171439f046d18bb63ac1889442a5_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="fact-identifier-494" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RhYmxlOmFmMDk3ZDQxMDI4ODRhMjc5MTRhMGIzNTY4NDIwODI1L3RhYmxlcmFuZ2U6YWYwOTdkNDEwMjg4NGEyNzkxNGEwYjM1Njg0MjA4MjVfMTctNy0xLTEtMTg0MDQ_9bae31a5-fce1-4c4b-8e9a-ec1aec3d59d5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8.53</ix:nonnumeric></span></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and exercisable as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i60a3b4ccd49e4dd19777488e4f48d5f0_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-495" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RhYmxlOmFmMDk3ZDQxMDI4ODRhMjc5MTRhMGIzNTY4NDIwODI1L3RhYmxlcmFuZ2U6YWYwOTdkNDEwMjg4NGEyNzkxNGEwYjM1Njg0MjA4MjVfMTgtMS0xLTEtMTg0MDQ_15152bac-8780-429b-87fc-8bcde8aba8d9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,013,110</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i60a3b4ccd49e4dd19777488e4f48d5f0_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="fact-identifier-496" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RhYmxlOmFmMDk3ZDQxMDI4ODRhMjc5MTRhMGIzNTY4NDIwODI1L3RhYmxlcmFuZ2U6YWYwOTdkNDEwMjg4NGEyNzkxNGEwYjM1Njg0MjA4MjVfMTgtMy0xLTEtMTg0MDQ_4bb749a4-2ba9-4c96-8137-1c0a1eeaa335" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8.13</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 7.75pt 0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i60a3b4ccd49e4dd19777488e4f48d5f0_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" format="ixt:fixed-zero" scale="0" id="fact-identifier-497" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RhYmxlOmFmMDk3ZDQxMDI4ODRhMjc5MTRhMGIzNTY4NDIwODI1L3RhYmxlcmFuZ2U6YWYwOTdkNDEwMjg4NGEyNzkxNGEwYjM1Njg0MjA4MjVfMTgtNS0xLTEtMTg0MDQ_5c8c7f00-2c78-4fcf-a19c-cdae75ca2e2e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 7.75pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="ib9d3171439f046d18bb63ac1889442a5_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="fact-identifier-498" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RhYmxlOmFmMDk3ZDQxMDI4ODRhMjc5MTRhMGIzNTY4NDIwODI1L3RhYmxlcmFuZ2U6YWYwOTdkNDEwMjg4NGEyNzkxNGEwYjM1Njg0MjA4MjVfMTgtNy0xLTEtMTg0MDQ_db1481b5-ef14-4fff-afa4-69397dce2ac9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.26</ix:nonnumeric></span></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding as of December 31, 2021 and expected to vest</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i60a3b4ccd49e4dd19777488e4f48d5f0_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-499" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RhYmxlOmFmMDk3ZDQxMDI4ODRhMjc5MTRhMGIzNTY4NDIwODI1L3RhYmxlcmFuZ2U6YWYwOTdkNDEwMjg4NGEyNzkxNGEwYjM1Njg0MjA4MjVfMTktMS0xLTEtMTg0MDQ_1eb73a46-6d7f-45d8-8243-6872aab2eafe" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,291,193</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i60a3b4ccd49e4dd19777488e4f48d5f0_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="fact-identifier-500" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RhYmxlOmFmMDk3ZDQxMDI4ODRhMjc5MTRhMGIzNTY4NDIwODI1L3RhYmxlcmFuZ2U6YWYwOTdkNDEwMjg4NGEyNzkxNGEwYjM1Njg0MjA4MjVfMTktMy0xLTEtMTg0MDQ_d4927db1-64d7-45aa-9040-5a63f0e2b3a2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.27</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 7.75pt 0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i60a3b4ccd49e4dd19777488e4f48d5f0_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:fixed-zero" scale="0" id="fact-identifier-501" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RhYmxlOmFmMDk3ZDQxMDI4ODRhMjc5MTRhMGIzNTY4NDIwODI1L3RhYmxlcmFuZ2U6YWYwOTdkNDEwMjg4NGEyNzkxNGEwYjM1Njg0MjA4MjVfMTktNS0xLTEtMTg0MDQ_d6e45410-7266-4fce-add1-6433bd314cd6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 7.75pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="ib9d3171439f046d18bb63ac1889442a5_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="fact-identifier-502" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RhYmxlOmFmMDk3ZDQxMDI4ODRhMjc5MTRhMGIzNTY4NDIwODI1L3RhYmxlcmFuZ2U6YWYwOTdkNDEwMjg4NGEyNzkxNGEwYjM1Njg0MjA4MjVfMTktNy0xLTEtMTg0MDQ_4fc57f2a-ca4f-454b-90c3-53cfd0b94aa9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9.02</ix:nonnumeric></span></span></td></tr></tbody></table></div></ix:nonnumeric></span><div style="text-align:justify"><span><br></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&nbsp;31, 2021, the Company had $<span><ix:nonfraction unitref="usd" contextref="i60a3b4ccd49e4dd19777488e4f48d5f0_I20211231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-503" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RleHRyZWdpb246Y2Q2NTY3YjhkMjAyNDFkZTg1YmRiNTRkNDljMDgzMjdfMTA5OTUxMTYzMjg0MA_58e889f6-382d-4aff-9477-3cb21d04132b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.6</ix:nonfraction></span>&nbsp;million of total unrecognized share-based compensation expense related to stock options, which is expected to be recognized over a weighted-average period of approximately&nbsp;<span><ix:nonnumeric contextref="ib9d3171439f046d18bb63ac1889442a5_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="fact-identifier-504" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RleHRyZWdpb246Y2Q2NTY3YjhkMjAyNDFkZTg1YmRiNTRkNDljMDgzMjdfMTA5OTUxMTYzMzAwOA_279ca4ea-335f-4515-a5fe-ed9599d16ba0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.9</ix:nonnumeric></span> years.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="fact-identifier-505" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RleHRyZWdpb246Y2Q2NTY3YjhkMjAyNDFkZTg1YmRiNTRkNDljMDgzMjdfNjA0NzMxMzk2NTU3NA_97a05280-2ce1-41a0-a384-5489edfb3e71" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock unit (“RSU”) activity during the year ended December&nbsp;31, 2021 is shown below. </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:69.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.401%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i29cf34bcc25e40cb820c6d1976855b2f_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-506" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RhYmxlOjAzZTcxNmQ2MTViNzQxMmJhNDc3MWZmNzJjYjkyNTIzL3RhYmxlcmFuZ2U6MDNlNzE2ZDYxNWI3NDEyYmE0NzcxZmY3MmNiOTI1MjNfMS0xLTEtMS0xODAwMQ_67805c58-cd4f-4059-b152-c4592cc5576b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">143,000</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i29cf34bcc25e40cb820c6d1976855b2f_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="fact-identifier-507" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RhYmxlOjAzZTcxNmQ2MTViNzQxMmJhNDc3MWZmNzJjYjkyNTIzL3RhYmxlcmFuZ2U6MDNlNzE2ZDYxNWI3NDEyYmE0NzcxZmY3MmNiOTI1MjNfMS0zLTEtMS0xODAwMQ_8d919870-be75-4b7d-ba47-633273cab857" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.38</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i51f8d7f1fbd74f8f984824ea54416009_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-508" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RhYmxlOjAzZTcxNmQ2MTViNzQxMmJhNDc3MWZmNzJjYjkyNTIzL3RhYmxlcmFuZ2U6MDNlNzE2ZDYxNWI3NDEyYmE0NzcxZmY3MmNiOTI1MjNfMi0xLTEtMS0xODAwMQ_352653e2-27d4-4f11-a2d6-c3a4c55d58a3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">47,435</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i51f8d7f1fbd74f8f984824ea54416009_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="fact-identifier-509" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RhYmxlOjAzZTcxNmQ2MTViNzQxMmJhNDc3MWZmNzJjYjkyNTIzL3RhYmxlcmFuZ2U6MDNlNzE2ZDYxNWI3NDEyYmE0NzcxZmY3MmNiOTI1MjNfMi0zLTEtMS0xODAwMQ_a20212f1-eadc-4e46-974b-ba5da8a3bd98" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.78</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="shares" contextref="i51f8d7f1fbd74f8f984824ea54416009_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-510" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RhYmxlOjAzZTcxNmQ2MTViNzQxMmJhNDc3MWZmNzJjYjkyNTIzL3RhYmxlcmFuZ2U6MDNlNzE2ZDYxNWI3NDEyYmE0NzcxZmY3MmNiOTI1MjNfMy0xLTEtMS0xODAwMQ_c853634f-cd0e-4c69-95c3-4c57f759d8de" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">189,435</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i51f8d7f1fbd74f8f984824ea54416009_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="fact-identifier-511" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RhYmxlOjAzZTcxNmQ2MTViNzQxMmJhNDc3MWZmNzJjYjkyNTIzL3RhYmxlcmFuZ2U6MDNlNzE2ZDYxNWI3NDEyYmE0NzcxZmY3MmNiOTI1MjNfMy0zLTEtMS0xODAwMQ_b74c693b-6f1e-4a73-a79c-59a515a44f1a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.23</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="shares" contextref="i51f8d7f1fbd74f8f984824ea54416009_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-512" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RhYmxlOjAzZTcxNmQ2MTViNzQxMmJhNDc3MWZmNzJjYjkyNTIzL3RhYmxlcmFuZ2U6MDNlNzE2ZDYxNWI3NDEyYmE0NzcxZmY3MmNiOTI1MjNfNC0xLTEtMS0xODAwMQ_3bdde7cc-d157-42c1-afb7-ac5c95630881" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,000</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i51f8d7f1fbd74f8f984824ea54416009_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="fact-identifier-513" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RhYmxlOjAzZTcxNmQ2MTViNzQxMmJhNDc3MWZmNzJjYjkyNTIzL3RhYmxlcmFuZ2U6MDNlNzE2ZDYxNWI3NDEyYmE0NzcxZmY3MmNiOTI1MjNfNC0zLTEtMS0xODAwMQ_fad2e0c1-03df-4f1e-85f4-5af959345955" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.38</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i536b401f49be405b870ac402e75bb048_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:fixed-zero" scale="0" id="fact-identifier-514" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RhYmxlOjAzZTcxNmQ2MTViNzQxMmJhNDc3MWZmNzJjYjkyNTIzL3RhYmxlcmFuZ2U6MDNlNzE2ZDYxNWI3NDEyYmE0NzcxZmY3MmNiOTI1MjNfNS0xLTEtMS0xOTY2Ng_d7537d24-fc20-4c1c-8cdf-a083a4f3b672" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i536b401f49be405b870ac402e75bb048_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="fact-identifier-515" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RhYmxlOjAzZTcxNmQ2MTViNzQxMmJhNDc3MWZmNzJjYjkyNTIzL3RhYmxlcmFuZ2U6MDNlNzE2ZDYxNWI3NDEyYmE0NzcxZmY3MmNiOTI1MjNfNS0zLTEtMS0xODAwMQ_c82e5413-7317-4020-9460-74bfaa2536cb" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div></ix:nonnumeric></span><div style="text-align:justify"><span><br></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total grant date fair value and the total vest date fair value of RSUs vested during the year ended December&nbsp;31, 2021 were both approximately $<span><ix:nonfraction unitref="usd" contextref="i51f8d7f1fbd74f8f984824ea54416009_D20210101-20211231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-516" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RleHRyZWdpb246Y2Q2NTY3YjhkMjAyNDFkZTg1YmRiNTRkNDljMDgzMjdfMTY0OTI2NzQ1MTQwMg_3c0e2606-3e3b-4453-aed5-be37e67f4393" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="usd" contextref="i536b401f49be405b870ac402e75bb048_I20211231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-517" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RleHRyZWdpb246Y2Q2NTY3YjhkMjAyNDFkZTg1YmRiNTRkNDljMDgzMjdfMTY0OTI2NzQ1MTQwMg_c2c8e2fb-a9af-48d9-b5ca-daaeb146187d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.2</ix:nonfraction></span></ix:nonfraction></span> million. As of December&nbsp;31, 2021, the Company had <span><ix:nonfraction unitref="usd" contextref="i536b401f49be405b870ac402e75bb048_I20211231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:fixed-zero" scale="6" id="fact-identifier-518" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RleHRyZWdpb246Y2Q2NTY3YjhkMjAyNDFkZTg1YmRiNTRkNDljMDgzMjdfMTY0OTI2NzQ1MjA3OA_63fffe71-a83f-4b08-b02b-ad5f48a6feef" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">no</ix:nonfraction></span> unrecognized share-based compensation expense related to service-condition RSU awards.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April&nbsp;19, 2021, the Company’s stockholders approved the Brickell Biotech, Inc. Employee Stock Purchase Plan (the “ESPP”), which had a first eligible purchase period commencing on July&nbsp;1, 2021. The ESPP allows qualified employees to purchase shares of the Company’s common stock at a price per share equal to <span><ix:nonfraction unitref="number" contextref="i39a3ed5ab3674ef8a5d3562bc4955a3b_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" scale="-2" id="fact-identifier-519" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RleHRyZWdpb246Y2Q2NTY3YjhkMjAyNDFkZTg1YmRiNTRkNDljMDgzMjdfMjA5Mg_aca5c388-7cf6-49b8-ac1d-03bcadea0ae5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">85</ix:nonfraction></span>% of the lower of: (i) the closing price of the Company’s common stock on the first trading day of the applicable purchase period or (ii) the closing price of the Company’s common stock on the last trading day of the applicable purchase period. New <span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="bbi:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod" format="ixt-sec:durwordsen" id="fact-identifier-520" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RleHRyZWdpb246Y2Q2NTY3YjhkMjAyNDFkZTg1YmRiNTRkNDljMDgzMjdfMjU5OQ_8766af42-eca7-49f5-9d4d-c0ce822d50a2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">six-month</ix:nonnumeric></span> purchase periods begin each January 1 and July 1. As of December&nbsp;31, 2021, the Company had <span><ix:nonfraction unitref="shares" contextref="ic8c46b385c9d410ba351bdf9a1cdef7b_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-521" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RleHRyZWdpb246Y2Q2NTY3YjhkMjAyNDFkZTg1YmRiNTRkNDljMDgzMjdfMzg0ODI5MDcxMDM3NQ_62a9c5a7-d0a6-49e3-9ef9-a7f43787e61f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,450,715</ix:nonfraction></span> shares available for issuance and <span><ix:nonfraction unitref="shares" contextref="ibeb42d5fcd6b44c7bf55d0f49eaa5cc1_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-522" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RleHRyZWdpb246Y2Q2NTY3YjhkMjAyNDFkZTg1YmRiNTRkNDljMDgzMjdfMTY0OTI2NzQ1MjE5MQ_3454b6bc-f7d4-4d31-a9d7-6cce9e5f9c0c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">149,285</ix:nonfraction></span> cumulative shares had been issued under the ESPP. </span></div></ix:continuation></span><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><span><ix:continuation id="i763938f4ee6d4d0c9f737f2ffe5166b2" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="fact-identifier-524" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RleHRyZWdpb246Y2Q2NTY3YjhkMjAyNDFkZTg1YmRiNTRkNDljMDgzMjdfMjYwMA_ec21f96c-801e-461c-a356-452c80aed4dc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense reported in the consolidated statements of operations was allocated as follows (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:69.066%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended<br>December&nbsp;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9b104686d0234f5b80fa09d742216b81_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="fact-identifier-525" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RhYmxlOmMyY2FhMzNiMTc1YTQ5NDNiOTA3OGMyMDM0YmYzOWUxL3RhYmxlcmFuZ2U6YzJjYWEzM2IxNzVhNDk0M2I5MDc4YzIwMzRiZjM5ZTFfMi01LTEtMS0xNjM1MQ_5aa60f48-f273-458e-abb6-cafb9637d20d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">478</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i13107484a8a144969c7fbd351687ace2_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="fact-identifier-526" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RhYmxlOmMyY2FhMzNiMTc1YTQ5NDNiOTA3OGMyMDM0YmYzOWUxL3RhYmxlcmFuZ2U6YzJjYWEzM2IxNzVhNDk0M2I5MDc4YzIwMzRiZjM5ZTFfMi03LTEtMS0xNjM1MQ_6c0a1079-03bc-477c-b28f-a426fee65c97" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">392</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8f0337209ceb487e9346447e0c16e3a6_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-527" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RhYmxlOmMyY2FhMzNiMTc1YTQ5NDNiOTA3OGMyMDM0YmYzOWUxL3RhYmxlcmFuZ2U6YzJjYWEzM2IxNzVhNDk0M2I5MDc4YzIwMzRiZjM5ZTFfMy01LTEtMS0xNjM1MQ_7295c421-8b60-469c-b266-100e0348c3b2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,785</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="if0ffa5e709694f368ca08366889ace83_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-528" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RhYmxlOmMyY2FhMzNiMTc1YTQ5NDNiOTA3OGMyMDM0YmYzOWUxL3RhYmxlcmFuZ2U6YzJjYWEzM2IxNzVhNDk0M2I5MDc4YzIwMzRiZjM5ZTFfMy03LTEtMS0xNjM1MQ_7efc8d12-8157-4b64-b911-0a26475cc34e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,601</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-529" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RhYmxlOmMyY2FhMzNiMTc1YTQ5NDNiOTA3OGMyMDM0YmYzOWUxL3RhYmxlcmFuZ2U6YzJjYWEzM2IxNzVhNDk0M2I5MDc4YzIwMzRiZjM5ZTFfNC01LTEtMS0xNjM1MQ_99e6b20d-aa9b-4909-802a-fdaca0acecf6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,263</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-530" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV84Mi9mcmFnOmNkNjU2N2I4ZDIwMjQxZGU4NWJkYjU0ZDQ5YzA4MzI3L3RhYmxlOmMyY2FhMzNiMTc1YTQ5NDNiOTA3OGMyMDM0YmYzOWUxL3RhYmxlcmFuZ2U6YzJjYWEzM2IxNzVhNDk0M2I5MDc4YzIwMzRiZjM5ZTFfNC03LTEtMS0xNjM1MQ_295cb5d6-12b5-4135-bf61-e2c078d34fca" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,993</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div></ix:nonnumeric></span></ix:continuation></span><div style="text-align:justify"><span><br></span></div><div id="ie1e15c78f2af410c8f1490215e82bdbe_94"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 9. <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="fact-identifier-531" continuedat="i9d57dbe7d4c64e8f91e53e605a98e90a" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RleHRyZWdpb246YTA5Y2U4NTRjNTJjNDlhYWEyZTY1ODkyY2JmZWJjYzZfNjQ4OA_0e635168-7980-4095-b27d-1ddc8692a08b" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">INCOME TAXES </ix:nonnumeric></span></span></div><span><ix:continuation id="i9d57dbe7d4c64e8f91e53e605a98e90a" continuedat="i0be8d6d3761d40868da8cf811ed8b4cb" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&nbsp;31, 2021 and 2020, the Company recorded no income tax benefits for the NOL incurred in each year, due to its uncertainty of realizing a benefit from those items.</span></div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="fact-identifier-533" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RleHRyZWdpb246YTA5Y2U4NTRjNTJjNDlhYWEyZTY1ODkyY2JmZWJjYzZfNjQ5MA_c2c970de-55d1-4f20-aa1a-948a2b70f3b3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the U.S. federal statutory income tax rate to the Company’s effective income tax rate is as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:69.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 6.62pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended<br>December&nbsp;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="fact-identifier-534" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjRjMzAzZGU1MWVhYjRlMzA5YzUwMjA3NDdkNDhlZWMwL3RhYmxlcmFuZ2U6NGMzMDNkZTUxZWFiNGUzMDljNTAyMDc0N2Q0OGVlYzBfMi0xLTEtMS0xNjM1MQ_3835b2bb-0ab6-4c3a-bef4-314c02895c87" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21.00</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="fact-identifier-535" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjRjMzAzZGU1MWVhYjRlMzA5YzUwMjA3NDdkNDhlZWMwL3RhYmxlcmFuZ2U6NGMzMDNkZTUxZWFiNGUzMDljNTAyMDc0N2Q0OGVlYzBfMi0zLTEtMS0xNjM1MQ_6db77cee-b3a4-48f2-81c3-d7ad5d039282" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21.00</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="fact-identifier-536" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjRjMzAzZGU1MWVhYjRlMzA5YzUwMjA3NDdkNDhlZWMwL3RhYmxlcmFuZ2U6NGMzMDNkZTUxZWFiNGUzMDljNTAyMDc0N2Q0OGVlYzBfMy0xLTEtMS0xNjM1MQ_699716cf-3741-4093-ad9d-96082c0ae7c6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4.93</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="fact-identifier-537" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjRjMzAzZGU1MWVhYjRlMzA5YzUwMjA3NDdkNDhlZWMwL3RhYmxlcmFuZ2U6NGMzMDNkZTUxZWFiNGUzMDljNTAyMDc0N2Q0OGVlYzBfMy0zLTEtMS0xNjM1MQ_eb711ff3-a4de-4242-81eb-788c200bfda5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.80</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="INF" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="fact-identifier-538" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjRjMzAzZGU1MWVhYjRlMzA5YzUwMjA3NDdkNDhlZWMwL3RhYmxlcmFuZ2U6NGMzMDNkZTUxZWFiNGUzMDljNTAyMDc0N2Q0OGVlYzBfNS0xLTEtMS0xNjM1MQ_8b7054f6-3e83-4a44-937f-ffb21f6bed9e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.22</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="INF" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="fact-identifier-539" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjRjMzAzZGU1MWVhYjRlMzA5YzUwMjA3NDdkNDhlZWMwL3RhYmxlcmFuZ2U6NGMzMDNkZTUxZWFiNGUzMDljNTAyMDc0N2Q0OGVlYzBfNS0zLTEtMS0xNjM1MQ_3a8f1c3e-61c7-46c6-b816-1c32e3fe0617" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.11</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent differences and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="fact-identifier-540" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjRjMzAzZGU1MWVhYjRlMzA5YzUwMjA3NDdkNDhlZWMwL3RhYmxlcmFuZ2U6NGMzMDNkZTUxZWFiNGUzMDljNTAyMDc0N2Q0OGVlYzBfNi0xLTEtMS0xNjM1MQ_97ec15cd-caed-4cea-a56e-6b2a724fde34" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.29</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="fact-identifier-541" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjRjMzAzZGU1MWVhYjRlMzA5YzUwMjA3NDdkNDhlZWMwL3RhYmxlcmFuZ2U6NGMzMDNkZTUxZWFiNGUzMDljNTAyMDc0N2Q0OGVlYzBfNi0zLTEtMS0xNjM1MQ_18327ec0-2669-4373-aaad-4469acfc8047" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.18</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="number" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="INF" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="fact-identifier-542" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjRjMzAzZGU1MWVhYjRlMzA5YzUwMjA3NDdkNDhlZWMwL3RhYmxlcmFuZ2U6NGMzMDNkZTUxZWFiNGUzMDljNTAyMDc0N2Q0OGVlYzBfOC0xLTEtMS0xNjM1MQ_958ee270-9d2d-44a4-b981-c645bb9944d8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.36</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="number" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="INF" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="fact-identifier-543" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjRjMzAzZGU1MWVhYjRlMzA5YzUwMjA3NDdkNDhlZWMwL3RhYmxlcmFuZ2U6NGMzMDNkZTUxZWFiNGUzMDljNTAyMDc0N2Q0OGVlYzBfOC0zLTEtMS0xNjM1MQ_8a8715a6-b473-47a4-919c-f7b158b90015" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.35</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in tax rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" format="ixt:fixed-zero" scale="-2" id="fact-identifier-544" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjRjMzAzZGU1MWVhYjRlMzA5YzUwMjA3NDdkNDhlZWMwL3RhYmxlcmFuZ2U6NGMzMDNkZTUxZWFiNGUzMDljNTAyMDc0N2Q0OGVlYzBfOS0xLTEtMS0xNjM1MQ_c62d32bc-8c62-477d-acfe-9cd735e539d5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="number" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="INF" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="fact-identifier-545" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjRjMzAzZGU1MWVhYjRlMzA5YzUwMjA3NDdkNDhlZWMwL3RhYmxlcmFuZ2U6NGMzMDNkZTUxZWFiNGUzMDljNTAyMDc0N2Q0OGVlYzBfOS0zLTEtMS0xNjM1MQ_822df7c9-28be-4928-8bb3-76a9af7530bc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.32</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in deferred tax asset valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="number" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="INF" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="fact-identifier-546" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjRjMzAzZGU1MWVhYjRlMzA5YzUwMjA3NDdkNDhlZWMwL3RhYmxlcmFuZ2U6NGMzMDNkZTUxZWFiNGUzMDljNTAyMDc0N2Q0OGVlYzBfMTAtMS0xLTEtMTYzNTE_a9061486-fcaa-4569-9a31-a14ef8e2bd8a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">29.08</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="number" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="INF" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="fact-identifier-547" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjRjMzAzZGU1MWVhYjRlMzA5YzUwMjA3NDdkNDhlZWMwL3RhYmxlcmFuZ2U6NGMzMDNkZTUxZWFiNGUzMDljNTAyMDc0N2Q0OGVlYzBfMTAtMy0xLTEtMTYzNTE_12af4ca8-067b-421f-81be-33f5fae306d5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">23.42</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:fixed-zero" scale="-2" id="fact-identifier-548" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjRjMzAzZGU1MWVhYjRlMzA5YzUwMjA3NDdkNDhlZWMwL3RhYmxlcmFuZ2U6NGMzMDNkZTUxZWFiNGUzMDljNTAyMDc0N2Q0OGVlYzBfMTEtMS0xLTEtMTYzNTE_5049adce-1139-4d08-8b5c-744c322ff7d7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:fixed-zero" scale="-2" id="fact-identifier-549" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjRjMzAzZGU1MWVhYjRlMzA5YzUwMjA3NDdkNDhlZWMwL3RhYmxlcmFuZ2U6NGMzMDNkZTUxZWFiNGUzMDljNTAyMDc0N2Q0OGVlYzBfMTEtMy0xLTEtMTYzNTE_2cdf10e2-bd56-4342-839a-8749edb30faa" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></tbody></table></div></ix:nonnumeric></span><div><span><br></span></div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="fact-identifier-550" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RleHRyZWdpb246YTA5Y2U4NTRjNTJjNDlhYWEyZTY1ODkyY2JmZWJjYzZfNjQ4NQ_5e5e8d12-8dfc-4b14-823d-24f1c24725db" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximate deferred tax assets (liabilities) resulting from timing differences between financial and tax bases were associated with the following items (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:69.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 6.62pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended<br>December&nbsp;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOL carryforwards</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i136a713ea34e4a3a8a8e3a24f4fa59ed_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-551" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjJkOWYxNzJhYzQ4OTQ2MDU4OWQ3YTZhNDQ0MjY5Njc5L3RhYmxlcmFuZ2U6MmQ5ZjE3MmFjNDg5NDYwNTg5ZDdhNmE0NDQyNjk2NzlfMi0xLTEtMS0xNjM1MQ_e4d2e0ee-55d2-4d72-96cb-6d717bcb710c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">100,831</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i79b48cfc81254328ac1dae75e4c81c8f_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-552" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjJkOWYxNzJhYzQ4OTQ2MDU4OWQ3YTZhNDQ0MjY5Njc5L3RhYmxlcmFuZ2U6MmQ5ZjE3MmFjNDg5NDYwNTg5ZDdhNmE0NDQyNjk2NzlfMi0zLTEtMS0xNjM1MQ_c2905653-9cb7-4ca4-a969-25b965bfa884" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">90,035</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development and other tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i136a713ea34e4a3a8a8e3a24f4fa59ed_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-553" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjJkOWYxNzJhYzQ4OTQ2MDU4OWQ3YTZhNDQ0MjY5Njc5L3RhYmxlcmFuZ2U6MmQ5ZjE3MmFjNDg5NDYwNTg5ZDdhNmE0NDQyNjk2NzlfMy0xLTEtMS0xNjM1MQ_e2bcdedf-61b5-497d-8286-2162977db4eb" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">16,881</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i79b48cfc81254328ac1dae75e4c81c8f_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-554" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjJkOWYxNzJhYzQ4OTQ2MDU4OWQ3YTZhNDQ0MjY5Njc5L3RhYmxlcmFuZ2U6MmQ5ZjE3MmFjNDg5NDYwNTg5ZDdhNmE0NDQyNjk2NzlfMy0zLTEtMS0xNjM1MQ_3442dfa5-3b41-4e70-aeac-540458f88082" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15,566</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciable assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i136a713ea34e4a3a8a8e3a24f4fa59ed_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-555" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjJkOWYxNzJhYzQ4OTQ2MDU4OWQ3YTZhNDQ0MjY5Njc5L3RhYmxlcmFuZ2U6MmQ5ZjE3MmFjNDg5NDYwNTg5ZDdhNmE0NDQyNjk2NzlfNC0xLTEtMS0xNjM1MQ_6a02188b-cd01-4cfd-99a9-3f2acc566b1a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,481</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i79b48cfc81254328ac1dae75e4c81c8f_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-556" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjJkOWYxNzJhYzQ4OTQ2MDU4OWQ3YTZhNDQ0MjY5Njc5L3RhYmxlcmFuZ2U6MmQ5ZjE3MmFjNDg5NDYwNTg5ZDdhNmE0NDQyNjk2NzlfNC0zLTEtMS0xNjM1MQ_d77afad0-4811-4a37-a7b0-0bb41f78a971" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,356</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i136a713ea34e4a3a8a8e3a24f4fa59ed_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="3" id="fact-identifier-557" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjJkOWYxNzJhYzQ4OTQ2MDU4OWQ3YTZhNDQ0MjY5Njc5L3RhYmxlcmFuZ2U6MmQ5ZjE3MmFjNDg5NDYwNTg5ZDdhNmE0NDQyNjk2NzlfNS0xLTEtMS0xNjM1MQ_257cbcc7-7b9f-4bb9-b0c6-2c768869ba5c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">95</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i79b48cfc81254328ac1dae75e4c81c8f_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="3" id="fact-identifier-558" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjJkOWYxNzJhYzQ4OTQ2MDU4OWQ3YTZhNDQ0MjY5Njc5L3RhYmxlcmFuZ2U6MmQ5ZjE3MmFjNDg5NDYwNTg5ZDdhNmE0NDQyNjk2NzlfNS0zLTEtMS0xNjM1MQ_9d045a6e-e092-4494-a334-9ec6a96d96e7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">818</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i136a713ea34e4a3a8a8e3a24f4fa59ed_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-559" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjJkOWYxNzJhYzQ4OTQ2MDU4OWQ3YTZhNDQ0MjY5Njc5L3RhYmxlcmFuZ2U6MmQ5ZjE3MmFjNDg5NDYwNTg5ZDdhNmE0NDQyNjk2NzlfNy0xLTEtMS0xNjM1MQ_61955947-154d-482f-81cb-fe2e9ef4b209" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,470</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i79b48cfc81254328ac1dae75e4c81c8f_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="3" id="fact-identifier-560" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjJkOWYxNzJhYzQ4OTQ2MDU4OWQ3YTZhNDQ0MjY5Njc5L3RhYmxlcmFuZ2U6MmQ5ZjE3MmFjNDg5NDYwNTg5ZDdhNmE0NDQyNjk2NzlfNy0zLTEtMS0xNjM1MQ_c0fd44ea-daf1-423b-a5fb-508307472b9b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">361</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i136a713ea34e4a3a8a8e3a24f4fa59ed_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-561" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjJkOWYxNzJhYzQ4OTQ2MDU4OWQ3YTZhNDQ0MjY5Njc5L3RhYmxlcmFuZ2U6MmQ5ZjE3MmFjNDg5NDYwNTg5ZDdhNmE0NDQyNjk2NzlfOC0xLTEtMS0xNjM1MQ_1f5d1c9a-f642-4c36-8a3d-9284ccfc9377" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,238</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i79b48cfc81254328ac1dae75e4c81c8f_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="fact-identifier-562" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjJkOWYxNzJhYzQ4OTQ2MDU4OWQ3YTZhNDQ0MjY5Njc5L3RhYmxlcmFuZ2U6MmQ5ZjE3MmFjNDg5NDYwNTg5ZDdhNmE0NDQyNjk2NzlfOC0zLTEtMS0xNjM1MQ_13078877-4efb-417f-b815-50ca105d9f0a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">373</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i136a713ea34e4a3a8a8e3a24f4fa59ed_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="fact-identifier-563" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjJkOWYxNzJhYzQ4OTQ2MDU4OWQ3YTZhNDQ0MjY5Njc5L3RhYmxlcmFuZ2U6MmQ5ZjE3MmFjNDg5NDYwNTg5ZDdhNmE0NDQyNjk2NzlfOS0xLTEtMS0xNjM1MQ_3bec7ad5-d872-4933-8dc2-89c4ea3c783e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i79b48cfc81254328ac1dae75e4c81c8f_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="fact-identifier-564" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjJkOWYxNzJhYzQ4OTQ2MDU4OWQ3YTZhNDQ0MjY5Njc5L3RhYmxlcmFuZ2U6MmQ5ZjE3MmFjNDg5NDYwNTg5ZDdhNmE0NDQyNjk2NzlfOS0zLTEtMS0xNjM1MQ_37af72ef-7e2f-47b7-a18a-458df73d4f4e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">22</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax asset</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i136a713ea34e4a3a8a8e3a24f4fa59ed_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-565" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjJkOWYxNzJhYzQ4OTQ2MDU4OWQ3YTZhNDQ0MjY5Njc5L3RhYmxlcmFuZ2U6MmQ5ZjE3MmFjNDg5NDYwNTg5ZDdhNmE0NDQyNjk2NzlfMTAtMS0xLTEtMTYzNTE_50f80594-9c8e-476a-b818-4f2819d2d114" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">127,011</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i79b48cfc81254328ac1dae75e4c81c8f_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-566" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjJkOWYxNzJhYzQ4OTQ2MDU4OWQ3YTZhNDQ0MjY5Njc5L3RhYmxlcmFuZ2U6MmQ5ZjE3MmFjNDg5NDYwNTg5ZDdhNmE0NDQyNjk2NzlfMTAtMy0xLTEtMTYzNTE_51c7de1c-f51f-45d9-ab02-a65058a1b2b6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">115,531</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i136a713ea34e4a3a8a8e3a24f4fa59ed_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-567" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjJkOWYxNzJhYzQ4OTQ2MDU4OWQ3YTZhNDQ0MjY5Njc5L3RhYmxlcmFuZ2U6MmQ5ZjE3MmFjNDg5NDYwNTg5ZDdhNmE0NDQyNjk2NzlfMTEtMS0xLTEtMTYzNTE_f39f668a-5879-4c9c-8b92-09704a407d80" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">127,011</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i79b48cfc81254328ac1dae75e4c81c8f_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-568" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjJkOWYxNzJhYzQ4OTQ2MDU4OWQ3YTZhNDQ0MjY5Njc5L3RhYmxlcmFuZ2U6MmQ5ZjE3MmFjNDg5NDYwNTg5ZDdhNmE0NDQyNjk2NzlfMTEtMy0xLTEtMTYzNTE_77a535d6-139b-4d4a-bfec-24c94adb28a8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">115,531</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 38.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i136a713ea34e4a3a8a8e3a24f4fa59ed_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:fixed-zero" scale="3" id="fact-identifier-569" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjJkOWYxNzJhYzQ4OTQ2MDU4OWQ3YTZhNDQ0MjY5Njc5L3RhYmxlcmFuZ2U6MmQ5ZjE3MmFjNDg5NDYwNTg5ZDdhNmE0NDQyNjk2NzlfMTItMS0xLTEtMTYzNTE_1a7b7a31-baed-4921-87dc-b868c8c9881c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i79b48cfc81254328ac1dae75e4c81c8f_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:fixed-zero" scale="3" id="fact-identifier-570" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjJkOWYxNzJhYzQ4OTQ2MDU4OWQ3YTZhNDQ0MjY5Njc5L3RhYmxlcmFuZ2U6MmQ5ZjE3MmFjNDg5NDYwNTg5ZDdhNmE0NDQyNjk2NzlfMTItMy0xLTEtMTYzNTE_26a3d5fe-fc93-48dd-b7ab-914e0d9af308" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div></ix:nonnumeric></span></ix:continuation></span><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div><span><br></span></div><span><ix:continuation id="i0be8d6d3761d40868da8cf811ed8b4cb" continuedat="i053cda6dbd014beb9a9c02a10750cfc8" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&nbsp;31, 2021, the Company had deferred tax assets of $<span><ix:nonfraction unitref="usd" contextref="i136a713ea34e4a3a8a8e3a24f4fa59ed_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-572" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RleHRyZWdpb246YTA5Y2U4NTRjNTJjNDlhYWEyZTY1ODkyY2JmZWJjYzZfNTQ3_f9d70b83-9476-46c6-9ec1-396902377c12" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">127.0</ix:nonfraction></span>&nbsp;million. Due to uncertainties surrounding the Company’s ability to generate future taxable income to realize these assets, a full valuation allowance has been established to offset the net deferred tax asset.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Sections 382 and 383 of the Internal Revenue Code (“IRC”), annual use of the Company’s NOL and credit carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period. The most recent Section 382 analysis was completed through December 31, 2011 as a result of a previous ownership change on December 29, 2006, as determined per the provisions of Section&nbsp;382 of the IRC as a result of various stock issuances used to finance the Company’s operations. Such ownership change resulted in annual limitations on the utilization of tax attributes, including NOL carryforwards and tax credits. A Section 382 analysis has not been conducted for the period between January 1, 2012 through December 31, 2021. As such, the Company cannot provide any assurance that a change in ownership within the meaning of the IRC has not occurred between those dates. If a change in ownership were to have occurred, additional NOL and tax credit carryforwards could be eliminated or restricted. If eliminated, the related asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&nbsp;31, 2021&nbsp;and 2020, the Company had available federal NOL carryforwards of approximately $<span><ix:nonfraction unitref="usd" contextref="i35c489743bbd40648d43e3752f9e88fb_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-573" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RleHRyZWdpb246YTA5Y2U4NTRjNTJjNDlhYWEyZTY1ODkyY2JmZWJjYzZfMjY5OA_46bf1fae-8de2-4546-af25-17be6ca68fed" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">455.9</ix:nonfraction></span>&nbsp;million and $<span><ix:nonfraction unitref="usd" contextref="i1206f2f7b6e948c8bf5cb270308ddcab_I20201231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-574" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RleHRyZWdpb246YTA5Y2U4NTRjNTJjNDlhYWEyZTY1ODkyY2JmZWJjYzZfMjcwNQ_1017ad34-e5b9-4a2f-99f7-bb24838e8102" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">420.8</ix:nonfraction></span>&nbsp;million, respectively. The NOLs generated after 2017, totaling $<span><ix:nonfraction unitref="usd" contextref="if069865715654e2f9cb3c0fe326b768a_I20171231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-575" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RleHRyZWdpb246YTA5Y2U4NTRjNTJjNDlhYWEyZTY1ODkyY2JmZWJjYzZfMTA5OTUxMTYzODA4MA_0e3c5d3c-e2a8-41f6-b688-9da73b5477cc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">134.4</ix:nonfraction></span> million, will carry forward indefinitely and be available to offset up to 80% of future taxable income each year. NOLs generated before 2018, totaling $<span><ix:nonfraction unitref="usd" contextref="iec4608c916754d509543ef637b768f07_I20181231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-576" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RleHRyZWdpb246YTA5Y2U4NTRjNTJjNDlhYWEyZTY1ODkyY2JmZWJjYzZfMTA5OTUxMTYzODI5OQ_ca884863-085a-4360-846e-9f2bf0cacbcb" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">321.5</ix:nonfraction></span> million, will expire from 2022 through 2037. In addition, the Company had federal research and development credits and orphan drug credit carryforwards of $<span><ix:nonfraction unitref="usd" contextref="i2ef51a60951147c688025855b9f5d94e_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-577" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RleHRyZWdpb246YTA5Y2U4NTRjNTJjNDlhYWEyZTY1ODkyY2JmZWJjYzZfMzA0MA_d27c6bb8-b7ba-444a-b097-560fed26f0b5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">26.6</ix:nonfraction></span>&nbsp;million and $<span><ix:nonfraction unitref="usd" contextref="ida3cc67b545b49469682a9e8d3a9e6da_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-578" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RleHRyZWdpb246YTA5Y2U4NTRjNTJjNDlhYWEyZTY1ODkyY2JmZWJjYzZfMzA0Nw_6b50fa5b-2ffe-46b5-a130-4e4f91b6e41d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">27.7</ix:nonfraction></span>&nbsp;million as of December&nbsp;31, 2021&nbsp;and 2020, respectively, to reduce future federal income taxes, if any. The Company also has available state NOL carryforwards of approximately $<span><ix:nonfraction unitref="usd" contextref="i74d9a9e7131a4ebe8b34298a8a4575aa_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-579" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RleHRyZWdpb246YTA5Y2U4NTRjNTJjNDlhYWEyZTY1ODkyY2JmZWJjYzZfMzIwMA_8adc4dc2-7419-4563-85d5-9f7a6d2f46b1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">429.0</ix:nonfraction></span>&nbsp;million and $<span><ix:nonfraction unitref="usd" contextref="ifaaa1052eae2429ca6be054fc2faa42b_I20201231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-580" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RleHRyZWdpb246YTA5Y2U4NTRjNTJjNDlhYWEyZTY1ODkyY2JmZWJjYzZfMzIwNw_0214b56d-1328-4a75-9066-7f3a259c82a6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">382.7</ix:nonfraction></span>&nbsp;million as of December&nbsp;31, 2021&nbsp;and 2020, respectively.</span></div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" name="bbi:SummaryOfFederalAndStateCarryforwardsAndCreditsMaturityTableTextBlock" id="fact-identifier-581" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RleHRyZWdpb246YTA5Y2U4NTRjNTJjNDlhYWEyZTY1ODkyY2JmZWJjYzZfNjQ4Ng_795fae66-34d8-49ab-bd34-5ce34fe2fe33" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All federal and state NOL and credit carryforwards listed above are reflected before the reduction for amounts effectively eliminated under Sections 382 and 383. Based upon statute, federal and state NOLs and credits are expected to expire as follows (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:23.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Federal NOLs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">State NOLs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Federal R&amp;D Credit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Federal Orphan Drug Credit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">State R&amp;D Credit</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ia377f4b4864f4191994d91d3152ca408_I20211231" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-582" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjMwZGU3NGQ4ODRlNDRmYjhiNDMyZjc1ZWVlNGE0MzE1L3RhYmxlcmFuZ2U6MzBkZTc0ZDg4NGU0NGZiOGI0MzJmNzVlZWU0YTQzMTVfMy0xLTEtMS0xNjM1MQ_0db17bf8-aafd-4fc3-8c7e-23974f14d05d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">22,420</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i92e0bb7447214495bd04667d15186df7_I20211231" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:fixed-zero" scale="3" id="fact-identifier-583" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjMwZGU3NGQ4ODRlNDRmYjhiNDMyZjc1ZWVlNGE0MzE1L3RhYmxlcmFuZ2U6MzBkZTc0ZDg4NGU0NGZiOGI0MzJmNzVlZWU0YTQzMTVfMy0zLTEtMS0xNjM1MQ_9bfe0a4b-b9da-45ec-b90c-b5cff5cb0b75" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i54d116e3b680474ebfebb6cc1da9fa04_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="3" id="fact-identifier-584" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjMwZGU3NGQ4ODRlNDRmYjhiNDMyZjc1ZWVlNGE0MzE1L3RhYmxlcmFuZ2U6MzBkZTc0ZDg4NGU0NGZiOGI0MzJmNzVlZWU0YTQzMTVfMy01LTEtMS0xNjM1MQ_8e976a37-38d7-4b45-b775-b06e38010fc2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">483</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4bfca4cc8bba4d5e9724f98399c5231a_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-585" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjMwZGU3NGQ4ODRlNDRmYjhiNDMyZjc1ZWVlNGE0MzE1L3RhYmxlcmFuZ2U6MzBkZTc0ZDg4NGU0NGZiOGI0MzJmNzVlZWU0YTQzMTVfMy03LTEtMS0xNjM1MQ_1b26cea2-e3b9-4d38-a55e-0b6fd4c48e5b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,610</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ie9162577024e474bbb8ef516a461528a_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:fixed-zero" scale="3" id="fact-identifier-586" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjMwZGU3NGQ4ODRlNDRmYjhiNDMyZjc1ZWVlNGE0MzE1L3RhYmxlcmFuZ2U6MzBkZTc0ZDg4NGU0NGZiOGI0MzJmNzVlZWU0YTQzMTVfMy05LTEtMS0xNjM1MQ_4a5704a0-5bc9-47ab-a0c3-1583675e25e1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i055e8d473e5f460088db865a971a2e90_I20211231" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-587" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjMwZGU3NGQ4ODRlNDRmYjhiNDMyZjc1ZWVlNGE0MzE1L3RhYmxlcmFuZ2U6MzBkZTc0ZDg4NGU0NGZiOGI0MzJmNzVlZWU0YTQzMTVfNC0xLTEtMS0xNjM1MQ_2fc3a13f-f598-4fa4-be6a-8482be62799c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">22,398</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8bbe926f88884d4e854c2e429801b32f_I20211231" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:fixed-zero" scale="3" id="fact-identifier-588" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjMwZGU3NGQ4ODRlNDRmYjhiNDMyZjc1ZWVlNGE0MzE1L3RhYmxlcmFuZ2U6MzBkZTc0ZDg4NGU0NGZiOGI0MzJmNzVlZWU0YTQzMTVfNC0zLTEtMS0xNjM1MQ_375810dc-8af0-478d-8ef0-f2c0bac0f7ff" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i49e62605df6747c6ad4117475d1fb987_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="3" id="fact-identifier-589" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjMwZGU3NGQ4ODRlNDRmYjhiNDMyZjc1ZWVlNGE0MzE1L3RhYmxlcmFuZ2U6MzBkZTc0ZDg4NGU0NGZiOGI0MzJmNzVlZWU0YTQzMTVfNC01LTEtMS0xNjM1MQ_62d2f17a-0587-4035-9d10-7e6489ff5c7d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">322</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i88decd1b1a234431a2bfe501b616ec2e_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="3" id="fact-identifier-590" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjMwZGU3NGQ4ODRlNDRmYjhiNDMyZjc1ZWVlNGE0MzE1L3RhYmxlcmFuZ2U6MzBkZTc0ZDg4NGU0NGZiOGI0MzJmNzVlZWU0YTQzMTVfNC03LTEtMS0xNjM1MQ_8804b5ee-d4ca-4486-8dac-edf7b8deb530" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">929</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="if015fe594d1f45d68fd0d5b29b7e029d_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:fixed-zero" scale="3" id="fact-identifier-591" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjMwZGU3NGQ4ODRlNDRmYjhiNDMyZjc1ZWVlNGE0MzE1L3RhYmxlcmFuZ2U6MzBkZTc0ZDg4NGU0NGZiOGI0MzJmNzVlZWU0YTQzMTVfNC05LTEtMS0xNjM1MQ_2b803e04-4f38-40cd-b5ec-ecd082e0a0b0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ief836506794f4fb4ac09c658d878fb63_I20211231" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-592" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjMwZGU3NGQ4ODRlNDRmYjhiNDMyZjc1ZWVlNGE0MzE1L3RhYmxlcmFuZ2U6MzBkZTc0ZDg4NGU0NGZiOGI0MzJmNzVlZWU0YTQzMTVfNS0xLTEtMS0xNjM1MQ_603595dd-b1c2-41a1-9606-dc31f1c37e56" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">25,032</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="if2fd9a0736ed4d1699213bd8e7662e31_I20211231" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:fixed-zero" scale="3" id="fact-identifier-593" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjMwZGU3NGQ4ODRlNDRmYjhiNDMyZjc1ZWVlNGE0MzE1L3RhYmxlcmFuZ2U6MzBkZTc0ZDg4NGU0NGZiOGI0MzJmNzVlZWU0YTQzMTVfNS0zLTEtMS0xNjM1MQ_65a67880-3a8a-473e-8a25-1cbae25e5bb4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ia6a33dddb3224c30a28ed87c7a88e87b_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="3" id="fact-identifier-594" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjMwZGU3NGQ4ODRlNDRmYjhiNDMyZjc1ZWVlNGE0MzE1L3RhYmxlcmFuZ2U6MzBkZTc0ZDg4NGU0NGZiOGI0MzJmNzVlZWU0YTQzMTVfNS01LTEtMS0xNjM1MQ_114cba49-0ece-4d2a-b3e5-5e3871691c73" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">213</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="idf114d19233c49ecb4a3a0bdff3b4730_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="3" id="fact-identifier-595" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjMwZGU3NGQ4ODRlNDRmYjhiNDMyZjc1ZWVlNGE0MzE1L3RhYmxlcmFuZ2U6MzBkZTc0ZDg4NGU0NGZiOGI0MzJmNzVlZWU0YTQzMTVfNS03LTEtMS0xNjM1MQ_215d5d25-9dda-4f3d-86dd-ec156a5ed18a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">663</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iccf7a6c422244f209239a5cceb1fd0e1_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:fixed-zero" scale="3" id="fact-identifier-596" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjMwZGU3NGQ4ODRlNDRmYjhiNDMyZjc1ZWVlNGE0MzE1L3RhYmxlcmFuZ2U6MzBkZTc0ZDg4NGU0NGZiOGI0MzJmNzVlZWU0YTQzMTVfNS05LTEtMS0xNjM1MQ_3a9b2416-3e90-4c40-81c8-72bd36caf18e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="icba3d25c77924f07b976d8ed0d1f674d_I20211231" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-597" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjMwZGU3NGQ4ODRlNDRmYjhiNDMyZjc1ZWVlNGE0MzE1L3RhYmxlcmFuZ2U6MzBkZTc0ZDg4NGU0NGZiOGI0MzJmNzVlZWU0YTQzMTVfNi0xLTEtMS0xNjM1MQ_8478bff6-c1fb-47e9-a6f7-73bc7f7ed865" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">27,190</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9ed137c836424891ae89e0522e0531bd_I20211231" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:fixed-zero" scale="3" id="fact-identifier-598" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjMwZGU3NGQ4ODRlNDRmYjhiNDMyZjc1ZWVlNGE0MzE1L3RhYmxlcmFuZ2U6MzBkZTc0ZDg4NGU0NGZiOGI0MzJmNzVlZWU0YTQzMTVfNi0zLTEtMS0xNjM1MQ_d5ad88d4-a56f-4ae8-b2b1-46fb4bc1a8de" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i99e282fca2d6495aa43c86ffa521681a_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="3" id="fact-identifier-599" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjMwZGU3NGQ4ODRlNDRmYjhiNDMyZjc1ZWVlNGE0MzE1L3RhYmxlcmFuZ2U6MzBkZTc0ZDg4NGU0NGZiOGI0MzJmNzVlZWU0YTQzMTVfNi01LTEtMS0xNjM1MQ_2b3064c3-ee1a-48ed-95ac-03854755d449" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">456</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefaa5c4a7c97470ca20fbb972d15809c_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="3" id="fact-identifier-600" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjMwZGU3NGQ4ODRlNDRmYjhiNDMyZjc1ZWVlNGE0MzE1L3RhYmxlcmFuZ2U6MzBkZTc0ZDg4NGU0NGZiOGI0MzJmNzVlZWU0YTQzMTVfNi03LTEtMS0xNjM1MQ_da3d95fe-b0e2-4f2b-bc04-1f5d157e14f2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">507</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i75390603508c4979a7101c91da59e41c_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:fixed-zero" scale="3" id="fact-identifier-601" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjMwZGU3NGQ4ODRlNDRmYjhiNDMyZjc1ZWVlNGE0MzE1L3RhYmxlcmFuZ2U6MzBkZTc0ZDg4NGU0NGZiOGI0MzJmNzVlZWU0YTQzMTVfNi05LTEtMS0xNjM1MQ_7ad0171c-6257-4d4a-9823-64f0305d0e8b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i27c3cd712f364388b6f58cda40a050e9_I20211231" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-602" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjMwZGU3NGQ4ODRlNDRmYjhiNDMyZjc1ZWVlNGE0MzE1L3RhYmxlcmFuZ2U6MzBkZTc0ZDg4NGU0NGZiOGI0MzJmNzVlZWU0YTQzMTVfNy0xLTEtMS0xNzYyNg_04dd8478-31ff-4c42-82de-6420d0876d44" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">224,441</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ie0ee826e5fdc4ad191c11eec2cd9704b_I20211231" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-603" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjMwZGU3NGQ4ODRlNDRmYjhiNDMyZjc1ZWVlNGE0MzE1L3RhYmxlcmFuZ2U6MzBkZTc0ZDg4NGU0NGZiOGI0MzJmNzVlZWU0YTQzMTVfNy0zLTEtMS0xNzYyNg_69e091a8-e74c-4705-8c97-4babd153c6bd" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">389,944</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8bad8ed177f24dea9d15095e335759e4_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-604" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjMwZGU3NGQ4ODRlNDRmYjhiNDMyZjc1ZWVlNGE0MzE1L3RhYmxlcmFuZ2U6MzBkZTc0ZDg4NGU0NGZiOGI0MzJmNzVlZWU0YTQzMTVfNy01LTEtMS0xNzYyNg_468aad41-b7e1-4c07-bb0d-3ad5417d1e4a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,066</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="icaa1655b26314906b0ae1a0f7373c717_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-605" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjMwZGU3NGQ4ODRlNDRmYjhiNDMyZjc1ZWVlNGE0MzE1L3RhYmxlcmFuZ2U6MzBkZTc0ZDg4NGU0NGZiOGI0MzJmNzVlZWU0YTQzMTVfNy03LTEtMS0xNzYyNg_d09265e4-46a1-4aad-a6a2-10827f95dea7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">13,306</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i21637a81f1f649a2bb7c8c62210df99f_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:fixed-zero" scale="3" id="fact-identifier-606" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjMwZGU3NGQ4ODRlNDRmYjhiNDMyZjc1ZWVlNGE0MzE1L3RhYmxlcmFuZ2U6MzBkZTc0ZDg4NGU0NGZiOGI0MzJmNzVlZWU0YTQzMTVfNy05LTEtMS0xNzYyNg_b9f110dc-5f98-43ad-a6ea-7523376ccf85" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8e7c32c46b4347a380789e24ffa11089_I20211231" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-607" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjMwZGU3NGQ4ODRlNDRmYjhiNDMyZjc1ZWVlNGE0MzE1L3RhYmxlcmFuZ2U6MzBkZTc0ZDg4NGU0NGZiOGI0MzJmNzVlZWU0YTQzMTVfNy0xLTEtMS0xNjM1MQ_feb2f07f-2d43-4628-b993-76021bc4ac12" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">134,424</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2226ff53aa6a47f7bba1d2bafb644439_I20211231" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-608" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjMwZGU3NGQ4ODRlNDRmYjhiNDMyZjc1ZWVlNGE0MzE1L3RhYmxlcmFuZ2U6MzBkZTc0ZDg4NGU0NGZiOGI0MzJmNzVlZWU0YTQzMTVfNy0zLTEtMS0xNjM1MQ_f512743b-c138-40f8-9d96-cf07b3f2535a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">39,084</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ia893a09aeca64349aec659edad8bb1ef_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:fixed-zero" scale="3" id="fact-identifier-609" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjMwZGU3NGQ4ODRlNDRmYjhiNDMyZjc1ZWVlNGE0MzE1L3RhYmxlcmFuZ2U6MzBkZTc0ZDg4NGU0NGZiOGI0MzJmNzVlZWU0YTQzMTVfNy01LTEtMS0xNjM1MQ_97a10087-ff8b-4c59-8860-73f03a5864e0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i123e03f06e61449ba99dfad20ff96163_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:fixed-zero" scale="3" id="fact-identifier-610" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjMwZGU3NGQ4ODRlNDRmYjhiNDMyZjc1ZWVlNGE0MzE1L3RhYmxlcmFuZ2U6MzBkZTc0ZDg4NGU0NGZiOGI0MzJmNzVlZWU0YTQzMTVfNy03LTEtMS0xNjM1MQ_9d7b22a3-9774-45fd-a7f5-585e62e5c5f7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i66ddca61491244439bcf9e0d19cbfb1e_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-611" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjMwZGU3NGQ4ODRlNDRmYjhiNDMyZjc1ZWVlNGE0MzE1L3RhYmxlcmFuZ2U6MzBkZTc0ZDg4NGU0NGZiOGI0MzJmNzVlZWU0YTQzMTVfNy05LTEtMS0xNjM1MQ_7c52ab43-cfb0-4e57-a4de-4f8687a69959" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,572</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Totals</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i35c489743bbd40648d43e3752f9e88fb_I20211231" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-612" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjMwZGU3NGQ4ODRlNDRmYjhiNDMyZjc1ZWVlNGE0MzE1L3RhYmxlcmFuZ2U6MzBkZTc0ZDg4NGU0NGZiOGI0MzJmNzVlZWU0YTQzMTVfOC0xLTEtMS0xNjM1MQ_d0688104-ea84-47ed-8b8c-b09d8a605277" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">455,905</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i74d9a9e7131a4ebe8b34298a8a4575aa_I20211231" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-613" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjMwZGU3NGQ4ODRlNDRmYjhiNDMyZjc1ZWVlNGE0MzE1L3RhYmxlcmFuZ2U6MzBkZTc0ZDg4NGU0NGZiOGI0MzJmNzVlZWU0YTQzMTVfOC0zLTEtMS0xNjM1MQ_61e302e7-93ca-44bb-ad57-5bd8db2e9a8b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">429,028</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i6a502aca50a64ba18b73ea0ce99d6515_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-614" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjMwZGU3NGQ4ODRlNDRmYjhiNDMyZjc1ZWVlNGE0MzE1L3RhYmxlcmFuZ2U6MzBkZTc0ZDg4NGU0NGZiOGI0MzJmNzVlZWU0YTQzMTVfOC01LTEtMS0xNjM1MQ_f5db093c-5466-4a41-8ad9-457f0c31b79a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,540</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i32fa7409baf340ddbe1255d4f16f1f40_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-615" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjMwZGU3NGQ4ODRlNDRmYjhiNDMyZjc1ZWVlNGE0MzE1L3RhYmxlcmFuZ2U6MzBkZTc0ZDg4NGU0NGZiOGI0MzJmNzVlZWU0YTQzMTVfOC03LTEtMS0xNjM1MQ_e4c1d82e-8a17-4cb1-a711-7112eb81a9a6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">17,015</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i7e43190ff0834525a23e0adddd8a0b6b_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-616" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RhYmxlOjMwZGU3NGQ4ODRlNDRmYjhiNDMyZjc1ZWVlNGE0MzE1L3RhYmxlcmFuZ2U6MzBkZTc0ZDg4NGU0NGZiOGI0MzJmNzVlZWU0YTQzMTVfOC05LTEtMS0xNjM1MQ_af5ae282-2ff5-4d65-95d3-e92508ca7446" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,572</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div></ix:nonnumeric></span><div style="text-align:justify"><span><br></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated the positive and negative evidence bearing upon its ability to realize the deferred tax assets. Management has considered the Company’s history of cumulative net losses incurred since inception and its lack of commercialization of any products and has concluded that it is more likely than not that the Company will not realize the benefits of the deferred tax assets. Accordingly, a full valuation allowance has been established against the deferred tax assets as of December&nbsp;31, 2021&nbsp;and 2020. Management reevaluates the positive and negative evidence at each reporting period. The Company’s valuation allowance increased by approximately $<span><ix:nonfraction unitref="usd" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-617" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RleHRyZWdpb246YTA5Y2U4NTRjNTJjNDlhYWEyZTY1ODkyY2JmZWJjYzZfNDQxNQ_0697a3cf-5451-4793-99c8-d0cb88d7449c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11.5</ix:nonfraction></span>&nbsp;million for the year ended December&nbsp;31, 2021. For the year ended December&nbsp;31, 2020, the valuation allowance increased by $<span><ix:nonfraction unitref="usd" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-618" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RleHRyZWdpb246YTA5Y2U4NTRjNTJjNDlhYWEyZTY1ODkyY2JmZWJjYzZfNDQ4NQ_c8d0d9bb-cb7e-4ee5-83ba-cb0fb0b686e7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4.9</ix:nonfraction></span>&nbsp;million.</span></div></ix:continuation></span><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><span><ix:continuation id="i053cda6dbd014beb9a9c02a10750cfc8" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. While the Company believes that it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcome of examinations by tax authorities in determining the adequacy of its provision for income taxes.</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:58.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></tbody></table></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had previously acquired gross unrecognized tax benefits with a balance of $<span><ix:nonfraction unitref="usd" contextref="id3b10aa2a59c42e1a26bc5d4f5f555bb_D20210101-20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-620" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RleHRyZWdpb246YTA5Y2U4NTRjNTJjNDlhYWEyZTY1ODkyY2JmZWJjYzZfNTYzMg_6060c01b-02ee-4139-8b9c-7af8f1afed74" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="usd" contextref="i4f7b72e5e2664c888c7cb4c551807c1a_D20200101-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-621" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmUxZTE1Yzc4ZjJhZjQxMGM4ZjE0OTAyMTVlODJiZGJlL3NlYzplMWUxNWM3OGYyYWY0MTBjOGYxNDkwMjE1ZTgyYmRiZV85NC9mcmFnOmEwOWNlODU0YzUyYzQ5YWFhMmU2NTg5MmNiZmViY2M2L3RleHRyZWdpb246YTA5Y2U4NTRjNTJjNDlhYWEyZTY1ODkyY2JmZWJjYzZfNTYzMg_6da63e71-fcaf-4558-ba05-c33ef43e9fb8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21.7</ix:nonfraction></span></ix:nonfraction></span>&nbsp;million as of each of December&nbsp;31, 2021 and 2020, none of which would affect the effective tax rate, due to the Company’s full valuation allowance on its deferred tax assets. The Company does not anticipate any significant decreases in its unrecognized tax benefits over the next 12 months. The Company’s policy is to recognize the interest expense and/or penalties related to income tax matters as a component of income tax expense.&nbsp;The Company had no accrual for interest or penalties on its consolidated balance sheets as of December&nbsp;31, 2021 and 2020, and has not recognized interest and/or penalties in its consolidated statements of operations for the years ended December&nbsp;31, 2021 and 2020.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&nbsp;31, 2021, the Company’s U.S. federal and state tax returns remain subject to examination by tax authorities beginning with the tax year ended December 31,&nbsp;2018. However, due to NOLs and credit carryforwards being generated and carried forward from prior tax years, substantially all tax years may also be subject to examination.</span></div></ix:continuation></span><div style="margin-bottom:12pt;text-align:justify"><span><br></span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><div id="ie1e15c78f2af410c8f1490215e82bdbe_199"></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br></span></div><div id="ie1e15c78f2af410c8f1490215e82bdbe_127"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9A. CONTROLS AND PROCEDURES</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports that we file under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosures. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the design and operation of our disclosure controls and procedures, as such term is defined in Rule 13a-15(e) and 15d-15(e) promulgated under the Exchange Act, as of the end of the period covered by this report. Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective and were operating at a reasonable assurance level as of December&nbsp;31, 2021.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management Report on Internal Controls over Financial Reporting</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of consolidated financial statements for external purposes in accordance with U.S.&nbsp;GAAP.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management assessed our internal control over financial reporting as of December&nbsp;31, 2021, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework). Management’s assessment included evaluation of elements such as the design and operating effectiveness of key financial reporting controls, process documentation, accounting policies, and our overall control environment.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on this assessment, management has concluded that our internal control over financial reporting was effective as of the end of the fiscal year to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external reporting purposes in accordance with U.S. GAAP. We reviewed the results of management’s assessment with the audit committee of our board of directors.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inherent Limitations on Effectiveness of Controls</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including the principal executive officer and principal financial officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well-designed and operated, can provide only reasonable, </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">not absolute, assurance that the control system’s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has determined that there were no changes in our internal control over financial reporting that occurred during the three months ended December&nbsp;31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="text-align:justify"><span><br></span></div><div id="ie1e15c78f2af410c8f1490215e82bdbe_154"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9B. OTHER INFORMATION</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-align:justify"><span><br></span></div><div id="ie1e15c78f2af410c8f1490215e82bdbe_2224"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="text-align:justify"><span><br></span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><div id="ie1e15c78f2af410c8f1490215e82bdbe_202"></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III.</span></div><div><span><br></span></div><div id="ie1e15c78f2af410c8f1490215e82bdbe_205"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference to our 2022&nbsp;Proxy Statement to be filed with the SEC within 120 days after December&nbsp;31, 2021.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors has adopted a Code of Conduct applicable to all officers, directors, and employees, which is available on our website (https://www.ir.brickellbio.com) under “Governance.” We intend to satisfy the disclosure requirement under Item 5.05 of Form 8-K regarding amendment to, or waiver from, a provision of our Code of Conduct by posting such information on the website address and location specified above.</span></div><div style="text-align:justify"><span><br></span></div><div id="ie1e15c78f2af410c8f1490215e82bdbe_208"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 11. EXECUTIVE COMPENSATION</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference to our 2022&nbsp;Proxy Statement to be filed with the SEC within 120 days after December&nbsp;31, 2021.</span></div><div><span><br></span></div><div id="ie1e15c78f2af410c8f1490215e82bdbe_211"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference to our 2022&nbsp;Proxy Statement to be filed with the SEC within 120 days after December&nbsp;31, 2021.</span></div><div><span><br></span></div><div id="ie1e15c78f2af410c8f1490215e82bdbe_214"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference to our 2022&nbsp;Proxy Statement to be filed with the SEC within 120 days after December&nbsp;31, 2021.</span></div><div><span><br></span></div><div id="ie1e15c78f2af410c8f1490215e82bdbe_217"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference to our 2022&nbsp;Proxy Statement to be filed with the SEC within 120 days after December&nbsp;31, 2021.</span></div><div style="text-align:justify"><span><br></span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><div id="ie1e15c78f2af410c8f1490215e82bdbe_220"></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV.</span></div><div><span><br></span></div><div id="ie1e15c78f2af410c8f1490215e82bdbe_157"></div><div style="-sec-extract:summary;margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)(1) Financial Statements</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements required by this item are submitted in a separate section beginning on page <a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1e15c78f2af410c8f1490215e82bdbe_193" tabindex="18">75</a> of this Annual Report.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)(2)&nbsp;Financial Statement Schedules</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial statement schedules have been omitted because they are either not required, not applicable, or the information is otherwise included.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)(3)&nbsp;Exhibits</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Exhibit Index, which is incorporated herein by reference.</span></div><div style="margin-bottom:6pt;padding-left:18pt;padding-right:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT INDEX</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:8.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.568%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description of Exhibit</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date of Filing</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed Herewith</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/819050/000081905021000053/a202104198kex32.htm" tabindex="18">Amended and Restated Certificate of Incorporation, as amended through April 19, 2021</a></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/19/2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/819050/000081905020000113/a20200331ex32.htm" tabindex="18">Amended and Restated Bylaws, as currently in effect</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/14/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/819050/000081905019000010/ex41.htm" tabindex="18">Specimen Common Stock Certificate</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-8</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/10/2019</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/819050/000081905021000031/a20210309s3exhibit43.htm" tabindex="18">Form of Senior Indenture</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-3</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/9/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/819050/000081905021000031/a20210309s3exhibit44.htm" tabindex="18">Form of Subordinated Indenture</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-3</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/9/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/819050/000081905020000205/a202010s1exhibit42.htm" tabindex="18">Form of Warrant to Purchase Common Stock issued in connection with the Company’s October 2020 Offering</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/13/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/819050/000081905020000205/a202010s1exhibit43.htm" tabindex="18">Form of Pre-Funded Warrant issued in connection with the Company’s October 2020 Offering</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/13/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/819050/000081905020000205/a202010s1exhibit44.htm" tabindex="18">Form of Warrant Agency Agreement issued in connection with the Company’s October 2020 Offering</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/13/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/819050/000081905020000146/a20200617s1aexhibit44.htm" tabindex="18">Form of Warrant Agency Agreement between Brickell Biotech, Inc. and American Stock Transfer &amp; Trust Company, LLC in connection with the Company’s June 2020 offering</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/17/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/819050/000081905020000146/a20200617s1aexhibit42.htm" tabindex="18">Form of Warrant to Purchase Common Stock issued in connection with the Company’s June 2020 offering</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/17/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/819050/000081905020000127/a20200608s1aexhibit43.htm" tabindex="18">Form of Pre-Funded Warrant to Purchase Common Stock issued in connection with the Company’s June 2020 offering</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/8/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/819050/000081905022000016/a2021123110kex410.htm" tabindex="18">Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Exchange Act</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">×</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1†</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/819050/000081905019000006/ex102licenseagreementkaken.htm" tabindex="18">License, Development and Commercialization Agreement, dated March 31, 2015, including certain amendments, by and between Brickell Biotech, Inc. and Kaken Pharmaceutical Co., Ltd.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/3/2019</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:8.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.568%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2†</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/819050/000081905020000127/a20200608s1aexhibit102.htm" tabindex="18">Amendment to License, Development and Commercialization Agreement, dated February 24, 2016, by and between Brickell Biotech, Inc. and Kaken Pharmaceutical Co., Ltd.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/8/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3†</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/819050/000081905019000006/ex103rightoffirstnegotiati.htm" tabindex="18">Amendment No. 2 to License, Development and Commercialization Agreement, dated October 6, 2017, by and between Brickell Biotech, Inc. and Kaken Pharmaceutical Co., Ltd., including Right of First Negotiation Agreement, as amended, dated October 6, 2017, by and between Brickell Biotech, Inc. and Kaken Pharmaceutical Co., Ltd.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/3/2019</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4†</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/819050/000081905020000127/a20200608s1aexhibit104.htm" tabindex="18">Clinical Supply Agreement, dated as of July 30, 2019, by and between Brickell Biotech, Inc. and Kaken Pharmaceutical Co., Ltd., and First Amendment to Clinical Supply Agreement, dated as of October 18, 2019</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/8/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5†</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/819050/000081905020000127/a20200608s1aexhibit105.htm" tabindex="18">Letter Agreement for Supply of API, dated as of April 26, 2020, by and between Brickell Biotech, Inc. and Kaken Pharmaceutical Co., Ltd.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/8/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6†</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/819050/000081905020000205/a202010s1exhibit106.htm" tabindex="18">Letter Agreement, dated as of September 3, 2020, by and between Brickell Biotech, Inc. and Kaken Pharmaceutical Co., Ltd.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/13/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7†</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/819050/000081905021000029/a2020123110kex107.htm" tabindex="18">Letter Agreement for Supply of API, dated as of December 8, 2020, by and between Brickell Biotech, Inc. and Kaken Pharmaceutical Co., Ltd.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/9/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8†</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/819050/000081905021000132/a2021063010qex104.htm" tabindex="18">Brickell-Kaken Amendment to Clinical Supply Agreement and License, Development and Commercialization Agreement, dated as of May 14, 2021, by and between Brickell Biotech, Inc. and Kaken Pharmaceutical Co., Ltd.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/12/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9†</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/819050/000081905020000020/a202002188kexhibit101.htm" tabindex="18">Amended and Restated License Agreement, dated February 17, 2020, by and among Brickell Biotech, Inc., Brickell Subsidiary, Inc., Bodor Laboratories, Inc., and Dr. Nicholas S. Bodor</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/18/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10†</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/819050/000081905020000020/a202002188kexhibit102.htm" tabindex="18">Settlement Agreement, dated February 17, 2020, by and among Brickell Biotech, Inc., Brickell Subsidiary, Inc., Bodor Laboratories, Inc., and Dr. Nicholas S. Bodor</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/18/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11†</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/819050/000081905021000137/a202109018kex101.htm" tabindex="18">License and Development Agreement, dated as of August 27, 2021, by and between Voronoi Inc. and Brickell Biotech, Inc.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/1/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12†</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/819050/000081905022000003/a202202028kex101.htm" tabindex="18">Exclusive License Agreement, dated as of February 2, 2022, by and between Carna Biosciences, Inc. and Brickell Biotech, Inc.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/2/2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/819050/000081905019000006/ex1010leaseandamendments.htm" tabindex="18">Boulder Lease Agreement, as amended, dated August 4, 2016, by and between Brickell Biotech, Inc. and BMC Properties, LLC</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/3/2019</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/819050/000081905021000132/a2021063010qex101.htm" tabindex="18">Fourth Amendment to Lease Agreement, dated as of June&nbsp;17, 2021, by and between Brickell Biotech, Inc. and GPIF 5777 Flatiron LLC (f/k/a BMC Properties, LLC)</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/12/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15+</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/819050/000081905020000180/a2020063010qex102.htm" tabindex="18">Form of Indemnification Agreement by and between the Company and its directors and executive officers</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/12/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16+</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/819050/000081905019000006/ex1011employmentagreementrb.htm" tabindex="18">Employment Agreement, dated November 16, 2018, by and between Brickell Biotech, Inc. and Robert Brown</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/3/2019</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17+</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/819050/000081905019000006/ex1012employmentagreementas.htm" tabindex="18">Second Amended and Restated Employment Agreement, dated November 27, 2018, by and between Brickell Biotech, Inc. and Andy Sklawer</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/3/2019</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:8.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.568%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18+</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/819050/000081905021000170/a2021093010qex102.htm" tabindex="18">Employment Agreement, dated August 26, 2021, by and between Brickell Biotech, Inc. and Monica Luchi</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/9/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19+</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/819050/000081905020000237/a202011248kexhibit102.htm" tabindex="18">Consulting Agreement by and between Brickell Biotech, Inc. and Danforth Advisors LLC, effective as of December&nbsp;1, 2020</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/24/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20+</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/819050/000081905019000006/ex1014employmentagreementjb.htm" tabindex="18">Brickell Biotech, Inc. Letter Agreement, dated July 10, 2018, by and between Brickell Biotech Inc. and Jose Breton</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/3/2019</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21+</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/819050/000081905020000205/a202010s1exhibit1017.htm" tabindex="18">First Amended and Restated Employment Agreement, dated September 1, 2020, by and between Brickell Biotech, Inc. and Deepak Chadha</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/13/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22+</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/819050/000081905019000006/ex1015employmentagreementdm.htm" tabindex="18">Employment Agreement, dated July 1, 2019, and Amendment to Employment Agreement, dated August&nbsp;27,&nbsp;2019, by and between Brickell Biotech, Inc. and David R. McAvoy</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/3/2019</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23+</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/819050/000081905021000053/a202104198kex101.htm" tabindex="18">Brickell Biotech, Inc. 2020 Omnibus Long-Term Incentive Plan, as amended through April 19, 2021</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/19/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24+</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/819050/000117184317003411/exh_991.htm" tabindex="18">Amended and Restated Stock Incentive Plan of Vical Incorporated</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/1/2017</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.25+</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/819050/000081905019000010/ex992.htm" tabindex="18">Amended and Restated 2009 Equity Incentive Plan of Brickell Biotech, Inc.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-8</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/10/2019</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.26</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/819050/000081905021000053/a202104198kex102.htm" tabindex="18">Brickell Biotech, Inc. Employee Stock Purchase Plan</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/19/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.27+</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/819050/000081905020000180/a2020063010qex103.htm" tabindex="18">Form of Restricted Stock Unit Award Agreement under the Brickell Biotech, Inc. 2020 Omnibus Long-Term Incentive Plan</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/12/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.28+</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/819050/000081905021000029/a2020123110kex1025.htm" tabindex="18">Form of Incentive Stock Option Award Agreement under the Brickell Biotech, Inc. 2020 Omnibus Long-Term Incentive Plan</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/9/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.25</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.29+</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/819050/000081905020000180/a2020063010qex104.htm" tabindex="18">Form of Non-Qualified Stock Option Award Agreement under the Brickell Biotech, Inc. 2020 Omnibus Long-Term Incentive Plan</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/12/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.30</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/819050/000081905020000020/a202002188kexhibit103.htm" tabindex="18">Securities Purchase Agreement, dated February 17, 2020, by and between Brickell Biotech, Inc. and Lincoln Park Capital Fund, LLC</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/18/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.31</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/819050/000081905020000024/a20200228s3exhibit43.htm" tabindex="18">Series A Warrant issued by Brickell Biotech, Inc. to Lincoln Park Capital Fund, LLC</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-3</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/28/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.32</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/819050/000081905020000024/a20200228s3exhibit44.htm" tabindex="18">Series B Warrant issued by Brickell Biotech, Inc. to Lincoln Park Capital Fund, LLC</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-3</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/28/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.33</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/819050/000081905020000020/a202002188kexhibit106.htm" tabindex="18">Purchase Agreement, dated February 17, 2020, by and between Brickell Biotech, Inc. and Lincoln Park Capital Fund, LLC</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/18/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.34</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/819050/000081905020000020/a202002188kexhibit107.htm" tabindex="18">Registration Rights Agreement, dated February 17, 2020, by and between Brickell Biotech, Inc. and Lincoln Park Capital Fund, LLC</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/18/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.35</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/819050/000081905020000084/a202004148kexhibit11.htm" tabindex="18">At Market Issuance Sales Agreement, dated April 14, 2020, by and between Brickell Biotech, Inc. and Oppenheimer &amp; Co. Inc.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/14/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.36</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/819050/000081905021000031/a20210309s3exhibit12.htm" tabindex="18">At Market Issuance Sales Agreement, dated March 9, 2021, by and among the Company, Oppenheimer &amp; Co. Inc. and William Blair &amp; Company, L.L.C.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-3</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/9/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/819050/000081905022000016/a2021123110kex211.htm" tabindex="18">List of Subsidiaries</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">×</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/819050/000081905022000016/a2021123110kex231.htm" tabindex="18">Consent of Ernst &amp; Young&nbsp;LLP</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">×</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1e15c78f2af410c8f1490215e82bdbe_169" tabindex="18">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:8.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.568%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/819050/000081905022000016/a2021123110kex311.htm" tabindex="18">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">×</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/819050/000081905022000016/a2021123110kex312.htm" tabindex="18">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">×</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/819050/000081905022000016/a2021123110kex321.htm" tabindex="18">Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">×</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">×</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">×</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">×</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">×</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">×</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">×</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">×</span></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:2.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicates a management contract or compensatory plan.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">×</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">†</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Certain confidential information contained in this agreement has been omitted because it (i) is not material and (ii) would be competitively harmful if publicly disclosed.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This certification is being furnished pursuant to 18 U.S.C. Section 1350 and is not being filed for purposes of Section 18 of the Exchange Act and is not to be incorporated by reference into any filing of the Registrant, whether made before or after the date hereof.</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div id="ie1e15c78f2af410c8f1490215e82bdbe_223"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16. FORM 10-K SUMMARY</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><div id="ie1e15c78f2af410c8f1490215e82bdbe_226"></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><span><br></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="text-align:center"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:40.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.068%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brickell Biotech, Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: March 15, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Robert. B. Brown</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Robert B. Brown</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Executive Officer)</span></div><div style="text-align:justify"><span><br></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Albert N. Marchio, II</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Albert N. Marchio, II</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Financial Officer)</span></div><div style="text-align:justify"><span><br></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="margin-bottom:6pt;text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:29.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Robert B. Brown</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and Director<br>(Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 15, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert B. Brown</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Albert N. Marchio, II</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer<br>(Principal Financial Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 15, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Albert N. Marchio, II</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jose Breton</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Controller and Chief Accounting Officer<br>(Principal Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 15, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jose Breton</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Reginald L. Hardy</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Co-Founder and Chairman of the Board of Directors</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 15, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reginald L. Hardy</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Dennison T. Veru</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 15, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dennison T. Veru</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Vijay B. Samant </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 15, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vijay B. Samant</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Gary A. Lyons</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 15, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gary A. Lyons</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></tbody></table></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div>

</body>
</html>